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Nanomaterials are already revolutionizing medical treat-
ments and diagnostics and could have the potential to
diagnose and treat various life-threatening diseases. Well
advanced technologies that have become possible, thanks
to the properties of materials at the nanoscale, are the
application of magnetic and gadolinium oxide nanoparticles
in MRI imaging, magnetic immunoassays, magnetic hyper-
thermia, the use of drug nanosuspensions to improve drug
dissolution and bioavailability, and many others. Various
nanoscale carriers have been developed and are currently
being explored for targeted delivery of therapeutics in order
to increase the efficacy of the drugs and eliminate problems
such as systemic toxicity. Nanoengineered scaffolds produced
by various traditional and innovative techniquesmay give the
opportunity to regenerate tissues and organs. The potential
of nanoscale systems to bring healthcare treatments to a
new dimension has galvanized research in this field and new
applications are being reported almost every week. The aim
of this special issue is to present some of the exciting new
developments in the field, highlight current challenges, and
point towards future directions.
This special issue contains a collection of excellent con-
tributions from established laboratories around the world.
It contains instructive reviews and original research articles
dealing with the diverse areas that are the subject of this
special issue.
Three excellent reviews were published in this special
issue.These reviews present comprehensive summaries of the
recent developments in the particular field, critical assess-
ment of published literature, and the authors’ prospective of
the future directions. A review from the group of K. Ostrikov
deals with the challenges associated with controlling the
behavior of stem cells. The review focuses on using plasma-
based techniques for the manufacturing and modification of
tailored nanostructured surfaces for stem cell control. The
review also provides the authors’ views on the links between
plasma physics, materials science, nanoscience, and stem
cell biology. Another excellent review by J. E. Jackson et al.
focuses on the use of nanoparticles as novel drug carriers
in wound repair and regeneration. The authors’ motivation
for writing this review is the growing number of antibiotic-
resistant bacteria, in conjunction with an increase in popu-
lation age and clinical obesity that urgently requires novel,
more efficient methods for wound care. The review critically
discusses the advantages and limitations of nanotechnology
for the treatment of wounds and other cutaneous disorders.
Another review published in the special issue focuses on
nanoparticle-based drug delivery for treating lung cancer.
This review summarizes current progress in nanoparticle-
based drug delivery systems that target lung cancer treatment.
The review further outlines the challenges in the areas of
pharmacology, toxicology, immunology, large-scale manu-
facturing, and regulatory issues that hinder the transition of
these new therapies from the bench to the bedside.
Fourteen quality research articles were selected for pub-
lication in this special issue. Several of these articles tackle
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problems related to drug delivery and offer innovative solu-
tions. M. Fathi et al. present novel caffeic acid nanocarri-
ers. The problems with improving the solubility of poorly
soluble drugs through nanosuspensions are addressed by R.
Yadollahi et al. In another article, X. Wang and cowork-
ers report a novel magnetic-membrane-based microfluidic
platform for controllable release. pH responsive polymeric
micelles for delivery of hydrophobic drug are described by
B. A. Moosa et al. Infections are an important problem
with medical treatments. An article by M. Seidenstuecker
et al. is focused on the release kinetics and antibacterial
efficacy of microporous 𝛽 TCP coatings. B. M. Sahoo et
al. report on the microwave enhanced drug synthesis as an
enabling technology to synthesize potential antimicrobial
agents. The special issue also contains articles presenting
novel opportunities for regenerative medicine. An in vivo
study on the use of electrospun nanofibrous scaffolds for
ligament-bone healing is provided by J. Zhu et al. The group
of Y. Cong from Peking University reports on the fabrication
of conductive polypyrrole nanofibers by electrospinning. M.
Larsson et al. report on novel “Nanocomposites of polyacrylic
acid nanogels and biodegradable polyhydroxybutyrate for bone
regeneration and drug delivery.” The special issue also con-
tains an interesting article entitled “Magnetic and structural
studies of CoFe2O4 nanoparticles suspended in an organic
liquid.” The authors suggest that these nanoparticles can be
of interest for medical imaging. Surface properties have been
recognized as important mediators of cellular behavior. The
role of substrate topography in endothelial cell proliferation
is elucidated in an article entitled “Enhanced Ca2+ entry
and tyrosine phosphorylation mediate nanostructure-induced
endothelial proliferation.” The issues of potential hazards
associated with the use of nanomaterials in medicine are
also embedded in the special issue via an article by V.
Balakrishnan et al. entitled “In vitro evaluation of cytotoxicity
of colloidal amorphous silica nanoparticles designed for drug
delivery on human cell lines.”
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Biodegradable cell scaffolds and local drug delivery to stimulate cell response are currently receiving much scientific attention.
Here we present a nanocomposite that combines biodegradation with controlled release of lithium, which is known to enhance
bone growth. Nanogels of lithium neutralized polyacrylic acid were synthesized by microemulsion-templated polymerization and
were incorporated into a biodegradable polyhydroxybutyrate (PHB) matrix. Nanogel size was characterized using dynamic light
scattering, and the nanocomposites were characterized with regard to structure using scanning electron microscopy, mechanical
properties using tensile testing, permeability using tritiated water, and lithium release in PBS using a lithium specific electrode.
The nanogels were well dispersed in the composites and the mechanical properties were good, with a decrease in elastic modulus
being compensated by increased tolerance to strain in the wet state. Approximately half of the lithium was released over about
three hours, with the remaining fraction being trapped in the PHB for subsequent slow release during biodegradation.The prepared
nanocomposites seem promising for use as dual functional scaffolds for bone regeneration. Here lithium ions were chosen asmodel
drug, but the nanogels could potentially act as carriers for larger and more complex drugs, possibly while still carrying lithium.
1. Introduction
To introduce additional functionality in a biodegradable pol-
yhydroxybutyrate (PHB) matrix, polyacrylic acid (PAA) na-
nogels were incorporated to form a hybrid solid-gel na-
nocomposite. This highly designed material structure ap-
proach is in line with recent developments in the biomaterials
field.
Biodegradable materials have long been investigated for
use in tissue engineering and drug delivery, as seen from
literature [1–3], but attention has turned towards structured
and/or multifunctional materials [3, 4]. One material class
that has been widely investigated for use in biomedical
applications is polyhydroxyalkanoates (PHA), as it incorpo-
rates a range of naturally occurring biocompatible aliphatic
polyesters, including PHB [5]. The characteristics and mate-
rial properties of different PHA vary greatly, for example,
mechanical properties and degradation rates can be tailored
by the monomer composition [2, 3, 5]. When it comes to
PHB it has a strong tendency for crystallization [5] and has
a slow biodegradation rate compared to most biodegradable
polyesters [6].With regard tomechanical properties it is hard
and brittle, where the brittleness is a disadvantage [5], and
copolymers/composites may be better suited for biomedical
applications [2, 5]. Nonetheless, PHB is generally nontoxic
[5], likely because the polymer and its final degradation prod-
ucts are naturally occurring in humans [7, 8], and has been
investigated for use in bone tissue engineering [2, 5, 9–11] and
nerve scaffolding [12–14], among other applications. Recently
there have been reports on creating nano-microporous PHB
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matrixes using an aqueous emulsion as template for the voids
in the material [6, 15].
PAA is an anionic polyelectrolyte that is easily polymer-
ized and crosslinked into macroscopic hydrogels that can
swell hundreds of times their dry weight, especially when
the acid protons are neutralized with sodium [16]. PAA is a
pharmaceutically used excipient also known under the name
Carbopol [17]. There have been numerous studies on the
use of PAA as a component in materials for biomedical
applications, both because of its high swelling capability and
because the polyanionic charge allows for easy loading of
cationic molecules. In the last decade, there have been some
reports on the preparation of PAA nanogels [18–20], and
such nanogels have been investigated as drug carriers [18,
19]. Based on available literature on PHB, PAA nanogels,
and other materials where nanodrug carriers have been
incorporated in amacroscopicmatrix [21–23], we recognized
that if PAA nanogels could be synthesized and incorporated
into PHB matrixes, then they could provide additional
functionality to the materials by acting as drug carriers and
possibly also altering themechanical properties for beneficial
effects. However, rather than incorporating conventional
drugs into the PAA nanogels, as already proven possible, the
very small monovalent cation lithium was chosen as a model
substance. Lithium has been shown to activate the Wnt-
signaling pathway [24, 25], leading to accumulation of 𝛽-
catenin protein [25], a protein that in turn positively regulates
osteoblasts [26], which clearly is of interest for bone-tissue
engineering. In fact, lithium has been shown to increase
bone mass and improve fracture healing in mice/rats [24, 26,
27]. Given the interest in PHB for bone-tissue regeneration
lithium is a relevant choice as model drug; in addition, if
controlled release is possible for lithium it will surely be
possible for larger cationic drugs, especially if polyvalent.
In this study, we report on the successful preparation
of drug loaded PHB-PAA nanogel composite films with
designed structure, controlled release of lithium, and im-
proved mechanical properties.
2. Materials and Methods
2.1. Materials. Acetone, acrylic acid anhydrous, chloroform
puriss p.a, lithium hydroxide, N,N󸀠-methylenebisacrylamid
(MBA), poly-[(R)-3-hydroxybutyric acid] (PHB), polysor-
bate 80, poly[(R)-3-hydroxybutyric acid], potassium per-
sulfate, Span 80, and N,N,N󸀠,N󸀠-Tetramethylenediamine
(TEMED) were purchased from Sigma Aldrich. Hexane was
purchased from Fischer scientific. Milli-Q (Millipore) water
was used throughout the experiments.
2.2. Preparation of Lithium Loaded PAA Nanogels by Reverse
Microemulsion Polymerization. Adapted from work by oth-
ers [18, 19], the following method was used for PAA nanogel
preparation. In a vial 3.43 g Span 80 and 2.62 g Tween 80
were added, followed by 100mL hexane (oil phase). The flask
was capped and the content mixed with a magnetic stirrer so
that tween and span were fully dissolved. The aqueous phase
was prepared as follows: 1.5mL of 10% (w/w) LiOH in H
2
O
was added to 500 𝜇L acrylic acid. Subsequently, using H
2
O
as solvent, 214𝜇L of 5% (w/v) MBA suspension, 500 𝜇L 2%
(w/v) potassium persulfate, and 40 𝜇L of 20% (w/v) TEMED
were added.
The microemulsion was formed by dropwise addition of
the aqueous phase into the oil phase while a homogenizer
(IKA, Taquara) was running at 14000 rpm. After the addition,
the speed of the homogenizer was increased to 24000 rpm for
3min, followed by 14000 rpm until all foam had disappeared
(about 45 sec). The emulsion was transferred to a 60∘C water
bath and was stirred at 400 rpm using a magnetic stirrer. For
the first 10 minutes the emulsion was covered with aluminum
foil and bubbled with N
2
, after which the vial was capped
and the reaction was allowed to proceed for 6 h, after which
the vial was vented, resealed, and left under stirring at room
temperature overnight. For washing, product and solvent
were transferred to 50mL falcon tubes, and centrifuged
at 5100 rpm for 6 h at 4∘C using a Sigma 4k15 centrifuge
(Labex). The supernatants were decanted and the pellets
were resuspended in acetone for a total volume of 20mL
and were centrifuged again at 5100 rpm for 10min at 4∘C,
repeated three times. Finally, the pellets were re-suspended in
acetone (final volume 5mL) and mixed with magnetic stirrer
overnight. The opaque dispersions were centrifuged down,
the acetone was discarded, and the pellets were dispersed in
1mL chloroform, pooled, and stored until further use and
analysis.
2.3. Nanogel Size Characterization. Prior to washing samples
were taken out and dispersed in H
2
O. The dispersion was
centrifuged, and the supernatant was diluted 100 times and
filtered with a 0.20 𝜇m filter before analysis by dynamic light
scattering (DLS) using a N4 plus submicron particle size
analyzer (Beckman Coulter). The program was set to run at
room temperature and measured all angles (5.7∘, 11.1∘, 23.0∘,
30.2∘, 62.6∘, and 90.0∘) for 6min.
2.4. Film Preparation. Pure PHB films were prepared as
follows: 560mgPHBwas dissolved in 8mL chloroformunder
magnetic stirring in a 58∘C water bath for 1 h. The solution
was left to cool down to room temperature after which the
PHB solution was poured in a glass petri dish. Film casting
was performed by allowing the chloroform to evaporate
without lid for 2min before loosely covering the dish with
a lid until the next day, at which point the evaporation was
complete. To ensure an even evaporation, the glass petri dish
had double layered tape on two edges.
PHB films containing PAA nanogels were prepared as
above, with the following differences: PHB was dissolved in
6mL chloroform, and the desired mass of PAA nanogels
were mixed with 2mL chloroform. The nanogel dispersion
was then mixed with the PHB solution using a homogenizer
(DI18, IKA) for 15 s, and casting was performed as for pure
PHB films.
2.5. Film Structure Characterization. Dry films and freeze-
dried (LABCONCO, FreeZone 6) swollen films were cut into
sections to display the interior regions of the films. Before
Journal of Nanomaterials 3
the SEM analysis, all samples were sputter coated with gold
in argon atmosphere for about 1min using a S150B Sputter
Coater (Edwards). SEM analysis was conducted using a LEO
Ultra 55 SEM equipped with a field emission gun (LEO
Electron Microscopy Group).
2.6. Swelling Analysis. Filmswere cut in 1.5×2 cmpieces. Dry
weight and thickness of the pieces were recorded. The pieces
were swollen in Milli-Q water or PBS buffer (pH 7.4). At pre-
determined time times, excess water was removed by blotting
the films on a paper and the weight and thickness of the
samples were noted. The film pieces were then resubmerged.
The swelling was calculated as
Swelling degree (𝑄) =
𝑊
𝑠
−𝑊
𝑑
𝑊
𝑑
, (1)
where𝑊
𝑠
is the weight of the swollen sample and𝑊
𝑑
is the
dry weight.
2.7. Tensile Testing. Each film was cut into three rectangular
strips using an 8.5mm thick parallel cutter. The average
thickness of each stripe was determined from three different
sites. The films were mounted into the tensile tester (Instron)
and were pulled until breakage while the force displacement
was recorded.
2.8. Water Permeability. Film pieces were cut out, and the
thickness was measured in triplicates and placed between
the donor and acceptor compartment in diffusion cells.
Subsequently, 50mL of Milli-Q water was simultaneously
added to the donor and acceptor compartments and 10 𝜇L
of tritiated water (400 kBq) was added to the donor com-
partments. During the experiment, the cells were placed on a
rotating table formixing at ambient temperature. At specified
times 500 𝜇L was extracted from the acceptor compartment
and replaced with Milli-Q water. To determine the diffusive
flow across the films, the tritium activity in the acceptor
compartment was compared to the initial activity in the
donor compartment using a liquid scintillation analyser (Tri-
carb 2810TR, Perkin Elmer).Thepermeability (𝑃) of the films
was calculated using the following equation:
2𝑃𝑆
𝑉
𝑡 = − ln(
𝐶
𝑑,0
− 2𝐶
𝑎
𝐶
𝑑,0
) , (2)
where 𝑆 is the area through which diffusion occurs, 𝑉 is the
volume of the individual donor and acceptor compartments,
𝑡 is the time, 𝐶
𝑑,0
is the concentration in donor compartment
at time zero, and 𝐶
𝑎
is the concentration in the acceptor
compartment at time 𝑡. From a plot of − ln[(𝐶
𝑑,0
−2𝐶
𝑎
)/𝐶
𝑑,0
]
versus time, 𝑃 was calculated from the slope [28]. To elimi-
nate contributions from film thickness (ℎ), 𝑃was normalized
by multiplication with ℎ at time zero.
2.9. Lithium Release. PHB films containing 15 and 25% PAA
were cut into 1.8 × 2 cm pieces that were subsequently
immersed in 30mL PBS buffer under stirring. At prede-
termined times a calibrated ion specific electrode (ISE) for
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Figure 1: Exemplifying plot of intensity-size distribution for the
nanogels in water.
Table 1: Average sizes and relative mass fraction, determined from
DLS using the angle of 90∘.
Diameter (nm) Std. dev. (nm) Relative mass fraction
79 5.4 3.3
200 13.7 1
lithium ions was used to measure the concentration of re-
leased lithium ions.
3. Results and Discussion
3.1. PAA Nanogel Synthesis and Characterization. Nanogels
of PAA were prepared by reverse phase microemulsion
polymerization. The model drug lithium was incorporated
into the gels by neutralizing the carboxylic acid of the acrylic
acid monomers prior to the polymerizations reaction. The
condition of electroneutrality as well as the low chemical
potential of lithium ions in the hydrophilic nanogels, com-
pared to in the hydrophobic solvents used for washing, would
lead to lithium remaining in the gels.
Analysis of the nanogels using DLS revealed two popu-
lations with different size, as shown in Figure 1. The average
size of the two populations was about 80 nm and 200 nm,
respectively. Similar results were obtained for all angles,
indicating a spherical geometry of the nanogels.
From the intensity distribution the mass ratio between
the two populations was calculated, recognizing that larger
particles are given more weight in intensity distribution
obtained from DLS. The calculations revealed that the mass
fraction of nanogels in the population with smaller size was
about three times the mass fraction in the population with
larger size (see Table 1).
3.2. Casting of PHB-Nanogel Composite Films. Films of PHB
with or without nanogels were prepared by solvent evapo-
ration. All prepared films had thicknesses in the range of
95 𝜇m–150 𝜇m and displayed a smooth surface. Pure PHB
films were slightly opaque, and with increasing nanogel
4 Journal of Nanomaterials
(a) (b) (c)
Figure 2: Photos of, (a) a PHB film, (b) PHB films containing 5% (w/w) PAA, and (c) PHB films containing 25% (w/w) PAA.
(a)5 𝜇m
(a)
(b)5 𝜇m
(b)
(c)5 𝜇m
(c)
(d)5 𝜇m
(d)
Figure 3: SEMmicrographs showing the cross-sections of dry PHB films with different amounts of PAA nanogels: (a) PHB+5% (w/w) PAA;
(b) PHB + 10% (w/w) PAA; (c) PHB + 15% (w/w) PAA, and (d) PHB + 25% (w/w) PAA.
content the opaqueness increased, so that the films with 25%
nanogels appeared close to white (Figure 2).
3.3. Morphology of the PHB-Nanogel Composite Films. To
characterize the morphology of the formed nanocomposite
films they were analysed using SEM. Analyses were per-
formed both on dry films and on films swollen and subse-
quently freeze-dried. The dry films revealed an increasing
porosity with increasing nanogel content (Figure 3).
For swollen and freeze-dried films, the trend of increasing
porosity with increasing nanogel content was even more pro-
nounced (Figure 4), not surprising given that the PAA na-
nogels should swell in water and delocalize the surrounding
PHB to some extent. Upon freeze drying the changed struc-
ture should remain to large parts. In summary, the nanogels
were well dispersed throughout the nano-composite, induced
a more porous structure, and swelled in water to further
increase the porosity of the PHB matrix.
3.4. Swelling and Water Permeability of the PHB-Nanogel
Composite Films. Swelling and permeability are both of rel-
evance for biomedical applications. The swelling influences
mechanical properties and mass transfer in the material,
while permeability is a measurement of how easy molecules
can be transported through the material.
In PBS pure PHB films displayed little swelling, but the
swelling increased with increasing nanogel content. A large
increase in swelling (per mass nanogel) was seen for the sam-
ples with the lowest nanogel content (5%), followed by small-
er increase with additional nanogel addition (Figure 5(a)).
The trend was similar for swelling in Milli-Q water but
with some notable differences. The swelling of pure PHB
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Figure 4: SEM micrographs showing the cross-sections of swollen and subsequently freeze-dried PHB films with different PAA nanogel
content: (a) PHB; (b) PHB + 15% (w/w) PAA; (c) PHB + 25% (w/w) PAA.
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Figure 5: Swelling behavior of PHB films with different PAA nanogel content. (a) % mass increase in PBS buffer, (b) % mass increase in
Milli-Q water, (c) % thickness increase in PBS buffer, and (d) % thickness increase in Milli-Q water. ◊ = PHB, ◻ = PHB + 5% PAA, Δ =
PHB + 10% PAA, X = PHB + 15% PAA, I = PHB + 25% PAA. Error bars indicate one standard deviation (𝑛 = 3).
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Figure 6: Water permeability normalized for initial film thickness
for PHB films with different PAA nanogel content. Error bars indi-
cate min/max (𝑛 = 2–5).
was somewhat increased in Milli-Q water, while the swelling
of the composites was reduced for all nanogel contents
(Figure 5(b)). To elucidate the dimensional changes upon
swelling the thickness of swollen samples was measured in
addition to weight. It was found that most of the swelling
occurred by increasing the thickness of the samples (Figures
5(c) and 5(d)). The exact mechanisms behind the observed
swelling, behaviours may be complex and merit further
investigation before conclusions are drawn. However, what
can be stated is that the nanogels increased the swelling of
the composite and that they should exist in a swollen gel
state inside submerged composites. Furthermore, since the
thickness of PHB increased upon submersion in PBS the PHB
did indeed swell; that is, the increase inmass was not only due
to water becoming trapped in cracks and pores.
It is well known that for polymer materials the diffusion
coefficient quickly increases with swelling of the material
[29] and that in a composite combining regions with small
and large diffusion coefficients the spatial distribution of
those will influence the permeability [30]. Therefore, perme-
ability analysis was conducted on pure PHB films and the
composites. Very low permeability was observed for pure
PHB films and composites with 5% and 10% nanogels, while
for films with higher (15% and 25%) nanogel content the
permeability increased rapidly (Figure 6). The results are
explained as follows: the diffusion is slow in PHB, while it is
fast in the swollen nanogels. Below a critical nanogel content
there is no connectivity between them and the permeability
is limited by diffusion through PHB. However, at higher
nanogel concentrations they form a coherent network that
percolates through the films, effectively creating channels
with large diffusion coefficient, with increased permeability
as a consequence. The results are in agreement with those
from the SEM analysis and are highly relevant for predicting
drug release behaviour of the PHB-nanogel composites. For
composites with ≤10% nanogels drug release would likely
be controlled by degradation of the PHB, while for higher
nanogel content at least a fraction of the loaded drug would
be released faster through diffusion.
3.5. Release of Lithium from the PHB-Nanogel Composite
Films. Having established the structure and permeability
of the PHB-nanogel composites, the release of lithium was
investigated for nanogel contents of 15% and 25%. Com-
posites with lower nanogel content were excluded as the
permeability analysis had revealed them to only allow for very
limited diffusion through them. Worth mentioning is that in
vivo the composites with very low permeability should release
nanogels and loaded drugs as the PHB degrade.
Both the composites with 15% and 25% nanogels dis-
played a close to linear release of lithium during the first
1.5 h, after which the drug release levelled off. At the final
measuring time of 7 h the percent of lithium released from
the gels was 41% and 58% for nanogel contents of 15% and
25%, respectively (Figure 7). The fact that the drug release
is far from 100% indicates that a fraction of the nanogels
are not part of the percolating network; thus, the release of
lithium from this fraction is extremely slow, so that only
the release of lithium in the percolating nanogel fraction is
detected.Theobservation that a higher percent of lithiumwas
released from the composites with higher nanogel content
is coherent with that the fraction of nanogels belonging
to the percolating network increases with nanogel content,
as expected. The lithium release profiles indicate that the
prepared PHB-nanogel composites can be loaded with drug
for controlled diffusive release of active agents, if the nanogel
content is high enough. At lower nanogel content the release
will instead be determined by PHB degradation. If desired it
should be possible to achieve a combination of fast diffusion
controlled release and slow degradation controlled release by
choosing suitable nanogel content.
3.6. Mechanical Properties of the PHB-Nanogel Composite
Films. Even if PHB has been investigated with promising
results for bone-tissue regeneration, it has been stated that
its brittleness may limit the use of pure PHB in therapeutic
applications [2, 5]. Recognizing the importance of mechan-
ical properties in biomedical applications the PHB-nanogel
composite films were analysed using tensile testing in the
dry and equilibrium swollen state. With increasing nanogel
content the elastic modulus (𝐸) decreased from 1.4GPa to
0.7GPa and from 1GPa to 0.5GPa for dry and equilibrium
swollen samples, respectively (Figure 8(a)). The decrease in
𝐸 with nanogel addition was expected, especially in the
wet state where 𝐸 of the nanogel phase is very low. With
regard to tolerance to extension (the percent extension at
which breakage occurred) there was no conclusive effect of
nanogel content for the dry samples. However, for equi-
librium swollen samples tolerance to extension surprisingly
increased (Figure 8(b)).This improvement in extension prop-
erties suggests that the wet nanogels interact with the PHB on
a molecular level, causing plasticizing of the material.
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Figure 7: Release of lithium ions from PHB-nanogel composite films in PBS. (a) 15% (w/w) nanogels, (b) 25% (w/w) nanogels. The different
markers indicate two independent experiments.
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Figure 8: (a) Elastic modulus and (b) extension at breakage for dry (◻) and swollen (◊) PHB films with different PAA nanogel content. Error
bars indicate one standard deviation (𝑛 = 3).
The results from the tensile testing revealed that the PHB-
nanogel composites retained a high elastic modulus, even if
decreased to about half. More importantly the composites
seem to overcome the limitation of the inherent brittleness
of PHB, making the composites highly interesting for thera-
peutic uses.
4. Conclusion
Composite films composed of PHB and PAA nanogels were
prepared and characterized. The results indicate that the
composites may be well suitable for biomedical uses as a
biodegradable material where nanostructural design may be
used to tune drug release mechanism, from diffusion con-
trolled to degradation controlled. Furthermore, controlled
release was demonstrated for the small lithium ion which
together with improved tolerance to deformation suggest the
nanocomposites to be suitable for bone-tissue engineering.
Lithium is a relevant therapeutic substance in itself, but even
more, the fact that controlled release is achieved for the
small monovalent lithium ion clearly indicates potential for
delivery of more complex substances. Further investigations
involving the material would involve both fundamental
investigations of the mechanisms behind swelling behaviour
and mechanical properties, as well as applied in vivo studies
using lithium and other therapeutic substances.
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Wound healing is an area of unmet clinical need. Current treatments include occlusive dressings, hydrogels, and antimicrobials
to control infection. However with the growing number of antibiotic-resistant bacteria and the increase in population age and
clinical obesity, it is becoming proportionally harder to treat wounds with the drugs that have worked in the past. There is an
urgent requirement for efficient mechanism-based treatments and more efficacious drug delivery systems. The potential of using
nanoparticles as a drug delivery system has been identified and investigated. Nanoparticles have the ability to protect and carry
drugs to specific targets in the body, enabling slower degradation, enhancing drug penetration, improving treatment efficacy with
lower systemic absorption, and reducing unwanted side effects. Here we discuss the advantages and limitations of nanotechnology
for the treatment of wounds and other cutaneous disorders.
1. Introduction
The skin is the largest organ in the body and is the first line
of defence against invading pathogens.The primary function
of the skin is to act as a protective barrier against the envi-
ronment as any large insult or loss of skin integrity can lead to
disability or death [1, 2]. Adult cutaneous wound healing is a
complicated process involving a cascade of events and inter-
actions between numerous cells and cellmediators [3, 4].This
process aims to restore the complete skin barrier function
quickly, often at the expense of correct anatomical repair [5].
There are several dressings and devices currently available on
the medical wound care market impregnated with a range of
compounds which aim to optimise the wound healing envir-
onment, providing faster, more efficient wound healing [6].
There are, however, many limitations with using these dress-
ings in clinical practice including poor skin penetration, low
stability, and localised side effects. Consequently, there is a
need for the development of novel and more efficient drug-
delivery systems [7]. The advent of nanotechnologies has the
potential to fulfil this and the design and implementation of
target-selective, time-controlled drug delivery systems for
cutaneous healing and regenerative medicine now exists
[8, 9].
While naturally occurring nanoporous minerals have
been used on an industrial scale as effective catalysts for dec-
ades, today there are a number of different substances used
for the production of nanoporousmaterials including carbon,
silicon, silicates, ceramics, metals, various polymers, metallic
minerals, and compounds of organic materials [10]. The use
of micro- and nanotechnology is becoming more frequent in
biomedical science, both in the development of diagnostics
and in clinical therapies. Development of novel therapies in
cutaneous healing has been greatly facilitated by the discov-
ery of novel nanomaterials including nanoparticles, nanotu-
bes, nanoengineered scaffolds, and nanoscale surface modi-
fications [11]. The use of this technology has the potential
to increase drug efficacy and decrease adverse effects by deliv-
ering specific quantities of drugs to specific target sites over
a determined period of time. Nanomaterials are currently
being investigated for their applications in cutaneous wound
healing and their potential uses include molecule delivery,
nanofibres for tissue scaffolds and surface modification for
implantable materials [12]. Nanotherapy is manipulation of
matter, at an atomic or molecular scale, used for delivery of
therapeutic agents to tissues in vivo [13]. The main exam-
ples of nanotherapy being developed for use in cutane-
ous medicine include solid lipid nanoparticles, which are
2 Journal of Nanomaterials
nanoparticles made of lipids and lipids blends, and nanos-
tructured lipid carriers, a second generation of smarter drug
carrier systems made up of physiological, biodegradable, and
biocompatible lipid materials and surfactants.These are both
currently accepted as applicable routes for the delivery of
drugs in vivo [14, 15]. The aim of this paper is to review
the potential of nanomaterials for the improvement of cuta-
neous healing, while comparing current clinical therapies to
developing ones and assessing the strengths and limitations
of both.
2. Transcutaneous Delivery of Nanoparticles
Penetration of nanoparticles through intact skin is a contro-
versial topic and has been a major focus of research in both
the pharmaceutical and cosmetic industry examining the
transcutaneous delivery of both nonbiodegradable and bio-
degradable nanomaterials [16]. Titanium dioxide (TiO2) and
zinc oxide (ZnO) are two of the most widely characterized
nonbiodegradable nanoparticles studied in this regard due to
their wide use in both sunscreens and cosmetics. There are,
however, conflicting studies reporting on the epidermal pen-
etration of titanium dioxide and its accumulation in several
majors organs. This has raised safety and toxicity concerns
due to oxidative stress induced by deposited nanoparticles
after prolonged dermal exposure [13, 17]. In recent years,
however, developments in nanotechnology have highlighted
the potential use of biodegradable nanoparticles including
liposomes, niosomes, nanosized emulsions, and solid lipid
nanoparticles as the carrier systems for drug delivery through
the protective stratum corneum [18]. Solid lipid nanoparticles
(SLN) are a new generation of nanoparticulate active-sub-
stance vehicles with advantages of controlled release, low irri-
tation, and protection of active compounds [19]. Their small
particle size ensures close contact with the stratum corneum
and improved penetration of the encapsulated agent through
the skin layers [20]. The complete biodegradation of lipid
nanoparticles and their biocompatible chemical nature has
highlighted lipid nanoparticles as “nanosafe carriers” for top-
ical drug delivery with studies examining their use for deliv-
ery of glucocorticoids (prednicarbate, betamethasone, and
prednisolone) and nonsteroidal anti-inflammatory drugs (in-
domethacin, celecoxib, ketoprofen, ketorolac, flurbiprofen)
for potential treatment of acne, skinmycoses, atopic dermati-
tis, and psoriasis [21].
The efficacy of topically applied drugs used in clinical der-
matology is determined by their mechanism of action and
their ability to pass through the protective skin barrier. Drug
permeation through the skin occurs via the passive diffusion
of drugs through the transepidermal or transappendageal
route [13]. In contrast, transcutaneous delivery of nanoparti-
cles is dependent on a number of factors including desquama-
tion rate of stratum corneum, permeation pathway, and the
size of nanoparticles [22].Themajority of studies to date sug-
gest that nanoparticles only permeate the superficial layers of
the skin in vivo and remain in the stratum corneum, while
only a few studies suggest full epidermal penetration and
dermal absorption. It is generally accepted that nanoparticles
do not diffuse across the basement membrane and their dep-
osition in the skin occurs through follicular penetration
(Figure 1(a)) [18]. In the context of clinical dermatology, con-
trolled drug delivery and release via the hair follicles using
nanoparticles offer an exciting opportunity for therapy devel-
opment as hair follicles are surrounded by capillaries and
antigen presenting cells, are associated with the sebaceous
glands, and are the host of stem cells in the bulge region of the
hair follicle [23]. Consequently delivery of drugs, proteins,
or antibodies to the epidermis through follicular penetration
offers novel avenues of therapy development for number of
dermatological conditions where patients still have intact
skin eg eczema, psoriasis, mycoses and atopic dermatitis (fur-
ther discussed in Section 4 and Table 1).
One area of current research focus is the potential use of
nanoparticles for noninvasive transcutaneous immunisation.
Compared to microparticles which cannot penetrate the skin
to the extent that would allow the application of the required
dose of antigen nanoparticles, delivery through the follicular
pathway has been shown to penetrate deeper into the hair
follicle than molecules in solution, help stabilize the protein
based antigens, and can improve and modulate immune res-
ponse [40]. This particular route of drug/vaccine delivery is
particularly important for immunocompromised patients
including the elderly, patients with poor wound healing, and
young children [41]. Studies by Mittal et al. demonstrate an
effective needle-free application of vaccines across the skin by
delivery of polymeric nanoparticles using ovalbumin antigen
and a double emulsion nanotechnology method using phar-
maceutically biocompatible and biodegradable polymers
poly(lactide-co-glycolide) (PLGA) or chitosan-coated PLGA
(Chit-PLGA) demonstrating increased protection from
cleavage and functional biological activity of the antigen [41].
In addition, epidermal permeation of nanoparticles has also
been reported following mechanical stress including the use
of harsh vehicles or skin damage following needle puncture
or wounding [13].
Transcutaneous delivery of nanoparticles and dermal ab-
sorption of drugs, proteins, or antibodies to patients suffering
from chronic inflamed wounds or nonhealing ulcers are not
hindered by the protective skin barrier as those patients have
large open wounds. For patients with open wounds, treat-
ments can be delivered using nanotechnology by incorporat-
ing drug carrying nanoparticles into dressings or hydrogels
allowing controlled sustained release of nanoparticles to the
dermis (Figure 1(b)). Preliminary in vitro and in vivo studies
have shown that both solid lipid nanoparticle and nanos-
tructured lipid carrier hydrogels can be used to successfully
deliver flurbiprofen to skin with sustainable and controlled
drug delivery over 24 hrs with functional anti-inflammatory
effects on the tissue [30]. Current research developments are
focused on designing biodegradable dressings and dermal
scaffolds incorporating nanoparticle delivery systems for the
controlled release of drugs, proteins, and antibodies to open
wounds in vivo.
The use of antibody based therapy for treatment of cuta-
neous diseases has been demonstrated previously with
Infliximab (trade name Remicade), a monoclonal antibody
against tumour necrosis factor alpha (TNF-𝛼) used to treat
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Figure 1:Nanoparticle technology for transcutaneous delivery of drug agents to intact orwounded skin leading to improvedwoundoutcomes.
(a) Transepithelial delivery of nanoparticles is limited by the poor penetration through the protective stratum corneum. Transappendageal
nanoparticle delivery through hair follicle offers potential for treatment of conditions where skin is intact. ((b)-(c)) Incorporation of drug
carrying nanoparticles into dressings and scaffolds allows controlled sustained release of biologically active agents into open wounds
intradermally hence resulting in improved healing and reduced scarring.
Table 1: The use of nanoparticle technology for delivery of drugs transcutaneously targeting the most common cutaneous pathologies.
Nanoparticle
type Drug Skin type Study
Delivery type and
penetration
Targeted cutaneous
disease pathology Literature studies
Solid lipid
nanoparticle
Glucocorticoids,
corticosteroids Human
In vitro
and in vivo
Transepidermal
delivery, no
penetration to the
dermis
Inflammatory skin
diseases,
dermatitis,
rheumatic disease
Sivaramakrishnan et al.,
2004 [24]; Jensen et al.,
2010 [25]; Zhang and
Smith, 2011 [26]; Schlupp et
al., 2011 [27]; Puglia et al.,
2006 [28]
Solid lipid
nanoparticle
Nonsteroidal
anti-inflammatory
drugs
Human In vitroand in vivo
Delivery via NP
enriched hydrogels
with sustained
continued drug
release to the dermis
Musculoskeletal
disorders
Jain et al., 2005 [29];
Bhaskar et al., 2009 [30]
Solid lipid
nanoparticle
Antiandrogens,
retinoids Human
In vitro
and in vivo
Transappendageal NP
delivery to hair
follicle and upper
papillary dermis
Skin acne
Munster et al., 2005 [31];
Sˇtecova´ et al., 2007 [32];
Castro et al., 2007 [33]
Solid lipid
nanoparticle Antifungal agents Human
Ex vivo
and in vivo
Topical gel delivery of
NP with penetration
to upper papillary
dermis
Skin mycoses Bhalekar et al., 2009 [34];Sanna et al., 2007 [35]
Solid lipid
nanoparticle
Retinoids,
furocoumarins
Mouse
and
human
In vivo Topical gel delivery tothe epidermis Psoriasis
Fang et al., 2008 [19];
Agrawal et al., 2010 [15];
Lin et al., 2010 [36]
Solid lipid
nanoparticle Tacrolimus Porcine
In vitro
and in vivo
Topical gel delivery
with dermal
penetration
Atopic dermatitis Pople and Singh, 2010 [37]
Nanostructured
lipid carriers
Antihypersensitive
drugs and
anaesthetics
Mouse
and
human
In vitro
and in vivo
Topical gel delivery to
the epidermis
Hair loss treatment
and pain relief after
surgery
Silva et al., 2009 [38];
Puglia et al., 2011 [39]
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autoimmune diseases including psoriasis [42]. While the use
of nanotechnology for the delivery of antibodies to wounds
using scaffolds in vivo is yet to be demonstrated, nanotech-
nology has been used in numerous studies exploring the
delivery of antibodies to tissue in vivo using experimental
animals models of breast [43] and colon [44] cancer and
osteoarthritis [45]. In addition, recent studies using nano-
medicine to deliver therapeutic antibody in the experimental
model of myeloma have shown that a combination therapy of
anti-ABCG2mAb and paclitaxel loaded iron oxide magnetic
nanoparticles has a significant effect on reduction of tumour
growth in vivo compared to paclitaxel, iron oxide nanoparti-
cles, or anti-ABCG2mAb treatment alone hence demonstrat-
ing the synergetic effect of combinational therapy in nano-
medicine [46].
3. Nanotechnology and Cutaneous Infection
With the evolution of new antibiotic resistant strains of bacte-
ria, wound infection rates are increasing andmore aggressive
wound management is required [47]. Infection in wounds,
particularly in chronic, nonhealing, and burn wounds is a
leading cause of morbidity andmortality. Good clinical prac-
tice involves using systemic and topical antimicrobial pro-
phylaxis to reduce themicrobial load in thewound as infected
wounds have slower healing outcomes [48]. One of the cur-
rent strategies for combating these infections is the use of
noblemetals as antimicrobial agents.The leader in this field is
silver which has been used for its antimicrobial properties for
centuries [49]. Silver based compounds are highly toxic to
microorganisms showing strong effects on 16 bacterial species
including E. coli [50]. It is now regularly used as an antimi-
crobial prophylaxis treatment for burns, open wounds, and
chronic ulcers [51]. Silver in its metallic state is inert but upon
reaction with wound fluid andmoisture from skin it becomes
ionized and highly reactive [52]. It binds to tissue proteins,
blocks bacterial respiratory enzyme pathways, and causes
structural changes of the bacterial cell wall and nuclearmem-
brane hence leading to cell death [53–55].Nanosilver particles
are commonly used in many forms in the treatment of
wounds. Silver nitrate is a common antimicrobial used in the
treatment of chronic wounds; however, it can be irritating to
tissues and also causes semipermanent staining of tissues and
surfaces to which it contacts [56]. Silver sulfadiazine (SSD)
was introduced as a topical chronic and burn wound treat-
ment in the 1960s to overcome the shortcomings of silver
nitrate, but both are limited due to a short therapeutic win-
dow, silver inactivation bywoundfluid, and the formation of a
pseudoeschar [57]. Using new nanotechnology to create sus-
tained release of silver nanoparticles increases the therapeutic
window of each dressing. One of these nanosilver impreg-
nated dressings is Acticoat, which is an absorbent rayon-pol-
yester core sandwiched between two layers of silver-coated,
high-density polyethylene [57].The outer layer works to pro-
vide antimicrobial effects whilst the inner core maintains a
moist wound environment [58].
The use of silver dressings for the management of burns
and chronic wounds is now a globally accepted therapy, with
Acticoat leading the way for the worldwide management of
burns. The efficacy of Acticoat and silver sulfadiazine against
several strains of bacteria including MRSA showed 100%
clearance for both dressings by the end of the study. Acticoat;
however, showed a significantly higher clearance at days 6 and
12 [59]. The effectiveness of Acticoat to chlorhexidine acetate
and fusidic acid also showed no significant difference in
effectiveness against resistant bacteria, however Acticoat was
suggested as the best choice of treatment due to its sustained
release properties [60].
New advances in polymer technology are allowing many
dressings, previously used only to provide an optimal healing
environment, to be impregnated with silver nanoparticles to
add to their effectiveness. Bacterial cellulose hydrogels pro-
duced byAcetobacter xylinum have long been used to provide
an effective, moist healing environment but without any anti-
microbial activity, and the risk of infection was high. Impreg-
nation of these dressings with silver nanoparticles by immer-
sion in silver nitrate has significantly improved the efficiency
of these hydrogels [61]. Although the powerful antimicrobial
effects of silver compounds are well documented, there is evi-
dence to suggest that it may have a negative effect on wound
healing. Studies have shown that silver compounds can delay
wound healing by extending the inflammation phase [62].
They have also been shown to be highly toxic to keratinocytes
and fibroblasts [51]. A large oral intake of silver causes a con-
dition known as “argyria” which is characterised by silver
granule deposition into the skin leading to a permanent blue/
gray discoloration [63]. In patients affected by argyria, silver
granules can be found in all organs of the body and recent case
studies have suggested that argyria can be an effect of topical
delivery of silver in dressings such as Acticoat [64–66].
Treatment of burn wounds with Acticoat has caused raised
liver enzymes and argyria like symptoms in some patients
[67]. This has resulted in changes in clinical guidelines with
current recommendation of using these dressings for shorter
period of time and intermittently hence highlighting the need
for improved design of dressings with antibacterial activity
and functional wound promoting ability.
4. Dermatological Advances
Skin diseases are one of themost widespread complaints with
over 80% of the population suffering from a condition at
some point in their lives [68]. Although some are merely a
cosmetic issue, others are more serious, causing pain, severe
scarring, andmorbidity. Due to the lower risk of systemic side
effects and the ability to apply directly to the problem area,
topical treatments of skin disease are preferred [69]. Current
treatments are effective but many carry severe side effects so
there remains a need for more advanced technology and
nanotechnology is fast becoming a leader in this field.
Acne is a common skin disease with a high rate of pre-
valence in adolescents. It is characterised by increased sebum
production, ductal cornification, bacterial colonization of the
pilosebaceous ducts, and inflammation [70]. Acne can be
severe and often results in permanent scarring and disfigure-
ment. The most common treatment for mild to moderate
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acne is the use of oral retinoids.This is a highly effective treat-
ment option; however, it does cause a high incidence of side
effects including sensitivity to sunlight, irritation, and ery-
thema, resulting in low patient compliance. The encapsula-
tion of retinoids into solid lipid nanoparticles (SLN) for use
as a topical treatment has increased drug penetration, im-
proved efficacy, and reduced side effects [61]. The current
treatment formoderate to severe and prolonged acne involves
the use of oral antiandrogens, such as combined cyproterone
acetate/ethinyl estradiol to reduce sebum secretion and acne
lesions. However, these drugs have severe side effects includ-
ing feminisation of themale fetus in females, and use inmales
can lead to loss of libido, gynecomastia, and loss of bonemin-
eral density [71]. To avoid these systemic effects and to reduce
the side effects, research has led to the discovery of liposomes
and solid lipid nanoparticles (SLN) loaded with steroidal and
antisteroidal antiandrogens (drospirenone and cyproterone).
The use of these nanoparticles increases drug penetration
fourfold, increases the efficacy, and reduces the side effects
when compared to oral drug options [72].
Psoriasis is a chronic skin inflammatory disorder that
drastically impairs quality of life.Themost common forms of
treatment currently are topical; however, with limited infor-
mation on their mechanism of action and evidence of accu-
mulation in adipose tissue [73], their use in clinical practice
is limited.The advent of new lipid nanoparticle drug delivery
systems has the possibility to improve the efficacy and safety
of these topical compounds [68]. One of the most common
treatments for mild psoriasis is topical application of Tret-
inoin, a metabolite of vitamin A. Although effective against
psoriasis, this treatment has severe side effects including ery-
thema, burning, and increased sensitivity to light [74]. To
overcome this, tretinoin has been incorporated into SLN,
which not only improved permeation and efficacy, but also
significantly decreased the incidence of erythema and sun
sensitivity [75]. More severe psoriasis can be treated with
Acitretin, an oral retinoid which although effective also has
severe side effects including alopecia, skin peeling, and chei-
litis [76]. Once incorporated into SLN, a higher deposit of
Acitretin at the plaque site as well as significantly improved
therapeutic response and a significant reduction in local side
effects has been observed [68]. In addition, a recent clinical
trial using Acitretin delivered via nanostructured lipid car-
riers demonstrated significantly improved clinical effects on
patients with psoriasis [15].
Fungal skin infections are one of themost widespread dis-
eases known to man with topical therapy the preferred
method of treatment due to high patient compliance, self-
administration, and low risk of systemic side effects [77]. Cur-
rent treatments although effective are relatively slow-acting
and so SLN are being investigated to improve efficacy. There
are several antifungal agents used for the treatment of human
mycoses which are currently undergoing investigation of
their efficacywhen incorporatedwith SLN includingmicona-
zole nitrate [78], clotrimazole [79], ketoconazole [80] and
econazole nitrate [35].
The results from these studies show that when the drugs
were incorporated into an SLN there was an increased rate
and level of skin penetration, higher efficacy, and less local
side effects. Selected examples of current research develop-
ments using nanoparticle technologies for the delivery of
drugs transcutaneously are presented in Table 1.
5. Development of Nanoengineered
Dermal Scaffolds for Improved Healing
and Reduced Scar Formation
The impact of scarring, both mentally and physically, im-
mensely affects a large number of patients and their families
which is often witnessed following burn injuries to large area
of the body. Currently, there is a lack of effective scaffold treat-
ments available for treatments of nonhealingwounds, with no
approved scaffold treatments that have been shown to reduce
scar formation during wound healing [81]. In the case of
major burns where injury damages the deep dermis and no
sources of cells for regeneration remain, there is a require-
ment to provide a dermal scaffold to fill in the deep wound
[82]. Current commercial products address some of the
immediate demands of wound care including protective cov-
ering or lost epidermal/dermal material; however, these are
far from optimal, often addressing only one aspect of injury.
Current scaffolds are made from xenobiotic animal derived
materials and have short shelf life, nontrivial application, and
high production costs [81, 83]. While there is a wide range
of biologic and polymeric materials currently available on
the market their efficacy is far from optimal highlighting the
need for the development of next generation scaffolds which
actively promote healing, and decrease scarring [81].
In the past five years there has been a significant increase
in the in vivo use of both synthetic and natural biodegradable
polymers and materials. Through the process of electrospin-
ning, nanofibres can be processed to create nanofibrous scaf-
folds with open and interconnected porosity. Poly-(𝜀-capro-
lactone) (PCL)/gelatin nanofibrous scaffolds have been
shown to have improved biocompatibility and improved
mechanical, physical, and chemical properties, allowing im-
proved wound healing and dermal reconstitution [82]. In
addition, nanofibrous scaffolds facilitate the impregnation of
allogeneic keratinocytes, xenogenic fibroblasts, and antibac-
terial agents for improved wound healing and decreased
infection rates [14, 84, 85].
Theuse of nanotechnology nowprovides a novel platform
for the design of functionalized, treatment specific scaffolds
which, in addition to providing a matrix for cell proliferation
and differentiation, can also carry drug containing nanopar-
ticles. Enzymes, present in the wound environment, can dy-
namically degrade the nanoparticles allowing the optimal
dose of biologically active drug to be released intradermally
over a sustained period. This may promote rapid cellular
migration under the dressing and onto and into the scaffold,
resulting in regenerative wound healing and reduced scar
formation (Figure 1(c)). While the use of nanotechnology for
drug delivery using dermal scaffold is still being developed,
further research in nanomedicine offers hope for improved
treatment options in cutaneous medicine.
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6. Conclusion
Nanotechnology presents an exciting new opportunity for the
development of a safer and more efficient drug strategy for
many dermatological conditions.While there are a number of
examples of nanoparticle cosmetic products currently on the
market, commercially available nanoparticle products for
drug delivery through healthy orwounded skin are still under
development [21, 22]. With the advent of new nano-based
drug delivery systems which can be specifically formulated to
target specific cells and fit a desired release profile and pen-
etration depth, the face of medical research is truly evolving.
There is, however, much research still to be performed to
understand the chronic effects and to continue to improve
patient tolerance and drug efficacy in vivo.
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Stem cells (SC) are among the most promising cell sources for tissue engineering due to their ability to self-renew and differentiate,
properties that underpin their clinical application in tissue regeneration. As such, control of SC fate is one of the most crucial
issues that needs to be fully understood to realise their tremendous potential in regenerative biology. The use of functionalized
nanostructured materials (NM) to control the microscale regulation of SC has offered a number of new features and opportunities
for regulating SC. However, fabricating andmodifying suchNM to induce specific SC response still represent a significant scientific
and technological challenge. Due to their versatility, plasmas are particularly attractive for the manufacturing and modification of
tailored nanostructured surfaces for stemcell control. In this review,we briefly describe the biological role of SC and themechanisms
by which they are controlled and then highlight the benefits of using a range of nanomaterials to control the fate of SC. We then
discuss how plasma nanoscience research can help produce/functionalise these NMs for more effective and specific interaction
with SCs.The review concludes with a perspective on the advantages and challenges of research at the intersection between plasma
physics, materials science, nanoscience, and SC biology.
1. Introduction
Controlling the fate of stem cells (SC) is one of the most
crucial issues in regenerative biology and medicine. This
versatile type of cell, with promising applications due to their
ability to renew their own population and become other types
of cells (Figure 1(c)), constitutes the fundamental element
of cell therapy. The approach depends upon isolation of SC
cells from a tissue as is the case for adult or somatic SC or
undifferentiated SC from a culture of pluripotent SC then
culture in vitro to generate differentiated mature functional
cells for use in regeneration of aged, injured, and diseased
tissues. However, cell therapy presents challenges that goes
beyond the usual tissue engineering—which combine high-
performance materials and signaling factors with living cells
to restore tissue functions. It involves cells which, when stim-
ulated by specific growth/differentiation factors (e.g., soluble
proteins, insoluble attached proteins, and extracellularmatrix
(ECM) molecules), give rise to a range of heterogeneous
cell types (Figure 1(c)). The success of this approach relies
on knowing which of these factors affects SC fate and how
this interaction occurs. This is a very difficult task and also
depends on how and when the factors are delivered, that is,
affected by the growth factor presentation (conformation)
and time dependent. Studies also show that it is not only the
chemical factors but also the physical interaction between
the biomaterials and SC that influence the behavior of cells
in culture [1, 2] since it directs the forces exerted by cells
on the ECM and are believed to trigger gene activation and
suppression [3–6].
This suggests the important role of controlling the envi-
ronmental material properties (density, stiffness, and archi-
tecture) as well as regarding how exactly the growth/
differentiation factors are presented and delivered (Figure 2).
For this task, biomaterials are being developed to contain
and deliver combinations of factors in a controllable way.
Gels that mimic the ECM, functionalized polymers, inert
metals/alloys, calcium phosphates, nanoparticles, nanofea-
tured surfaces, and several others are just some examples
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of functional materials that are currently used to study
and control SC fate [1, 7–13]. Although there has been
a considerable advance in the area of gels and scaffolds,
here we focus on nanomaterials (nanoparticles, nanofibers,
and nanostructured surfaces) that can influence selection,
proliferation, and differentiation of SC.
To achieve a greater degree of control, reproducibility,
scalability, and synthetic materials have gained a significant
advantage over naturally occurring materials [1]. In order to
precisely design nanomaterials’ architecture, its mechanical
properties and binding sites for the proper presentation of
ligands, techniques to produce and functionalize these mate-
rials are required. As an attractive alternative to widely used
lithography and chemistry processes, we discuss some of the
new advances in self-assembled plasma-made nanomaterials
[14]. Furthermore, the plasma environment can be used to
produce building blocks for nanoscale assembly and reactive
free radicals for surface modification and in addition can be
used for controlled synthesis and processing of self-organized
nanomaterials [15].
This reviewwill briefly describe in Section 2 the biological
role of SC and some of the knownmechanisms by which they
can be controlled. Section 3 will then highlight the benefits
of using a range of nanomaterials to control the fate of SCs.
Within Section 4, we discuss howplasma nanoscience has the
potential to produce or functionalize these NMs to improve
their interaction with SCs. The review will conclude with
a perspective on the advantages and challenges of research
at the intersection between cell biology, plasma science,
materials science, nanoscience, and engineering.
2. The Biological Role of Stem Cells
2.1. Basic Information. Stem cells (SC) are present in mam-
mals from the beginning of their life until their death. They
form the first cell aggregates, during embryogenesis, and are
able to self-renew their own population and, in order to form
an adult animal, can differentiate into virtually any cell type;
moreover, within the adult mammal tissue, specific adult SC
are also responsible for regenerating mature injured tissues
[1, 7–9]. Due to these two defining properties, namely, self-
renewability and specific differentiation, SC play a pivotal
role in cell therapy for treating/restoring damaged tissues by
direct replacement of diseased cells [1, 8, 9, 17].
Stem cells can be divided into two broad categories:
pluripotent (embryonic SC (ESC) or induced SC (iPSC))
and adult SC. Each of these different SC types is derived
or obtained in different ways [7, 9] (Figures 1(a) and 1(b)).
For example, ESC are derived from cells that are removed
from the inner cell mass of the blastocyst (or embryoblast);
iPSC are a reprogrammed adult cell (from any tissue cell
back to pluripotent stem cells) [21, 22]; and the adult SC are
found in adult tissues within specific anatomical locations
and niches. Adult SCs are found in many tissues and organs
such as the bone marrow, gastrointestinal tract, skin, and
within the central nervous system where their physiological
role is to provide an ongoing supply of mature cells or to
facilitate tissue repair [1, 7–9, 23] (Figure 1(b)). Although
adult SCs’ ability to proliferate and differentiate decreases
with the age of the donor and also with time spent in cell
culture [24, 25], the use of this approach in cell therapy
still remains of great importance as for some tissues it is
relatively easy to isolate and manipulate their resident SCs.
For example, hematopoietic stem cells are readily isolated
from bone marrow or blood and are routinely used for
transplantation [26].
Since 1981, whenmouse ESC (mESC)were first isolated by
Evans and Kaufman [27], the use of these cells in regenerative
medicine has been the subject of great interest [8], especially
in tissue engineering because of the major limitations of
artificial implants [9]. The use of ESC as a cellular model also
helps us to understand early developmental events at the
molecular and cellular level and potentially models of disease
progression and epigenetic regulation of cellular fate [28, 29].
This review will focus on, but is not limited to, SC fate control
by use of synthetic nanomaterials, combined or not with the
defined growth factors (rather than isolating SC or growth
factors themselves). For a discussion of the isolation of SC
from different adult tissues [30–32] and the generation of
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pluripotent cells from multipotent ones through reprogram-
ming, we refer the interested reader to a number of other
reviews [21, 22, 33, 34].
2.2. Controlling the Fate of Stem Cells. Growth factors, which
for the remainder of this paper will include hormones, pro-
teins, and cytokines, have been shown in numerous works
to improve the control over either adult or pluripotent SC.
Theappropriate use of biochemical signals directly added into
the culture medium can maintain or differentiate SC [35–
38]. Retinoic acid (RA), activin-A, TGF-beta, and insulin-
like growth factor 1 (IGF-1) are seen as being responsible
for promoting differentiation of murine ESC (mESC) into
lung epithelial progenitor cells and pancreatic endocrine cells
(alpha, beta, gamma, and delta) [39, 40]. In addition to
the great importance to choose which growth factor to use
for SC control, the cellular niche—the specific tissue site
responsible for regulation of SC fate in the body [9, 41, 42]
(Figure 1(b))—helps us to understand the role of the growth
factor availability and presentation time as well as the need
for a material support for insoluble transmembrane receptor
ligands, as well as its specific presentation to the cells. The
material selection can be based on the desire to maintain an
undifferentiated SC in a culture for a long time or to directly
control cell differentiation [1, 9].
For proper application in tissue engineering or adult
SC-based therapy, it is desirable to choose/manufacture
a biomaterial that closely mimics the “robust spatial and
temporal microenvironment of biophysical and biochemical
signals” (such as chemokines, cytokines, and growth factors,
membrane ligands, and ECMmolecules) [7, 26]. Ideally, this
microenvironment is an artificial version of the stem cell
niche, promoting SC self-renewal or specific differentiation
without loss of the key SC attributes [7, 41–45]. Therefore, to
control SC behavior and achieve homogeneous and efficient
cell differentiation, it is crucial to understand the effects of
the identity, presentation, and density of the differentiation
factors (e.g., ligands and signals), as well as the material
micro- and nanoarchitecture and mechanical properties,
which will be described in the next section [3, 9, 11].
The hydrogel is a well-established culture media that has
been used for decades to mimic the microenvironment of
stem cells in the human body [2, 8, 46–48]. This is due to its
high water content, elasticity, biocompatibility, and the ability
of nutrients and growth factors to diffuse through it [46–49].
Hydrogels, either natural or synthetic, closely resemble the
consistency of the native body tissue by adjusting the hydro-
gels’ crosslinks [8, 50]. Thus they provide efficient adhesion
sites for cells and biological signals and also guidance for cell
orientation and proliferation [3].
These materials can be used instead of feeder-cell layers
for supporting hESC culture and maintenance and were
first reported by Xu et al. [51–53] using natural hydrogels,
with proven ability to differentiate hESCs [54]. Collagen is
an example of a natural hydrogel which is capable of cell
encapsulation [55], support of ESC-derived endothelial cells,
[56] and, in high concentrations, inhibit the embryonic body
(EB) apoptosis and enhance its differentiation [54].Moreover,
collagen in association with fibronectin or laminin was
able to differentiate SC into endothelial and cardiomyocyte
cells, respectively [54]. Furthermore, denaturated collagen
becomes porous gelatin, and is also biocompatible and
extensively used [57, 58]. Other important natural materials
hyaluronic acid and alginate, are both able to encapsulate SC
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and keep them undifferentiated [59] and also differentiate SC
into cardiac [60] and hepatic lineage [61] (Figure 1(c)). Like-
wise, the commercial Matrigel, comprising multiple natural
ECMcomponents, has the ability to direct SC into endothelial
cells [62] and enhanced neovascular formation [63].
2.3. Present-Day Challenges. The use of natural materials,
however, presents some limitations, like batch-to-batch vari-
ations, weak mechanical properties, and manufacturing dif-
ficulties [64]. Synthetic hydrogels, however, are not usually
subject to these limitations and instead offer relatively easy
control over biochemical properties and represent risk-free
media [7–9, 65, 66]. The most commonly used synthetic
biomaterials include polyethylene glycol (PEG), polyvinyl
alcohol (PVA), polylactic acid (PLA), and poly(L)lactic acid
(PLLA), and polylactic-co-glycolic acid (PLGA), which are
microfabricated to be active, degradable, porous, and/or stiff
enough to induce SC differentiation both in vitro and in
vivo [1, 8, 9]. The first biomaterial listed, PEG, is a polymer
composed of nanofibers and is capable of cell encapsulation
and differentiation in numerous tissues (e.g., bone tissue [67,
68]). Also being able tomaintain a neural SC culture, PLA can
be produced with aligned fibers and induce aligned neural
cells [20]. The PLGA usually helps differentiating neural SC
into neural cells [69]. Moreover, when mixed with PLLA,
it also promotes differentiation of ESCs into numerous cell
lineages [70–72].
All these results highlight some important factors about
the medium architecture and applied forces, present in the
natural cell niche, that mechanically control SC fate [2, 73].
Some limitations for the use of hydrogels in the mechanical
control of SC fate, however, include an inability to be syn-
thesised at a stiffness that mimics higher mechanical strength
tissues such as bone, cartilage, and ligaments [8]. Moreover,
although other studies show that hydrogels provide a 3D
structure to support cells, this is not always in the right spatial
dimension (e.g., nanoscale), as that conferred by nanofibrillar
proteins secreted by cells (e.g., collagen) present in cellular
niche [9, 69, 74].
Although the successful application of synthetic hydro-
gels modified with numerous growth factors (GF) to mimic
the SC niche and control the SC fate has been demonstrated,
the strict control of its chemical functionalization, degrada-
tion rates, ligandpresentation, andmechanical properties still
remain challenging.The strategies adopted nowadays involve
the use of nanomaterials [75, 76]. For example, some growth
factors can be adsorbed on nanoparticle surfaces and then
controllably released in the culture medium. Nanomaterials
can also be added to hydrogels in order to control stiffness.
Micro- and nanoscale patterning is now capable of building
materials with specific topographies in order to control the
cell focal interaction in different scales and shapes as well
as providing spots for the attachment of localized ligands
and preventing diffusion [77]. New technologies also provide
better control over the surface chemistry of biomaterials. For
example, functionalization with chemical radicals allows the
attachment of biological factors or may lead to hydrophilic
properties depending on the specific applications.
3. Materials Science Approaches for
Stem Cell Control
3.1. Brief Overview and Critical Factors. Substantial research
efforts in micro- and nanoscale science and technology are
aimed at controlling material topography, surface biochem-
istry, and mechanical properties, in order to mimic and
understand the natural cellular environment. In this way,
many techniques (e.g., chemical vapor deposition, lithogra-
phy, and sputtering) have achieved high fabrication resolu-
tions which made it possible to study the effects of mate-
rial properties on cell-material interactions [78–81]. These
techniques may be used to fabricate nanomaterials, such
as nanoparticles, nanodots, nanostructured surfaces, and
nanoarchitectured scaffolds composed of nanofibers which
can directly affect the cells’ focal attachment and apply forces
that change the cell shape and alignment—important factors
in controlled cell differentiation [2, 73]. Furthermore, some
of these techniques are used to chemically modify the surface
with reactive radicals [82, 83], control degradation rates,
hydrophilicity [84], and ensure proper presentation of the
growth factors, either soluble or attached, thereby directly
influencing SC behavior [7–9, 85].
As extensively reported, the ECM plays a significant role
in controlling cellular behavior by different factors (forces,
topography, growth factors, and ligands) at different levels—
frommacro- to nanoscales [1, 7, 9–11, 86]. Here we emphasize
that materials science approaches hold a major potential
for the recreation of diverse cellular environments, which
can control these factors in order to better mimic and
understand the natural physicochemical ECM features, any
relevant spatial, and temporal scales [7, 8, 10]. The most
advanced approach is to reduce the complex in vivo system
to a controllable simplified systemwhere the desirable factors
(e.g., density, porosity, surface energy, topography, chemical
radicals, surface ligands, and soluble factors) are combined
with the custom designed nanostructures, surfaces, or scaf-
folds [15]. This approach is very promising to increase our
understanding of the most relevant factors for SC control [7].
In the following, we will discuss engineered biomaterials
with nanofeatures, either functionalized or functionalized
with the specific growth factors.This approach helps tomain-
tain SCs “stemness,” which is essential for stem cell therapy
or, alternatively, to differentiate the SCs, which is crucial for
tissue engineering. Nanomaterials will be discussed in order
of increasing dimensionality (from 0D to 3D).
3.2. Zero- and One-Dimensional Nanomaterials. Having at
least two dimensions in the nanoscale, 0D and 1D materials
have huge surface/volume ratios which enable properties
that are different compared to film/bulk materials. These
properties are mainly guided by the materials’ composition,
size, and shape, crystallinity, and how they emerge as a
surface property [76, 87–89]. Depending on the media, some
characteristics, such as the surface charge, hydrophobicity,
particle aggregation, and dissolution, are of great importance
for biological applications. Moreover, these properties regu-
late the interaction of nanomaterials with proteins dispersed
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in the media [75, 76, 90, 91] and with cells (e.g., binding
receptors, blocking pores, and membrane rupture) [92–94].
Nanoparticles, nanodots, nanowires, carbon nanotubes
(CNT), graphene flakes, and many other zero- and one-
dimensioned materials have found numerous applications
in biomedicine. For example, quantum dots and CNTs have
been used for in vivo imaging [95, 96], and nanofibers and
nanoparticles have been used for gene/drug delivery [97, 98].
Moreover, magnetic nanoparticles were also used to induce
hyperthermal tumor reduction [89]; Ag andAunanoparticles
[99] have bactericidal properties (Ag, Au [99]) whereas TiO
2
,
ZnO, and organic [100] nanoparticles have been shown to
have high UV absorbance. Recently, other versatile materials
have been designed for high-precision sensing [101, 102].
Despite many biomedical-related applications of this
class of nanomaterials, only a few applications on direct
SC differentiation and maintenance have been reported in
the literature. Meanwhile, these small building blocks can
dramatically change the media properties, like hydrogels’
stiffness and polymers’ conductivity. Recently, it was reported
that a hybrid hydrogel-CNTs reinforced scaffold induced a
rapid hMSC proliferation [103]. Their effect was due to the
suitable mechanical properties of the scaffold. These prop-
erties could be achieved by controlling the CNT quantity,
for the formation of specific tissues (e.g., cardiac [104]). The
CNTwere also incorporated in polymer matrices to fabricate
electrically conductive scaffolds, aiming at differentiation and
interaction with neural and cardiac cells via electric signals
[103, 105, 106].
It is well known that nanomaterials in a biological fluid
bind with proteins differently from plain substrates [75,
76, 90], forming an organized and complex (e.g., time-
dependent) structure called the “protein corona.” Some
common proteins, like albumin, immunoglobulin, and fib-
rinogen, are found to bind strongly to CNTs, iron oxide,
and polymeric particles. The properties listed above (e.g.,
surface composition, hydrophobicity, and charge) influence
the protein adsorption and mediate cell-NP interaction (e.g.,
binding, uptake).Therefore, the understanding of the forma-
tion of the protein corona is seen as one of the important
objectives in bio-nanoscience [76, 90–93].
Ranging from microseconds to days [91], the duration of
protein-nanoparticle interaction can be used for controllable
protein delivery through to SC control. It can be directly
introduced into nondegradable (or with difficult degradation
rate control) scaffolds [10, 103] or in vivo [3], as was done
before with other biochemical factors loaded into micro-
spheres [107, 108]. Nanoparticle-protein interaction also rep-
resents a promising application of protein presentation in
diversified conformations [1, 7, 76, 86, 109], which is an
important issue in the SC fate selection.
Using nanomaterials, it is also possible to produce unique
thin films. For example, TiO
2
nanoparticles increase MSC
attachment by altering surface roughness [110]. In another
study, the use of TiN nanoparticles also promotes hMSCs
attachment. More than merely cell attachment, applications
of these nanomaterial films can be extended, targeting
protein binding and presentation as well as controllable
hydrophobicity.
3.3. Two-Dimensional Nanomaterials. Biomaterial designed
surfaces are the simplest, more controllable- and well-
explored model for probing factors for controlling the cell
fate (different ligand presentation strategy can be found in
Figure 2(b)). The development of building and patterning
techniques has made it easier to improve the understanding
of cell biology over the smallest scale of the interaction
between the cells and their natural niches. Furthermore,
this development made it possible to mimic such niches
by appropriate material patterns—from hydrogels using soft
embossing technique to hard ceramics by electron beam
lithography (EBL). The EBL technique—just one example
among many useful techniques—can provide virtually any
topographical nanoarchitecture desired (e.g., cones, tubes,
pitches, and domes) in order to mimic the cell niche.
Cells have the ability to sense and adapt to these envi-
ronmental nanofeatures, using their filopodia [17, 111–113].
Although this has been known, at least since 1952 [114], the
improvement of fabrication techniques over the last decade
has allowed the study of interactions at markedly smaller
scales. Topography combined with material composition and
hardness was shown to exert spatially resolved forces over
the cells’ cytoskeleton [2, 16–18, 115–117], thereby modifying
the cell shape and possibly controlling their fate. Chen et al.
showed that smaller ECM islands change cell morphology
(leading to a more rounded shape), profoundly altering the
actin cytoskeleton and the organization of focal contacts
[115, 116] (Figures 3(a) and 3(b)).
More examples of the options for nanoscale control over
different cell types can be found elsewhere related to the
dimensions and type of the nanostructure (e.g., grooves, pits,
and pores) [16, 18, 112, 113, 118]. For example, an increase in
the apoptotic response of endothelial cells was related to a
decrease in the diameter of the cell’s culture size [16]. Cell fate
is therefore controlled by complex intracellular mechanisms
affected not only by the size and type of nanostructure
but also by symmetry. Highly ordered square nanoarrays
produced by EBL induced low fibroblasts adhesion (Figure 4)
[113]. Moreover, normalised array data show broad downreg-
ulation of genes in fibroblasts cultured on hexagonal pattern,
indicating that mechanical forces lead to changes in gene
regulation [117]. However, the same hexagonal symmetry of
gold nanodots bindingwith integrin receptors has shown that
separation between dots is an important factor to control cell
adhesion and proliferation [119].
These and many other mechanisms can be used to direct
SC growth and differentiation [120].The samemechanisms to
control the cell shape, alignment, and adhesion using mimic-
designed biomaterials were studied in order to control stem
cell proliferation and differentiation [17]. A similar effect of
low adhesion induced by highly ordered nanotopographies
was reported by Dalby et al., where they demonstrated
significantly increased hMSC osteogenic differentiation [18].
Mesenchymal stem cells also show clear alignment and
elongationwhen cultured on a surface with nanogrooves [121,
122]. Yim et al. also reported that the upregulation of neuronal
markers (SOX2, MAP2, neurofilament light peptide, and
tyrosine hydroxylase) was observed and enhanced if the
surface was coated with retinoic acid [121].
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Figure 3: (a) Substrate controlling the cell shape and fate. (b) The signal islands strategy being applied to control stem cells. (c) Different
nanostructured surface exerts different forces over the cytoskeleton of the cell. (d) Example of nanostructured organization (hexagonal,
square, dislocated square, and disordered). ((a) and (b) reprinted from [16] with permission from AAAS. (c) reprinted from [17], Copyright
(2009), with permission fromElsevier. (d) reprinted by permission fromMacmillan Publishers Ltd.: NatureMaterials [18], Copyright (2007).)
The above studies suggest that nanotopological cues
may be used to direct hMSC and hESC into specific cell
lineages. Acting as a component of the ECM, they change
the cell shape—that is, modify the cytoskeleton structure—by
controlling the number and density of focal adhesion sites in
response to nanostructures shape, size, and symmetry (Fig-
ures 3(c) and 3(d)). A direct consequence is the change in the
cell’s cytoskeleton’s structure which in turn activates specific
genes via mechanotransduction mechanisms (Figure 3(c)),
which are presently not fully understood. Moreover, nanoto-
pography can be used as a spatially well-defined platform
to exert proper presentation of immobilized biochemical
factors (e.g., proteins, ligands, and radical groups) in order to
control cell adhesion,migration, and differentiation [66, 123].
Furthermore, surface nanoarchitecturing can dramatically
change the surface properties, for example, hydrophilicity
[18] and biocompatibility [101].
Graphene is another 2D material being actively studied
for SC support. Although it is a relatively new material, its
surface properties were shown to promote growth and pro-
liferation of hMSC on a range of graphene-coated substrates
[124] and to enhance the differentiation of human neural
stem cells (hNSC) [125]. Moreover, graphene and graphene
oxide were shown to stimulate hMSC differentiation toward
the osteogenic lineage [126–128]. These materials were also
studied as a platform for induced pluripotent SC and induced
differentiation of these cells into an endodermal type [129].
3.4.Three-Dimensional Nanomaterials. Thenatural niche for
tissue-specific adult SCs is not a plane surface. In contrast, it
is three-dimensional and presents biological cues at different
scales and directions (Figure 1(b)) [1, 7–9, 130]. Moreover,
cells are not static and can “feel” the presence of tension and
electrical signals in media. A 3D fibrous scaffold is a viable
model to use as a mimic of body tissue when studying the
proliferation and differentiation of SCs [131–133]. Whilst 2D
materials represent a simple model for isolating the control
factors for SCs in fundamental research, 3Dmaterials possess
a more complex architecture which can be tailored more
precisely for real tissue engineering.The combination of these
scaffolds and adult cells (e.g., fibroblasts and osteoblasts) for
the regeneration of connective tissues is well documented
[9, 134–138].
Commonly made of biopolymers, nanofibrous scaffolds
(NFS) are used to support SC growth (attachment, prolif-
eration, and organization) and differentiation [8, 10, 11, 70].
Recent studies reported that NFS can promote the differenti-
ation of hMSCs even without intentional addition of growth
factors [139]. However, similar to other nanoarchitectured
surfaces, nanofibers can also be designed for molecule/ligand
presentation and delivery [140–142]. In addition to surface
composition andmechanical properties, diffusion of GFs and
migration of cells should be taken into account.
Nevertheless, the results previously discussed for 2D
materials, such as cell alignment to substrate and controlling
cell size and shape, also hold for 3D materials. For example,
using the electrospinning technique, Li et al. produced
and used polymer NFS to induce differentiation of hMSC
into the chondrocyte lineage in order to substitute for the
micromass cell pellet culture [143]. The same group reported
the differentiation of hMSCs from a single patient into
adipogenic, chondrogenic, and osteogenic lineages utilizing
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Figure 4: (a) Self-assembled peptide, micro- and SEM view of the produced scaffold. (b) Matrix elasticity controlling the stem cell fate.
(c) Cells growing on nano- and microfibers scaffolds with visible evidences of cell alignment with fibers produced via electrospinning. ((a)
reprinted from [19] with permission from AAAS., (b) reprinted from [2], Copyright (2006), with permission from Elsevier., (c) reprinted
from [20], Copyright (2005), with permission from Elsevier).
the same NF matrix [144]. The same technique was also used
to produce aligned nano- and micro-FS [20]. Neural SCs
cultured on that media grew such that they were aligned
with the fibers, independently of their diameter (Figure 4(c)).
However, the differentiation rates were higher (as evidenced
by a strong protein expression) on the nanofibrous rather
than on the microfibrous scaffolds [20]. Importantly, not
only differentiation but SC proliferation was reported using
synthetic polyamide NF matrix [133].
A notable advantage of these materials is the reasonably
high level of control over elasticity, an important character-
istic due to the strong influence over the SC fate [2, 145].
This property is hard to control when using 2D materials
and can be set closer to the elasticity of biological tissues
using nanofibers [7]. Moreover, introduction of carbon nan-
otubes/fibers into polymeric matrices can lead to an increase
in mechanical properties, electrical conductivity, and reac-
tivity of the biomaterials [146, 147]. Recently, Subramony
et al. [134] showed the time control ofmechanical stimulation
during MSC growth and its effects on cell differentiation.
Mechanical tension combined with the matrix alignment
led to the development of fibroblasts in vitro without any
significant chemical influence.
Instead of polymers, another two classes of materials
that are used for NF 3D scaffolds deserve specific attention,
namely, carbon nanotubes/fibers and self-assembled peptide
nanofibers (Figure 4(a)). Carbon nanomaterials have already
been discussed in this review. Nevertheless, nanofibers of
this abundant and nontoxic material have been effective in
differentiating neural stem cells as well as offering good
electrical conductivity, high reactivity [146], and increased
absorption of laminin [148]. On the other hand, some
peptide sequences known to direct SC differentiation can
self-assemble in order to form a high-density NF scaffold
[19]. Some useful characteristics of these peptide scaffolds
are the high water content and the diffusion of nutrients,
bioactive factors, and oxygen sufficient for the survival of
large numbers of cells for extended periods of time [19].
4. Potential Use of Plasmas for Materials for
Stem Cell Control
4.1. Plasma-Based Process Overview. Plasma-based synthesis
and processing of nanomaterials are an interdisciplinary
research field [14, 15, 149]. A wide range of applications
resulted from the control over the properties involved in
plasma-based systems such as source power, frequency, and
chemistry. A range of species such as ions, electrons, atoms,
and radicals are present in a plasma discharge. The principal
property of plasma processes is the capability to deliver these
species at a desired substrate with controllable energy, thus
enabling nanoscale self-assembly [150–155] and deterministic
fabrication of nanomaterials [14, 15, 152, 156–164]. Some
examples of plasma-produced nanomaterials are presented in
Figure 5. Interestingly, these carbon-based nanostructures—
vertically aligned graphene and carbon nanotubes—can only
be obtained via plasma-based processes [165].
The focus on direct medical applications of plasmas—
where the related substrate can be a living tissue—is also
increasing [166, 167]. For example, low-temperature plasmas
have been used for treating diseases in animal models [88,
168, 169]. Reactive species produced in low-temperature
plasma (e.g., free radicals as well as reactive oxygen and
nitrogen species (ROS/RNS) such as O, OH, H
2
O
2
, O
3
, NO,
and NO
2
) [169, 170]) have a fundamental role in chemical
reactions, as they can be used to regulate the level of ROS
and RNS in intracellular space in order to control cell fate
[88, 167]. The role of ROS and RNS in cell control is widely
studied; amongst other things they have been shown to
influence cell “stemness” [171] and proliferation [172, 173].
Recently, atmospheric-pressure plasma jets showed a
special selectivity, killing cancer cells without affecting nor-
mal cells [174]. These and similar (e.g., dielectric barrier
discharges) devices were also used under different doses to
inactivate pathogens and microorganisms such as bacteria,
fungi, and viruses [168, 169, 175]. This type of plasma
has found numerous applications in medicine and several
others such as sterilization of surgical instruments, skin,
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Figure 5: SEM of plasma-produced carbon nanostructures. (a) Vertical aligned graphene (VAG) on a TEM grid. (b) Detail of VAG. (c) Side
view of high-density vertical aligned carbon nanotubes (VACN). (d) Top view of low-density VACN tips. Original research results from the
Plasma Nanoscience Laboratories at CSIRO.
and wound disinfection/healing [88, 176–180]. Atmospheric
pressure plasmas have also been demonstrated to support
“plasma bullets” [181, 182]; such exotic structures are likely to
lead to a range of promising medical applications and should
be the subject of further investigation.
Control over SC fatemediated by plasmas is also possible;
for example [183], atmospheric-pressure room-temperature
plasmas can effectively induce in vitro differentiation of
neural stem cells (NSCs) predominantly into neuronal lin-
eage. After plasma treatment, the murine NSC exhibited
rapid proliferation and differentiation into neurons with high
efficiency.
There are, however, potential disadvantages associated
with the use of plasmas for direct medical application;
these are largely related to the presence of plasma-generated
energetic ROS/RNS and UV radiation [184]. Studies have
shown that, depending on the specific conditions (i.e., plasma
dose/irradiation and cell type), plasmas may affect cell prop-
erties (i.e., adhesion, membrane permeability, migration, and
apoptosis/necrosis) and possibly damage DNA and modify
proteins [184]. Further study and clinical trials are required
before practical use of plasmas as direct medical tools.
Plasmas may also be used to fabricate micro- and nanos-
tructures (see Figure 5) as well as appropriately functional-
ized surfaces, suitable for SC control. The aim of the rest of
this section is to track where plasma technologies have an
implication over materials production and modification for
stem cell control and highlight where it could have potential
uses.
4.2. Plasma-Based Nanofabrication. The existence of ener-
getic species in plasmas makes it suitable for dry etching
applications andmany other materials synthesis and process-
ing [152, 157, 159, 163, 185]. These techniques can produce
patterns in hard materials at micro- and nanoscales. These
patterns in turn can be used to control the alignment and
shape of SCs. The material removed from a target using
plasmas can also be used for functional thin film deposition,
with almost no restriction over the target composition or
substrate shape—which is an advantage for coating 3D
materials [14, 15, 149, 186]. Moreover, the properties of these
thin films can be precisely tailored, for example, to enable
degradation after use [159, 187]. Other considerations for
biological applications are the production time and cost [16],
which can be reduced in plasma processes [151, 153, 188].
The applications, namely, etching, deposition and, surface
modification, are the most common in literature, although
plasma-based processes are capable of producing a variety
of nanomaterials [151, 189], namely, nanoparticles [190, 191],
nanodots [155, 192], and various allotropes of carbon (e.g.,
nanodiamond [15], nanotubes [158, 189], nanocones [193],
nanowalls, and graphene [102, 160, 161, 194]). Plasma tech-
niques also provide the control over the properties of these
nanomaterials (e.g., size, shape, and surface reactivity) [99,
152, 157, 162, 163, 195]. As discussed above, these properties are
essential to bind proteins and cells, as well as for the delivery
of specific (e.g., differentiation) factors in order to control
the SC fate. Moreover, due to the unique ability to dissociate
molecules (e.g., hydrogen), the control over some properties
is not achievable by other techniques such as neutral gas-
based CVD or by wet chemistry routes [165].
The control over the nanostructural properties is related
to the plasma ability to generate and concentrate building
units (BU) of nanoscale matter [15, 99]. Moreover, these
BU can be directly delivered to a substrate and build a
wide range of complex architectures discussed previously to
mimic the SC natural niche and control cell fate. The plasma
environments have specific features and control self-assembly
of nanostructures into patterns and arrays (often termed
“mask-less”). Plasma processes have also been reported to
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lead to a sustainable energy saving and reduction of green-
house emissions. Interestingly, carbon nanotubes and other
one-dimensional nanostructures show pronounced vertical
alignment which is not common to thermal CVD [165].
For the same reason, plasma-based technologies have
long been reported as an effective route for surface treatment
[15]. The importance of this fact is, for example, the ability
to chemically improve the biocompatibility of the surface
by increasing its hydrophilicity, which in turn increases the
cell proliferation [8, 158, 163]. Moreover, several limitations
(e.g., control over chemical properties and difficulties in
sterilization) could be overcome by plasma-based techniques.
Furthermore, plasma-based techniques were used to func-
tionalize important nanomaterials such as CNTs leading to
better substrates for the enhancement of cell growth and
proliferation [196].
Regarding the control of SC fate, it is well known that the
proliferation (without differentiation) or the differentiation
to desired lineages requires both growth factors and, for
some specific SC, mechanical stimulation. Several strategies
can be followed to reach this goal, for example, produc-
tion of specific tailored nanostructures with or without
bound/immobilised growth factors that directly promote
SC expansion or controlled differentiation. These nanos-
tructures can be added to hydrogels/nanoscaffolds in order
to temporally control the delivery of GFs and migration
of cells. Surfaces can also be plasma-tailored with desired
nanostructures tomechanically guide the SC via focal contact
or be used as binding point to ligands/chemical radicals or
both, leading to SC proliferation/differentiation according to
the input stimulus.
An example involving a plasma-treated nanostructure
coated with a specific GF was reported by Arnold et al.
[119]. In order to understand the role of a precise molecular
arrangement on cell response, a substrate was patterned with
Au nanodots (<8 nm), highly ordered with controllable dis-
tances, via self-assembly of diblock copolymermicelles. After
the assembly of the nanodots, the polymer was completely
removed by the plasma treatment and the dot-patterned sub-
strate was functionalized with a specific peptide (c(RGDfK)),
which has a high affinity to the 𝛼]𝛽-integrin. Due to the
small surface area of the nanodot, only one integrin can
attach to each dot and the effect of the arranged binding
sites could be studied. Such an approach is powerful as it
enables control over the presentation of mass amounts of
specific signals/ligands at precise spatial locations and size
scales and therefore an ability to dissect how cells respond
to variations in ligand density. There is great potential to
exploit this approach to critically examine the presentation of
defined amounts of combinations of biological signals to stem
cells.We predict that sophisticated nanoengineering based on
plasma generated biomaterials will underpin a new era in cell
culture.
5. Conclusions and Challenges for
Future Research
In this review, we have discussed sources and applications of
SCs and themechanisms by which they can be controlled and
subsequently, the use of nanomaterials to control SCs. We
have pointed out the properties that make low-temperature
plasmas a suitable tool to use in the production and func-
tionalization of these NMs for more effective and specific
interaction with SCs, both through direct treatment and as
a versatile nanofabrication tool [15].
Due to the many unique characteristics of low-temper-
ature plasmas, we believe that the direct use of plasmas,
especially atmospheric plasmas, should be considered as a
viable strategy to direct SC differentiation. Plasmas as a
nanofabrication tool should be focused on developing “lab on
a chip” devices as suitable platforms for the differentiation of
SCs into any cell lineage throughmechanical and/or electrical
stimulus.
Tissue engineering and SC biology can benefit greatly
from advances in plasma nanoscience [15]. Nanomaterial
design is leading to a greater degree of control over cell
attachment and migration in order to grow multilevel tissues
(or organs, e.g., skin). This control also contributes to basic
studies on mimicking ECM properties and ligands quantity
and presentation as well as elucidating the role of time in
growth factors delivery.
Acknowledgments
F. F. Borghi acknowledges the support from the Science
Without Borders Program of the Brazilian Government, A.
E. Rider and Z. J. Han acknowledge the support from the
CSIRO Sensors and Sensor Network TCP, and A. E. Rider
and S. Kumar acknowledge the support from the CSIRO
OCE Postdoctoral Fellowship schemes. This work is partially
supported by the Australian Research Council (ARC) and
CSIRO’s OCE Science Leadership Program.
References
[1] K. Saha, J. F. Pollock, D. V. Schaffer, and K. E. Healy, “Designing
synthetic materials to control stem cell phenotype,” Current
Opinion in Chemical Biology, vol. 11, no. 4, pp. 381–387, 2007.
[2] A. J. Engler, S. Sen, H. L. Sweeney, and D. E. Discher, “Matrix
elasticity directs stem cell lineage specification,” Cell, vol. 126,
no. 4, pp. 677–689, 2006.
[3] J. A. Burdick and G. Vunjak-Novakovic, “Engineered microen-
vironments for controlled stem cell differentiation,” Tissue
Engineering A, vol. 15, no. 2, pp. 205–219, 2009.
[4] G. H. Altman, R. L. Horan, I. Martin et al., “Cell differentiation
bymechanical stress,”TheFASEB Journal, vol. 16, no. 2, pp. 270–
272, 2002.
[5] D. L. Butler, N. Juncosa-Melvin, G. P. Boivin et al., “Functional
tissue engineering for tendon repair: a multidisciplinary strat-
egy usingmesenchymal stem cells, bioscaffolds, andmechanical
stimulation,” Journal of Orthopaedic Research, vol. 26, no. 1, pp.
1–9, 2008.
[6] V. Terraciano, N.Hwang, L.Moroni et al., “Differential response
of adult and embryonic mesenchymal progenitor cells to
mechanical compression in hydrogels,” Stem Cells, vol. 25, no.
11, pp. 2730–2738, 2007.
[7] M. P. Lutolf, P.M. Gilbert, andH.M. Blau, “Designingmaterials
to direct stem-cell fate,” Nature, vol. 462, no. 7272, pp. 433–441,
2009.
10 Journal of Nanomaterials
[8] E. Dawson, G. Mapili, K. Erickson, S. Taqvi, and K. Roy,
“Biomaterials for stem cell differentiation,” Advanced Drug
Delivery Reviews, vol. 60, no. 2, pp. 215–228, 2008.
[9] N. S. Hwang, S. Varghese, and J. Elisseeff, “Controlled differen-
tiation of stem cells,” Advanced Drug Delivery Reviews, vol. 60,
no. 2, pp. 199–214, 2008.
[10] C. Chai andK.W. Leong, “Biomaterials approach to expand and
direct differentiation of stem cells,” Molecular Therapy, vol. 15,
no. 3, pp. 467–480, 2007.
[11] C. Cha, W. B. Liechty, A. Khademhosseini, and N. A. Peppas,
“Designing biomaterials to direct stem cell fate,”ACS Nano, vol.
6, no. 11, pp. 9353–9358, 2012.
[12] T. M. A. Henderson, K. Ladewig, D. N. Haylock, K. M. Mclean,
and A. J. O. Connor, “Cryogels for biomedical applications,”
Journal of Materials Chemistry B, vol. 1, pp. 2682–2695, 2013.
[13] J. Nigro, J. F. White, J. A. M. Ramshaw, D. N. Haylock,
S. K. Nilsson, and J. A. Werkmeister, “The effect of bovine
endosteum-derived particles on the proliferation of human
mesenchymal stem cells,” Biomaterials, vol. 31, no. 21, pp. 5689–
5699, 2010.
[14] K. Ostrikov, U. Cvelbar, and A. B. Murphy, “Plasma
nanoscience: setting directions, tackling grand challenges,”
Journal of Physics D, vol. 44, no. 17, Article ID 174001, 2011.
[15] K. Ostrikov, E. C. Neyts, and M. Meyyappan, “Plasma
nanoscience: from nano-solids in plasmas to nano-plasmas in
solids,” Advances in Physics, vol. 62, no. 2, pp. 113–224, 2013.
[16] C. S. Chen, M. Mrksich, S. Huang, G. M. Whitesides, and D. E.
Ingber, “Geometric control of cell life and death,” Science, vol.
276, no. 5317, pp. 1425–1428, 1997.
[17] F. Guilak, D.M.Cohen, B. T. Estes, J.M.Gimble,W. Liedtke, and
C. S. Chen, “Control of stem cell fate by physical interactions
with the extracellular matrix,” Cell Stem Cell, vol. 5, no. 1, pp.
17–26, 2009.
[18] M. J. Dalby, N. Gadegaard, R. Tare et al., “The control of human
mesenchymal cell differentiation using nanoscale symmetry
and disorder,” Nature Materials, vol. 6, no. 12, pp. 997–1003,
2007.
[19] G. A. Silva, C. Czeisler, K. L. Niece et al., “Selective differ-
entiation of neural progenitor cells by high-epitope density
nanofibers,” Science, vol. 303, no. 5662, pp. 1352–1355, 2004.
[20] F. Yang, R. Murugan, S. Wang, and S. Ramakrishna, “Electro-
spinning of nano/micro scale poly(l-lactic acid) aligned fibers
and their potential in neural tissue engineering,” Biomaterials,
vol. 26, no. 15, pp. 2603–2610, 2005.
[21] K. Okita, T. Ichisaka, and S. Yamanaka, “Generation of
germline-competent induced pluripotent stem cells,” Nature,
vol. 448, no. 7151, pp. 313–317, 2007.
[22] M.Wernig, A.Meissner, R. Foreman et al., “In vitro reprogram-
ming of fibroblasts into a pluripotent ES-cell-like state,”Nature,
vol. 448, no. 7151, pp. 318–324, 2007.
[23] M. Mimeault and S. K. Batra, “Concise review: recent advances
on the significance of stem cells in tissue regeneration and
cancer therapies,” StemCells, vol. 24, no. 11, pp. 2319–2345, 2006.
[24] C. Fehrer and G. Lepperdinger, “Mesenchymal stem cell aging,”
Experimental Gerontology, vol. 40, no. 12, pp. 926–930, 2005.
[25] A. Stolzing and A. Scutt, “Age-related impairment of mesenchy-
mal progenitor cell function,” Aging Cell, vol. 5, no. 3, pp. 213–
224, 2006.
[26] L. B. To, D. N. Haylock, P. J. Simmons, and C. A. Juttner, “The
biology and clinical uses of blood stem cells,” Blood, vol. 89, no.
7, pp. 2233–2258, 1997.
[27] M. J. Evans and M. H. Kaufman, “Establishment in culture of
pluripotential cells from mouse embryos,” Nature, vol. 292, no.
5819, pp. 154–156, 1981.
[28] L. Jakobsson, J. Kreuger, and L. Claesson-Welsh, “Building
blood vessels—stem cell models in vascular biology,” The
Journal of Cell Biology, vol. 177, no. 5, pp. 751–755, 2007.
[29] S.-I. Nishikawa, L. M. Jakt, and T. Era, “Embryonic stem-cell
culture as a tool for developmental cell biology,”Nature Reviews
Molecular Cell Biology, vol. 8, no. 6, pp. 502–507, 2007.
[30] D. J. Prockop, “Marrow stromal cells as stem cells for non-
hematopoietic tissues,” Science, vol. 276, no. 5309, pp. 71–74,
1997.
[31] M. F. Pittenger, “Multilineage potential of adult human mes-
enchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147,
1999.
[32] J. A.Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., “Embryonic
stem cell lines derived from human blastocysts,” Science, vol.
282, no. 5391, pp. 1145–1147, 1998.
[33] K. Takahashi and S. Yamanaka, “Induction of pluripotent stem
cells from mouse embryonic and adult fibroblast cultures by
defined factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.
[34] M. Tada, Y. Takahama, K. Abe, N. Nakatsuji, and T. Tada,
“Nuclear reprogramming of somatic cells by in vitro hybridiza-
tion with ES cells,” Current Biology, vol. 11, no. 19, pp. 1553–1558,
2001.
[35] G. Bianchi, A. Banfi, M. Mastrogiacomo et al., “Ex vivo enrich-
ment of mesenchymal cell progenitors by fibroblast growth
factor 2,” Experimental Cell Research, vol. 287, no. 1, pp. 98–105,
2003.
[36] I. Martin, A. Muraglia, G. Campanile, R. Cancedda, and R.
Quarto, “Fibroblast growth factor-2 supports ex vivo expansion
and maintenance of osteogenic precursors from human bone
marrow,” Endocrinology, vol. 138, no. 10, pp. 4456–4462, 1997.
[37] L. A. Solchaga, K. Penick, J. D. Porter, V. M. Goldberg, A.
I. Caplan, and J. F. Welter, “FGF-2 enhances the mitotic and
chondrogenic potentials of human adult bone marrow-derived
mesenchymal stemcells,” Journal of Cellular Physiology, vol. 203,
no. 2, pp. 398–409, 2005.
[38] S. Tsutsumi, A. Shimazu, K. Miyazaki et al., “Retention of mul-
tilineage differentiation potential of mesenchymal cells during
proliferation in response to FGF,” Biochemical and Biophysical
Research Communications, vol. 288, no. 2, pp. 413–419, 2001.
[39] H. J. Rippon, J. M. Polak, M. Qin, and A. E. Bishop, “Derivation
of distal lung epithelial progenitors from murine embryonic
stem cells using a novel three-step differentiation protocol,”
Stem Cells, vol. 24, no. 5, pp. 1389–1398, 2006.
[40] M. Nakanishi, T. S. Hamazaki, S. Komazaki, H. Okochi, and M.
Asashima, “Pancreatic tissue formation from murine embry-
onic stem cells in vitro,” Differentiation, vol. 75, no. 1, pp. 1–11,
2007.
[41] D. T. Scadden, “The stem-cell niche as an entity of action,”
Nature, vol. 441, no. 7097, pp. 1075–1079, 2006.
[42] S. J. Morrison and A. C. Spradling, “Stem cells and niches:
mechanisms that promote stem cell maintenance throughout
life,” Cell, vol. 132, no. 4, pp. 598–611, 2008.
[43] R. Peerani and P. W. Zandstra, “Enabling stem cell therapies
through synthetic stem cell-niche engineering,” The Journal of
Clinical Investigation, vol. 120, no. 1, pp. 60–70, 2010.
[44] P. M. Gilbert and H. M. Blau, “Engineering a stem cell house
into a home,” Stem Cell Research &Therapy, vol. 2, no. 1, article
3, 2011.
Journal of Nanomaterials 11
[45] D. N. Haylock and P. J. Simmons, “Approaches to hematopoietic
stem cell separation and expansion,” inHandbook onAdult Stem
Cell Biology, p. 615, Elsevier/Academic Press, San Diego, Calif,
USA, 2004.
[46] A. S. Hoffman, “Hydrogels for biomedical applications,”
Advanced Drug Delivery Reviews, vol. 54, no. 1, pp. 3–12, 2002.
[47] J. L. Drury and D. J. Mooney, “Hydrogels for tissue engineering:
scaffold design variables and applications,” Biomaterials, vol. 24,
no. 24, pp. 4337–4351, 2003.
[48] J. Kopecˇek and J. Yang, “Hydrogels as smart biomaterials,”
Polymer International, vol. 56, no. 9, pp. 1078–1098, 2007.
[49] J. A. Hubbell, “Biomaterials in tissue engineering,” Biotechnol-
ogy, vol. 13, no. 6, pp. 565–576, 1995.
[50] W. E. Hennink and C. F. van Nostrum, “Novel crosslinking
methods to design hydrogels,”Advanced Drug Delivery Reviews,
vol. 54, no. 1, pp. 13–36, 2002.
[51] C. Xu, M. S. Inokuma, J. Denham et al., “Feeder-free growth of
undifferentiated human embryonic stem cells,” Nature Biotech-
nology, vol. 19, no. 10, pp. 971–974, 2001.
[52] M. Amit, C. Shariki, V. Margulets, and J. Itskovitz-Eldor,
“Feeder layer- and serum-free culture of human embryonic
stem cells,” Biology of Reproduction, vol. 70, no. 3, pp. 837–845,
2004.
[53] G. M. Beattie, A. D. Lopez, N. Bucay et al., “Activin Amaintains
pluripotency of human embryonic stem cells in the absence of
feeder layers,” Stem Cells, vol. 23, no. 4, pp. 489–495, 2005.
[54] S. Battista, D. Guarnieri, C. Borselli et al., “The effect of
matrix composition of 3D constructs on embryonic stem cell
differentiation,” Biomaterials, vol. 26, no. 31, pp. 6194–6207,
2005.
[55] C.-F. Chang, M.-W. Lee, P.-Y. Kuo, Y.-J. Wang, Y.-H. Tu, and
S.-C. Hung, “Three-dimensional collagen fiber remodeling by
mesenchymal stem cells requires the integrin-matrix interac-
tion,” Journal of Biomedical Materials Research A, vol. 80, no.
2, pp. 466–474, 2007.
[56] K. E. McCloskey, M. E. Gilroy, and R. M. Nerem, “Use of
embryonic stem cell-derived endothelial cells as a cell source
to generate vessel structures in vitro,” Tissue Engineering, vol. 11,
no. 3-4, pp. 497–505, 2005.
[57] M. S. Ponticiello, R. M. Schinagl, S. Kadiyala, and F. P. Barry,
“Gelatin-based resorbable sponge as a carrier matrix for human
mesenchymal stem cells in cartilage regeneration therapy,”
Journal of Biomedical Materials Research, vol. 52, no. 2, pp. 246–
255, 2000.
[58] S. Tielens,H.Declercq, T. Gorski, E. Lippens, E. Schacht, andM.
Cornelissen, “Gelatin-based microcarriers as embryonic stem
cell delivery system in bone tissue engineering: an in-vitro
study,” Biomacromolecules, vol. 8, no. 3, pp. 825–832, 2007.
[59] S. Gerecht, J. A. Burdick, L. S. Ferreira, S. A. Townsend, R.
Langer, and G. Vunjak-Novakovic, “Hyaluronic acid hydrogel
for controlled self-renewal and differentiation of human embry-
onic stem cells,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 104, no. 27, pp. 11298–11303,
2007.
[60] C. Ventura, M. Maioli, Y. Asara et al., “Butyric and retinoic
mixed ester of hyaluronan: a novel differentiating glycoconju-
gate affording a high throughput of cardiogenesis in embryonic
stem cells,”The Journal of Biological Chemistry, vol. 279, no. 22,
pp. 23574–23579, 2004.
[61] T. Maguire, A. E. Davidovich, E. J. Wallenstein et al., “Control
of hepatic differentiation via cellular aggregation in an alginate
microenvironment,” Biotechnology and Bioengineering, vol. 98,
no. 3, pp. 631–644, 2007.
[62] M. Ruhnke, H. Ungefroren, G. Zehle, M. Bader, B. Kremer,
and F. Fa¨ndrich, “Long-term culture and differentiation of rat
embryonic stem cell-like cells into neuronal, glial, endothelial,
and hepatic lineages,” Stem Cells, vol. 21, no. 4, pp. 428–436,
2003.
[63] V. Planat-Benard, J.-S. Silvestre, B. Cousin et al., “Plasticity of
human adipose lineage cells toward endothelial cells: physio-
logical and therapeutic perspectives,” Circulation, vol. 109, no.
5, pp. 656–663, 2004.
[64] C. Xu, J.-Q. He, T. J. Kamp et al., “Human embryonic stem cell-
derived cardiomyocytes can be maintained in defined medium
without serum,” Stem Cells and Development, vol. 15, no. 6, pp.
931–941, 2006.
[65] H. J. Lee, J.-S. Lee, T. Chansakul, C. Yu, J. H. Elisseeff, and S. M.
Yu, “Collagenmimetic peptide-conjugated photopolymerizable
PEG hydrogel,” Biomaterials, vol. 27, no. 30, pp. 5268–5276,
2006.
[66] R. McBeath, D. M. Pirone, C. M. Nelson, K. Bhadriraju, and C.
S. Chen, “Cell shape, cytoskeletal tension, and RhoA regulate
stem cell lineage commitment,” Developmental Cell, vol. 6, no.
4, pp. 483–495, 2004.
[67] F. Yang, C.G.Williams,D.-A.Wang,H. Lee, P.N.Manson, and J.
Elisseeff, “The effect of incorporating RGD adhesive peptide in
polyethylene glycol diacrylate hydrogel on osteogenesis of bone
marrow stromal cells,” Biomaterials, vol. 26, no. 30, pp. 5991–
5998, 2005.
[68] C. R. Nuttelman, M. C. Tripodi, and K. S. Anseth, “In vitro
osteogenic differentiation of human mesenchymal stem cells
photoencapsulated in PEG hydrogels,” Journal of Biomedical
Materials Research A, vol. 68, no. 4, pp. 773–782, 2004.
[69] Y. D. Teng, E. B. Lavik, X. Qu et al., “Functional recovery
following traumatic spinal cord injury mediated by a unique
polymer scaffold seeded with neural stem cells,” Proceedings of
the National Academy of Sciences of the United States of America,
vol. 99, no. 5, pp. 3024–3029, 2002.
[70] S. Levenberg, N. F. Huang, E. Lavik, A. B. Rogers, J. Itskovitz-
Eldor, and R. Langer, “Differentiation of human embryonic
stem cells on three-dimensional polymer scaffolds,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 100, no. 22, pp. 12741–12746, 2003.
[71] M. J. Mondrinos, S. Koutzaki, E. Jiwanmall et al., “Engineering
three-dimensional pulmonary tissue constructs,” Tissue Engi-
neering, vol. 12, no. 4, pp. 717–728, 2006.
[72] C. S. Young, H. Abukawa, R. Asrican et al., “Tissue-engineered
hybrid tooth and bone,” Tissue Engineering, vol. 11, no. 9-10, pp.
1599–1610, 2005.
[73] D. E. Discher, P. Janmey, and Y.-L. Wang, “Tissue cells feel and
respond to the stiffness of their substrate,” Science, vol. 310, no.
5751, pp. 1139–1143, 2005.
[74] E. K. F. Yim and K. W. Leong, “Significance of synthetic
nanostructures in dictating cellular response,” Nanomedicine:
Nanotechnology, Biology, and Medicine, vol. 1, no. 1, pp. 10–21,
2005.
[75] T. Cedervall, I. Lynch, S. Lindman et al., “Understanding
the nanoparticle-protein corona using methods to quntify
exchange rates and affinities of proteins for nanoparticles,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 104, no. 7, pp. 2050–2055, 2007.
[76] M. Lundqvist, J. Stigler, G. Elia, I. Lynch, T. Cedervall, and K. A.
Dawson, “Nanoparticle size and surface properties determine
12 Journal of Nanomaterials
the protein corona with possible implications for biological
impacts,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 105, no. 38, pp. 14265–14270, 2008.
[77] H. V. Unadkat, M. Hulsman, K. Cornelissen et al., “An
algorithm-based topographical biomaterials library to instruct
cell fate,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 108, no. 40, pp. 16565–16570, 2011.
[78] G. M. Whitesides, E. Ostuni, S. Takayama, X. Jiang, and D. E.
Ingber, “Soft lithography in biology and biochemistry,” Annual
Review of Biomedical Engineering, vol. 3, pp. 335–373, 2001.
[79] J. J. Norman and T. A. Desai, “Methods for fabrication of
nanoscale topography for tissue engineering scaffolds,” Annals
of Biomedical Engineering, vol. 34, no. 1, pp. 89–101, 2006.
[80] A. Khademhosseini, R. Langer, J. Borenstein, and J. P. Vacanti,
“Microscale technologies for tissue engineering and biology,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 103, no. 8, pp. 2480–2487, 2006.
[81] D. Falconnet, G. Csucs, H. M. Grandin, andM. Textor, “Surface
engineering approaches to micropattern surfaces for cell-based
assays,” Biomaterials, vol. 27, no. 16, pp. 3044–3063, 2006.
[82] B. G. Keselowsky, D. M. Collard, and A. J. Garc´ıa, “Integrin
binding specificity regulates biomaterial surface chemistry
effects on cell differentiation,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 102, no.
17, pp. 5953–5957, 2005.
[83] A. J. Garc´ıa, M. D. Vega, and D. Boettiger, “Modulation of cell
proliferation and differentiation through substrate- dependent
changes in fibronectin conformation,” Molecular Biology of the
Cell, vol. 10, no. 3, pp. 785–798, 1999.
[84] W. G. Brodbeck, J. Patel, G. Voskerician et al., “Biomaterial
adherent macrophage apoptosis is increased by hydrophilic and
anionic substrates in vivo,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 99, no. 16, pp.
10287–10292, 2002.
[85] P. X. Ma, “Biomimetic materials for tissue engineering,”
Advanced Drug Delivery Reviews, vol. 60, no. 2, pp. 184–198,
2008.
[86] D. Walczyk, F. B. Bombelli, M. P. Monopoli, I. Lynch, and K. A.
Dawson, “What the cell “sees” in bionanoscience,” Journal of the
American Chemical Society, vol. 132, no. 16, pp. 5761–5768, 2010.
[87] M.-E. Aubin-Tam and K. Hamad-Schifferli, “Structure and
function of nanoparticle-protein conjugates,” Biomedical Mate-
rials, vol. 3, no. 3, Article ID 034001, 2008.
[88] M. G. Kong, M. Keidar, and K. Ostrikov, “Plasmas meet
nanoparticles-where synergies can advance the frontier of
medicine,” Journal of Physics D, vol. 44, no. 17, Article ID 174018,
2011.
[89] Q. A. Pankhurst, J. Connolly, S. K. Jones, and J. Dobson, “Appli-
cations of magnetic nanoparticles in biomedicine,” Journal of
Physics D, vol. 36, no. 13, pp. R167–R181, 2003.
[90] T. Cedervall, I. Lynch, M. Foy et al., “Detailed identification
of plasma proteins adsorbed on copolymer nanoparticles,”
Angewandte Chemie—International Edition, vol. 46, no. 30, pp.
5754–5756, 2007.
[91] A. E. Nel, L. Ma¨dler, D. Velegol et al., “Understanding bio-
physicochemical interactions at the nano-bio interface,” Nature
Materials, vol. 8, no. 7, pp. 543–557, 2009.
[92] P. Decuzzi andM. Ferrari, “The role of specific and non-specific
interactions in receptor-mediated endocytosis of nanoparti-
cles,” Biomaterials, vol. 28, no. 18, pp. 2915–2922, 2007.
[93] H. Gao, W. Shi, and L. B. Freund, “Mechanics of receptor-
mediated endocytosis,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 102, no. 27, pp.
9469–9474, 2005.
[94] C. C. Fleck and R. R. Netz, “Electrostatic colloid-membrane
binding,” Europhysics Letters, vol. 67, no. 2, pp. 314–320, 2004.
[95] P. W. Barone, H. Yoon, R. Ortiz-Garc´ıa et al., “Modulation of
single-walled carbon nanotube photoluminescence by hydrogel
swelling,” ACS Nano, vol. 3, no. 12, pp. 3869–3877, 2009.
[96] C. Zavaleta, A. de la Zerda, Z. Liu et al., “Noninvasive Raman
spectroscopy in living mice for evaluation of tumor targeting
with carbon nanotubes,” Nano Letters, vol. 8, no. 9, pp. 2800–
2805, 2008.
[97] H. Valo, L. Peltonen, S. Vehvila¨inen et al., “Electrospray encap-
sulation of hydrophilic and hydrophobic drugs in poly(L-lactic
acid) nanoparticles,” Small, vol. 5, no. 15, pp. 1791–1798, 2009.
[98] T. E.McKnight, A. V.Melechko, D. K.Hensley, D. G. J.Mann, G.
D. Griffin, and M. L. Simpson, “Tracking gene expression after
DNA delivery using spatially indexed nanofiber arrays,” Nano
Letters, vol. 4, no. 7, pp. 1213–1219, 2004.
[99] Z. J. Han, I. Levchenko, S. Kumar et al., “Plasma nanofabrication
and nanomaterials safety,” Journal of Physics D, vol. 44, no. 17,
Article ID 174019, 2011.
[100] F. J. Aparicio, M. Holgado, A. Borras et al., “Transparent nano-
metric organic luminescent films as UV-active components in
photonic structures,”AdvancedMaterials, vol. 23, no. 6, pp. 761–
765, 2011.
[101] Y. Zhang, T. R. Nayak, H. Hong, and W. Cai, “Graphene: a
versatile nanoplatform for biomedical applications,” Nanoscale,
vol. 4, no. 13, pp. 3833–3842, 2012.
[102] A. E. Rider, S. Kumar, S. A. Furman, and K. Ostrikov, “Self-
organized Au nanoarrays on vertical graphenes: an advanced
three-dimensional sensing platform,” Chemical Communica-
tions, vol. 48, no. 21, pp. 2659–2661, 2012.
[103] S. R. Shin, H. Bae, J. M. Cha et al., “Carbon nanotube reinforced
hybrid microgels as scaffold materials for cell encapsulation,”
ACS Nano, vol. 6, no. 1, pp. 362–372, 2012.
[104] S. R. Shin, S. M. Jung, M. Zalabany et al., “Carbon-nanotube-
embedded hydrogel sheets for engineering cardiac constructs
and bioactuators,” ACS Nano, vol. 7, no. 3, pp. 2369–2380, 2013.
[105] C. Lau, M. J. Cooney, and P. Atanassov, “Conductive macro-
porous composite chitosan-carbon nanotube scaffolds,” Lang-
muir, vol. 24, no. 13, pp. 7004–7010, 2008.
[106] N. W. S. Kam, E. Jan, and N. A. Kotov, “Electrical stimulation
of neural stem cells mediated by humanized carbon nanotube
composite made with extracellular matrix protein,” Nano Let-
ters, vol. 9, no. 1, pp. 273–278, 2009.
[107] M. Yamamoto and Y. Tabata, “Tissue engineering bymodulated
gene delivery,” Advanced Drug Delivery Reviews, vol. 58, no. 4,
pp. 535–554, 2006.
[108] M. C. Wake, P. D. Gerecht, L. Lu, and A. G. Mikos, “Effects
of biodegradable polymer particles on rat marrow-derived
stromal osteoblasts in vitro,” Biomaterials, vol. 19, no. 14, pp.
1255–1268, 1998.
[109] F. Meder, J. Wehling, A. Fink et al., “The role of surface func-
tionalization of colloidal alumina particles on their controlled
interactions with viruses,”Biomaterials, vol. 34, no. 17, pp. 4203–
4213, 2013.
[110] D. S. Kommireddy, S. M. Sriram, Y. M. Lvov, and D. K.
Mills, “Stem cell attachment to layer-by-layer assembled TiO
2
nanoparticle thin films,” Biomaterials, vol. 27, no. 24, pp. 4296–
4303, 2006.
Journal of Nanomaterials 13
[111] R. G. Flemming, C. J. Murphy, G. A. Abrams, S. L. Good-
man, and P. F. Nealey, “Effects of synthetic micro- and nano-
structured surfaces on cell behavior,” Biomaterials, vol. 20, no.
6, pp. 573–588, 1999.
[112] A. S. G. Curtis, N. Gadegaard, M. J. Dalby, M. O. Riehle, C.
D. W. Wilkinson, and G. Aitchison, “Cells react to nanoscale
order and symmetry in their surroundings,” IEEE Transactions
on Nanobioscience, vol. 3, no. 1, pp. 61–65, 2004.
[113] M. J. Dalby, N. Gadegaard, M. O. Riehle, C. D. W. Wilkinson,
andA. S. G. Curtis, “Investigating filopodia sensing using arrays
of defined nano-pits down to 35 nm diameter in size,” The
International Journal of Biochemistry & Cell Biology, vol. 36, no.
10, pp. 2005–2015, 2004.
[114] P. Weiss and B. Garber, “Shape and movement of mesenchyme
cells as functions of the physical structure of the medium.
Contributions to a quantitative morphology,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 38, pp. 264–280, 1952.
[115] C. S. Chen, J. L. Alonso, E. Ostuni, G. M. Whitesides, and D.
E. Ingber, “Cell shape provides global control of focal adhesion
assembly,” Biochemical and Biophysical Research Communica-
tions, vol. 307, no. 2, pp. 355–361, 2003.
[116] C. S. Chen, M. Mrksich, S. Huang, G. M. Whitesides, and D.
E. Ingber, “Micropatterned surfaces for control of cell shape,
position, and function,”Biotechnology Progress, vol. 14, no. 3, pp.
356–363, 1998.
[117] M. J. Dalby, M. J. P. Biggs, N. Gadegaard, G. Kalna, C. D. W.
Wilkinson, andA. S.G.Curtis, “Nanotopographical stimulation
of mechanotransduction and changes in interphase centromere
positioning,” Journal of Cellular Biochemistry, vol. 100, no. 2, pp.
326–338, 2007.
[118] N. Gadegaard, S.Thoms, D. S. Macintyre et al., “Arrays of nano-
dots for cellular engineering,” Microelectronic Engineering, vol.
67-68, pp. 162–168, 2003.
[119] M. Arnold, E. A. Cavalcanti-Adam, R. Glass et al., “Activation
of integrin function by nanopatterned adhesive interfaces,”
ChemPhysChem, vol. 5, no. 3, pp. 383–388, 2004.
[120] P. J. Simmons, D. N. Haylock, and J. P. Le´vesque, “Influence of
cytokines and adhesion molecules on hematopoietic stem cell
development,” in Ex Vivo Cell Therapy, pp. 51–83, Elsevier, San
Diego, Calif, USA, 1999.
[121] E. K. F. Yim, S. W. Pang, and K. W. Leong, “Synthetic nanos-
tructures inducing differentiation of humanmesenchymal stem
cells into neuronal lineage,” Experimental Cell Research, vol. 313,
no. 9, pp. 1820–1829, 2007.
[122] S. Gerecht, C. J. Bettinger, Z. Zhang, J. T. Borenstein, G. Vunjak-
Novakovic, and R. Langer, “The effect of actin disrupting
agents on contact guidance of human embryonic stem cells,”
Biomaterials, vol. 28, no. 28, pp. 4068–4077, 2007.
[123] J. M. Curran, R. Chen, and J. A. Hunt, “The guidance of human
mesenchymal stem cell differentiation in vitro by controlled
modifications to the cell substrate,” Biomaterials, vol. 27, no. 27,
pp. 4783–4793, 2006.
[124] T. R. Nayak, H. Andersen, V. S. Makam et al., “Graphene for
controlled and accelerated osteogenic differentiation of human
mesenchymal stem cells,” ACS Nano, vol. 5, no. 6, pp. 4670–
4678, 2011.
[125] S. Y. Park, J. Park, S. H. Sim et al., “Enhanced differentiation of
human neural stem cells into neurons on graphene,” Advanced
Materials, vol. 23, no. 36, pp. H263–H267, 2011.
[126] W. C. Lee, C. H. Y. X. Lim, H. Shi et al., “Origin of enhanced
stem cell growth and differentiation on graphene and graphene
oxide,” ACS Nano, vol. 5, no. 9, pp. 7334–7341, 2011.
[127] S. W. Crowder, D. Prasai, R. Rath et al., “Three-dimensional
graphene foams promote osteogenic differentiation of human
mesenchymal stem cells,”Nanoscale, vol. 5, no. 10, pp. 4171–4176,
2013.
[128] O. Akhavan, E. Ghaderi, and M. Shahsavar, “Graphene
nanogrids for selective and fast osteogenic differentiation of
human mesenchymal stem cells,” Carbon, vol. 59, pp. 200–211,
2013.
[129] G.-Y. Chen, D. W.-P. Pang, S.-M. Hwang, H.-Y. Tuan, and Y.-C.
Hu, “A graphene-based platform for induced pluripotent stem
cells culture and differentiation,” Biomaterials, vol. 33, no. 2, pp.
418–427, 2012.
[130] D. N. Haylock and S. K. Nilsson, “Stem cell regulation by the
hematopoietic stem cell niche,” Cell Cycle, vol. 4, no. 10, pp.
1353–1355, 2005.
[131] Z. J. Han, A. E. Rider, M. Ishaq et al., “Carbon nanostructures
for hard tissue engineering,” RSC Advances, vol. 3, no. 28, pp.
11058–11072, 2013.
[132] S. Zhang, “Fabrication of novel biomaterials throughmolecular
self-assembly,” Nature Biotechnology, vol. 21, no. 10, pp. 1171–
1178, 2003.
[133] A. Nur-E-Kamal, I. Ahmed, J. Kamal, M. Schindler, and S.
Meiners, “Three-dimensional nanofibrillar surfaces promote
self-renewal inmouse embryonic stem cells,” StemCells, vol. 24,
no. 2, pp. 426–433, 2006.
[134] S. Subramony, B. Dargis, and M. Castillo, “The guidance of
stem cell differentiation by substrate alignment andmechanical
stimulation,” Biomaterials, vol. 34, no. 8, pp. 1942–1953, 2012.
[135] H. Liu and K. Roy, “Biomimetic three-dimensional cultures
significantly increase hematopoietic differentiation efficacy of
embryonic stem cells,” Tissue Engineering, vol. 11, no. 1-2, pp.
319–330, 2005.
[136] H. Tanaka, C. L. Murphy, C. Murphy, M. Kimura, S. Kawai,
and J. M. Polak, “Chondrogenic differentiation of murine
embryonic stem cells: effects of culture conditions and dexam-
ethasone,” Journal of Cellular Biochemistry, vol. 93, no. 3, pp.
454–462, 2004.
[137] E.Hadjipanayi, V.Mudera, andR.A. Brown, “Close dependence
of fibroblast proliferation on collagen scaffold matrix stiffness,”
Journal of Tissue Engineering and Regenerative Medicine, vol. 3,
no. 2, pp. 77–84, 2009.
[138] E. Cukierman, R. Pankov, and K. M. Yamada, “Cell interactions
with three-dimensional matrices,” Current Opinion in Cell
Biology, vol. 14, no. 5, pp. 633–639, 2002.
[139] M. D. Schofer, U. Boudriot, C. Wack et al., “Influence of
nanofibers on the growth and osteogenic differentiation of
stem cells: a comparison of biological collagen nanofibers and
synthetic PLLA fibers,” Journal ofMaterials Science:Materials in
Medicine, vol. 20, no. 3, pp. 767–774, 2009.
[140] Y. Soen, A. Mori, T. D. Palmer, and P. O. Brown, “Exploring the
regulation of human neural precursor cell differentiation using
arrays of signaling microenvironments,” Molecular Systems
Biology, vol. 2, article 37, 2006.
[141] E. Garreta, E. Genove´, S. Borro´s, and C. E. Semino, “Osteogenic
differentiation of mouse embryonic stem cells and mouse
embryonic fibroblasts in a three-dimensional self-assembling
peptide scaffold,” Tissue Engineering, vol. 12, no. 8, pp. 2215–
2227, 2006.
14 Journal of Nanomaterials
[142] I. Ahmed, A. S. Ponery, A. Nur-E-Kamal et al., “Mor-
phology, cytoskeletal organization, and myosin dynamics of
mouse embryonic fibroblasts cultured on nanofibrillar sur-
faces,”Molecular and Cellular Biochemistry, vol. 301, no. 1-2, pp.
241–249, 2007.
[143] W.-J. Li, R. Tuli, C. Okafor et al., “A three-dimensional nanofi-
brous scaffold for cartilage tissue engineering using human
mesenchymal stem cells,” Biomaterials, vol. 26, no. 6, pp. 599–
609, 2005.
[144] W.-J. Li, R. Tuli, X. Huang, P. Laquerriere, and R. S. Tuan,
“Multilineage differentiation of humanmesenchymal stem cells
in a three-dimensional nanofibrous scaffold,” Biomaterials, vol.
26, no. 25, pp. 5158–5166, 2005.
[145] J. Holst, S. Watson, M. S. Lord et al., “Substrate elasticity
provides mechanical signals for the expansion of hemopoietic
stem and progenitor cells,”Nature Biotechnology, vol. 28, no. 10,
pp. 1123–1128, 2010.
[146] G. Wei and P. X. Ma, “Partially nanofibrous architecture of 3D
tissue engineering scaffolds,” Biomaterials, vol. 30, no. 32, pp.
6426–6434, 2009.
[147] S.-F. Wang, L. Shen, W.-D. Zhang, and Y.-J. Tong, “Preparation
and mechanical properties of chitosan/carbon nanotubes com-
posites,” Biomacromolecules, vol. 6, no. 6, pp. 3067–3072, 2005.
[148] D. A. Stout and T. J. Webster, “Carbon nanotubes for stem cell
control,”Materials Today, vol. 15, no. 7-8, pp. 312–318, 2012.
[149] S. Samukawa, M. Hori, S. Rauf et al., “The 2012 plasma
roadmap,” Journal of Physics D, vol. 45, no. 25, Article ID 253001,
2012.
[150] D. Mariotti, V. Sˇvrcˇek, and D. G. Kim, “Self-organized nanos-
tructures on atmospheric microplasma exposed surfaces,”
Applied Physics Letters, vol. 91, no. 18, Article ID 183111, 2007.
[151] I. Levchenko, K. Ostrikov, K. Diwan, K. Winkler, and D.
Mariotti, “Plasma-driven self-organization ofNi nanodot arrays
on Si(100),” Applied Physics Letters, vol. 93, no. 18, Article ID
183102, 2008.
[152] S. Xu, I. Levchenko, S. Y. Huang, and K. Ostrikov, “Self-
organized vertically aligned single-crystal silicon nanostruc-
tures with controlled shape and aspect ratio by reactive plasma
etching,”Applied Physics Letters, vol. 95, no. 11, Article ID 111505,
2009.
[153] K. Ostrikov, I. Levchenko, and S. Xu, “Self-organized nanoar-
rays: plasma-related controls,” Pure and Applied Chemistry, vol.
80, no. 9, pp. 1909–1918, 2008.
[154] K. Ostrikov, I. Levchenko, U. Cvelbar, M. Sunkara, and M.
Mozetic, “From nucleation to nanowires: a single-step process
in reactive plasmas,” Nanoscale, vol. 2, no. 10, pp. 2012–2027,
2010.
[155] G. Arnoult, T. Belmonte, and G. Henrion, “Self-organization of
SiO
2
nanodots deposited by chemical vapor deposition using
an atmospheric pressure remote microplasma,” Applied Physics
Letters, vol. 96, no. 10, Article ID 101505, 2010.
[156] K. Ostrikov, “Colloquium: reactive plasmas as a versatile
nanofabrication tool,” Reviews of Modern Physics, vol. 77, no. 2,
pp. 489–511, 2005.
[157] U. Cvelbar, K. Ostrikov, and M. Mozetic, “Reactive oxygen
plasma-enabled synthesis of nanostructured CdO: tailoring
nanostructures through plasma-surface interactions,” Nan-
otechnology, vol. 19, no. 40, Article ID 405605, 2008.
[158] Z. Han, B. Tay, C. Tan, M. Shakerzadeh, and K. Ostrikov, “Elec-
trowetting control of Cassie-to-Wenzel transitions in super-
hydrophobic carbon nanotube-based nanocomposites,” ACS
Nano, vol. 3, no. 10, pp. 3031–3036, 2009.
[159] A. Michelmore, P. M. Bryant, D. A. Steele, K. Vasilev, J. W.
Bradley, and R. D. Short, “Role of positive ions in determining
the deposition rate and film chemistry of continuous wave
hexamethyl disiloxane plasmas,” Langmuir, vol. 27, no. 19, pp.
11943–11950, 2011.
[160] S. W. Lee, C. Mattevi, M. Chhowalla, and R. M. Sankaran,
“Plasma-assisted reduction of graphene oxide at low tempera-
ture and atmospheric pressure for flexible conductor applica-
tions,” The Journal of Physical Chemistry Letters, vol. 3, no. 6,
pp. 772–777, 2012.
[161] T. Kato and R. Hatakeyama, “Site- and alignment-controlled
growth of graphene nanoribbons from nickel nanobars,”Nature
Nanotechnology, vol. 7, no. 10, pp. 651–656, 2012.
[162] H. G. Yang, C. H. Sun, S. Z. Qiao et al., “Anatase TiO
2
single
crystals with a large percentage of reactive facets,” Nature, vol.
453, no. 7195, pp. 638–641, 2008.
[163] H.Watanabe, H. Kondo, M. Hiramatsu et al., “Surface chemical
modification of carbon nanowalls for wide-range control of
surface wettability,” Plasma Processes and Polymers, vol. 10, no.
7, pp. 582–592, 2013.
[164] K. Tai, T. J. Houlahan, J. G. Eden, and S. J. Dillon, “Integration of
microplasma with transmission electron microscopy: real-time
observation of gold sputtering and island formation,” Scientific
Reports, vol. 3, article 1325, 2013.
[165] M.Meyyappan, “A review of plasma enhanced chemical vapour
deposition of carbon nanotubes,” Journal of Physics D, vol. 42,
no. 21, Article ID 213001, 2009.
[166] M. Keidar, R.Walk, A. Shashurin et al., “Cold plasma selectivity
and the possibility of a paradigm shift in cancer therapy,” British
Journal of Cancer, vol. 105, no. 9, pp. 1295–1301, 2011.
[167] X. Yan, Z. Xiong, F. Zou et al., “Plasma-induced death of HepG2
cancer cells: intracellular effects of reactive species,” Plasma
Processes and Polymers, vol. 9, no. 1, pp. 59–66, 2012.
[168] G. Fridman, G. Friedman, A. Gutsol, A. B. Shekhter, V. N.
Vasilets, and A. Fridman, “Applied plasma medicine,” Plasma
Processes and Polymers, vol. 5, no. 6, pp. 503–533, 2008.
[169] M. G. Kong, G. Kroesen, G. Morfill et al., “Plasma medicine:
an introductory review,” New Journal of Physics, vol. 11, no. 11,
Article ID 115012, 2009.
[170] J. Heinlin, G. Isbary, W. Stolz et al., “Plasma applications in
medicine with a special focus on dermatology,” Journal of the
European Academy of Dermatology and Venereology, vol. 25, no.
1, pp. 1–11, 2011.
[171] P. Chaudhari, Z. Ye, and Y. Y. Jang, “Roles of reactive oxygen
species in the fate of stem cells,”Antioxidants &Redox Signaling,
2012.
[172] J. E. le Belle, N. M. Orozco, A. A. Paucar et al., “Proliferative
neural stem cells have high endogenous ROS levels that regulate
self-renewal and neurogenesis in a PI3K/Akt-dependant man-
ner,” Cell Stem Cell, vol. 8, no. 1, pp. 59–71, 2011.
[173] P.M. Burch andN.H.Heintz, “Redox regulation of cell-cycle re-
entry: cyclin D1 as a primary target for the mitogenic effects of
reactive oxygen and nitrogen species,” Antioxidants and Redox
Signaling, vol. 7, no. 5-6, pp. 741–751, 2005.
[174] M. Ishaq, M. M. Evans, and K. Ostrikov, “Effect of atmospheric
gas plasmas on cancer cell signalling,” International Journal of
Cancer, 2013.
[175] X. Pei, X. Lu, J. Liu et al., “Inactivation of a 25.5 𝜇m Enterococ-
cus faecalis biofilm by a room-temperature, battery-operated,
handheld air plasma jet,” Journal of Physics D, vol. 45, no. 16,
Article ID 165205, 2012.
Journal of Nanomaterials 15
[176] G. Fridman, M. Peddinghaus, M. Balasubramanian et al.,
“Blood coagulation and living tissue sterilization by floating-
electrode dielectric barrier discharge in air,” Plasma Chemistry
and Plasma Processing, vol. 26, no. 4, pp. 425–442, 2006.
[177] O. Lademann, H. Richter, A. Patzelt et al., “Application of a
plasma-jet for skin antisepsis: analysis of the thermal action of
the plasma by laser scanning microscopy,” Laser Physics Letters,
vol. 7, no. 6, pp. 458–462, 2010.
[178] A. B. Shekhter, V. A. Serezhenkov, T. G. Rudenko, A. V. Pekshev,
and A. F. Vanin, “Beneficial effect of gaseous nitric oxide on the
healing of skin wounds,” Nitric Oxide—Biology and Chemistry,
vol. 12, no. 4, pp. 210–219, 2005.
[179] M. Vleugels, G. Shama, X. T. Deng, E. Greenacre, T. Brock-
lehurst, and M. G. Kong, “Atmospheric plasma inactivation
of biofilm-forming bacteria for food safety control,” IEEE
Transactions on Plasma Science, vol. 33, no. 2, pp. 824–828, 2005.
[180] S. Deng, R. Ruan, C. K. Mok, G. Huang, X. Lin, and P. Chen,
“Inactivation of Escherichia coli on almonds using nonthermal
plasma,” Journal of Food Science, vol. 72, no. 2, pp. M62–M66,
2007.
[181] Y. Xian, X. Lu, J. Liu, S. Wu, D. Liu, and Y. Pan, “Multiple
plasma bullet behavior of an atmospheric-pressure plasma
plume driven by a pulsed dc voltage,” Plasma Sources Science
and Technology, vol. 21, no. 3, Article ID 034013, 2012.
[182] X. Lu, M. Laroussi, and V. Puech, “On atmospheric-pressure
non-equilibrium plasma jets and plasma bullets,” Plasma
Sources Science and Technology, vol. 21, no. 3, Article ID 034005,
2012.
[183] Z. Xiong, S. Zhao, X. Mao et al., “Selective neuronal differenti-
ation of neural stem cells induced by nanosecond microplasma
agitation,” Stem Cell Research, 2013.
[184] P. Attri, B. Arora, and E. H. Choi, “Utility of plasma: a new
road from physics to chemistry,” RSC Advances, vol. 3, no. 31,
pp. 12540–12567, 2013.
[185] J. Zheng, R. Yang, L. Xie, J. Qu, Y. Liu, and X. Li, “Plasma-
assisted approaches in inorganic nanostructure fabrication,”
Advanced Materials, vol. 22, no. 13, pp. 1451–1473, 2010.
[186] M. J. Dalby, N. Gadegaard, and C. D. W. Wilkinson, “The
response of fibroblasts to hexagonal nanotopography fabricated
by electron beam lithography,” Journal of Biomedical Materials
Research A, vol. 84, no. 4, pp. 973–979, 2008.
[187] S. Simovic, D. Losic, and K. Vasilev, “Controlled drug release
from porous materials by plasma polymer deposition,” Chemi-
cal Communications, vol. 46, no. 8, pp. 1317–1319, 2010.
[188] R. J. Anthony, K. Y. Cheng, Z. C. Holman, R. J. Holmes, and U.
R. Kortshagen, “An all-gas-phase approach for the fabrication
of silicon nanocrystal light-emitting devices,” Nano Letters, vol.
12, no. 6, pp. 2822–2825, 2012.
[189] S. Kumar, I. Levchenko, K. Ostrikov, and J. A. McLaughlin,
“Plasma-enabled, catalyst-free growth of carbon nanotubes on
mechanically-written Si features with arbitrary shape,” Carbon,
vol. 50, no. 1, pp. 325–329, 2012.
[190] X. Z. Huang, X. X. Zhong, Y. Lu et al., “Plasmonic Ag nanopar-
ticles via environment-benign atmospheric microplasma elec-
trochemistry,”Nanotechnology, vol. 24, no. 9, Article ID 095604,
2013.
[191] H. R. Maurer and H. Kersten, “On the heating of nano- and
microparticles in process plasmas,” Journal of Physics D, vol. 44,
no. 17, Article ID 174029, 2011.
[192] M. Shiratani, K. Koga, S. Ando et al., “Single step method to
deposit Si quantum dot films using H
2
+ SiH
4
VHF discharges
and electronmobility in a Si quantumdot solar cell,” Surface and
Coatings Technology, vol. 201, no. 9–11, pp. 5468–5471, 2007.
[193] S. Kumar, I. Levchenko, M. Keidar, and K. Ostrikov, “Plasma-
enabled growth of separated, vertically aligned copper-capped
carbon nanocones on silicon,” Applied Physics Letters, vol. 97,
no. 15, Article ID 151503, 2010.
[194] S. Kumar and K. Ostrikov, “Unidirectional arrays of vertically
standing graphenes in reactive plasmas,” Nanoscale, vol. 3, no.
10, pp. 4296–4300, 2011.
[195] S. Chattopadhyay, Y. F. Huang, Y. J. Jen, A. Ganguly, K. H. Chen,
and L. C. Chen, “Anti-reflecting and photonic nanostructures,”
Materials Science and Engineering R, vol. 69, no. 1–3, pp. 1–35,
2010.
[196] C. Cha, S. R. Shin, N. Annabi, M. R. Dokmeci, and A.
Khademhosseini, “Carbon-based nanomaterials: multifunc-
tional materials for biomedical engineering,” ACS Nano, vol. 7,
no. 4, pp. 2891–2897, 2013.
Hindawi Publishing Corporation
Journal of Nanomaterials
Volume 2013, Article ID 842951, 8 pages
http://dx.doi.org/10.1155/2013/842951
Research Article
Release Kinetics and Antibacterial Efficacy of Microporous
𝛽-TCP Coatings
Michael Seidenstuecker,1 Yahya Mrestani,2 Reinhard H. H. Neubert,2
Anke Bernstein,1 and Hermann O. Mayr1
1 Department of Orthopedics and Trauma Surgery, University of Freiburg Medical Center, Hugstetter Str. 55, 79106 Freiburg, Germany
2 Faculty of Natural Sciences I, Institute of Pharmacy, Martin-Luther-University, Wolf-Langenbeck-Str. 4, 06120 Halle/Saale, Germany
Correspondence should be addressed to Michael Seidenstuecker; michael.seidenstuecker@uniklinik-freiburg.de
Received 26 July 2013; Accepted 27 October 2013
Academic Editor: Krasimir Vasilev
Copyright © 2013 Michael Seidenstuecker et al.This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Purpose. The aim of this study was to impregnate microporous 𝛽-TCP scaffolds with different antibiotic solutions and to determine
their release behavior. Materials and Methods. We impregnated a 𝛽-TCP scaffold with antibiotics by using three methods: drop,
dip, and stream coating with 120mg/mL of antibiotic solution. After drying for 72 h at 37∘C, 2 mL of distilled water was added to
the antibiotic-coated plugs and incubated at 37∘C. After defined time points (1, 2, 3, 6, 9, and 14 days), the liquid was completely
replaced. The extracted liquid was analyzed by capillary zone electrophoresis and the Kirby Bauer disc diffusion test. For statistical
analysis, we calculated a mean and standard deviation and carried out an analysis of variance using ANOVA. Results. The VAN and
CLI release from the 𝛽-TCP scaffolds was rapid, occurring within 24 h with 89 ± 0.8% VAN and 90.4 ± 1.5% CLI regardless of the
type of insulation. After six days, the VAN and CLI were completely released. All samples taken at later time points had a VAN or
CLI concentration below the detection limit of 4𝜇g/mL.The released amounts of VAN and CLI within the first three days revealed
antimicrobial activity.
1. Introduction
Osteoinductive calcium phosphate ceramics are suitable
materials for delivery systems [1–5].This applies in particular
to the release of drugs to prevent bone infection. Local
drug delivery is especially valuable in association with bone
infection since it spares patients the adverse effects of system-
atically administrated drugs, reduces the risks from resistant
bacteria, and enables a high concentration of medication
at the infection site [6]. A variety of materials have been
used as carriers for the local delivery of antibiotics. These
materials are classified as biodegradable or nondegradable.
The most commonly used of the non-degradable material
is PMMA, which is often impregnated with antibiotics such
as gentamycin, clindamycin, or vancomycin. PMMA is not
only used as a bone cement or with an antibiotic offset
bone cement like PALACOS R+G, but also as antibiotic-
impregnated PMMA beads such as SEPTOPAL chains which
have been on the market for the last two decades. The major
drawback associated with PMMA beads is that they must be
surgically removed after exposure to antibiotic release, which
usually takes place four weeks after their implantation [7].
The use of biodegradable materials could therefore be advan-
tageous to eliminate the need for a second operation. The
most widely used biodegradable materials are polyglycolide
and polylactide (PLGA/PLLA). PLGA and PLLA can be used
as scaffolds [8], as biodegradable interference screws [9], as
coating [5, 10], or as a composite material in combination
with other biodegradable materials [11–13]. A disadvantage
of polylactide-based materials is that they contain acidic
degradation products [14].
Calcium phosphate ceramics (CPC) are suitable in this
respect also, since they too are biodegradable [15]. Thus,
various attempts have been made to combine CPC, mainly
hydroxyapatite (HA) and beta tricalciumphosphate (𝛽-TCP),
with antibiotics. Due to its better solubility in water, 𝛽-
TCP biodegrades faster [16]. HA and 𝛽-TCP have often
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been used as granules [17] or powder [1, 18], combined
with antibiotics. In most cases, the antibiotic was released
within 24 to 72 hours [5, 18, 19]. The powders and granules
are naturally very mechanically unstable. To produce TCP
materials with sufficient mechanical properties, the pores
must be small, and the porosity must be reduced to a value
approaching 40%. Our group showed that a 𝛽-TCP ceramic
with 5𝜇m interconnected micropores and with 40% porosity
demonstrates good mechanical stability [20]. It is therefore
suitable as a bone substitute material for fixation of cruciate
ligaments [20–22] and as a scaffold for bone tissue engineer-
ing. Due to the interconnected microporosity, the ceramic
is also suitable as a drug release system. Microporous 𝛽-
TCP ceramics can serve both as a prevention measure and to
treat surgical site infections (SSI), because it is mechanically
more stable than macroporous 𝛽-TCP or granules. We thus
loaded microporous ceramic materials with antibiotics for
SSI-prevention purposes applying three different methods.
We expected the TCP scaffold loaded with antibiotics (AB)
to release antibiotics continuously over a period of weeks.We
also anticipated that the loading procedure would not trigger
a loss of antimicrobial activity. SSI lead to an alteration in the
local pH level in the bone [23, 24].Therefore, all experiments
were conducted at a pH value of 5.0 and 7.4 to simulate
realistic in vitro conditions
2. Materials and Methods
2.1. Preparation of𝛽-TCPCeramics. Toproduce𝛽-TCPplugs,
80 g of 𝛼-tricalcium phosphate (𝛼-TCP; Ca
3
(PO
4
)
2
) and 20 g
of tricalcium phosphate (Art no 102143, Merck, Switzerland;
mixture of an apatite and some calcium hydrogen phosphate)
were mixed with 60.0 ± 0.2 g of a solution containing
0.2M Na
2
HPO
4
and +1% polyacrylic acid (Art. No 81132,
Fluka, Switzerland; Mw = 5.1 kDa). After 2.5min of intensive
stirring, the paste was poured into plastic syringes whose
tip had been cut off (Ø = 23mm). After 45 minutes, the
hardened paste was covered with 10mL of PBS 7.4 solution
and incubated for 3 days at 60∘C. The samples (Ø = 23mm;
𝐿 ≈ 70mm) were then dried at the same temperature and
sintered at 1250∘C for 4 h. Heating and cooling took place at
1∘C/min. The cylinders were then machined to obtain plugs
of 25mm long and 10mm in diameter. The last 2.5mm of
the plugs was given a spherical shape. The samples were
then washed in ethanol to remove residual wear particles and
calcined at 900∘C to burn off all organic residues.
2.2. Characterization of 𝛽-TCP Ceramics. X-ray diffraction
(XRD) was performed on a Bruker axs D8 Advance X-
ray diffractometer (Billerica, USA) using CuK
𝛼
radiation at
40 kV and 40mA. An XRD spectrum was obtained between
20∘ and 40∘ (2𝜃) in 0.01∘ steps. The XRD spectra of our
samples were compared to the standard spectra of 𝛽-TCP
from the Joint Committee on Powder Diffraction (JCPDS)
database (𝛽-TCP = JCPDS 9-169). Porosity was assessed
on a POROTEC Pascal 440 (Hofheim, Germany) mercury
porosimeter. To detect the morphology and for elementary
analysis, we used a PHILIPS XL 30 ESEM FEG (Hamburg,
Germany) and an FEI QUANTA 250 FEG (Hillsboro, USA)
with EDX unit. All images were taken with a backscattered
electron detector. For the ESEM investigations, the 𝛽-TCP
plugs were broken in the middle with a DUMONT (Mon-
tignez, Switzerland) cutting forceps and the breach area was
investigated. Because of using ESEM, there was no special
coating (carbon or gold) necessary on this breach area to
achieve better contrast between ceramics and antibiotics.
2.3. Sample Preparation. Vancomycin- (VAN-) hydrochlo-
ride (Cell Pharm, Hannover, Germany) and Clindamycin
(CLI) 2-phosphate (MP Biomedicals, Illkirch, France) solu-
tion with concentrations of 40, 80, and 120mg/mL were pre-
paredwith deionizedwater.The𝛽-TCP scaffoldswere divided
using a diamond band saw Exakt 310 (Exakt, Norderstedt,
Germany) into segments of 3mm ×Ø10mm.These segments
werewashed in pure ethanol (Carl Roth, Germany) to remove
the sawdust and dried at 37∘C for 24 h. Then they were
weighed with a Scaltec SBA 32 scale (Goettingen, Germany)
and stored in a compartment dryer at 37∘C. Ten samples were
used for each coating method.The loading experiments were
carried out in triplicate.
Dip Coating. Dip coating was done in 24-well cell culture
plates with 2mL quantities of 40, 80, and 120mg/mL VAN
and CLI solutions. The scaffolds were incubated in the
solutions for 24 h at room temperature (RT), transferred into
other 24-well cell culture plates, and dried for 72 h at 37∘C.
Drop Coating. Drop coating was done in 24-well cell culture
plates. A drop of 125 𝜇L of the 40, 80, and 120mg/mL VAN
or CLI solutions was placed on the front of the cylindrical
scaffold. The 24-well plates were sealed with Parafilm M
(Pechiney Plastic Packaging, Chicago, USA). After 2 h of
incubation at RT, the scaffold was turned over and a further
125 𝜇L drop of 40, 80 and 120mg/mL or VAN CLI solution
was placed on the other front. After 2 h of incubation at RT,
the scaffolds were placed in a clean 24 well plate and dried for
72 h at 37∘C.
Stream Coating. A third coating method was used to coat
the TCP scaffolds with antibiotics. Because of its setup, we
call this method “stream coating.” The scaffolds were put in
a 5mL syringe. The punch was pulled out and the ceramic
scaffold was placed directly onto the syringe outlet. Then the
scaffold was overlaid with 5mL of antibiotic solution. Four
mL of the solution was pressed through the scaffold, so that a
constant supernatant of VAN solution remained beyond the
scaffold. Pressures were increased by a 0.45 𝜇m syringe filter.
The scaffolds were then transferred to clean 24 well plates
(TPP) and dried at 37∘C for 72 h in a compartment dryer.
All samples were briefly swilled in deionized water after
the drying procedure to remove the AB from the outer sur-
face. The antibiotics’ load amounts for each coating method
were determined by weight in triplicate.
2.4. Drug Release. To assess the amount of antibiotic loaded,
the drug-loaded scaffolds were weighed again and placed in
24-well plates. Two unloaded scaffolds were used as blanks.
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Each 24-well plate was filled with 2mL of deionized water,
sealed with PARAFILM, and incubated at 37∘C. All tests were
conducted at pH values of 7.4 and 5.0. To setup a pH of 5.0,
0.1MHClwas used. After 1, 2, 3, 6, 9, and 14 days, the scaffolds
were removed and placed into new 24-well plates filled
with 2mL of deionized water. The solutions thus obtained
were stored at −4∘C for examination by capillary zone
electrophoresis (CZE) and disc diffusion method (DDM).
2.5. Capillary Zone Electrophoresis. CZE experiments were
performed on a Beckman Coulter P/ACE MDQ Molecular
Characterization System (Brea, USA) with a 40.5 cm fused
silica capillary (31 cm to detector) and 50 𝜇m inner diameter.
The analytic conditions were: field strength: 20 kV, tempera-
ture during measurement: 25∘C, and injection pressure: 2 psi
for 6 s. The detection wavelengths were 221 nm (VAN) and
200 nm (CLI). We prepared fresh running buffers, citric acid
buffer, pH 3.2 to detect VAN and borate buffer, pH 9.2 to
detect CLI [25].The capillarywas flushed for 6minwith 0.1M
NaOH, 6min with deionized water, and 6min with running
buffer at a pressure of 20 psi before injecting each sample. All
samples were measured in triplicate by UV.
2.6. Disc Diffusion Method. The released amounts of VAN
and CLI were tested with a standard NCCLS disc diffusion
test. DDM was performed on Mueller-Hinton agar (Carl
Roth, Germany). A suspension of Staphylococcus aureus
ATCC25923with a 0.5McFarland standardwas placed on the
Mueller-Hinton agar. OXOID paper discs (Wesel, Germany)
were moistened with 10 𝜇L sample liquid and placed on
Mueller Hinton agar. OXOID paper discs with 5 and 30 𝜇g
VAN and 2 and 10 𝜇g CLI were used as standards. After 24 h
incubation at 37∘C, the zone diameters were measured in the
usual manner.
2.7. Statistical Analysis. Origin 8.5.1 Professional (OriginLab
Corporation, Northhampton,USA)was used for graphic pre-
sentations and statistical analysis. A probability of error (𝑃)
of less than 0.05 was defined as significant. All samples were
measured in triplicate. Normal distribution was ascertained
by means of the Shapiro-Wilk-Test. The Mann-Whitney Test
was used to compare mean values.
3. Results
3.1. Characterization of 𝛽-TCP Ceramics. The EDX spectrum
(Figure 1) shows that the chemical composition on the surface
of the samples is made up of only Ca, P, and O atoms, as
would be expected in calcium phosphate ceramics such as
𝛽-TCP. A quantification of the EDX spectra (only Ca and P
without standards and with theoretical k-factors) results in
60 at% Ca and 40 at% P, that is, a Ca/P ratio of 1.5 and this is
equal to TCP. Figure 2 shows an XRD pattern of our 𝛽-TCP
sample in powder form (b) and the 𝛽-TCP standard from the
JCPDS database (𝛽-TCP = JCPDS 9-169) (a).The comparison
of the two XRD spectra reveals a clear consensus with no
signs of a further phase or a shift. Usingmercury porosimetry
we measured a mean pore radius of 2.44 ± 0.47 micron and
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Figure 1: EDX spectrum of 𝛽-TCP sample; spectrum taken with
Philips ESEM XL 30 FEG with 12 kV accelerator voltage and 100 sec
lifetime counting period.
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Figure 2: XRD patterns of the standard for 𝛽-TCP from JCPDS
database (𝛽-TCP = JCPDS 9-169) (a) and microporous 𝛽-TCP
sample (b).
a total porosity of 46 ± 1%. Figure 3 illustrates the pore size
distribution. We also found a small amount of nanoporosity;
the pore size distribution in Figure 3 shows a peak at 100 nm.
Figure 4 contains an ESEM image of this nanoporosity.
3.2. Coating Experiments. The average weight of the 𝛽-TCP
scaffolds before coating was 0.438 g ± 0.059 g (𝑁 = 90).
Table 1 summarizes our release-experiment results. The drop
coating methods produced the maximum charge amount in
all cases. The loading method we developed, in terms of load
quantity, is in the second place. The dip coating method
demonstrated the lowest load rate and took, compared to the
other methods, the longest time to complete.
3.3. Coated AB Examination via ESEM/EDX. Studies using
ESEM and EDX demonstrated that the antibiotic not only
adheres to the outer surface of the test specimens, but also
penetrates the core of the microporous ceramic. Figures 5
and 6 shows ESEM images that verify the diffusion of a sub-
stance into the porosities of the 𝛽-TCP scaffolds. The lighter
structures are 𝛽-TCP and the darker areas represent VAN or
CLI. Becausewe used a sensor for backscattered electrons, the
brightness of the calcium phosphate ceramics in the image
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0.01 0.1 1 10 100
0
30
60
90
120
150
180
210
240
270
300
1E − 3
Cu
m
ul
at
iv
e v
ol
um
e (
m
m
3
/g
)
Pore radius (𝜇m)
0
5
10
15
20
25
30
35
40
45
50
Re
lat
iv
e p
or
e v
ol
um
e (
%
)
Figure 3: Pore size distribution of microporous 𝛽-TCP ceramics.
Figure 4: Nanoporosity of 𝛽-TCP ceramics. Image taken with a
backscattered electron detector, 10 kV accelerator voltage, pressure
of 90 Pa, and magnification 30000x.
Table 1: Comparison of coating methods, quantities of antibiotics
in the porous ceramics, and load duration (𝑁 = 10).
Coating
Load quantity of AB [26] achieved with
AB solution of Loadduration
40mg/mL 80mg/mL 120mg/mL
Drop
coating 9.8 ± 2.3 14.7 ± 3.7 29.5 ± 2.5 4 h
Stream
coating 6.7 ± 1.3 11 ± 2.7 20.6 ± 3.6 5min
Dip
coating 9.4 ± 0.79 9.4 ± 1.9 16.1 ± 2.7 1 d
is an indication of the higher atomic number of Ca. As the
antibiotics mainly consist of carbon, they appear darker in
the photograph. The white bars in Figure 6 reveal VAN’s
penetration depths into the porous ceramics in case of dip and
drop coating.The penetration depth of drop-coated ceramics
was on average 1000𝜇m ± 127𝜇mand of dip-coated ceramics
amean 350 𝜇m±68𝜇m.TheEDX spectra in Figure 7 confirm
this by virtue of the presence of carbon, chloride and
Table 2: Recovery rate of VAN using CZE (𝑁 = 10).
Coating
method
Quantity of AB
in scaffold (mg)
Quantity of AB
recovered from
scaffold by CZE
(mg)
Recovery rate
(%)
Drop coating
pH 7.4 (VAN) 29.5 ± 2.5 27.2 92.2
Drop coating
pH 5.0 (VAN) 29.5 ± 2.5 29.1 98.6
Dip coating
pH 7.4 (VAN) 16.6 ± 1.3 16.04 96.6
Dip coating
pH 5.0 (VAN) 16.1 ± 2.7 14.5 89.8
Stream coating
pH 7.4 (VAN) 20.6 ± 3.6 19.5 94.5
Drop coating
pH 7.4 (CLI) 22.2 ± 2.8 22.0 99.1
Dip coating
pH 7.4 (CLI) 23.5 ± 2.9 23.4 99.6
sulfur, as VAN was available as VAN-HCl; we thus used the
chloride as a marker element. Sulphur was employed as the
elemental marker for CLI. Carbon is not found in the scaffold
material in the quantities identified here, and chloride and
sulphur never occur. In the EDXmeasurements we identified
traces of carbon detected in the unloaded 𝛽-TCP samples.
Those could be carbon residues from the microporous
ceramics’ manufacturing process. Further ESEM measure-
ments were taken to ascertain how deeply VAN and CLI
diffuse into the scaffold to rule out the possibility that
the antibiotics were located exclusively on the scaffolds’
perimeter.
3.4. Drug Release. These drug release experiments were
conducted using 24-well cell culture plates with deionized
water at pH 5.0, corresponding to the altered pH in the
presence of inflammation, and pH 7.4. However, we detected
no significant difference between the two pH values in the
quantities of VAN released.The drip-coated scaffolds showed
greater release of VAN during the first 24 h because of
the higher quantity of VAN available: 29.5 ± 2.5mg was
transferred to the scaffolds and 26.3 ± 2.9mg was released
within 24 h. In contrast, the dip-coated scaffolds were loaded
with 16.1 ± 2.7mg VAN and released 14.3 ± 0.8mg VAN
within 24 h (Figure 8). The stream coating method achieved
a load of 20.8 ± 3.6mg VAN, and 16.9 ± 2.5mg of VAN was
released after 24 h.
VAN was released rapidly at both pH values: 88.25 ±
3.6% within 24 h. The release of CLI was also rapid: 90.4 ±
1.5% within 24 h. The VAN and CLI releases were complete
after 6 days. All samples taken at later time points had a
VAN concentration below the detection limit of 1 𝜇g/mL or a
CLI concentration below the detection limit of 2𝜇g/mL. The
proportion of released VAN recovered by means of CZE was
94.3 ± 4.1%, and for CLI 99.4 ± 0.4%.
A comparison of the coated and recovered quantities of
VAN and CLI is shown in Table 2.
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(a) (b)
Figure 5: ESEM images of 𝛽-TCP impregnated (dip coating) with antibiotics. (a) CLI coating; (b) VAN coating. Images taken with a
backscattered electron detector, 10 kV accelerator voltage, pressure of 90 Pa, andmagnification 4000x; the calcium phosphate ceramic appears
(due toCa’s higher atomic number) brighter than the antibiotics, which consistmainly of hydrocarbons. All imageswere taken from the breach
area.
100𝜇m
100𝜇m
(a)
100𝜇m
100𝜇m
(b)
Figure 6: ESEM images of 𝛽-TCP. Comparison of VAN’s penetration depth into the ceramics: breach area of cylindrical ceramics, breach
along boresight, (a) drop coating; (b) dip coating; each image is a combination of three individual images taken with PHILIPS ESEM XL 30
FEG using a backscattered electron detector, 12 kV accelerator voltage, pressure of 100 Pa, magnification 500x, and the calcium phosphate
ceramic appears (due to Ca’s higher atomic number) brighter than the antibiotics, which consist mainly of hydrocarbons; top: frontal area
(where the drop was placed in case of drop coating) bottom: center of ceramic cylinder and the small images are enlargements of image
sections; the upper enlargement displays filled porosity and the lower empty porosity.
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Figure 7: EDX spectra of clindamycin (a) and vancomycin (b) compared to 𝛽-TCP (c); spectra taken with a PHILIPS XL 30 FEG ESEMwith
EDX unit, with 12 kV accelerator voltage and 100 sec lifetime counting period.
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Figure 8: Comparison of release kinetics: (a) cumulative release; (b) daily release.
3.5. Disc Diffusion Method. The antimicrobial activity of the
released VAN is shown in Table 3.We observed antimicrobial
activity only on the first 3 days; at later times, the amounts
released were below the MIC [27, 28] and also below the
detection limit of 1𝜇g/mL [29].
4. Discussion
Elemental analyses proved unequivocally that the samples
consist of pure phased beta-TCP. This material has also been
used in previous studies [20, 21, 30] because it is more highly
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Table 3: Released VAN concentrations and inhibition circles at
different time points (𝑁 = 3).
Day of
sampling
Vancomycin concentration
(mg/mL) detected via CZE
Inhibition circle
diameter (cm)
1 28.37 1.97 ± 0.23
2 2.66 1.8 ± 0.1
3 0.20 0.97 ± 0.06
6 0.02 0 ± 0
9 0.003 0 ± 0
13 0 0 ± 0
water-soluble than hydroxylapatite [16].The sintered molded
body of 𝛽-TCP exhibited a microporous structure, while in
the literature 𝛽-TCP only as granules or as a powder [1, 31],
incorporated in calcium phosphate cement [32, 33] or in the
form of a macroporous scaffold such as macroporous DePuy
Synthes chronOS.
With regard to filling the ceramics using ESEM and EDX,
we detected antibiotics within themicroporous ceramic; such
antibiotic penetration has not been demonstrated before, as
so far, the antibiotic has only been demonstrated on the
ceramic’s surface or barely under it.
If one compares how we loaded the ceramic with the
dip coating described by Y. Zhang and M. Zhang [34] and
Alkhraisat et al. [35], one observes that stream coating is
superior to the latter in terms of the time it takes to load while
loading the same amount of antibiotic.
(See Table 1) Hofmann et al. [33] describe results similar
to ours, namely a burst of vancomycin release within the first
24 hours. Examining calcium sulfate cements, Hesaraki et al.
[36] observed similar release characteristics as we did in our
experiments, which barely released anything after 72 h.
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The last decade has witnessed enormous advances in the development and application of nanotechnology in cancer detection,
diagnosis, and therapy culminating in the development of the nascent field of “cancer nanomedicine.” A nanoparticle as per
the National Institutes of Health (NIH) guidelines is any material that is used in the formulation of a drug resulting in a final
product smaller than 1 micron in size. Nanoparticle-based therapeutic systems have gained immense popularity due to their
ability to overcome biological barriers, effectively deliver hydrophobic therapies, and preferentially target disease sites. Currently,
many formulations of nanocarriers are utilized including lipid-based, polymeric and branched polymeric, metal-based, magnetic,
and mesoporous silica. Innovative strategies have been employed to exploit the multicomponent, three-dimensional constructs
imparting multifunctional capabilities. Engineering such designs allows simultaneous drug delivery of chemotherapeutics and
anticancer gene therapies to site-specific targets. In lung cancer, nanoparticle-based therapeutics is paving the way in the diagnosis,
imaging, screening, and treatment of primary and metastatic tumors. However, translating such advances from the bench to the
bedside has been severely hampered by challenges encountered in the areas of pharmacology, toxicology, immunology, large-scale
manufacturing, and regulatory issues.This review summarizes current progress and challenges in nanoparticle-based drug delivery
systems, citing recent examples targeted at lung cancer treatment.
1. Introduction
Worldwide lung cancer is the leading cause of cancer-related
deathswith a dismal 5-year survival rate of only 15% [1]. Every
year in the United States approximately 220,000 individuals
are diagnosed with lung cancer of which 85% of the cases
are classified as non-small-cell lung carcinoma (NSCLC) [1]
while the remaining cases are diagnosed as small-cell lung
carcinoma (SCLC). Current treatment strategies are strongly
dependent on the type of malignancy and stage at the time
of diagnosis but often involve a combination of surgery,
chemotherapy, and/or radiation therapy.
Chemotherapy, a first-line treatment option for ad-
vanced-stage lung cancer, is often administered intravenously
where it circulates throughout the body ultimately locat-
ing and destroying cancerous and normal tissues. Standard
first-line chemotherapy regimens for lung cancer include
platinum-based drugs such as cisplatin and carboplatin.
However, platinum-based chemotherapy is riddled with
dose-limiting side effects including nephro- and cardiotox-
icity, anemia, intestinal injury, and peripheral neuropathy
as well as less serious symptoms of uneasiness, nausea,
and fatigue. To mitigate many of these untoward effects,
platinum drugs are used in combination with other anti-
cancer agents. Combination therapy involving two to three
drugs increases the therapeutic effectiveness and reduces
the dosage of each individual drug required to produce
an observable therapeutic response. Common chemothera-
peutic agents for combination therapy include a platinum
drug with paclitaxel, gemcitabine, etoposide, or vinblastine.
However, like monotherapy, combination therapy is limited
by dose-dependent side effects and patient’s intolerability
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to the drug combination resulting in cessation of treatment
[2]. Additionally, the hydrophobic nature of the majority
of the cancer chemotherapeutics makes them poorly water
soluble and therefore limits their administration at high doses
[3, 4]. Thus, methods to improve tumor-targeted delivery of
chemotherapeutics that will result in increased drug efficacy
with improved pharmacological properties and minimal
toxicity to normal tissues remain a priority in cancer therapy.
Experimental therapies such as photodynamic therapy
(PDT), immunotherapy, and gene therapy provide promising
tools to fight lung cancer. In PDT, a photosensitizer activated
by laser light reacts with molecular oxygen to form reactive
oxygen species that function to annihilate cancer cells [5].
PDT is often used in combination with chemotherapy or
surgery. Porfimer sodium, a first-generation photosensitizer,
has been used in the treatment of early as well as advanced
lung carcinomas.More improved and efficient PDTagents are
currently available as a result of the extensive research efforts
in the last two decades. However, many of these photosen-
sitizers are poorly water soluble fettering their intravenous
administration [6].
Immunotherapy harnesses the body’s immune system to
fight cancer. Biomolecules or antigens are administered to
either trigger the immune system or reduce the immune
suppressing activities of the tumor [7]. Administration of
immunologically active agents disrupts the tumorigenic
cascades by directly blocking growth factors or hormones
and their receptors. Certain cancers including lung cancer
overexpress growth factor receptors such as the epider-
mal growth factor receptor (EGFR/Her1). Binding of the
ligand epidermal growth factor (EGF) to EGFR activates
cell proliferation and survival signaling pathways resulting
in rapid and uncontrolled tumor growth. Cetuximab, a
competitive anti-EGFR monoclonal antibody, counteracts
the cell proliferation signaling mediated by the endogenous
EGF ligand culminating in attenuation of the cell survival
signals and induction of tumor cell death. Gene therapy is a
relatively new concept with a large number of research teams
worldwide in active pursuit of identifying and delivering
cancer-suppressing genes for clinical applications [8]. Deliv-
ery vectors are a necessity in order to protect the therapeutic
genes until they reach their target site. Historically, viral
vectors have been used to deliver gene-based therapeutics
[9]; however, viral vector induced host immune responses
limits their therapeutic potential [10]. Definitively, there is a
growing need for development of safe and efficient delivery
vehicles for photosensitizers, chemotherapeutics, and tumor
suppressor genes.
Nanotechnology is not pervaded by some of the lim-
itations of viral vectors providing an avenue of incredible
potential for development of tumor-targeting drug delivery
systems. This continuously expanding niche will revolution-
ize cancer treatment and management [11]. More precisely,
nanoscale drug delivery systems hold great promise in suc-
cessfully formulating and enhancing the therapeutic efficacy
of a large number of anticancer agents [12]. Nanoparticles
are known to positively alter biodistribution increasing ther-
apeutic efficiency and reducing nonspecific toxicity of potent
anticancer drugs. Their superior biocompatibility, ability to
protect nucleic acids from degradation, and ability to deliver
therapeutic genes to cancer cells in vivo make nanoparticles
the ideal delivery vehicle [13, 14]. While many nanoparticle-
based therapies have been developed, such as Abraxane, an
albumin-bound paclitaxel nanoformulation for the treatment
of metastatic NSCLC [15], few have been translated into
clinical success. It continues to be a challenge to identify ideal
drug delivery systems for several classes of novel drugs with
different physicochemical characteristics and varying degrees
of therapeutic activities in the physiological environment.
This review summarizes current progress and challenges
in nanoparticle-based drug delivery systems, citing recent
examples of applying nanomedicine for lung cancer treat-
ment.
2. Progress in Nanoparticle Drug/Gene
Delivery Systems
2.1. Lipid-Based Nanocarriers. Liposomes, oil dispersions
(micelles), and lipid nanoparticles are the major classes
of lipid-based nanocarriers for drug and gene delivery
applications. Liposomes are bilayered phospholipid vesicles
commonly used to deliver hydrophobic and hydrophilic
drugs through either incorporation in the lipid bilayer itself
or encapsulation in the inner aqueous core, respectively.
Reduction of the number of lipid bilayers reduces the size of
the liposomes to nanosize increasing the circulation time and
tumor localization properties of encapsulated drugs [16].
Liposomes are becoming increasingly more popular
delivery vehicles for anticancer therapeutics due to their
strong biocompatibility properties. Over the last decade,
the liposomal research field has boomed generating many
new liposomal formulations such as cationic liposomes [17],
virosomes [18], temperature-sensitive liposomes [19], and
archaeosomes [20]. Despite these huge advances at the
bench, currently there are only two FDA-approved liposomal
formulations: DOXIL, a liposomal doxorubicin injection for
ovarian cancer, andMarqibo, a liposomal vincristine sulphate
injection for lymphoblastic leukemia.
In lung cancer treatment, liposomes may be a promising
delivery system for drugs and genes. The drug of choice for
the treatment of NSCLC for the last two decades, cisplatin,
is implicated in the development of nephrotoxicity in 20%
of patients receiving high doses [21]. In 2004, Boulikas
developed a liposome-based cisplatin drug called Lipoplatin
to reduce systemic toxicity of cisplatin [22]. Furthermore,
these researchers also demonstrated that lipoplatin injection
compared to standard therapy significantly reduced nephro-
toxicity to negligible levels in multiple rat tumor models
[23]. According to a recent report, lipoplatin is anticipated to
complete phase III clinical trial testing in 2013 and 2014 [24].
Paclitaxel, another chemotherapeutic drug widely used in the
treatment of lung cancer, was historically formulated using
Cremophore EL to enhance its solubility in physiological
fluids. However, this resulted in hypersensitivity reactions
complicating its systemic delivery. In 2010, a phase I clinical
trial in NSCLC patients with malignant pleural effusions
demonstrated in all cases investigated that treatment with
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paclitaxel formulated with a liposomal carrier had enhanced
therapeutic efficacy [25]. Moreover, a recent preclinical study
has shown that liposomal-paclitaxel formulation can be
modified to target lung cancer cells to reduce the inci-
dence of drug resistance [26]. Specifically, the liposomal
surface was decorated with the mitochondrial targeting
molecule d-𝛼-tocopheryl polyethylene glycol 1000 succinate-
triphenylphosphine conjugate (TPGS1000-TPP). These tar-
geted paclitaxel liposomes could significantly enhance their
cellular uptake inducing mitochondria-mediated apoptotic
cell death in humanA549 lung cancer cells. At present Lipusu,
a paclitaxel-liposome, is commercially available with several
other formulations under clinical investigation [27]. Table 1
lists current examples of liposomal formulations undergoing
clinical trials intended for the treatment of cancer. In a
randomized phase III multicenter trial, liposomal formula-
tion of cisplatin and paclitaxel combination therapy reached
effective therapeutic response while reducing nephrotoxicity
in NSCLC patients [28]. Interestingly, this liposomal drug
combination is reported to not only improve the targeting
efficiency to the primary tumor but also be effective against
metastasis.
Liposomes have also been used to deliver cancer vaccines
for the prevention or treatment of existing cancers. Studies
using therapeutic vaccine Biomira Liposomal Protein 25
(BLP25) have shown encouraging results in the treatment of
advanced NSCLC [29]. BLP25 uses a liposomal carrier that
targets the tumor-associated antigenMUC1 to prevent tumor
growth. A preclinical study in a human MUC1 transgenic
lung cancer mouse model (hMUC1.Tg) demonstrated that
pretreatment with a low dose of cyclophosphamide followed
by two cycles of liposome BLP25 treatment significantly
reduced the number of tumor foci [30]. Importantly, phase III
clinical studies using liposomeBLP25 are currently underway
[31].
Studies from our own laboratory have shown that
lipid based nanocarriers can be effectively used for gene
delivery in mouse lung cancer models. Preclinical studies
using the nontargeted nanoparticle system 1,2-dioleoyl-3-
Trimethylammonium Propane (DOTAP):cholesterol (Chol.)
carrying tumor suppressor genes such as p53, TUSC2/FUS1,
ormda-7/IL-24 [32] efficiently delivered therapeutic genes to
metastatic tumor sites culminating in a significant therapeu-
tic effect with increased animal survival. Preclinical studies
from our laboratory demonstrating efficacy and safety of
the DOTAP:Chol. nanoparticle system resulted in its clinical
testing for delivery of the TUSC2/FUS1 tumor suppressor
gene in NSCLC patients. Results from the phase I clinical
trial demonstrated that intravenous administration ofTUSC2
encapsulated in our DOTAP:Chol. nanoparticle system was
safe and well tolerated with no treatment-related toxicity.
Additionally, study results showed that the nanoparticles
were efficiently taken up by primary and metastatic tumors,
expression of transgene and gene products occurred, and spe-
cific alterations in TUSC2-regulated signaling pathways were
observed [32]. Results from this trial have led to discussion
for initiating a phase II study for lung cancer. Additional
phase I trials testing DOTAP:Chol.-based nanoparticle ther-
apy for breast, ovarian, andpancreatic cancers are anticipated.
The therapeutic genes to be deliveredwill vary and depend on
the cancer type.
Solid lipid nanocarriers (SLNs) are another class of vehi-
cle for drug and gene delivery. SLNs are superior to their lipid
counterparts in their enhanced stability, high drug loading,
improved biocompatibility, and ease of large-scale manufac-
turing production. Choi et al. [33] transfected p53-null H1299
lung cancer cells with SLN-carrier p53. The authors were able
to demonstrate efficient p53 protein expression compared
to commercially available Lipofectin suggesting that SLNs
could be used as highly efficient gene therapy vehicles in
lung cancer. In a recent report, researchers successfully
loaded SLNs with Bcl-2 siRNA and paclitaxel for synergistic
combination therapy as well as coencapsulated CdSe/ZnS
quantum dots to bestow optical traceability [34]. Collectively,
the properties of SLNs are ideally suited for combined chemo-
and/or gene-therapy and molecular imaging of cancer.
2.2. Polymeric Nanoparticles. As the name suggests, poly-
meric nanoparticles are synthesized from polymers. More
recently, biodegradable polymers such as poly(lactic acid)
(PLA), poly(lactic-co-glycolic) acid (PLGA), gelatin, albu-
min, chitosan, polycaprolactone, and poly-alkyl-cyanoacryl-
ates have gained popularity in use because of their con-
trolled and sustained release properties, subcellular size, and
biocompatibility. For instance, Abraxane, an FDA-approved
albumin-based nanoparticle carrying paclitaxel, is indicated
for first-line treatment of locally advanced or metastatic
NSCLC in combination with carboplatin in patients who
are not candidates for curative surgery or radiation ther-
apy. Polymer nanoparticles have been shown to enhance
the chemo- and radio-therapeutic efficacy of anticancer
agents [35]. Chemoradiation therapy involves the concurrent
administration of chemotherapy and radiotherapy for the
treatment of many cancers, including lung cancer. Chemora-
diation therapy is known to improve the local tumor control
and patient survival. Polyethylene glycol- (PEG-) modified
polylactic acid nanoparticles loaded with taxanes have sig-
nificantly improved the efficacy of chemoradiation therapy
in both in vitro and in an A549 lung tumor xenograft model
[36]. Other research groups have developed a cremophor-
free nanoformulation of paclitaxel and cisplatin using block
copolymers of PEG and polylactic acid for the treatment of
lung cancer [37]. This nanoformulation called Genexol-PM
has entered phase II clinical trials in patients with advanced
NSCLC. A separate phase II clinical trial is awaiting results
for the same nanocarrier modified to deliver gemcitabine
to untreated patients diagnosed with metastatic lung cancer
[38].
Traditional anticancer agents are loathed for their repug-
nant side effects including the discomfort and pain associated
with their administration. Historically, oral drug delivery
methods have not been feasible for the treatment of lung
cancer due to the inability of the therapeutic to penetrate
lung tumor sites and achieve efficient therapeutic concentra-
tion even at high administered doses. The size, shape, and
surface charge of nanoparticles provide an avenue for the
development of novel routes of administration for anticancer
agents. Recently, Jiang et al. [39] investigated three different
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Table 1: Ongoing or recently completed clinical trials of a few liposomal nanoformulations used for cancer chemotherapy∗.
Trade name/composition Indication Phase Stage
PEGylated Liposomal Doxorubicin AIDS-associated non-Hodgkin’s lymphoma I Completed
Doxil/CAELYX Liposomal Doxorubicin Malignant female reproductive system neoplasm, Ovariancancer I Active
Doxil Liposomal Doxorubicin Resistant solid malignancies I Completed
Liposomal Cytarabine Central nervous system malignancies,Stage IV breast cancer II Active
Liposomal Entrapped Paclitaxel Easy to
Use (LEP-ETU) Advanced cancer I Completed
Liposomal Daunorubicin
Hematologic cancer,
Chronic myelomonocytic leukemia
previously treated Myelodysplastic syndromes and
recurrent adult Acute myeloid leukemia
II Completed
BLP25 Liposome Vaccine Lung neoplasmsNon-small-cell lung carcinoma II Completed
CPX-351
Liposomal Cytarabine-Daunorubicin Acute myeloid leukemia I Active
Liposomal Vincristine Acute lymphoblastic leukemia II Active
Liposomal LE-SN38 Advanced cancer I Completed
IHL-305
Irinotecan Liposome Injection Advanced solid tumours I Active
Liposome Encapsulated Mitoxantrone
(LEM) Advanced cancer I Completed
Liposomal Encapsulated Docetaxel
(LE-DT) Advanced solid tumours I Completed
∗Data retrieved from US National Institutes of Health website (http://clinicaltrials.gov/) on August 21, 2013.
polymer-based nanoparticles composed of polycaprolactone
(PCL) that were surface modified with chitosan polymer
for oral administration of chemotherapy in lung cancer. The
mucoadhesive properties of the polymer increased the ther-
apeutic effect of anticancer drugs by selectively interacting
with the increased levels of mucin expressed in cancer cells
compared to normal cells. Similarly, another study reported
the use of PCL-based diblock copolymer nanoparticles for
treating lung cancer via oral administration [40]. Interest-
ingly, this nanoparticle showed advantages over the com-
mercially available Taxotere, an injectable docetaxel, in terms
of cytotoxicity against lung cancer cells. Another research
group designed a chitosan-based controlled drug delivery
system to deliver the potent antineoplastic agent lomustine.
The lomustine-loaded chitosan nanoparticles demonstrated
excellent control over drug release and enhanced its in
vitro cytotoxicity against the lung cancer cell line L132 [41].
Recently, attention has turned towards polymer nanoparticles
with expansile properties for the treatment of lung cancer.
A Lewis lung carcinoma mouse model demonstrated that
following surgical intervention paclitaxel-loaded expansile
nanoparticles delayed the local recurrence of subcutaneous
lesions as well as modestly improved the overall survivability
of the tumor-bearing animals [42].
The advantage of combining PLA or PLGA nanoparticles
with chitosan has recently materialized. Chitosan modifica-
tion of drug- or gene-loaded PLGA nanoparticles imparts
a positive charge to the nanoparticle surface, which aids
in cellular uptake and cytotoxicity towards lung cancer
cells [43, 44]. Identifying the potential of chitosan-modified
nanoparticles as drug or gene delivery vehicles provides
an opportunity for combined chemo- and gene-therapeutic
approaches with same or similar kinds of nanoparticle
systems. Currently, our lab is developing a chitosan/PLA-
hybrid-based nanoparticle system for combined delivery of
chemotherapeutics and tumor suppressor genes for lung
cancer. The nanoparticles are designed such that the rigid
PLA polymer matrix containing the chemotherapeutic drug
forms the inner core and is surface coated with siRNA
or DNA containing chitosan and decorated with tumor-
targeting moieties. The nanoparticle is less than 200 nm in
size and is physicochemically stable for at least 10 days in
solution as well as having a drug encapsulation efficiency
greater than 90% (data unpublished). The ultrastructure of
this drug-loaded nanoparticle system is shown in Figure 1.
Polymer nanoparticles have been extensively used in
studies aimed at delivering targeted chemotherapeutics to
lung cancer. Tseng et al. [45] developed a gelatin nanopar-
ticle system decorated with EGFR-targeted biotinylated EGF
(bEGF).These nanoparticles demonstrated enhanced cellular
uptake in EGFR overexpressing cancer cell lines holding
promise for targeted lung cancer therapy. Building on this
strategy, the same group reported an aerosol-targeted therapy
in a mouse model for lung cancer using bEGF-gelatin
nanoparticles loaded with cisplatin [46]. The aerosol-based
targeted drug delivery system resulted in enhanced drug
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Figure 1: Transmission electron microscopy of cationic polymer
coated poly (lactic acid) nanoparticle carrying the anticancer drug
cisplatin.
concentrations in tumor tissues contributing to anticancer
activity while direct tumor injection with the nanoparticles
yielded high therapeutic efficacy and reduced systemic toxi-
city of cisplatin. Additionally, gelatin nanoparticles have also
been used for the delivery of the hydrophobic drug resveratrol
towards NSCLC cells [47].
Dendrimers are branched polymers with a large number
of functional groups that radiate from a central core pro-
viding the opportunity to link multiple bioactive molecules.
A recent study illustrated the use of dendrimer-targeting
peptide conjugates as a carrier for drugs towardsNSCLC [48].
These dendrimer-peptide conjugates when administered to
a lung tumor-bearing athymic mouse model were efficiently
taken up by the cancer cells demonstrating their potential as a
drug carrier for the treatment of lung cancer [48]. In a related
study, a newly designed PEGylated dendrimer nanoparticle
showed promising application as an aerosol-inhaled drug
delivery modality [49]. The smaller dendrimer particles are
reported to enter the blood stream via inhalation while larger
particles are sequestered in the lung for an extended period
of time. In the future, this method of controlled drug delivery
to the lungs could provide an alternative to injectable drug
systems. Starpharma Holdings Ltd., Australia, released the
primary data of a study utilizing delivery of dendrimer-based
doxorubicin to rats burdened with metastatic breast cancer
in the lungs [50]. The authors concluded that there was
substantial improvement in the efficacy of doxorubicin when
delivered using dendrimers.
Hybrid polymer nanoparticles composed of PLGA and
chitosan demonstrated enhanced tumor uptake and cytotoxi-
city compared to unmodified nanoparticles in A549 cells [51].
More importantly, the modified nanoparticles administered
to a lung metastatic mouse model demonstrated a lung-
specific increase in biodistribution [51]. PLGA nanoparticles
have also successfully been used to codeliver paclitaxel and
STAT3 siRNA to the drug-resistant A549 cell line [52]. In
another study, paclitaxel-loaded PLGA nanoparticles dec-
orated with anti-EGFR demonstrated high binding affinity
to EGFR expressing cells in a mouse lung tumor model
indicating the potential of these nanoparticles for targeted
lung cancer therapy [53].
2.3. Metal-Based Nanoparticles. Noble metals such as gold
and silver have been extensively investigated for clinical appli-
cations, including their use in sensitive diagnostic imaging,
detecting, and classifying of lung cancer [54]. Peng et al.
[55] developed a gold nanoparticle-based biosensor system
with the capacity to detect lung cancer by analyzing an
individual’s exhaled breath.The sensor uses a combination of
an array of chemiresistors based on gold nanoparticles and
pattern recognition methods. Additionally, another research
group reported the detection of picograms of enolase 1
(ENO1), an immunogenic antigen associatedwithNSCLC, by
using an immunosensor that detects electrochemical signal
probes of gold nanoparticle congregates [56]. Recently, gold
nanoparticles have also successfully been tested as sensors for
discriminating and classifying different lung cancer histolo-
gies. The sensor was able to distinguish between normal and
cancerous cells, SCLCandNSCLC, andbetween two subtypes
of NSCLCs [57].
Additionally, gold nanoparticles have been used to deliver
anticancer drugs for enhanced therapeutic effectiveness. For
example, methotrexate (MTX) has poor tumor retention
ability due to its high water solubility, which likely con-
tributes to its slow or poor therapeutic response in patients.
However, gold nanoparticle conjugates of MTX have high
tumor retention and enhanced therapeutic efficacy in a
Lewis lung carcinoma mouse model [58]. Previously, we
have shown in NSCLC cells that anti-EGFR antibody (Clone
225) conjugated hybrid plasmonic magnetic nanoparticles
exhibited significant enhancement in anticancer activity by
inducing autophagy and apoptosis [59]. Other studies have
developed gold/iron oxide nanoclusters surface decorated
with fluorescently labeled antibodies for targeting EGFR
expressing epidermoid carcinoma cells [60]. Such design pro-
vides promising applications of gold-based nanoparticles in
simultaneous use in magnetic resonance imaging (MRI) and
therapy. Recently, gold nanoparticles have been applied in
PDT for delivery of the water soluble PDT agent purpurin-18-
N-methyl-D-glucamine (Pu-18-NMGA) towards A549 cells
[61]. PDT using Pu-18-NMGA-gold nanoparticle resulted
in higher photodynamic activity than free Pu-18-NMGA.
Similarly, silver nanoparticles have demonstrated antipro-
liferative effects in cancer cells [62, 63]. However, in vitro
exposure of human lung cancer cells to silver nanoparticles
resulted in reactive oxygen species-induced genotoxicity
raising concerns of an unfavorable risk to benefit ratio [64].
2.4. Other Nanoparticle Systems. Magnetic nanoparticles
have been extensively investigated and applied in diagnosis
and treatment of various cancers. Theranostic nanoparticles
concurrently facilitate imaging and delivery of therapeutic
agents. Magnetic hyperthermia is a noninvasive therapeutic
approach for lung cancer that entails the heat-induced abla-
tion of desired tumor tissue. When subjected to alternating
currents the magnetic material, such as superparamagnetic
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iron oxide (SPIO), nanoparticles generate sublethal heat
that causes local tissue damage. Sadhukha et al. [65] evalu-
ated in a mouse model the effectiveness of tumor-targeted
SPIO nanoparticles for hyperthermic destruction of NSCLC.
The EGFR-targeted SPIO nanoparticles showed enhanced
tumor retention and significantly inhibited lung tumor
growth.
Wang et al. [66] developed magnetic nanoparticles
capable of detecting micrometastasis in lung cancer. Mag-
netic nanoparticles conjugated with the epithelial tumor
cell marker pan-cytokeratin efficiently isolated circulating
tumor cells (CTCs) from patients diagnosed with lung can-
cer. The cells were further identified using quantum dots
(Qdots) coupled to theNSCLCmicrometastasismarker lung-
specific X protein (LUNX) and surfactant protein-A(SP-A)
antibody. This is the first study that reported the detec-
tion of micrometastasis in peripheral blood of lung cancer
patients. Magnetic nanoparticles have also been used to over-
come drug resistance. A cisplatin-resistant A549 lung tumor
xenograft model was chemosensitized with cisplatin loaded
magnetic nanoparticles. Molecular studies demonstrated
that cisplatin-loaded magnetic nanoparticle-treated tumors
had a significant reduction in localization of lung resis-
tance related proteins and enhanced cytotoxicity of cisplatin
[67].
Mesoporous silica nanoparticles (MSNs) have been
increasingly used in anticancer drug delivery research due
to their dynamic capacity for drug loading, controlled
drug release property, and multifunctional ability. Human
lung cancer cells primarily take up MSNs by endocytosis
[68]. MSNs have also been developed as a carrier for
radionuclide isotope holmium-165 (Ho165) and tested in a
xenograft tumor model [69]. In this model, MSNs were
able to hold the radionuclide without release and withstand
long irradiation times. Additionally, Ho165-carrying MSNs
predominantly accumulated in the tumor tissue follow-
ing intraperitoneal administration in tumor-bearing mice.
Importantly, MSNs enhanced the radio-therapeutic efficacy
of Ho165 and demonstrated their potential in managing
ovarian cancer metastasis. MSNs have also been developed
for inhalation treatment of lung cancer [70]. The elegant
nanoparticle system design fully exploited the dynamic drug
loading capabilities and multifunctionalization of MSNs. It
was designed to simultaneously carry cisplatin, doxorubicin,
and two different siRNAs targeted to MRP1 and Bcl-2.
Moreover, it was surface decorated with luteinizing hor-
mone releasing hormone (LHRH) peptide for targeted lung
cancer therapy. The nanoparticle system carrying siRNA
inhibited targeted mRNA causing suppression of cellu-
lar resistance to the chemotherapeutics accomplishing an
enhanced therapeutic efficacy of cisplatin and doxorubicin.
MSNs were also explored in targeted EGFR-based therapies.
MSNsmodifiedwith the cationic polymer polyethyleneimine
(PEI) and surface attached with EGFR ligands selectively
targeted EGFR overexpressing NSCLC cells [71]. Moreover,
these nanoparticles when loaded with the anticancer agent
pyrrolidine-2 had enhanced targeting and therapeutic effi-
ciencies compared to free drug in a subcutaneous lung cancer
model.
3. Challenges for Nanoparticle-Based Drug
Delivery in Lung Cancer Therapy
Thepast decade has witnessed tremendous growth and devel-
opment of drug delivery technology utilizing nanoparticle
systems. It is expected that the ongoing research efforts
in nanomedicine will continue to lead towards safe, effi-
cient, and feasible drug delivery and highly sensitive and
improved imaging agents for diagnostic and diseasemonitor-
ing applications. However, nanomedicine research is facing
numerous challenges in bridging rapidly developing novel
ideas and translating them into clinical practice. Synthesizing
nanoparticle drug delivery systems has always been com-
plicated by designing an appropriate size to carry effective
drug/gene payload and ability to target to the right place.
Inappropriate size distribution, undefined structure/shape,
poor biocompatibility, and improper surface chemistry are
possible risk factors in the biological environment. It has
been operose to devise the ideal nanoparticle system for
drug delivery to the lungs due to the variability in the
physicochemical properties and biological behavior of the
particles. A number of obstacles including immune reaction,
rate of clearance from circulation, efficiency in targeting,
and ability to cross biological barriers will follow when
these nanoparticle systems enter the preclinical and clinical
testing arenas. Having a solid understanding of the biological
behavior of nanoparticles is imperative to achieve the highest
drug delivery efficiency.
Identification of Physicochemical parameters are abso-
lutely critical in determining the particle-particle interaction
within a biological environment, aggregation tendencies,
adsorption of proteins on nanoparticle surface, and intracel-
lular trafficking of nanoparticles. A substantial variation in
any of these factors can contribute to poor drug delivery, loss
of therapeutic efficiency, and/or toxicity. Thus, the efficacy-
toxicity balance of nanoparticle systems largely depends
on their physicochemical properties. Particles larger than
500 nmare not recommended for intravenous administration
since these particles are rapidly eliminated from the cir-
culation. The ideal nanoparticle for delivering conventional
therapeutics to solid tumors is less than 200 nm in size with
a spherical shape and a smooth texture in order to easily
transport through tumor vasculature and into tumor cells.
Such physical characteristics are likely advantageous to the
nanoparticles in exploiting the enhanced permeation and
retention (EPR) effect associated with solid tumors. Passively
targeted nanoparticles enter through leaky vasculature of
the solid tumors and are retained in the tumor tissue for
extended periods of time due to impaired lymphatic flow.
This unique microphysiology of tumors is exploited by
many FDA-approved nanoformulations such as Doxil and
Abraxane. In solid tumors, such as lung cancer, the EPR
effect plays an important role in determining the efficacy
of the nanoparticle-based drug delivery system [72]. The
presence of a highly fenestrated blood vasculature in the
tumor facilitates the EPR effect allowing the enhanced
entry of colloidal nanoparticles into the tumor (Figure 2).
Additionally, the poor lymphatic flow in the tumor tissue
adds to this effect and results in enhanced retention of
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Figure 2: A schematic representation of the EPR effect. The leaky
vasculature and dysfunctional lymphatics of solid tumors allow the
preferential accumulation and retention of colloidal nanoparticles
in contrast to the tight vasculature of normal tissue, which excludes
nanoparticles.
nanoparticles within the tumor site. In contrast to tumor
tissues, the blood vasculature in normal tissues is intact and
less permeable attenuating the uptake of nanoparticles by
normal tissues. Furthermore, the size, shape, and surface
properties of nanoparticles are critically important for passive
targeting of solid tumors. The EPR effect usually applies to
particles that are less than 200 nm in size. However, particles
less than 50 nm in size frequently undergo extravasation
from the tumor through the fenestrations and are thus
less likely to be retained in the tumor tissue for extended
periods of time. Moreover, active targeting of nanoparticles
is accomplished by decorating the surface of the nanoparticle
with specific ligands to promote the binding and interaction
with overexpressed protein receptors on cancer cell surfaces.
This approach leads to preferential binding, uptake, and
intracellular accumulation of the drug or gene in the targeted
cells. However, the overall tumor accumulation and ther-
apeutic effect of targeted nanoparticles may be principally
controlled by the EPR effect [73].
Fabrication of polymeric nanoparticles with uniform
and sub-200 nm size requires critical control over each
and every step in the synthesis procedure, which is always
challenging. The size distribution of liposomes or vesicular
nanoparticles can be narrowed using common extrusion
procedures. However, burst release of the drug and poor
stability layer additional challenges in the development of
such nanoparticles.
Surface charge determines the fate of nanoparticles in
vivo. Particle-particle interactions and aggregation tend-
encies are largely dependent on the zeta potential of
the nanoparticles. Positively charged nanoparticles have
an increased affinity for the negatively charged cellular
membranes of all cells in the body. Most nanoparti-
cles designed for gene delivery applications use positively
charged polymers or lipids to achieve enhanced DNA to
nanoparticle interaction. Unfortunately, some cationic na-
noparticles have enhanced hemolytic properties inciting
concern for their safe use in gene delivery. For example,
cationic lipid composition of N [1-(2,3-dioleyloxy) propyl]-
N,N,N-trimethylammonium chloride and dioleoylphosphat-
idylethanolamine (DOTMA/DOPE) are reported to be
highly hemolytic while 3 beta-[N-(N󸀠,N󸀠-dimethylaminoet-
hane)-carbamoyl]-cholesterol (DC-chol)/DOPE liposomes
are moderately hemolytic [74].
Biocompatible polymer nanoparticles are an alternative
to cationic lipids for the charge-specific delivery of drugs
and/or genes. However, little is known in lung tumor models
about the effect of surface charge on biodistribution of
nanoparticles. PEGylation is routinely used to mask the
surface charge effectively camouflaging the nanoparticle from
opsonin proteins and significantly extending the half-life of
the nanoparticle in the circulation. Another important issue
in drug delivery is nanoparticle stability. Poor stability of
nanoparticle systems has been attributed to their aggregation
tendencies in the physiological environment. Once aggre-
gated, it is virtually impossible to redisperse the particles into
their original distribution pattern. While shear forces can be
used to redisperse the particles, this may lead to enhanced
drug leaching from the particles andultimately affect the drug
loading and therapeutic efficiencies.
Additionally, further consideration must be given to the
complexity of nanoparticles and how thismay have a negative
impact on drug delivery. Multifunctional nanoparticles are
hot topics in the field of nanomedicine [75]. A nanoparticle
with a large number of surface functional groups provides an
avenue for the attachment of multiple kinds of biomolecules
for targeted drug delivery and diagnostic applications for
lung cancer. A careful analysis of these nanoparticle systems,
however, is necessary prior to testing in an in vivo system.
Multifunctionalization generally increases the complexity of
the nanoparticle. While a large number of multifunctional
nanoparticles, such as theranostic systems targeted to lung
cancer are under development, Aurimune (CYT-6091) is cur-
rently the only known multifunctional nanoparticle system
with diagnostic and therapeutic properties that has entered
the clinical setting [76]. Aurimune consists of tumor necrosis
factor (TNF), a tumor growth inhibiting agent, bound to
colloidal gold nanoparticles for simultaneous imaging and
therapy.
Interestingly, increased scientific contributions to the
field of nanomedicine have resulted in the emergence of
a new area of research, nanotoxicology [77]. Even though
nanoparticles of various compositions have displayed strong
therapeutic properties towards various types of cancer in
preclinical studies, they also carry the risk of inducing toxicity
to normal cells. Emphases in particular towards inorganic-
and metal-based nanoparticles have demonstrated that some
nanoparticles induce toxicity to normal cells. For exam-
ple, silica nanoparticles in their amorphous state have the
potential to cause inflammatory reactions on target organs
resulting in apoptotic cell death [78]. Thus, the use of silica-
based nanoparticles for cancer therapy is limited to low con-
centrations (0.1mg/mL) in vitro [78].The toxicity of titanium
oxide (TiO
2
) nanoparticles towards healthy cells is also a
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matter of concern considering its biological applications [79].
Carbon nanotubes (CNTs) have also been reported to exhibit
toxicity to normal cells. CNTs upon interaction with live
cells generate reactive oxygen species causing mitochondrial
dysfunction and lipid peroxidation [80]. Therefore, stringent
in vitro and in vivo toxicity studies for each of the novel
nanoparticle systems must be conducted to ensure safety
prior to their application in humans.
4. Conclusion and Future Perspectives
Nanoparticle-based medicine has infinite potential with
novel applications continuously being developed for use in
cancer diagnosis, detection, imaging, and treatment. These
systems are already helping to address key issues with
traditional anticancer agents such as nonspecific targeting,
low therapeutic efficiencies, untoward side effects, and drug
resistance as well as surpassing their predecessors with the
ability to detect early metastasis. The ability of nanoparticles
to be tailored for a personalized medicine strategy makes
them ideal vehicles for the treatment of lung cancer. Numer-
ous nanoparticle-based experimental therapeutics for lung
cancer utilize a combinatorial approach balancing the design
with targeting and tracking moieties and anticancer agents.
In general, nanoparticles with multicomponent structures
allow design flexibility in drug delivery of poorly water
solublemolecules as well as imparting the ability to overcome
biological barriers and selectively target desired sites within
the body.
However, many challenges must be overcome in order
to expedite the translation of nanoparticle-based therapies
from the bench to the bedside. Nanomedicines are three-
dimensional structures of multiple components with pre-
ferred spatial arrangement to impart their function. Subtle
changes in the synthesis process or composition of the
complex that alter the physical and/or chemical proper-
ties can have adverse effects resulting in pharmacological
and immunological challenges. Pharmacokinetics (PK) and
biodistribution are known to be effected by small composi-
tional differences in nanoparticles [81]. Moreover, nanoparti-
cles oftentimes require higher bioavailability than traditional
small molecules since they are routinely designed for novel
routes of delivery such as by nasal or oral administration.
In vivo clearance of nanoparticles and release kinetics of
the active drug are also complicated by their physical and
chemical properties. PEGylation is oftentimes used to mask
the nanoparticle to evade detection by macrophages and
avoid opsonization and destruction. This strategy effectively
increases the circulation time enhancing the distribution and
accumulation of nanoparticles at the intended target site.
Ultimately, small molecules are cleared by the kidney while
larger particles are cleared by Kupffer cells and macrophages
in the liver and spleen [82]. Researches are also challenged
with nanoparticle induced immune responses, which can
be elicited by the nanocarrier, the payload, or both [83].
These findings enumerate the importance for identifying key
characteristics of each component and developing a thorough
understanding of the physicochemical properties to ensure
high reproducibility throughout the formulation process and
minimize pharmacological and immunological challenges.
Aside from the difficulty of nanoparticle design and
discovery, scientists must also battle the lack of standards in
the examination of nanomedicines, including manufactur-
ing processes, functional testing, and safety measurements.
Conceptually nanoparticle-based therapy must overcome
the same hurdles faced by any new drug: optimal design
of components and properties, reproducible manufacturing
processes, institution of analysis methods for sufficient char-
acterization, favorable pharmacology and toxicity profiles,
and demonstration of safety and efficacy in clinical trials.
Standard drugs are usually composed of a single active agent.
Nanoparticles are complex in nature with multiple active
components that can affect the pharmacological behavior.
Such complexity necessitates the modification of standard
testing of pharmacokinetic, bioequivalence, and safety mea-
surements. There is an immediate need for regulatory agen-
cies to develop an exhaustive list of tests and a streamlined
approval process to proactively address the emergence of
new products based on new technologies and facilitate
nanomedicine delivery to the clinic.
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We present a study of magnetic and structural properties of CoFe
2
O
4
nanoparticles suspended in an organic liquid. Transmission
electron microscopy shows that the nanoparticles have a narrow size distribution of average particle size 5.9 ± 1.0 nm. X-ray
diffraction shows that the particles are of cubic spinel crystal structure. Dynamic light scatteringmeasurements reveal the existence
of an organic shell around the CoFe
2
O
4
nanoparticles with an average hydrodynamic diameter of 14.4 nm. Coercive magnetic field
at 𝑇 = 5K is found to be 11.8 kOe. Disappearance of the coercive field and remanent magnetization at about 170K suggests that
the CoFe
2
O
4
nanoparticles are superparamagnetic at higher temperatures which is confirmed by the room temperatureMo¨ssbauer
spectrum analysis. Saturation magnetization of the nanoparticles of 80.8 emu/g(CoFe
2
O
4
) at 5 K reaches the value detected in the
bulk material and remains very high also at room temperature. The cobalt ferrite nanoparticle system synthesized in this work
exhibits magnetic properties which are very suitable for various biomedical applications.
1. Introduction
Ferrofluids are stable colloidal suspensions of single domain
magnetic particles in a carrier liquid. Stability of themagnetic
colloid depends on the thermal contribution and on the
balance between attractive and repulsive interactions. Mag-
netic dipole and van der Waals interactions have tendency to
agglomerate the particles. In order to prevent agglomeration,
the magnetic particles should be small enough (usually about
10 nm in size) and coated with a shell of an appropriate
material.This coating can be a sufactantmade of long chained
molecules or ionic if it is an electric shell [1–3]. The particles
are usually made of maghemite 𝛾-Fe
2
O
3
, magnetite Fe
3
O
4
,
and other ferrites of the type MFe
2
O
4
, where M = Mn,
Co, Ni, Cu. The carrier liquid is usually an organic solvent
or water. Ferrofluids respond to an external magnetic field.
This enables the ferrofluid’s location to be controlled through
the application of a magnetic field. Ferrofluids have a wide
range of applications. They can be used to improve the
performance of loud speakers [2]. Ferrofluids are also used
in high-speed computer disk drives to eliminate harmful
dust particles or other impurities that can cause the data-
reading heads to crash into the disks. In recent years, a lot
of research work has been devoted to biomedical applica-
tions of ferrofluids. In magnetic resonance imaging (MRI),
ferrofluids are used as contrast agents [3–5]. Ferrofluids
specially designed can carry drugs to specific locations in
the living body through the use of applied magnetic fields
[3, 6].Heat treatment of organs or tissues called hyperthermia
uses the property of ferrofluids of absorbing electromagnetic
energy. This allows heating of a localized part of a living
body, such as malignant tumor, up to temperature 42–46∘C
which reduces the viability of cancerous cells [3, 4, 6]. For
various applications, particularly in biomedicine, magnetic
particles in ferrofluids, besides the requirement for small
sizes, must have large enough magnetization. Depending on
the relative magnitude of anisotropy energy with respect
to thermal energy, the particles exhibit superparamagnetic
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behavior when magnetic moment of the particle overcomes
the anisotropy energy barrier by thermal activation. For a
given temperature 𝑇 and time 𝜏 characteristic to a specific
measurement, there is a critical particle diameter𝐷sp (assum-
ing spherical shape) that separates smaller particles 𝐷 < 𝐷sp
exhibiting superparamagnetism from larger particles 𝐷 >
𝐷sp which have ferro(ferri)magnetic properties. For cubic
magnetocrystalline anisotropy, the energy barrier is 𝐸 =
𝐾𝑉/4, where 𝑉 is the particle volume. The critical size of
the CoFe
2
O
4
particles with anisotropy constant 𝐾 = 2 ×
106 erg cm−3 at 𝑇 = 300K [7] and for 𝜏 = 102 s can be esti-
mated [8] as 𝐷sp ≈ 16 nm. In the case of axial magnetocrys-
talline anisotropy, the energy barrier is 𝐸 = 𝐾𝑉, and, for the
same values of the parameters𝐾, 𝑇, and 𝜏, the critical particle
size is𝐷sp ≈ 10 nm.
There are two dominant mechanisms of magnetic relax-
ation in a ferrofluid, the Brownian relaxation and Ne´el relax-
ation. When the relaxation is dominated by the Brownian
mechanism, the magnetic moment is rotated together with
the nanoparticle in the carrier liquid under the influence of an
external magnetic field [9]. Relaxation time for the Brownian
rotational motion is
𝜏
𝐵
=
3𝑉
ℎ
𝜂
𝑘
𝐵
𝑇
, (1)
where 𝑉
ℎ
is the hydrodynamic volume of the particle, 𝜂 is
the dynamic viscosity of the carrier liquid, and 𝑇 is the
temperature. At temperatures below the freezing point of the
carrier liquid, the particles are immobilized, and in that case
relaxation of the particle magnetic moment can take place
only by rotation of themomentwithin the particle. Relaxation
time for this rotation, known as the Ne´el relaxation, is
𝜏
𝑁
= 𝜏
0
exp( 𝐸
𝑘
𝐵
𝑇
) , (2)
where 𝜏
0
is the characteristic time of the system.
Up to now, the research attention has been focused
mainly on magnetic properties and magnetic relaxation in
ferrofluids with iron oxide nanoparticles (NPs) [10–15].These
materials are already in use as contrast agents for MRI and
are under investigation for several other applications. On
the other hand, the use of materials with larger magnetic
anisotropy and larger magnetic moment is considered since
it may allow the reduction of particle size. The bulk cobalt
ferrite is a magnetic material with almost the same saturation
magnetization as the bulk iron oxide Fe
3
O
4
, but with one
order of magnitude higher magnetocrystalline anisotropy
compared to magnetite. Because of these properties the
cobalt ferrite nanoparticle systems are promising materials
for high-density magnetic recording media and also very
interesting for various biomedical applications [16–20]. In
this work, we have synthesized CoFe
2
O
4
NPs in an organic
carrier liquid. Microstructure, morphology, and static and
dynamic magnetic properties of the prepared nanomaterial
were studied using X-ray diffraction (XRD), transmission
electron microscopy (TEM), dynamic light scattering (DLS),
Fourier-transform infrared (FTIR) spectroscopy, differential
scanning calorimetry (DSC), dc magnetization, ac suscepti-
bility measurements, andMo¨ssbauer spectroscopy.We found
that the properties of this NPs system correspond to ferroflu-
ids: it is stable for months, magnetic nanoparticles do not
agglomerate and have reproducible magnetic properties. Its
main characteristics are high saturationmagnetization at low
temperatures close to that of the bulkmaterial and superpara-
magnetic properties of most of the CoFe
2
O
4
nanoparticles at
room temperature.
2. Experimental Details
2.1. Synthesis. Synthesis of the CoFe
2
O
4
nanoparticles was
carried out via the polyol route using Co(II) acetate, Fe(III)
acetonylacetonate, and diethylene glycol (DEG) fromAldrich
Chemical Co as starting materials. These precursors were
taken in stoichiometric ratio for obtaining the CoFe
2
O
4
phase: 22.3775 g Fe(III) acetonylacetonate and 7.8870 g Co(II)
acetate were mixed as solutions inside of diethylene glycol
solvent which has been previously divided in two parts, the
first volume of 150mL for dissolution of Fe(III) acetonylace-
tonate and the second volume of 50mL for dissolution of
Co(II) acetate. The mixture of both solutions was magneti-
cally stirred under the flow of nitrogen. After that, the space
of the vessel filled with nitrogen was closed and the mixture
was heated firstly to 120∘C with a heating rate of 4∘C per
minute, and then the temperature was increased to 160∘C
and maintained at this level for 3 h. Finally, the temperature
was increased to 180∘C and after one hour was abruptly
lowered with a high cooling rate by cold water introduced
through corresponding inlet. The water flowed with a high
flux around the working volume of the vessel causing a
fast change of temperature from the top temperature to
the room temperature. The particle solution was filtered to
exclude aggregates. AVivaspin filter (polyethersulfone (PES),
Vivascience Sartorius, Hannover, Germany) with pore size
0.2 𝜇m was used and the filtering process was performed
by centrifuging the sample at 1750 rpm for about 30min
until all fluid had passed the filter. Besides the liquid sample,
a powder sample was also prepared by drying the suspension
of CoFe
2
O
4
NPs at 200∘C for 10 h.
2.2. Experimental Technique. X-ray characterization of the
sample was carried out on a Philips PW 1050 powder diffrac-
tometer using Cu K𝛼 radiation. The X-ray diffraction (XRD)
pattern was taken in the 17∘–70∘2𝜃 range with a step of 0.05∘
at a slow scan rate of 40 s per step. For transmission electron
microscopy (TEM) measurements, the sample was prepared
by drying a drop of the diluted suspension on a copper-
grid-supported perforated transparent carbon foil. High-
resolution transmission electron microscopy (HRTEM) and
energy dispersive X-ray spectroscopy (EDXS) were carried
out using a field-emission electron-source transmission elec-
tron microscope JEOL 2010 equipped with an EDXS micro-
analysis system (LINK ISIS EDS 300) operated at 200 kV.
Average Fe/Co ratio in the composition of the nanoparticles
was obtained from quantification of a large number of
EDXS spectra using the Oxford ISIS software. The spectra
were collected from areas of the sample containing several
hundreds of the nanoparticles. For the quantification of the
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spectra, the CoFe
2
O
4
ceramics were used as a standard.
The relative standard deviation of the method calculated
from 20 measurements of the Fe/Co ratio on the standard
was found to be inside ±2.6% (Fe/Costandard = 1.992 ±
0.052). The size distribution of the CoFe
2
O
4
nanoparticles
was measured by dynamic light scattering (DLS) using
Zetasizer Nano ZS (Malvern, UK) equipped with green
laser (532 nm). Intensity of scattered light was detected at
the angle of 173∘. All measurements were conducted at
room temperature. Ten measurements were performed for
each sample. All data processing was done by the Zetasizer
software 6.20 (Malvern instruments). The size distribution
is reported as distribution by number. Fourier-transform
infrared (FTIR) transmission spectrum was taken at room
temperature on a Perkin-Elmer 983G spectrophotometer in
the range 600–3900 cm−1. Differential scanning calorimetry
(DSC) measurements were performed using Setaram 151 R
(softer SETSOFT 2000) instrument in the temperature range
150–240K under helium atmosphere. Magnetic measure-
ments were carried out on a SQUID magnetometer (MPMS
XL-5, Quantum Design) equipped with an ac option. Zero-
field-cooled (ZFC) and field-cooled (FC) measurements of
magnetization were performed at applied magnetic fields
from 100 to 10000Oe in the temperature range from 2
to 300K. Magnetic field dependence of magnetization was
measured at applied magnetic fields up to 50 kOe in the
temperature range from 5 to 300K. The ac magnetization
measurements were made under an ac exciting field with
amplitude of 6.5Oe using different frequencies in the range
1–1500Hz. 57Fe Mo¨ssbauer spectrum was recorded at room
temperature using a conventional transmission Mo¨ssbauer
spectrometer operating in constant acceleration mode. The
source was 57Co in Rh matrix. Experimental data were fitted
to Lorentzian absorption lines by using a least square based
method. The spectrometer was calibrated using 𝛼-Fe foil at
room temperature. All the isomer shifts are given relative to
the center of the 𝛼-Fe spectrum.
3. Results and Discussion
3.1. Structure Analysis. Figure 1 shows the XRD pattern of
dry powder sample.The diffraction peaks are consistent with
those of the cubic spinel phase (space group Fd3m). The
lattice parameter obtained from Rietveld analysis was found
to be 𝑎 = 8.390 A˚. The average crystallite size determined
from the width of the X-ray diffraction lines using Scherrer’s
formula was estimated as 5 nm.
The morphology, particle size, and chemical composi-
tion of the CoFe
2
O
4
nanoparticles deposited from organic
liquid dispersion were characterized by TEM, HRTEM, and
EDXS. TEM analysis (Figure 2(a)) shows that the sample
contains the nanoparticles with a narrow size distribution.
The measurement of approximately 500 nanoparticles from
TEM images gave equivalent diameter of 5.9 ± 1.0 nm.
HRTEM imaging showed good crystallinity of the nanopar-
ticles (Figure 2(b)). The electron diffraction pattern (inset
of Figure 2(a)) corresponds to a spinel structure. The EDXS
spectra analysis confirmed stoichiometric composition of the
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Figure 1: Powder X-ray diffraction pattern of the CoFe
2
O
4
dried
powder sample indexed with the (hkl) reflections of the cubic spinel.
cobalt ferrite nanoparticles in the margins of the experimen-
tal uncertainty. The measured Fe/Co ratio was 2.08 ± 0.14.
The size distribution of the CoFe
2
O
4
nanoparticles in
the organic liquid was studied using dynamic light scattering
(DLS). The result is presented in Figure 3. Measured number
of particles as a function of hydrodynamic particle diameter
can be well described by a log-normal distribution:
𝑓 (𝑑) =
1
√2𝜋𝜎𝑑
exp[−
ln2 (𝑑/𝑑
0
)
2𝜎2
] . (3)
The best fit yields the distribution width 𝜎 = 0.22 and
median of the distribution 𝑑
0
= 14.1 nm related to the
average hydrodynamic diameter 𝑑av = 𝑑0 exp(𝜎
2/2) =
14.4 nm. The hydrodynamic diameters are larger than those
measured by TEM. This is because DLS measures the size
of the particles together with organic shell which cannot
be observed in the TEM images due to poor contrast with
respect to the background as a result of low electron density
of the organic structure. Difference between the average
hydrodynamic diameter of the particles and equivalent TEM
diameter gives a measure of the thickness of the organic shell.
The organic shell thickness thus estimated is about 4 nm.
FTIR transmission spectrum of the organic liquid sus-
pension of CoFe
2
O
4
NPs was measured at room temperature
in the region from 600 to 3900 cm−1 (Figure 4). The band at
2350 cm−1 can be assigned to (Co, Fe)-OH vibrations caused
by the interaction of theCoFe
2
O
4−𝑥
(OH)
𝑥
surface layer of the
nanoparticles with polar group chains of the diethylene glycol
(DEG). Almost negligible band at 2331 cm−1 belongs probably
to the symmetric stretching mode of the ]
𝑠
CH
2
. The band at
1625 cm−1 belongs to the ]
𝑠
(COO−) asymmetric stretching
mode of carboxyl acids. A slightly pronounced band at
1316 cm−1 belongs to the C-O-C stretching vibrations inside
of residual DEG chains [17, 21].The slightly pronounced band
arising from the residual DEG chains with missing other
characteristic bands for DEG at 1050 and 1080 cm−1 shows
4 Journal of Nanomaterials
(a) (b)
Figure 2: TEM (a) and HRTEM (b) images of the CoFe
2
O
4
nanoparticles. Electron diffraction pattern in the inset of Figure 2(a) was indexed
according to the spinel structure.
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Figure 3: Hydrodynamic size distribution of the CoFe
2
O
4
nanopar-
ticles suspended in the organic liquid measured by dynamic light
scattering. The solid curve is the fit of the dependence (3) to the
experimental data.
that DEG is mostly changed probably into diethylene glycol
acetate (ester compound) and diethylene glycol acetony-
lacetonate. The band at 2350 cm−1 proves the existence of
significant interaction between the CoFe
2
O
4−𝑥
(OH)
𝑥
surface
layer of the nanoparticles and organic shell. It can be noticed
also that a very small fraction of DEG remained unreacted
due to excess of DEG compared to carboxyl acid groups
inside of starting mixture for the synthesis of the organic
liquid suspension of CoFe
2
O
4
NPs.
3.2. Magnetic Properties
3.2.1. dc Magnetization. The temperature dependence of
zero-field-cooled and field-cooled magnetization curves for
the organic liquid suspension of CoFe
2
O
4
NPs was mea-
sured at applied magnetic fields from 100 to 10000Oe.
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Figure 4: Fourier-transform infrared transmission spectrum of
the organic liquid suspension of CoFe
2
O
4
nanoparticles at room
temperature.
The concentration of the CoFe
2
O
4
phase in the liquid sample
was 0.045 g/mL which corresponds to the volume fraction
of 0.84%. Magnetization values are expressed per unit mass
of CoFe
2
O
4
taking into account the mass fraction of the
CoFe
2
O
4
nanoparticles in the liquid. The representative
ZFC-FC curves for several selected magnetic field values
are shown in Figure 5. To explore possible aging effects,
we compared these measurements with the previous runs
performed several months ago. Measured magnetizations
were reproduced within a few percent of precision. As can
be seen, the ZFC and FCmagnetizations of the liquid sample
bifurcate at a certain temperature and show a broad peak
in the ZFC curve with a maximum at temperature 𝑇max.
The broad peak in the ZFC magnetization is characteristic
of superparamagnetic nanoparticles with size distribution
where the temperature of the maximum 𝑇max represents the
average blocking temperature. The temperature 𝑇max for the
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Figure 5: Temperature dependence of the zero-field-cooled (ZFC)
and field-cooled (FC) magnetization curves for the organic liquid
suspension of CoFe
2
O
4
nanoparticles at several selected magnetic
field values. The inset shows the temperature dependence of the
ZFC-FC magnetization of dry powder at 𝐻 = 1000Oe.
liquid sample extends in the range 156–164K depending
on the magnetic field values in the range 𝐻 ≤ 1000Oe.
Besides the broad peak in the ZFC magnetization, a cusp at
about 𝑇
𝑝
≈ 200Kwas also detected,which can be clearly seen
for magnetic fields 𝐻 ≥ 500Oe (Figure 5).
In order to get some insight into the origin of the cusp
in the ZFCmagnetization of the organic liquid suspension of
CoFe
2
O
4
NPs at about 200K, we have measured the ZFC-
FC magnetization of dry powder at 𝐻 = 1000Oe which
is shown in the inset of Figure 5. As can be seen, there is
no cusp in the ZFC magnetization of the powder sample
in contrast to the liquid sample where this cusp is clearly
observed. This finding suggests that the origin of the cusp in
the ZFC magnetization of the liquid sample at about 200K is
associated with the carrier liquid. We performed differential
scanning calorimetry (DSC) measurements on the liquid
sample and the result is presented in Figure 6. Three distinct
peaks in DSC graph were found. The first peak at about
204K indicates the temperature where a part of the organic
liquid enters the frozen or so called mixed state [11]. The
second peak at about 183 K probably is due to freezing of
the remaining part of the organic liquid. The peak at about
164K indicates transition temperature of the liquid from the
partly frozen (mixed) state to the completely frozen (solid)
state. It can be noticed that the temperature of the cusp
observed in the ZFC magnetization at about 𝑇
𝑝
≈ 200K is
just below the temperature 204K where the organic liquid
enters the frozen state. The fact that the magnetization of
themagnetic nanoparticles dispersed in the liquid is sensitive
to the Brownian motion of the particles in that liquid and
that there is no anomalous behavior of the magnetization
in the dry powder gives evidence that the cusp in the ZFC
magnetization of the organic liquid suspension of CoFe
2
O
4
NPs is due to the freezing of the organic liquid.
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Figure 6: Differential scanning calorimetry curve for the liquid
sample of the CoFe
2
O
4
nanoparticles in the temperature range 150–
240K.
The magnetic field dependence of magnetization for
the suspension of the CoFe
2
O
4
NPs at 𝑇 = 5K and
300K is presented in Figure 7.The𝑀(𝐻) curve at 𝑇 = 300K
exhibits superparamagnetic behavior: the coercive field 𝐻
𝑐
and remanent magnetization 𝑀
𝑟
are zero and the satura-
tion magnetization, estimated by extrapolation of the 𝑀
versus 1/𝐻 curve in the limit 1/𝐻 → 0, is 50.1 emu/g
(CoFe
2
O
4
). For comparison, saturation magnetization of the
bulk CoFe
2
O
4
at 300K is 𝑀
𝑠
(bulk) ≈ 76 emu/g [22]. At 𝑇 =
5K, the liquid sample exhibits hysteresis loop. The 𝑀(𝐻)
measurements carried out at magnetic fields in the range of
±50 kOe gave 𝐻
𝑐
= 11.8 kOe, 𝑀
𝑟
= 39.1 emu/g(CoFe
2
O
4
),
and 𝑀
𝑠
= 80.8 emu/g(CoFe
2
O
4
) which was estimated also
by the extrapolation of the 𝑀 versus 1/𝐻 dependence in the
limit 1/𝐻 → 0. The saturation magnetization at 𝑇 = 5K
falls into the region of the 𝑀
𝑠
values for the bulk CoFe
2
O
4
ranging from 80 to 94 emu/g [23]. The saturation magnetiza-
tion of the CoFe
2
O
4
NPs in the liquid sample at 5 K, as well as
that at room temperature, is considerably higher than that for
the CoFe
2
O
4
NPs obtained by either thermal decomposition
[24, 25], or microemulsion route [26], or mechanical milling
[27]. It appears that the method of synthesis applied in the
present work favors good crystallinity andmagnetic ordering
resulting in a high saturation magnetization.
Saturationmagnetization of 80.8 emu/g(CoFe
2
O
4
) for the
CoFe
2
O
4
NPs in the liquid sample at 𝑇 = 5K corresponds
to 𝜇
𝑠
= 3.4𝜇
𝐵
per unit chemical formulawhich is only slightly
larger than that for inverse spinel (3𝜇
𝐵
). Utilizing the formula
(Co
1−𝛿
Fe
𝛿
)[Co
𝛿
Fe
2−𝛿
]O
4
to describe the cation distribution
in the spinel structure of the CoFe
2
O
4
nanoparticles, where 𝛿
is the inversion parameter, and assuming that Fe3+ and Co2+
ions have a magnetic moment of 5𝜇
𝐵
and 3𝜇
𝐵
, respectively,
we find that 𝛿 = 0.91. The value of the inversion parameter
𝛿 indicates that the crystal structure of the CoFe
2
O
4
NPs is
very close to the inverse spinel.
Coercive field and saturation magnetization of the liquid
sample as a function of temperature are presented in the
6 Journal of Nanomaterials
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Figure 7: Magnetic field dependence of the magnetization for the
organic liquid suspension of the CoFe
2
O
4
nanoparticles at 5 K and
300K. The inset shows the temperature dependence of (a) coercive
field and (b) saturation magnetization.
inset of Figure 7. The coercive field decreases with increasing
temperature and vanishes at about 170K. The saturation
magnetization exhibits specific properties. First, there is
a small kink in the 𝑀
𝑠
versus 𝑇 plot at 170K where the
coercive field vanishes, and, second, the character of the
function 𝑀
𝑠
(𝑇) is changed at this temperature. Remanent
magnetization (not shown) also decreases with increasing
temperature and vanishes at about 170K.
The broad peak in the ZFC magnetization at 𝑇max
extending from 156 to 164K for the magnetic field in the
range 𝐻 ≤ 1000Oe as well as the disappearance of the
coercive field and remanent magnetization at about 170K
suggests that a large fraction of the CoFe
2
O
4
nanoparticles
in the organic liquid are subject to the blocking process at
temperatures below 170 K.
3.2.2. ac Magnetic Susceptibility. Figure 8 shows the tem-
perature dependence of (a) the real part 𝜒󸀠 and (b) the
imaginary part 𝜒󸀠󸀠 of the ac magnetic susceptibility for the
suspension of the CoFe
2
O
4
NPs at different frequencies in
the range 1–1500Hz. It can be seen that the real component
𝜒󸀠 has a maximum at a temperature 𝑇
𝑚1
in the vicinity
of 200K which shifts towards higher temperatures with
increasing frequency. The imaginary part 𝜒󸀠󸀠 has a maxi-
mum at a temperature 𝑇
𝑚2
around 160K which also shifts
towards higher temperatures with increasing frequency. This
property is not only characteristic of most of the spin glass
systems but also of the interacting and noninteracting super-
paramagnetic nanoparticles. It should be noticed that the
temperature 𝑇
𝑚1
falls into the temperature region of freezing
of the organic liquid, while 𝑇
𝑚2
falls into the temperature
region of the broad peak in the ZFC magnetization of the
liquid sample. In fact, the temperature 𝑇
𝑚2
is significantly
lower than the temperatures around 200K where the organic
liquid enters the frozen (mixed) state. Therefore, we could
expect that at 𝑇
𝑚2
the particles are mainly frozen and cannot
move, and relaxation of the particle magnetic moments in
that case should occur relative to the particle through theNe´el
relaxation.
According to Ne´el [28]magneticmoment of noninteract-
ing single domain particleswith uniaxialmagnetic anisotropy
relaxes via an activated process, 𝜏 = 𝜏
0
exp(𝐸/𝑘
𝐵
𝑇), that is,
the Arrhenius law, where 𝐸 is the barrier due to anisotropy
energy required for reversal of magnetic moment orientation
and 𝜏 is the relaxation time. At temperatures where the
relaxation time is comparable with the experimental time
scale, the spins will seem to be frozen. Thus, the blocking
temperature depends on the relaxation time 𝜏 ∼ 1/𝑓,
where 𝑓 is the frequency of the experiment. We assume that
the temperature of the maximum in 𝜒󸀠󸀠 is the blocking tem-
perature of the CoFe
2
O
4
particle magnetic moments. Taking
𝜏 = 1/2𝜋𝑓, the relation between 𝑇
𝑚2
and frequency 𝑓 is
𝑓 = 𝑓
0
exp(−𝐸/𝑘
𝐵
𝑇
𝑚2
), where 𝑓
0
= 1/2𝜋𝜏
0
. We find that
𝑇
𝑚2
can be fitted to the Arrhenius law. However, the fitted
parameters are large or even have unphysical values: 𝜏
0
=
1/2𝜋𝑓
0
= 2.9 × 10−18 s and 𝐸/𝑘
𝐵
= 5360K.
In the further analysis, we take the interparticle interac-
tions into account and describe the relaxation time of the
particles in the vicinity of the temperature 𝑇
𝑚2
by the Vogel-
Fulcher law,
𝜏 = 𝜏
0
exp[ 𝐸
𝑘
𝐵
(𝑇 − 𝑇
0
)
] , (4)
where 𝐸 is the energy barrier and the parameter 𝑇
0
depends
on the interparticle interactions [11]. Now, the relation
between 𝑇
𝑚2
and frequency 𝑓 is 𝑓 = 𝑓
0
exp[−𝐸/𝑘
𝐵
(𝑇
𝑚2
−
𝑇
0
)]. A good fit of the Vogel-Fulcher law, (4), to the exper-
imental data ln𝑓 versus 𝑇
𝑚2
(𝑓) is obtained with physically
meaningful parameters, and the result is shown in Figure 9.
The best fit yields 𝑓
0
= (1.6 ± 0.3) × 1011Hz, 𝜏
0
= 1/2𝜋𝑓
0
=
(1.0 ± 0.3) × 10−12 s, 𝐸/𝑘
𝐵
= (2300 ± 300)K and 𝑇
0
= (46.5 ±
5)K. The parameter 𝑇
0
presents the average value of the
interparticle interactions observed in the 𝜒󸀠󸀠(𝑇) dependence
in the measured frequency range. In the case of axial mag-
netocrystalline anisotropy, the energy barrier of superpara-
magnetic particles is related to the anisotropy constant, 𝐸 =
𝐾𝑉. For 𝐸/𝑘
𝐵
= 2300K and average volume of the particles
assuming spherical geometry ⟨𝑉⟩ = 1.075 × 10−19 cm3,
𝐾 = 3 × 106 erg/cm3, which is somewhat larger than that
in the bulk material [23]. High saturation magnetization of
the synthesized CoFe
2
O
4
NPs with a narrow size distribution
in combination with superparamagnetic properties observed
at room temperature makes these particles, with appropriate
coating and functionalization, very promising materials for
biomedical applications, especially in magnetic targeted drug
delivery and in magnetic fluid hyperthermia.
Temperature of the maximum in the real part of the
ac magnetic susceptibility 𝑇
𝑚1
appears in the vicinity of
200K, Figure 8(a), that is, in the region where the organic
liquid enters the frozen (mixed) state. In the mixed state,
the system is not yet a rigid solid and the nanoparticles
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Figure 8: Temperature dependence of (a) the real part 𝜒󸀠 and (b) the imaginary part 𝜒󸀠󸀠 of the ac magnetic susceptibility for the organic
liquid suspension of the CoFe
2
O
4
nanoparticles at different frequencies in the range 1–1500Hz.
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Figure 9: Frequency dependent temperature 𝑇
𝑚1
of the maximum
in the real part 𝜒󸀠 and temperature 𝑇
𝑚2
of the maximum in the
imaginary part 𝜒󸀠󸀠 of the acmagnetic susceptibility.The solid curves
represent fit of the Vogel-Fulcher law, (4), to the experimental data.
are free to move locally. Brownian relaxation arises as a
response of the nanoparticles magnetic moments to the
external magnetic field through the particle movement. The
Vogel-Fulcher law was found to describe successfully the
Brownian relaxation in the ferrofluids containing magnetite
nanoparticles [11, 15]. The exponential temperature depen-
dence of 𝜏
𝐵
is attributed to divergence of the viscosity of the
liquid at the characteristic temperature 𝑇󸀠
0
, as found in many
glass-forming liquids [29]. Using the Brownian relaxation
time in the form 𝜏
𝐵
= 𝜏󸀠
0
exp[𝐸󸀠/𝑘
𝐵
(𝑇 − 𝑇󸀠
0
)], the relation
between 𝑇
𝑚1
and frequency 𝑓 is 𝑓 = 𝑓󸀠
0
exp[−𝐸󸀠/𝑘
𝐵
(𝑇
𝑚1
−
𝑇󸀠
0
)]. We find that the Vogel-Fulcher law can be fitted to
the experimental data ln𝑓 versus 𝑇
𝑚1
(𝑓) with the following
parameters: 𝜏󸀠
0
= 1/2𝜋𝑓󸀠
0
= (2.6 ± 1.0) × 10−6 s, 𝐸󸀠/𝑘
𝐵
=
(2.0±0.2)×102 K, and 𝑇󸀠
0
= (168±10)K.The result of this fit
is shown also in Figure 9. Difference between the parameters
in the Vogel-Fulcher law describing the Ne´el relaxation
and the Brownian relaxation can be seen immediately. The
characteristic time of the system 𝜏󸀠
0
in the Brownian relax-
ation is much larger than 𝜏
0
in the Ne´el relaxation. The
large difference between the parameters 𝐸󸀠 associated with
the viscosity of the liquid [11] and 𝐸 in the Ne´el relaxation
also indicates different nature of the two relaxations. The
parameter 𝑇󸀠
0
should correspond to the temperature of the
divergence of the viscosity, that is, to the temperature where
the organic liquid passes from the partly frozen (mixed) state
to the completely frozen (solid) state. It is interesting to note
that 𝑇󸀠
0
= 168K obtained from the Vogel-Fulcher expression
for the Brownian relaxation time as a fitting parameter is
in good agreement with 𝑇 = 164K identified as transition
temperature from the mixed state to the solid state of the
organic liquid recorded in the DSC measurements.
3.2.3.Mo¨ssbauer Spectroscopy. 57FeMo¨ssbauermeasurement
was performed on the CoFe
2
O
4
nanoparticles with average
particle size of 5.9 nm. The experimental spectrum collected
at room temperature is presented in Figure 10.Themain con-
tribution to the spectrum belongs to a quadrupolar doublet
characteristic of a paramagnetic compound showing that the
quadrupole interaction is much stronger than the magnetic
hyperfine interaction.This quadrupolar doublet is ascribed to
8 Journal of Nanomaterials
In
te
ns
ity
 (×
1
0
6
a.u
.)
3.34
3.36
3.38
3.40
3.42
−12 −8 −4 0 4 8 12
Velocity (mm/s)
Sextet 1
Doublet 1
Doublet 2
Singlet
Icalc
Iobs
Figure 10: Mo¨ssbauer spectrum of the CoFe
2
O
4
nanoparticles in
the dried powder sample at room temperature.
the superparamagnetic CoFe
2
O
4
nanoparticles. Besides the
quadrupolar doublet, a six-line hyperfine pattern of lower
intensity was also recorded.The presence of both the doublets
and sextets in the Mo¨ssbauer spectrum is usually detected
in an assembly of ultrafine particles with a size distribution.
The Mo¨ssbauer spectrum of the CoFe
2
O
4
powder sample
has been fitted as a superposition of a broad singlet, two
quadrupolar doublets, and one sextet. The broad singlet is
introduced to delineate process of magnetic relaxations in
some grains due to the particle size distribution. The isomer
shift values of two doublets, (0.34 ± 0.01)mm/s and (0.43 ±
0.06)mm/s, indicate the presence of the Fe3+ ions in two dif-
ferent local environments.Thequadrupolar splitting values of
these doublets are (0.55±0.03)mm/s and (1.98±0.19)mm/s,
respectively. Therefore, both doublets are assigned to the
Fe3+ ions, one located in the particle core and the other
located at the particle surface.The doublet withmore positive
isomer shift (0.43mm/s) and higher quadrupolar splitting
(1.98mm/s) can be ascribed to the iron ions located at the
surface layer of the particles. The hyperfine field is obtained
as 𝐵hyp = (437 ± 1) kOe. This hyperfine field is somewhat
lower than the minimal value of the B-site hyperfine field
found in the bulk cobalt ferrite [30]. Lower values of the
hyperfine fields, compared to those usually reported for the
cobalt ferrite nanoparticles [31, 32], were obtained to be about
440 kOe at the room temperature Mo¨ssbauer spectrum of
the CoFe
2
O
4
NPs with average diameter of 9.6 nm [33]. In
a detailed analysis of the Mo¨ssbauer spectra of the CoFe
2
O
4
NPs with average particle size of 5.1, 8.6, and 12.2 nm,
acceptable fitting data were obtained only when the B-site
pattern was assumed to be a superposition of more than one
sextet, including those with lower hyperfine fields [27]. The
Mo¨ssbauer spectrum of the CoFe
2
O
4
powder sample studied
in the present work indicates that most of the CoFe
2
O
4
nanoparticles are superparamagnetic at room temperature,
while a minor fraction of the nanoparticles have blocked
magnetic moments with blocking temperatures above 300K.
Because the contribution of the CoFe
2
O
4
particles with
blocked magnetic moments is minor in the spectrum, more
detailed analysis concerning the hyperfine fields is unreliable.
4. Conclusion
The synthesis procedure of the organic liquid suspension
of the CoFe
2
O
4
nanoparticles applied in the present work
appears to be very promising from the aspect of the tailoring
of these particles with well-pronounced magnetic properties.
The narrow size distribution of the particles, high saturation
magnetization, and superparamagnetic properties at room
temperature make them very attractive and suitable for
application in biomedicine, especially in magnetic targeted
drug delivery and in magnetic fluid hyperthermia.
Acknowledgment
Financial support for this study was granted by the Ministry
of Education, Science and Technological Development of
Serbia (Project no. 172026).
References
[1] S. Odenbach, “Magnetic fluids—suspensions of magnetic
dipoles and their magnetic control,” Journal of Physics Con-
densed Matter, vol. 15, no. 15, pp. S1497–S1508, 2003.
[2] S. Odenbach, “Recent progress in magnetic fluid research,”
Journal of Physics Condensed Matter, vol. 16, no. 32, pp. R1135–
R1150, 2004.
[3] C. Scherer and A. M. Figueiredo Neto, “Ferrofluids: properties
and applications,” Brazilian Journal of Physics, vol. 35, no. 3, pp.
718–727, 2005.
[4] C. C. Berry, “Progress in functionalization of magnetic
nanoparticles for applications in biomedicine,” Journal of
Physics D, vol. 42, no. 22, Article ID 224003, 9 pages, 2009.
[5] H. Tan, J. M. Xue, B. Shuter, X. Li, and J. Wang, “Synthesis of
PEOlated Fe
3
O
4
@SiO
2
nanoparticles via bioinspired silification
for magnetic resonance imaging,” Advanced Functional Materi-
als, vol. 20, no. 5, pp. 722–731, 2010.
[6] R. Rahisuddin, P. K. Sharma, M. Salim, and G. Garg, “Appli-
cation of ferrofluid: as a targeted drug delivery system in nan-
otechnology,” International Journal of Pharmaceutical Sciences
Review and Research, vol. 5, no. 3, pp. 115–119, 2010.
[7] R. Skomski and J. M. D. Coey, Permanent Magetism, Institute of
Physics Publishing, Bristol, UK, 1999.
[8] M. Walker, P. I. Mayo, K. O’Grady, S. W. Charles, and R. W.
Chantrell, “The magnetic properties of single-domain particles
with cubic anisotropy. I. Hysteresis loops,” Journal of Physics,
vol. 5, no. 17, pp. 2779–2792, 1993.
[9] E. Blums, A. Cebers, and M. M. Maiorov, Magnetic Fluids,
Walter de Gruyter, Berlin, Germany, 1997.
[10] T. Jonsson, J. Mattsson, C. Djurberg, F. A. Khan, P. Nordblad,
and P. Svedlindh, “Aging in amagnetic particle system,” Physical
Review Letters, vol. 75, no. 22, pp. 4138–4141, 1995.
Journal of Nanomaterials 9
[11] J. Zhang, C. Boyd, andW. Luo, “Two mechanisms and a scaling
relation for dynamics in ferrofluids,” Physical Review Letters,
vol. 77, no. 2, pp. 390–393, 1996.
[12] A. Skumiel, A. Jo´zefczak, T. Hornowski, andM. Labowski, “The
influence of the concentration of ferroparticles in a ferrofluid
on its magnetic and acoustic properties,” Journal of Physics D,
vol. 36, no. 24, pp. 3120–3124, 2003.
[13] M. Blanco-Manteco´n and K. O’Grady, “Interaction and size
effects in magnetic nanoparticles,” Journal of Magnetism and
Magnetic Materials, vol. 296, no. 2, pp. 124–133, 2006.
[14] L.-Y. Zhang, Y.-H. Dou, L. Zhang, and H.-C. Gu, “Magnetic
behaviour and heating effect of Fe
3
O
4
ferrofluids composed of
monodisperse nanoparticles,” Chinese Physics Letters, vol. 24,
no. 2, pp. 483–486, 2007.
[15] M. B. Morales, M. H. Phan, S. Pal, N. A. Frey, and H. Srikanth,
“Particle blocking and carrier fluid freezing effects on the
magnetic properties of Fe
3
O
4
-based ferrofluids,” Journal of
Applied Physics, vol. 105, no. 7, Article ID 07B511, 3 pages, 2009.
[16] G. Baldi, D. Bonacchi, C. Innocenti, G. Lorenzi, and C. Sangre-
gorio, “Cobalt ferrite nanoparticles: the control of the particle
size and surface state and their effects on magnetic properties,”
Journal of Magnetism and Magnetic Materials, vol. 311, no. 1, pp.
10–16, 2007.
[17] G. Baldi, D. Bonacchi, M. C. Franchini et al., “Synthesis and
coating of cobalt ferrite nanoparticles: a first step toward the
obtainment of new magnetic nanocarriers,” Langmuir, vol. 23,
no. 7, pp. 4026–4028, 2007.
[18] G. Baldi, G. Lorenzi, and C. Ravagli, “Hyperthermic effect of
magnetic nanoparticles under electromagnetic field,” Processing
and Applications of Ceramics, vol. 3, no. 1-2, pp. 103–109, 2009.
[19] M. C. Franchini, G. Baldi, D. Bonacchi et al., “Bovine serum
albumin-based magnetic nanocarrier for MRI diagnosis and
hyperthermic therapy: a potential theranostic approach against
cancer,” Small, vol. 6, no. 3, pp. 366–370, 2010.
[20] V. Cabuil, V. Dupuis, D. Talbot, and S. Neveu, “Ionic mag-
netic fluid based on cobalt ferrite nanoparticles: influence of
hydrothermal treatment on the nanoparticle size,” Journal of
Magnetism and Magnetic Materials, vol. 323, no. 10, pp. 1238–
1241, 2011.
[21] H. Guo, X. Yang, T. Xiao, W. Zhang, L. Lou, and J. Mugnier,
“Structure and optical properties of sol-gel derived Gd
2
O
3
waveguide films,” Applied Surface Science, vol. 230, no. 1–4, pp.
215–221, 2004.
[22] H. Shenker, “Magnetic anisotropy of cobalt ferrite (Co
1.01
Fe
2.00
O
3.62
) and nickel cobalt ferrite (Ni
0.72
Fe
0.20
Co
0.08
Fe
2
O
4
) ,”
Physical Review, vol. 107, no. 5, pp. 1246–1249, 1957.
[23] V. A. Brabers, “Progress in spinel ferrite research,” inHandbook
of Magnetic Materials, K. H. J. Buschow, Ed., vol. 8, North-
Holland, Amsterdam, The Netherlands, 1995.
[24] M. Grigorova, H. J. Blythe, V. Blaskov et al., “Magnetic prop-
erties and Mo¨ssbauer spectra of nanosized CoFe
2
O
4
powders,”
Journal of Magnetism and Magnetic Materials, vol. 183, no. 1-2,
pp. 163–172, 1998.
[25] V. Blaskov, V. Petkov, V. Rusanov et al., “Magnetic properties
of nanophase CoFe
2
O
4
particles,” Journal of Magnetism and
Magnetic Materials, vol. 162, no. 2-3, pp. 331–337, 1996.
[26] N.Moumen, P. Veillet, andM. P. Pileni, “Controlled preparation
of nanosize cobalt ferrite magnetic particles,” Journal of Mag-
netism and Magnetic Materials, vol. 149, no. 1-2, pp. 67–71, 1995.
[27] E. Manova, B. Kunev, D. Paneva et al., “Mechano-synthesis,
characterization, and magnetic properties of nanoparticles of
cobalt ferrite, CoFe
2
O
4
,” Chemistry of Materials, vol. 16, no. 26,
pp. 5689–5696, 2004.
[28] L. Ne´el, “Thermoremanent magnetization of fine powders,”
Review of Modern Physics, vol. 25, no. 1, pp. 293–295, 1953.
[29] N. Menon and S. R. Nagel, “Evidence for a divergent suscepti-
bility at the glass transition,” Physical Review Letters, vol. 74, no.
7, pp. 1230–1233, 1995.
[30] G. A. Sawatzky, F. van der Woude, and A. H. Morrish,
“Mo¨ssbauer study of several ferrimagnetic spinels,” Physical
Review, vol. 187, no. 2, pp. 747–757, 1969.
[31] N. Moume, P. Bonville, and M. P. Pileni, “Control of the size of
cobalt ferrite magnetic fluids:Mo¨ssbauer spectroscopy,” Journal
of Physical Chemistry, vol. 100, no. 34, pp. 14410–14416, 1996.
[32] A. Hutlova, D. Niznansky, J.-L. Rehspringer, C. Estourne`s, and
M. Kurmoo, “High coercive field for nanoparticles of CoFe
2
O
4
in amorphous silica sol-gel,” Advanced Materials, vol. 15, no. 19,
pp. 1622–1625, 2003.
[33] S. R. Ahmed, S. B. Ogale, G. C. Papaefthymiou, R. Ramesh,
and P. Kofinas, “Magnetic properties of CoFe
2
O
4
nanoparticles
synthesized through a block copolymer nanoreactor route,”
Applied Physics Letters, vol. 80, no. 9, pp. 1616–1618, 2002.
Hindawi Publishing Corporation
Journal of Nanomaterials
Volume 2013, Article ID 719168, 6 pages
http://dx.doi.org/10.1155/2013/719168
Research Article
pH Responsive Self-Assembly of Cucurbit[7]urils and
Polystyrene-Block-Polyvinylpyridine Micelles for Hydrophobic
Drug Delivery
Basem A. Moosa, Afnan Mashat, Wengang Li, Karim Fhayli, and Niveen M. Khashab
Controlled Release and Delivery Lab, Advanced Membranes and Porous Materials Center,
King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia
Correspondence should be addressed to Niveen M. Khashab; niveen.khashab@kaust.edu.sa
Received 25 June 2013; Revised 7 September 2013; Accepted 9 September 2013
Academic Editor: Haifeng Chen
Copyright © 2013 Basem A. Moosa et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Polystyrene-block-polyvinylpyridine (PS-b-P4VP) polypseudorotaxanes with cucurbit[7]urils (CB[7]) were prepared from water
soluble PS-b-P4VPH+ polymer and CB[7] in aqueous solution at room temperature. At acidic and neutral pH, the pyridinium
block of PS-b-P4VP is protonated (PS-b-P4VPH+) pushing CB[7] to preferably host the P4VP block. At basic pH (pH 8), P4VP
is not charged and thus is not able to strongly complex CB[7]. This phenomenon was verified further by monitoring the release
of pyrene, a hydrophobic cargo model, from a PS-b-P4VPH+/CB[7] micellar membrane. Release study of UV active pyrene from
the membrane at different pH values revealed that the system is only operational under basic conditions and that the host-guest
interaction of CB[7] with P4VPH+ significantly slows down cargo release.
1. Introduction
Self-assembly of polystyrene-block-poly(4-vinylpyridine)
PS-b-P4VP amphiphilic block copolymer has been studied
extensively with different metals (because a variety of metal
salts can be selectively coordinated to the PVP block) and
at different temperatures and pH values [1–8]. PS-b-P4VP
is a well-known block copolymer that is commercially
available and can be easily synthesized by sequential anionic
polymerization of styrene followed by 4-vinylpyridine (4VP)
in tetrahydrofuran (THF) at −78∘C under nitrogen [9].
Multiple changes in aggregate morphology (spheres, rods,
lamellae, and mixture of aggregates) of this block copolymer
have been described as a function of pH [7]. The reason for
this behavior ormorphological complexity can be ascribed to
the amphiprotic nature of P4VPwhere the addition of acid or
base introduces ionic groups into the corona chains. Polymer
micellar morphologies are useful in the field of controlled
drug release, and so we reported the morphological changes
and Dox release from PS-b-P4VP micellar membrane at
different pH values [8].
Cucurbit[n]urils (CB[n], 𝑛 = 5–8 of glycoluril units)
are a class of barrel-shaped macrocyclic hosts with sym-
metric carbonyl-lined portals [10–16]. They are capable of
forming inclusion complexes with appropriately sized guest
compounds in water with high affinity (𝐾
𝑎
> 105M−1)
[17]. Cucurbit[7]uril (CB[7]) has been shown to form a
variety of strong, stable complexes with pyridinium cation
type compounds. Polymers with such aromatic moieties
promote the creation of a wide range of macromolecular
architectures in water, which are held together by host-
guest interaction with CB[7]. Pseudorotaxanes, a class of
supramolecular species in which a molecular thread is encir-
cled by a molecular bead, have been studied extensively [18–
21]. Many reports on CB[7] have been published, including
the recognition of CB[7] towards the aliphatic amines ions,
pyridylmethyl-ended alkylammonium ions, and other guest
molecules. The formation of pseudorotaxanes, rotaxanes,
pseudopolyrotaxanes, polyrotaxanes, molecular machines,
molecular necklaces, and so forth from CB[7] has also been
reported [18–20, 22–24]. Inclusion complexes with CB[7]
can induce self-assembly of block copolymer complexes
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and result in the formation of systems of pseudorotaxane
with different morphologies and physical properties [25].
By complexing stimuli-responsive polymers with CB[7],
a wide variety of polymer/CB[7] complexes with amphiphilic
properties may be produced. We recently reported the pH
sensitive behavior of PS-b-P4VP micelles; however, the host-
guest interaction and self-assembly of this block copolymer
with macrocycles such as CB[7] have not been reported
before [8].Herein, self-assembly of PS-b-P4VPH+withCB[7]
to afford a controlled release system for hydrophobic cargo
is reported. It is a supramolecular approach using CB[7] to
slow cargo release, which can be very crucial for drug delivery
systems. PS-b-P4VPH+ was used in this study because its
self-assembly and morphology at different pH values are
extensively studied in the literature. Pyrene was chosen as the
cargo as it is a neutral, UV active, and hydrophobic molecule
(most drugs are hydrophobic) that is too big to be enclosed
by CB[7]. Moreover, CB[7] does not absorb at 245 nm, so
it will not affect UV measurements [26]. PS-b-P4VP/CB[7]
micellar solution was casted into a membrane and tested
under different pH values (Figure 1).
2. Experimental Section
2.1. Materials. Polystyrene-b-poly(4-vinylpyridine) block
copolymer (PS-b-P4VP, 81 000-b-57 000 g/mol) was pur-
chased from Polymer Source, Inc. Dimethylformamide
(DMF), CB[7], pyrene, and other buffer solutions were used
as purchased from Sigma-Aldrich, USA.
2.2. PS-b-P4VPH+⋅CB[7] Polypseudorotaxanes Complex for
NMR. To a stirred solution of 5mg CB[7] in 1mL, D
2
O/DCl
(pD 3) was added a solution of 10mg of PS-b-P4VP in 0.5mL
d
7
-DMF and stirred for 10 hours at room temperature. The
solution was filtered and the filtrate was characterized by 1H-
NMR, SEM, and TEM.
2.3. pH Responsive Micellar Membrane Preparation. Amicel-
lar solution containing 20wt% PS-b-P4VP block copolymer
was loaded with pyrene (0.005𝜇g per 2𝜇g polymer) in DMF.
Water (0.5mL)was then added dropwise to theDMF solution
and stirred overnight. The mixture was then transferred into
a dialysis bag where it was dialyzed in water (pH 3) and
CB[7] (5mg) aqueous solution at room temperature (20∘C)
overnight. The dialysis bag was then removed and washed
with water three times before the contents were lyophilized
for 48 hrs. The mixture was then redissolved in a minimum
amount of DMF and casted on a glass plate using casting
blades with 200𝜇m gate height. The room temperature was
20∘C with 60% relative humidity. The glass plate was then
immersed in water to peel the membrane off.The membrane
was finally air dried overnight before UV testing.The control
solution was prepared using the same method but without
incorporating CB[7]. The release test was carried out using
2mg of the casted membrane and using UV spectrometer
Cary 5000, at 245 nm at a series of pH values (pH 4.0 to 8.0)
two times on duplicate.
2.4. Instruments. Pyrene release from micellar membrane
was measured using UV-Vis spectrophotometer Cary 5000,
at 245 nm. Scanning electron microscopy (SEM) images
were obtained using a Quanta 600 FEG scanning electron
microscope (SEM) from FEI company, USA. The 1H NMR
spectrum was recorded on Bruker Avance III (400MHz)
spectrometer, using DMF-d
7
as the solvent. Dynamic light
scattering (DLS) measurements were done using the Zeta-
sizerNano fromMalvern Instruments. Transmission electron
microscope (TEM) images were obtained using Titan 3 80–
300 electron microscope (TEM) from FEI company, USA.
3. Results and Discussion
The complexation of CB[7] with PS-b-P4VPH+ was first
verified by NMR. Figure 2 revealed (i) disappearance of
styrene peaks, (ii) shifting of pyridine peaks in acidic media,
and (ii) broadening of all peaks.This suggests that themotion
of both blocks in an aqueous solution is highly restricted
and the absence of the styrene peaks (Figure 2(b)) proves
the formation of what is called a “frozen micelle” [22, 23],
as the NMR cannot detect the hydrophobic core of the
particles. When CB[7] was added (Figure 2(c)), a clear shift
of the pyridinium block was observed which suggests a
complexation between the protonated pyridine and CB[7].
PS-b-P4VPH+ and PS-b-P4VPH+/CB[7] micelles were
then characterized using SEM and TEM. More aggregates
were observed using TEM in PS-b-P4VPH+/CB[7] sample
(Figure 3(b)) versus PS-b-P4VPH+ (Figure 3(a)). A slight
difference in terms of morphology between the nanoparticles
with andwithoutCB[7] can be seen using SEM.The surface of
the polymeric micelles was smooth (Figure 4(a)), while that
of the complex was coarse (Figure 4(b)).
DLS measurements showed a distribution of the hydro-
dynamic diameter with mean values of 76 and 66 nm for PS-
P4VPH+ nanoparticles and PS-P4VPH+/CB[7] nanoparti-
cles, respectively (Figure 4).Thedifference in size of nanopar-
ticles in the dried and solvated phase is consistent with that of
a swollen composite polymeric system in aqueousmedia.The
diameter distribution observed by DLS can be explained by
interparticle interactions or the statistical distribution of the
number of macromolecules within individual particles [27].
3.1. Payload Release Investigation. To investigate the host-
guest effect of CB[7] complexation on hydrophobic cargo
release, pyrene was loaded into PS-P4VPH+ micelles as
described in the experimental section. UV spectrometer was
employed to measure the amount of pyrene released into the
aqueous solution at a series of pH values (pH 4.0 to 8.0) at
room temperature (Figure 5).
Two types of pyrene-loaded membranes were prepared,
one with (pH 4󸀠−8󸀠) and the other without CB[7] (pH 4−8)
(control experiment). PS-b-P4VPmicellar membrane (2mg)
was placed in the bottom of a UV spectrometer cell without
stirring. At pH 4-5, negligible amount of pyrene was released
from both samples, where at pH 6-7, a very small amount
of pyrene <5% was released during a long period of time
(Figure 5), which suggests that (i) the encapsulation efficiency
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Figure 3: TEM images of (a) PS-P4VPH+ and (b) PS-P4VPH+CB[7] complex where more aggregates can be observed.
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of this membrane is ∼95% (no major leakage) and (ii) it is
very stable at physiological pH 7.4. At pH 8, a clear release
of pyrene was observed which is due to the deprotonation
of the pyridinium ion block, which forms the corona shell
of the micelle at high pH as we previously reported [8]. The
pyridinium molecules shrink and expose the pyrene-loaded
PS core to the buffer solution, resulting in a substantial pyrene
release (Figure 5). The major difference between the two
profiles pH 8 and pH 8󸀠 is that the pyrene release was slower
in the presence of CB[7]. This is due to CB[7] threading
the pyridinium block which will decrease the deprotonation
rate and thus hinders the release of pyrene. To calculate
the loading efficiency, the membrane was digested at pH 1
and the amount of released pyrene was measured by UV.
Pyrenewas loaded into themicellarmembranewith a loading
efficiency of about 0.02wt%, which means that every 2mg of
the micellar membrane contains 0.4 𝜇g of pyrene.
4. Conclusion
A supramolecular approach for building a potential con-
trolled drug delivery system is both simple and efficient.
CB[7] strongly complexes P4VPH+, making up the corona
shell of the micelle, at acidic and neutral pH which affords
a closed delivery system with minimal leakage. Under basic
conditions, the micelles will shrink and cargo release will be
initiated. The presence of CB[7] slows down the release rate
and thus provides more control over this system. Designing
drug delivery systems that offer prolonged drug release and
are only operational under basic pH, such that the pancreatic
cancer duct can afford both controlled and targeted release to
diseased tissues [28, 29]. Further studies are now underway
to incorporate this concept into biocompatible block copoly-
mers for in vivo applications.
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Background. Drugs with low oral bioavailability due to the first pass metabolism are good candidates for transdermal delivery.
Objectives.The aim of this work was preparation of transdermal nanoemulsion of metoprolol which has high first pass metabolism.
Methods.Three commercially available types of lecithin (200, 100p, and 170), three short chain alcohol (n-butanol, isopropyl alcohol,
and n-propanol), and isopropyl myristate (IPM) were used as surfactant, cosurfactant, and oil phase, respectively. The aqueous
phase was composed of metoprolol tartrate. Nanoemulsions with different surfactant/cosurfactant weight ratio, various amounts
of drug, and different types of alcohol were prepared, and their phase diagrams were studied. Drug release, permeability, and
diffusion coefficient of the drugwere studied using hairless rat skin.Results. A significant increase in drug solution ratewas observed
with increasing the metoprolol content in the nanoemulsions, while it decreased when lecithin concentration increased from 40%
to 60%. Increasing the water content resulted in a significant increase in metoprolol release. N-butanol enhanced the drug flux
from nanoemulsions more than n-propanol and isopropyl alcohol. The o/w nanoemulsions of metoprolol showed high flux and
permeability through the skin.Conclusion. Bothw/o ando/wnanoemulsions ofmetoprolol could enhance permeation anddiffusion
of metoprolol through rat skin.
1. Introduction
The human skin is a readily accessible area for drug delivery.
It covers a surface of 2m2 in an average adult body with the
thickness of about 2.97 ± 0.28mm that uptakes one-third of
whole blood circulation [1, 2]. Skin is a barrier that protects
the body against chemical and microbial agents; it also
controls body temperature and has some roles in controlling
blood pressure [2]. Skin consists of three layers: epidermis,
dermis, and hypoderm.The epidermis has four regions: basal
layer, spiny layer, stratum granulosum, and upper most stra-
tum corneum; the latter consists of keratinized, dehydrated,
and highly cornified cells which are inlaid in continuous
matrix of lipid membranous sheets constantly replacing
internal layers. The water intake of stratum corneum is about
20%. The human skin surface contains average 10–70 hair
follicles and 200–250 sweat ducts on every square centimeter
area of the skin [1, 3, 4]. Currently, skin is a good candidate
for drug delivery and systemic pharmacological approach.
Transdermal drug delivery has some benefits: skipping first
pass metabolism in liver, steady infusion of a drug over an
extended period of time, better compliance of the patient
due to ease of usage and reduced frequency of use, a choice
for drugs with low therapeutic index and short half life,
and so easy elimination of drug when toxicity occurs during
the application [3, 5, 6]. Also transdermal drug delivery has
some disadvantages such as the possibility of local irritation
and skin’s low permeability. Considering that variability may
occur due to differences in skin permeation due to differences
in subcutaneous fat deposition the reduction of inconstancy
in the plasma concentration of drug may be restricted. The
release of drug from its carrier depends on the concentration
of drug in the carrier, physiochemical properties, and pres-
ence of polar groups and molecular weight of the drug. Its
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absorbance depends on the application site of use, thickness,
temperature, hydration status, and integrity of skin, pH of the
drug, and its molecular size [1, 2, 6, 7].
Nanoemulsions are multiphase systems consisting of
water, oil, surfactant, and alcohol, which form a transparent
solution. In fact, they are small-scale of emulsions whether
oil in water or water in oil with a size range in the order
of 5–50 nm, while particle size of dispersed phase in emul-
sions is >0.1 𝜇m, so the emulsions seem milky. The average
droplet size in traditional emulsions grows continuously with
time, leading to separation of phases due to gravity, but
the nanoemulsions are stable, and the particle size does
not change during storage [8]. Their ability to solubilize
the insoluble drugs and their transparency and constancy
make nanoemulsions suitable carriers for transdermal drug
delivery [9, 10].
The nanoemulsions include four types according to the
Winsor’s classification: (I) the surfactant is preferentially
soluble in water causing the formation of oil-in-water (o/w)
nanoemulsions, (II) the surfactant is remarkably soluble in
the oil phase and forms water-in-oil (w/o) nanoemulsions,
(III) there is a middle phase having lots of surfactant that
coexists with water and oil phases with low amount of
surfactant, and (IV) the fourth type is a single-phase micellar
solution that forms when a sufficient quantity of amphiphile
(an alcohol) is added [11].
Lecithin is a natural surfactant isolated from eggs or
soya bean. It can form gels when combined with water and
nonpolar solvents. Organogels have gelling agent molecules
such as lecithin as a surfactant, a continuous phase of non-
polar solvent, and a polar solvent that is water in most cases
[12, 13]. They have the properties of oil and aqueous based
formulations and are clear, viscoelastic, thermodynamically
stable, and biocompatible. The organogels have a jelly-like
structure with three-dimensional network. A lot of organic
solvents such as linear or cyclic alkanes, esters of fatty acids,
and amines can be used to form organogels in the presence
of lecithin [13]. Lecithin molecules assemble to each other
and form enormous cylindrical micelles when a little amount
of water, formamide or glycerin is added to the nonpolar
media [12]. Lecithin has a wide variety of roles in food indus-
tries, pharmaceuticals, and cosmetics as a viscosity modifier,
solubilizer, emulsifier, stabilizer, and penetration enhancer
[14]. Lecithin consists of phosphatidyl choline, phosphatidyl
ethanolamine, phosphatidyl serine, and phosphatidyl inositol
and some other substances such as triglycerides and fatty
acids [15].
When lecithin is added to the organic media it is dis-
persed randomly. By adding the trace amount of water the
lecithin molecules will assemble in spherical reverse micellar
form. Tubular or cylindrical micellar aggregates of lecithin
molecules will form when the amount of water is increased.
Next step is formation of long, flexible, andworm-like tubular
micelle structures in the presence of much more water, and
at last these tubular microstructures overlap and entangle
with each other to form a three-dimensional gel network
among which the organic solvent is entrapped. Some other
beneficial properties of organogels are the ability of solving
a wide variety of different molecules, resistance to microbial
contamination, and optical transparency [12], so they have
the essential criteria for transdermal drug delivery.
Microemulsions are homogenous systems by some
unique characteristics which make them a good choice for
delivering drugs and are widely used in pharmaceutical
companies. They have been also used for oral and intramus-
cular injection routes [16–18]. The lecithin organogels have
been used for preparation of local sodium salicylate [16],
methimazole [19], and ketoprofen [20].
Intravenous nanoemulsions have been on the market for
parenteral nutrition since the 1950s; meanwhile, they have
also been used successfully for IV drug delivery [21].
Nanoemulsions were tested on surfaces by the US Army
in December 1999 for a broad-spectrum decontamination
of anthrax spore surrogates. It was tested again in March
2001 as a chemical decontamination agent. All tests were
successful. The technology has been tested on gangrene
and Clostridium botulism spores and can even be used on
contaminated wounds to salvage limbs. The nanoemulsion
technology can be formulated into a cream, foam, liquid, or
spray to decontaminate a variety of materials marketed as
NANOSTAT (NanoBio Corp.) [22].
Nanoemulsions are being used to deliver either recombi-
nant proteins or inactivated organisms to a mucosal surface
to produce an immune response. The first applications, an
influenza vaccine and anHIV vaccine, can proceed to clinical
trials. Additional research is ongoing to complete the proof of
concept in animal trials for other vaccines including hepatitis
B and anthrax. The University of Michigan has exclusively
licensed this technology to NanoBio [22].
Metoprolol is a potent 𝛽
1
-selective adrenergic blocking
agent. The 𝛽
1
-adrenoceptor antagonists are extensively used
in various cardiovascular disorders. The oldest drug of this
family is propranolol, but because of its blocking effect on
smooth and skeletal muscles it is contraindicated in patients
with asthma and should be used with caution in diabetic
individuals [23]. Now metoprolol is widely used as a first
choice drug in the treatment of mild to moderate hyperten-
sion and stable angina and is helpful in postinfarction patients
[24]. These benefits are gained due to blocking peripheral
adrenoceptors, decreasing rennin secretion from kidneys,
and decreasing oxygen use in myocard [25].
Unfortunately, this drug undergoes a wide first pass
metabolism but this deactivation can be overcome by fabri-
cating the drug in transdermal therapeutic systems [26]. Nair
et al. [27] used the combination of iontophoresis with sodium
lauryl sulfate and showed augmented metoprolol delivery
which rendered skin drug depot eventually released over a
period of time. The transdermal matrix films of metoprolol
tartrate were also prepared by casting on mercury substrate
employing different ratios of polymers, ethyl cellulose (EC)
and polyvinyl pyrrolidone (PVP), using dibutyl phthalate
(DBT) as a plasticizer [28]. Based on the physical evaluation,
in vitro drug release, and permeation characteristics, it was
concluded that, for potential therapeutic use, monolithic
drug matrix films composed of EC : PVP, may be suitable
for the development of a transdermal drug delivery system
of metoprolol [28]. Matrix and membrane controlled trans-
dermal therapeutic systems were prepared from methacrylic
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Table 1: Formulation of the different types of metoprolol nanoemulsions.
Formulation Metoprololtartrate (mg)
Lecithin
170 (g)
Lecithin
200 (g)
Lecithin
100p (g)
Isopropyl
myristate (g) Butanol (mL)
Isopropyl
alcohol (mL) n-Propanol (mL)
F1 40 0.64 — — 0.96 — 0.3 —
F2 80 0.48 — — 0.72 — 1.1 —
F3 100 0.4 — — 0.6 — 1.4 —
F4 10 0.64 — — 0.96 — — 0.4
F5 20 0.64 — — 0.96 — — 0.2
F6 40 0.64 — — 0.96 — — 0.6
F7 60 0.64 — 0.96 — — 0.2
F8 40 — 0.64 — 0.96 — — 0.3
F9 40 — 0.64 0.96 — — 0.8
F10 131 — 0.51 — 0.17 — — 0.65
F11 40 — — — — — — —
F12 80 0.64 — — 0.96 — 0.4 —
F13 80 0.4 — — 0.6 — 0.4 —
F14 40 — 0.51 — 0.17 — — 0.4
F15 40 0.48 — — 1.12 — — 0.6
F16 40 0.8 — — 0.8 — — 0.1
F17 40 0.64 — — 0.96 0.7 — —
polymers (Eudragit NE) applying different sucrose fatty acid
esters to control the drug release and cutaneous absorption of
metoprolol [29]. Eudragit RL-100 and polyvinyl acetate have
also been used in production of the matrix type transdermal
drug delivery systems ofmetoprolol by film casting technique
which showed statistically significant reduction in mean
blood pressure inmethyl prednisolone-induced hypertensive
rats [30]. Ghosh et al. [23] studied the effect of n- decylmethyl
sulfoxide (nonionic surfactant) as a percutaneous absorption
enhancer in permeation rate of metoprolol across human
cadaver skin. They used 1.5mm polyacrylate patches (10%
w/w) containing varying concentrations of n-decyl methyl
sulfoxide and tested for skin permeation potential. It was
found that incorporation of n-decyl methyl sulfoxide up
to 3% w/w concentration did not produce any significant
change in skin permeation rate. A concentration of 5% w/w
of this surfactant showed 40% enhancement in metoprolol
permeation rate. They concluded that metoprolol permeated
quite efficiently through both hairless mouse and human
cadaver skin when applied from the polyacrylate patch with
no significant lag time. Use of electrical outflow has also been
reported for increasing drug permeation due to opening skin
pores [30].
Considering the different reports on transdermal delivery
of metoprolol and the good results obtained by other drugs
used in the basis of nanoemulsions for enhanced permeation
in the skin, the aim of the present work was to prepare
lecithin nanoemulsion for transdermal delivery ofmetoprolol
in the treatment of hypertension. To our knowledge there
is no report on the production of metoprolol lecithin based
nanoemulsions and, its designing is novel.
2. Material and Methods
2.1. Materials. Lecithin 200, 100p were from Locus Meyer
industry, Germany, lecithin 170 was fromDegussa, Germany,
n-butanol, isopropyl alcohol, n-propanol, potassium mono-
hydrogen phosphate (K
2
HPO
4
), NaOH, and sodium lauryl
sulphate (SLS) were from Merck Chemical Company, Ger-
many, cellulose membrane from Biocin industry, Belgium,
isopropyl myristate from Aldrich company, Germany, and
metoprolol was fromAlborz Darou, Iran, as a gift sample. All
the materials were of analytical grades.
2.2. Animals. Healthy male Wistar albino rats weighing
180–280 g were purchased from Pastur Institue, Tehran, Iran.
Animals had free access to standard rat chow and tapwater ad
libitum. They were kept in a temperature-controlled environ-
ment in animal house of Isfahan University of Medical Sci-
ence at 23±2∘Cwith an alternating cycle of 12 h light and dark.
2.3. Preparation of Lecithin Organogels of Metoprolol. For
preparation of lecithin organogels of metoprolol lecithin was
added to 40∘Cwater while being stirred on a magnetic stirrer
at 300 rpm. After complete dissolution of lecithin isopropyl
myristate was added at room temperature leading to the
formation of a turbid lotion. Finally, by adding one of the
three short chain alcohols of n-butanol, isopropyl alcohol,
or n-propanol as cosurfactants, the organogel was achieved.
After the preliminary tests 16 formulations were selected
according to the ratio of lecithin/isopropyl myristate and
metoprolol percent that are shown in Table 1. Among these
formulations one that had the least amount of alcohol was
selected as the optimum formulae.
2.4. Lecithin-Oil-Water Phase Diagram. Different amounts of
water were added to the lotion of lecithin/isopropyl myristate
in fixed ratio of 1 : 1.5. The studied variables were the percent
of metoprolol in solution, the type of alcohol (n-propanol,
isopropyl alcohol, and n-butanol), and the different amounts
of lecithin. Finally, the effect of lecithin amount, metoprolol
percent, alcohol type, and the ratio of lecithin/isopropyl
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myristate on the transparent region of nanoemulsion was
estimated. As the amount of water increases, the microemul-
sion turned to a viscous gel. Phase diagrams for the organogel
system also demonstrate the behavior of organogel system
such as cloudiness, isotropicity, optical transparency, and
viscosity.
2.5. The Nanoemulsion Characteristic of
Metoprolol Organogels
2.5.1. Particle Size Measurements. The mean particle size of
nanoemulsions was measured by photon correlation spec-
troscopy (PCS) at a fixed angle of 90∘ (Zetasizer, ZEN 3600,
Malvern Instrumental, UK). Nanodispersion was suitably
diluted to measure mean particle size and polydispersity
index. Dynamic light scattering (also known as photon
correlation spectroscopy or quasielastic light scattering) is
a technique in physics that can be used to determine the
size distribution profile of small particles in suspension or
polymers in solution. It can also be used to probe the behavior
of complex fluids such as concentrated polymer solutions. So,
none of the ingredients of the formulation interfered with the
particle size measurements.
2.5.2. Turbidity of Nanoemulsions. All the samples were
tested with spectrophotometer at the wave length of 580 nm,
and the absorbance was read. Then the absorbance was
changed to transmittance.
2.5.3. Birefringency. The microemulsions were assessed
through the polarizing microscope. The rotation of scaled
sheet shows the birefringency of the system.
2.5.4. Rheologic Characteristics. For investigation of rheo-
logic behavior of the samples a Rheomat device (RM/180
model, Mettler, Germany) was used. The measuring tube
diameter was 15.18mm, the measuring bob diameter was
14mm, the shear rate was in the range of 6.5–129 (S−1),
and the fill volume was 9mL. For drawing the rheogram,
shear rate was increased for the samples till maximum. The
shearing stress was plotted against shear rate.
2.5.5. Drug Release Studies In Vitro. In vitro permeation stud-
ies were performed using Franz diffusion cell. The cellulose
membrane was previously soaked for 24 h in PBS in order
to open the pores. These membranes were mounted between
the donor and receptor compartment of the diffusion cell.
2 g of the formulated nanoemulsions was placed over the
membranes. The receptor compartment of the diffusion cell
was filled with phosphate buffer pH 7.4. The solution in
the receptor compartment was constantly and continuously
stirred using magnetic stirrer at 37 ± 2∘C. 2mL samples were
withdrawn at predetermined time intervals of 30, 60, 120, 180,
240, and 300min and replaced with an equal volume of fresh
phosphate buffer with the same temperature. The samples
were suitably diluted and analyzed to determine drug content
using UV spectrophotometer at a wave length of 275.9 nm.
All tests were done in triplicate. For each sample there was a
blank. The actual concentration of samples was calculated by
using
𝐶
𝑛
= C +
𝐶
𝑛−1
× 𝑉
𝑉
𝑡
, (1)
where 𝐶
𝑛
is the actual concentration of sample 𝑛, 𝐶 is the
apparent concentration, 𝐶
𝑛−1
is the actual concentration of
sample 𝑛 − 1,𝑉 is the volume of sample, and𝑉
𝑡
is the volume
of total sample.
2.5.6. Measurement of Drug Penetration from Rat Skin. All
test conditions in this experiment were as mentioned earlier
in previous section but with some modifications; the freshly
excised full thickness hairless abdomen skin of male Wistar
rat was mounted on glass diffusion cells with the stratum
corneum side in intimate contact with donor phase and
the dermal side facing the receptor solution. Samples from
the receptor compartment were withdrawn at predetermined
time intervals, and the concentration of drug released was
measured.
2.5.7. The Diffusion Coefficient and Permeation Coefficient
Measurements. Flux of drug was estimated from Fick’s first
law of diffusion:
𝐽
𝑆
=
1
𝑆
𝑑𝑄
𝑑𝑡
, (2)
in which 𝑆 is the surface area of diffusion cell and 𝑑𝑄/𝑑𝑡 is the
slope of drug release curve [5]. For determination of diffusion
coefficient the following equation was used:
𝐾 = 2𝐶o × 𝑆(
𝐷
𝜋
)
1/2
, (3)
where 𝐾 is the slope of the cumulative drug release profile,
𝐶o is the amount of primary drug, 𝑆 is the surface area of
diffusion cell, and𝐷 is drug diffusion.
For calculating the permeation of drug, the following was
used:
𝑀 = 𝑃𝑆C
𝑑
𝑡, (4)
where𝑀 is the amount of drug released, 𝑃 is the permeation
coefficient, 𝑆 is the surface area through which drug perme-
ates, and 𝐶
𝑑
is the amount of drug in donor phase [5].
2.6. Data Analysis. For the evaluation of drug release kinetics
Excel 2007 software was used, and the statistical analysis
was done using SPSS software version 10. All data were
expressed as mean ± SD and were compared by analysis of
variance (ANOVA) test followed by the post hoc test of LSD.
A significant level of 𝑃 < 0.05 was considered in all cases.
3. Results and Discussion
3.1. Metoprolol in a Lecithin Base Organogel for Transdermal
Delivery in Hypertension. Transdermal drug delivery has its
advantages in drug delivery such as elimination of first pass
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Figure 1: The effect of lecithin type on the transparent region of
w/o metoprolol nanoemulsion containing IPM/lecithin/isopropyl
alcohol/and 0.4 g of 10%metoprolol solution (LEC : ALC represents
the mixture of lecithin and alcohol used as the surfactant and
cosurfactant).
metabolism, ease of application and reduction of inconstancy
in the plasma concentration of drug. Metoprolol is an
antihypertensive drug with short half life which needs to
be used, frequently; meanwhile it goes under a high first
pass metabolism so that its oral bioavailability is just 50%.
Bioavailability is reduced by about 20–30% for the controlled
release preparation compared to the conventional tablets.
Therefore, this drug is a good candidate for transdermal
delivery [27–29].
3.2. Formulation Types. In order to increase the permeation
of metoprolol, different ratio of soya lecithin and isopropyl
myristate (from 90 : 10 to 10 : 90) was used. The best ratios
of lecithin/IPM were 40 : 60, 50 : 50, and 30 : 70. The formu-
lations containing more than 50% of lecithin and less than
30% could not be prepared, since more than 50% of lecithin
could not be dissolved in IPM, and when its concentration
was less than 30% too much alcohol was needed to prepare
the nanoemulsion [31].
3.3. PhaseDiagram. Phase diagrams seen in Figures 1–4 show
the effect of lecithin type, alcohol type, drug content, and
lecithin/isopropyl myristate ratio on the transparent region
of nanoemulsions, respectively.
By increasing purity of lecithin (type 200 was the most
pure one and type 100p had the lowest purity) the transparent
region increased (Figure 1) as Nasser and coworkers [32] also
showed in their study. By increasing alcohol chain (Figure 2)
the transparent region decreased. Trotta et al. [33] reported
such a phenomenon in their study too. Increasing drug
content (Figure 3) did not change the transparent region,
but 15% of metoprolol decreased the transparent region
because of decreasing the surface tension [33]. Changing
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Figure 2:The effect of alcohol type on the transparent region of w/o
metoprolol nanoemulsion containing IPM/lecithin 170/isopropyl
alcohol/and 0.4 g of 10% metoprolol solution (LEC : ALC represents
the mixture of lecithin and alcohol used as the surfactant and
cosurfactant).
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Figure 3: The effect of drug content in aqueous solution on the
transparent region of w/o metoprolol nanoemulsion containing
IPM/lecithin 170/isopropyl alcohol/and aqueous solution of differ-
ent drug contents (LEC : ALC represents the mixture of lecithin and
alcohol used as the surfactant and cosurfactant).
in IPM/lecithin ratio did not change the transparent region
(Figure 4).
3.4. Characteristics of the Nanoemulsions of
Metoprolol Organogel
3.4.1. Turbidity and Particle Size of Nanoemulsions. There is
a close and direct relationship between transparency and
the particle size. All samples were transparent when seen
with eyes and showed a particle size between 17 and 49 nm
except F
3
and F
15
which had larger particle size. Table 2
shows the transmittance and particle size of the samples. The
samples with more transparency and smaller particle size
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Figure 4: The effect of lecithin/IPM ratio on the transparent region
of w/o metoprolol nanoemulsion containing IPM/lecithin 170/iso-
propyl alcohol/and 0.4 g of 10% metoprolol solution (LEC : ALC
represents the mixture of lecithin and alcohol used as the surfactant
and cosurfactant).
Table 2: The results of turbidity measurement of nanoemulsions
according to the transmittance of light.
Formulation Particle size (nm) Transmittance (%)
F1 34 60
F2 20 71
F3 256 40
F4 44 50
F5 42 53
F6 40 53
F7 49 50
F8 17 85
F9 47 52
F10 19 75
F11 — 90
F12 18 73
F13 37 60
F15 301 32
F16 32 65
F17 41 57
were better choices for studying the drug release parameters.
The most transparent formulation was the aqueous solution
of metoprolol (F
11
) after that the nanoemulsion of F
8
had
the highest transparency while F
15
was the most turbid one.
Both these formulations have similar amounts of drug and
are prepared using n-propanol as the cosurfactant, but F
8
contains more lecithin 200 which has higher purity than the
type of lecithin 170 used in less amounts in F
11
. The former
has also lower amounts of IPM.
DLS method may be used even for suspensions which
are dispersed systems with micrometric particles and quite
turbid so turbidity of some samples does not interfere with
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Figure 5: The rheogram of w/o metoprolol nanoemulsion con-
taining IPM/lecithin/isopropyl alcohol/and 0.4 g of 10% metoprolol
solution with different ratios of lecithin 170 : IPM.
the PCS measurements. Moreover, as mentioned in the
methods all samples were diluted suitably before particle size
measurements.
3.4.2. Birefringency. The microemulsions were assessed
through the polarizing microscope; none of the samples
showed light scattering; the background was dark; and no
birefringency was seen, representing the production of na-
noemulsions.
3.4.3. Rheologic Behavior. Flow properties of different nanoe-
mulsions are shown in Figures 5–7. Initially, the flow of
organogels did not change by changing the shearing stress,
but after a while with the increasing in the rate of shear,
shearing stress increased linearly too. Adding the amount of
lecithin increased shearing stress (Figure 5), while increased
amounts of water decreased it (Figure 6). Changing the
amount of drug did not change the shearing stress (Figure 7).
Rheologic behavior is a sign of flow and dispersion of
a system and also affects the release process [34, 35]. So
knowledge of the rheologic behavior of a transdermal drug
delivery system is obviously important. Lecithin organogels
show Newtonian behavior before they become gels but by
adding water they show non-Newtonian behavior [36].Three
types of flow are seen in these systems: plastic, pseudoplastic,
and dilatant flow. As seen in Figures 5–7 all studied formu-
lations had plastic flow behavior; when the organogels were
sheared at low shear rates, they behaved like a solid and
show elasticity. With a subsequent increase in shear rate, the
tubular structures are weakened.The gelling molecules break
the physical interactions of the tubules until the shear stress
is high enough to destroy the organogel structure, so they
flow in linear form [12]. Increasing the ratio of lecithin/IPM
from 30 : 70 (F
15
) to 40 : 60 (F
6
) and 50 : 50 (F
16
) increased
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Figure 6: The rheogram of w/o metoprolol nanoemulsion con-
taining IPM/lecithin/isopropyl alcohol/and 0.4 g of 10% metoprolol
solution with different water contents.
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Figure 7: The rheogram of w/o metoprolol nanoemulsion contain-
ing IPM/lecithin/isopropyl alcohol/and 0.4 g of different concentra-
tions of metoprolol solution.
viscosity and shearing stress of the formulations (Figure 5).
By changing thewater content of nanoemulsions from0.4 g in
F
12
to 0.8 g in F
2
and 1 g in F
13
the viscosity and shearing stress
decreased too (Figure 6). Nasser and coworkers achieved
similar results in their study on the ketorolac thrometamine
organogels in which, by increasing the water content of
nanoemulsions, the viscosity and shearing stress decreased
[31]. Changing the drug content from 2.5 to 15% did not have
significant effect on the rheologic behavior of nanoemulsions,
and no change in viscosity was observed (Figure 7).
3.5. In Vitro Drug Release. The results of flux calculation,
regression coefficient, and permeation and diffusion of dif-
ferent formulations are written in Table 3.
As Table 3 indicates in formulations of F
16
, F
15
and F
6
the flux and drug release rate is the lowest. In formulation of
F
15
by increasing the ratio of lecithin : IPM, the coefficients
of permeation and diffusion decreased (Table 3). Increasing
the lecithin : IPM from 30 : 70 to 40 : 60 and 50 : 50 drug
release (flux) decreased; it can be interpreted in this way
that thermodynamic activity of drug is decreased in higher
concentration of lecithin. In higher concentrations of lecithin
there are cylindrical micelles which trap the drug, so the flux
of drug and its release rate decreased (Table 3) (𝑃 < 0.05)
(cf. F
16
, F
15
, and F
6
). Aboofazeli and coworkers achieved
similar results in their study on the ketorolac thrometamine
organogels [31]. By increasing the drug content from 2.5 to
10% the rate of drug release enhanced (F
4
, F
5
, and F
6
), and
after that by increasing the drug content to 15% the rate
of release declined again (Table 3) (𝑃 < 0.05) (compare
F
7
and F
6
). These results confirm the fact that release
profile is attributed to drug concentration. The explanation
for this phenomenon is that the thermodynamic activity
increases by increasing drug concentration until it reaches
the saturated concentration, and after this concentration
the thermodynamic activity decreases, and accordingly the
release declines. Santoyo and coworkers [37] achieved similar
results in their study on piroxicam release from propylene
glycol gels. AlsoHenmi et al. [38] reported that indomethacin
release from oily gels consisting of soya phospholipid was
directly contributed to the drug concentration.
Increasing water content increased the flux and drug
release rate from the formulations (Table 3) (cf. F
2
, F
12
, and
F
13
).This is becausewater can enhance drug permeation from
cellulose acetate pores [31]. According to the type of alcohol
it was observed that flux was lower in formulations which
were prepared by n-propanol and isopropanol than those
by n-butanol (𝑃 < 0.05) (Table 3) (cf. F
1
, F
17
, and F
6
). N-
propanol and isopropanol are dispersed majorly in aqueous
phase, so drug was trapped in inner phase of w/o emulsions,
and consequently its release decreased, but water solubility of
n-butanol is lower than the other two alcohols [16]; therefore,
it may be concluded that the drug was entrapped more in the
outer phase causing the faster and increased flux.
Comparing the drug release rate, flux, permeation, and
diffusion from formulations containing 0.4 g of a 10% meto-
prolol solution with nanoemulsions containing the same
amount of drug but with a different type of nanoemulsion
revealed that o/w nanoemulsion formulations released the
drug faster than w/o types, because w/o nanoemulsions trap
drug more and prevent their fast release; that is, representing
drug is passed more in time [10] (compare F
8
and F
14
)
(Table 3).
Increasing the purity of lecithin decreased the release
from formulation where lecithin 100p increased drug perme-
ability more than other lecithin types (𝑃 < 0.05) (cf. F
9
, F
8
,
and F
6
) (Table 3). This result is contrary to Aboofazeli and
coworkers’ [16] results that can be interpreted in this way that
the more pure lecithin can absorb more water in the core
of nanoemulsion and decrease drug release rate as discussed
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Table 3: Flux, release rate (𝑑𝑄/𝑑𝑡), regression coefficient (𝑅2) of the curve plotted from changes of 𝑑𝑄 against 𝑑𝑡, permeation (𝑃), and
diffusion coefficient (𝐷) of different formulations through cellulose acetate membrane and (†) rat skin.
Formulation Flux (𝜇g/cm2/min) ± SD 𝑑𝑄/𝑑𝑡 (𝜇g/min) ± SD ∗𝑅2± SD 𝑃 (cm/min) ± SD 𝐷 (cm2/min) ± SD
F1 0.29 ± 0.01 1.53 ± 0.08 0.971 ± 0.002 (2.46 ± 0.28) × 10
−4 (6.60 ± 0.88) × 10−9
F2 9.66 ± 0.30 51.38 ± 1.59 0.993 ± 0.001 (1.63 ± 0.04) × 10
−4 (2.67 ± 0.16) × 10−6
F3 21.21 ± 0.21 112.83 ± 1.12 0.995 ± 0.005 92.24 ± 0.02) × 10
−4 (6.38 ± 0.16) × 10−6
F6 1.58 ± 0.01 6.16 ± 0.09 0.938 ± 0.001 (2.76 ± 0.04) × 10
−5 (2.01 ± 0.06) × 10−7
F7 0.93 ± 0.03 4.96 ± 0.19 0.991 ± 0.002 (1.89 ± 0.05) × 10
−5 (4.83 ± 0.39) × 10−8
F8 0.70 ± 0.03 3.73 ± 0.18 0.964 ± 0.006 (1.98 ± 0.09) × 10
−5 (4.31 ± 0.50) × 10−8
F9 1.25 ± 0.02 6.66 ± 0.13 0.995 ± 0.002 (2.92 ± 0.061) × 10
−5 (2.03 ± 0.07) × 10−7
F10 7.38 ± 0.26 39.26 ± 1.39 0.998 ± 0.001 (4.61 ± 0.20) × 10
−5 (6.21 ± 0.52) × 10−7
F11 43.00 ± 1.03 228.68 ± 5.46 0.964 ± 0.003 (1.59 ± 0.03) × 10
−3 (2.65 ± 0.52) × 10−4
F12 4.50 ± 0.16 24.02 ± 0.81 0.957 ± 0.007 (4.64 ± 0.19) × 10
−5 (5.32 ± 0.40) × 10−7
F13 9.00 ± 0.13 47.92 ± 0.70 0.993 ± 0.001 (1.59 ± 0.01) × 10
−4 (2.87 ± 0.07) × 10−6
F14 5.32 ± 0.16 28.30 ± 0.91 0.993 ± 0.007 (1.33 ± 0.11) × 10
−6 (3.43 ± 0.55) × 10−6
F15 5.32 ± 0.16 28.30 ± 0.91 0.987 ± 0.001 (2.96 ± 0.25) × 10
−5 (2.11 ± 0.30) × 10−7
F16 0.65 ± 0.02 3.46 ± 0.12 0.986 ± 0.001 (1.93 ± 0.06) × 10
−5 (4.37 ± 0.36) × 10−8
F17 2.62 ± 0.03 13.96 ± 0.17 0.993 ± 0.001 (5.19 ± 0.08) × 10
−5 (7.11 ± 0.24) × 10−7
†F2 3.38 ± 0.17 18.00 ± 0.89 0.961 ± 0.001 (3.68 ± 0.21) × 10
−5 (8.29 ± 0.27) × 10−7
†F11 22.24 ± 0.21 118.30 ± 1.21 0.987 ± 0.001 (4.53 ± 0.06) × 10
−4 (2.76 ± 0.05) × 10−5
†F10 3.07 ± 0.20 16.37 ± 1.04 0.960 ± 0.001 (2.47 ± 0.15) × 10
−5 (5.32 ± 0.83) × 10−8
earlier about the effect of water content of nanoemulsions on
the drug release rate and flux.
Comparing the drug release rate through the cellulose
acetate membrane and rat skin (†F
2
, †F
10
, and †F
11
) it was
observed that in all formulations the flux and drug release
rate was higher when using cellulose acetate membrane (𝑃 <
0.05) (Table 3). It is similar to the study of Malaz et al. [39] on
release profile of tretinoin gels through synthetic membrane
and rat skin. This low release of drug through rat skin relates
to complexity of skin texture which does not allow drug
molecules to penetrate.
The release rate and flux of metoprolol from an aqueous
solution (F
11
) through rat skin was more than both w/o (F
2
)
and o/w (F
10
) types of nanoemulsions (𝑃 < 0.05) (Table 3)
due to drug entrapment in nanoemulsions. Drug release rate,
or flux in rat skin did not differ so much in w/o (†F
2
) and o/w
(†F
10
) nanoemulsions type (𝑃 > 0.05) (Table 3).
Increase in the amount of flux enhances drug permeation
and diffusion coefficient. Drug permeation and diffusion
coefficient weremore in the formulations studied by cellulose
acetate membrane than rat skin (Table 3) (cf. F
2
, F
10
, and F
11
with †F
2
, †F
10
, and †F
11
). The highest flux and permeation
was seen in F
11
(aqueous drug solution) and the lowest was
seen in F
10
(o/w types of nanoemulsion) (𝑃 < 0.05).
In spite of promising results obtained from nanoemul-
sions for transdermal uses attention to toxicological aspects
of nanosized delivery systems should not be ignored.
Lipid-based nanoparticles such as liposomes, micelles, and
nanoemulsions are platforms that must be compatible with
the physiological environment and prevent undesirable
interactions with the immune system. At present there is
little experimental evidence on the potential toxicity of
nanoemulsions [40]. Nevertheless, there are a number of
physicochemical and physiological mechanisms associated
with the small particle size in nanoemulsions that could
potentially cause toxicity. Avoiding immune stimulation or
suppression is an important consideration when developing
new strategies in drug and gene delivery.The organic solvents
are usually removed by evaporation during the preparation
of the nanoemulsions, but some residual solvent may remain
in the final product. It is therefore important to be aware of
the potential toxic effects associated with any residual organic
solvents if nanoemulsions are produced using this approach.
The potential toxicity of emulsifiers and solvents that are
suitable for utilization within foods, pharmaceuticals, and
other consumer products has been published by various orga-
nizations, including the World Health Organization [41]. In
the present study all FDAaccepted ingredientswere used, and
no toxicity has been reported for them so far. There are also
many reports on the safety of transdermal nanoemulsions.
For example, the in vivo toxicity of meloxicam nanoemulsion
gel was assessed by histopathological examination in rat
which turned out to be nonirritant and biocompatible [42].
Also there was no observed mortality or any signs of toxicity
during the experimental period of using thymoquinone-rich
fraction nanoemulsions [43].
4. Conclusion
O/w nanoemulsion released higher amount of metopro-
lol through cellulose acetate membrane compared to w/o
nanoemulsions; however, permeation and diffusion of drug
through rat skin from w/o and o/w nanoemulsion did not
differ significantly. Formulations containing 10% aqueous
solution ofmetoprolol had higher drug release rate, and those
containing lecithin 200 were preferred because of using less
alcohol for elucidating the systems.
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Electrospinning nanofibrous scaffold was commonly used in tissue regeneration recently. Nanofibers with specific topological
characteristics were reported to be able to induce osteogenic differentiation of MSCs. In this in vivo study, autologous tendon grafts
with lattice-like nanofibrous scaffold wrapping at two ends of autologous tendon were used to promote early stage of ligament-
bone healing after rabbit ACL reconstruction. To utilize native MSCs from bone marrow, an MSCs specific affinity peptide E7 was
conjugated to nanofibrousmeshes. After 3months, H-E assessment and specific staining of collagen type I, II, and III showed direct
ligament-bone insertion with typical four zones (bone, calcified fibrocartilage, fibrocartilage, and ligament) in bioactive scaffold
reconstruction group. Diameters of bone tunnel were smaller in nanofibrous scaffold conjugated E7 peptide group than those in
control group. The failure load of substitution complex also indicated a stronger ligament-bone insertion healing using bioactive
scaffold. In conclusion, lattice-like nanofibrous scaffold with specific MSCs affinity peptide has great potential in promoting early
stage of ligament-bone healing after ACL reconstruction.
1. Introduction
Tissue engineering technique emerges as a new tool in tissue
regeneration these years. Nanosized material was frequently
used as scaffold in tissue engineering because of its superior
characteristics like huge surface area and superior biological
compatibility. Nanofibrous scaffold fabricated by electrospin-
ning technique has been used in bone, neuron, and ligament
regeneration. We developed a specific nanotopographical
electrospun scaffold which could induce osteogenesis of rat
bone marrow derived mesenchymal stem cells (MSCs) in
vitro. And now we want to testify the ability of this scaffold in
accelerating bone formation at the ligament-bone insertion
sites after rabbit ACL reconstruction.
Nanofibrous scaffolds are appropriated for cell adhesion
and growing because of the huge surface area and fibers in
nanoscalewhich canmimic natural extracellularmatrix [1, 2].
Among the methods of fabricating nanofibrous scaffolds,
electrospinning is the most widely used given its simplicity
and efficiency. However, mechanical properties of electro-
spunmeshes render it impossible to be a substitution for ACL
reconstruction alone. Therefore some researchers designed
composite scaffold combining firm artificial material with
nanofibrous surfacemade by electrospinning [3, 4]. But autol-
ogous tendons especially hamstring tendons, which were
commonly used in clinical surgery, were still verified to be
better than artificial scaffolds for their good biocompatibility
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and mechanical properties [5, 6]. So combining autologous
tendon and electrospunmeshes to form a new scaffold should
satisfy both the mechanical and cell growth requirements.
MSCs have beenwidely used in tissue engineering studies
and have been proved to have great potential in clinical
application because of their convenience in isolation, lack of
significant immunogenicity, high capacity of expansion, and
potential to differentiate into tissue-specific cell types [7–9].
HoweverMSCs should be first homed and entrapped into the
site of tissue damage so as to allowMSCs to properly perform
their functions during the whole repair process [10]. In our
previous research we screened an affinity peptide of bone
marrow-derivedMSCsusing phage display technique to solve
the problem of low efficiency and engraftment of MSCs in
tissue engineering [11]. As a result, covalently conjugating the
peptide E7 on the synthetic electrospun mesh significantly
enhanced the MSC recruitment of scaffold in vivo. Therefore
we used this technique for the same purpose in our study.
As new bone formation is of vital importance for
ligament-bone healing after ACL reconstruction, many com-
posite scaffolds were designed to promote osteogenesis of
MSCs at the insertion site. In bone tissue engineering,
compositionmimic native extracellularmatrix like hydroxya-
patite, collagen, chitosan, and so forth was added to promote
osteogenic differentiation of MSCs [12, 13]. Also, bioactive
cytokines like BMP2 were used as chemical inductive agents,
and mechanical stimulation can promote osteogenic differ-
entiation of MSCs as well [14]. In recent years, topological
characteristics of nanofibrous scaffold was confirmed to be
an important factor in deciding the destiny of cell growing
on them. Specific topographical scaffold can promote cell
adhesion, migration, proliferation, and differentiation [15,
16]. In our previous research, we found that the lattice-
like nanofibrous mesh can promote osteogenesis of rat
MSCs by regulating integrin b1 (ITGB1), ras homolog gene
family member A (RhoA)/Rho-associated protein kinase
(ROCK), extracellular regulated protein kinases (ERK), and
runt related transcription factor 2 (Runx2) expression [17].
However, few studies were available that have tested the
osteoinductive ability of electrospun meshes in vivo. In this
study, we designed a new scaffold, which is combined lattice-
like nanofibrous meshes with bone marrow MSCs affinity
peptide, and was used in rabbit ACL reconstruction model
together with autologous hamstring tendon. The aim of this
study is to compare the osteogenic ability of tendon grafts
with or without nanofibrous scaffolds and to explore the
potential application of electrospun scaffolds in ligament
tissue engineering.
2. Methods and Materials
2.1. Electrospinning PLLA Nanofibrous Scaffold. Lattice-like
patterned poly-L-lactide (PLLA) nanofibrous scaffolds were
fabricated as described in our previous research.The polymer
solution was prepared by dissolving 1.0 g of PLLA powders in
10mL tetrafluoroethylene and stirred overnight.The solution
was electrospun from a 20mL syringe with a steel needle
(inner diameter of 0.5mm) at a rate of 0.5mL/h continuously
with a programmable syringe pump (Top 5300, Japan). A
voltage (12 kV) was applied to the tip of the needle by the
use of a high-voltage supply (DW-P303-1AC, China) when a
fluid jet was ejecting. To obtain patterned PLLA nanofibrous
scaffolds, a copper wire grid (𝑟 = 10 cm) was used as a
collector at a distance of 15 cm from the tip of the needle.
Before using, all scaffolds were exposed to a vacuum oven
(DZF-6210, Bluepard, China) at room temperature for 2
weeks to remove residual solvent.
2.2. MSCs Affinity Peptide E7 Biopanning and Conjugation.
The bone marrow MSCs of Wistar rats were harvested using
standard protocol in our lab. MSCs were derived from two
lower extremities of rats with the approval of the Animal
Ethics Committee of PekingUniversityThirdHospital. MSCs
specific affinity peptide was biopanning by the phage display
technique following a previously described procedure with
modifications [11, 18]. In brief, first a peptide phage display
library was commercially constructed (Ph.D.-7 phage display
library, NEB, Beverly, MA, USA) and incubated with MSCs,
synovial cells were used as negative control. Then the phage
clones binding MSCs were amplified, titrated and, purified
according to the manufacturer’s standard protocol. Three to
four rounds of selection were performed until the optimal
results were obtained. The experiments were duplicated for
verification. A specific peptide was identified in the MSC-
affinity clones and designated as E7. The peptides were
dissolved in DMSO to yield a 2mg/mL concentration before
usage.
The PLLAmeshes were immersed into a 10%w/v solution
of 1,6-hexanediamine (Sigma, St. Louis, MO, USA) prepared
in isopropanol at 37∘C for 1 h. After the exposure, the PLLA
meshes were thoroughly washed in ultrapure water and dried
under vacuum at room temperature. For the conjugation of
E7 peptides to the surface of meshes, the aminated PLLA
meshes were washed thrice with activation buffer (0.1M
PBS containing 0.15M NaCl, pH 7.2) before treatment, and
sulfosuccinimidyl-4- (N-maleimidomethyl) cyclohexane-1-
carboxylate (sulfo-SMCC) (Thermo Fisher Scientific Inc.,
Rockford, IL, USA) was used as a cross-linker. A total of
500mL (2mg/mL) sulfo-SMCC solution was added onto
the aminated PLLA meshes, incubated for 1 h at room
temperature, and washed with conjugation buffer (activation
buffer containing 0.1M EDTA, pH 7.0). The peptides were
dissolved in conjugation buffer at a concentration of 0.1mM.
Up to 500mL of the peptide solution was applied onto the
sulfo-SMCC-treated PLLA scaffold and incubated overnight
at 4∘C.Thepeptide conjugatedPLLAmesheswere thoroughly
washed thrice with ultrapure water and dried under vacuum
at room temperature. The whole mesh was cut into 1 cm2,
sterilized by immersing in 75% ethanol over-night, washed
thrice with ultrapure water, and immersed in PBS over 4 h.
Before implantation, themesheswere kept in 4∘C refrigerator.
2.3. MSCs Attachment on Different Scaffolds. The MSCs at
passage 3 were seeded onto the blank or E7-conjugated
lattice PLLA meshes. After 24 h of incubation, the PLLA
meshes were washed from three to five times with PBS
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and fixed with 4% paraformaldehyde for 10min at room
temperature. Cells were then preincubated in 100𝜇L of
primary blocking solution (PBS, 1%BSA, and 0.1% NP-40)
for 20min and then incubated with 10−7M Alexa Fluor 488
phalloidin conjugate (Molecular Probes) for 1 h. After three
washes in PBS, nuclei were stained with 10𝜇g/mL Hochest
33342 at room temperature for 30min. Mounting medium
(35 𝜇L, Zhongshan) was dispensed onto the cells, and a glass
coverslip was placed on the slide before placing it in the
freezer prior to observation. Actin structures were examined
by laser confocal scanningmicroscopy (FV 1000Olympus IX-
81). Cell attachment was observed by confocal microscope
at both ridge regions and nonwoven regions of lattice. And
percentage of cell attachment to material within each group
were measured using Image-Pro Plus 6.0 software (Media
Cybernetics, Silver Spring,MD,USA) by 5 randomareaswere
used in one photograph.
2.4. ACL Reconstruction Surgery. Animal experiments were
approved by Ethical Committee of third hospital, Peking
University. Forty-eight New Zealand white rabbits (12 weeks
old, 2.5–3.0 kg) were divided into three groups: BIO group
(lattice-like PLLA scaffold with MSCs affinity peptide; n 16),
PLLA group (lattice-like PLLA scaffold alone; n 16), and
control group with single reconstruction surgery. Hamstring
tendon grafts were harvested from both two knees of each
rabbit. Then two tendons were bound by braiding two ends
with 3–0 braided nylon thread. Nanofibrous meshes were
braiding together with tendon in BIO or PLLA reconstruc-
tion groups at this time. The right knee joint of each rabbit
was exposed using a midline skin incision, and lateral parap-
atellar arthrotomy was performed.The patella was dislocated
totally with the knee extended. With the knee placed in its
hyperflexive state, the original ACL was removed by sharp
dissection of the tibial and femoral attachment sites, while the
fat pad was left intact. Using a 2.0mm diameter Kirschner
wire and a drill, bone tunnels were made from the ACL
femur attachment sites to the lateral femoral condyles, as
well as from the ACL tibial attachment sites to the medial
tibia. The tibial sites were distal and lateral to the tibial
tubercles. After placing the grafts into two bone tunnels,
both two ends were fixed by bone bridge (Figures 3(a)–
3(f)). This was done with the knee at 45∘ of flexion, while
the constructs were manually exposed to maximum tension.
Penicillin (200000U/kg) was subcutaneously administered
to prevent postoperative infection. Enhanced antibiotic was
used for 3 days after surgery. At 1 or 3months after surgery, the
knee joints were harvested for histological and mechanical
examinations. At the specified times, rabbits were sacrificed
by intravenous air embolism.
2.5. Measurement of Bone Tunnel by CT Scanning. All 48
hind limbs were harvest after rabbit was sacrificed imme-
diately. Whole limb was scanned by 64-row CT scanner
(LightSpeedVCT;GEMedical System,Chalfont StGiles, UK)
using the same parameter of human hands scanning. Both
the femoral and tibial tunnels were measured by one and
the same technician, to ensure no operating errors. The
cross-section of bone tunnel was determined by 3 steps: first
step, confirm the middle of articular according the patellar
position; then draw the long axis of bone tunnel in femora or
tibia by adjusting the sagittal and coronal plane to show the
longest tunnel; at last the cross sectional images were taken
perpendicular to the long axis of bone tunnel (Figure 4). All
slices of each sample were scanned and theminimal diameter
of bone tunnel could be calculated by 3-dimensional recon-
struction. All data were analyzed by 3-different researchers
and both femoral and tibial tunnel diameter was taken as one
specimen.
2.6. Histological and Immunohistological Assessment. Eight
of specimens in each group were prepared for histological
assessment. Ligament-bone insertion was harvested by cut-
ting from sagittal plane 1 cm away articular. After all soft
tissue removing, transplanted ligament was cut off in the
middle part, fixed in formalin (4% formalin in phosphate-
buffered saline), and embedded in paraffin. Six micron thick
tissue sections were cut from these paraffin blocks. All of
the specimens were stained with hematoxylin and eosin (H-
E), sirius red, and immunohistochemical staining to display
the histological characteristics and distribution of collagen
type I, II, and III. Distribution of collagen type I and III was
displayed by sirius red staining and observed by polarized
light microscope (Laica DM2500,Wetzlar, Germany). Distri-
bution of collagen II was evaluated with a specific antibody
to rabbit collagen type II (Calbiochem, Darmstadt, Ger-
many). Before staining, the samples were treated with pepsin
working solution (ZhongShanJinQiao, Beijing, China) for
15min and then incubated with primary antibody overnight.
Following PBS washing, biotinylated secondary antibodies
were added for 1 hour at 37∘C, then the samples were
colorated with 3,3-diaminobenzidine (DAB). Each specimen
was viewed by light microscopy (Olympus BH-2, Tokyo,
Japan) and photographs were taken from 3 randomly chosen
representative microscopic fields at a magnification of 40–
200x.
2.7. Biomechanical Test of Substitution Complex. After CT
scanning, the lower extremities of another 8 animals in each
group were disarticulated at the hip joint and stored at −80∘C
refrigerator. Beforemechanical testing, each kneewas thawed
overnight at 4∘C and all soft tissues around the knee were
carefully removed except the ACL.The prepared femur-ACL-
tibia complex was then mounted onto a conventional tensile
tester.The femur and the tibia were fixed in cupreous holders
using 2 Kirschner wires. The knee was fixed at 45∘ of flexion
with maximal tensile resistance during testing.The specimen
was cycled between 0 and 0.5mm deformation 10 times at a
rate of 5mm/min for pretension. Subsequently, the specimen
was stretched to failure at a rate of 0.1mm/s. The load-
deformation curve was recorded and the ultimate load was
then obtained. The linear stiffness was defined as the best-
fitting straight line drawn through the linear portion of the
load-deformation curve. The specimens were kept moist at
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all times during preparation and testing with normal saline
solution.
2.8. Statistical Analysis. All data were shown as the mean
with standard deviation. One-way analysis of variance was
performedwhen comparing data of 3 groups.Other statistical
comparisons were performed with the paired-samples 𝑡-test.
SPSS 14.0 software was used for statistical calculation. The
significance level was set at 𝑃 < 0.05.
3. Results
3.1. Lattice-Like PLLA Nanofibrous Meshes Synthesis and
Observation. Propelled by electrostatic forces, lattice-like
fibrous PLLAmeshes could be obtained by using copper wire
grid as collector (Figure 1(a)). The lattice-like mesh macro-
scopically resembled gauzes and followed the pattern of grid
(Figure 1(b)). Detailed structure of nanofibers in the scaffolds
was observed by scanning electron microscopy (Figures 1(c),
1(e), and 1(f)). Fibers depositing on the ridge regions were
parallel-aligned (Figure 1(e)) while in those regions between
ridges were randomly distributed (Figure 1(f)). The diameter
of nano fibers ranged from 200 to 1200 nm (Figure 1(e)).
3.2. MSCs Attachment on PLLA Nanofibrous Meshes. The
attachment of MSCs on scaffolds with or without affinity
peptide was observed by laser scanning confocal microscope.
Staining of cytoskeleton and nuclei of MSCs showed well
attaching and spreading of cells on both two kinds of
scaffolds. But the cell number was obviously different on E7
conjugated PLLAmeshes at different regions of latticemeshes
(Figures 2(a) and 2(c)). Cell morphology of MSCs growing
on E7 conjugated PLLA meshes appeared better organized
and was more compliance with the nanofiber distribution
than on PLLA meshes (Figures 2(b) and 2(d)). Percentage of
cell attachment to different kinds of scaffolds was obviously
different, which was 89.72 ± 1.66% and 60.24 ± 10.42% (𝑃 <
0.05) on PLLA meshes with or without E7 peptide.
3.3. Gross Observation. Twenty-four rabbits were sacrificed
at 1 or 3 months after ACL reconstruction surgery, respec-
tively. Gross morphology of knee joint was compared after
operation between three groups. At 12 weeks the regenerated
ligament showed a stable fixation in all three groups without
any ends pulling out of tunnels. There was not obvious
infection in joint cavity; meanwhile synovial fluid was clear
in three groups. But all joints exhibited a little degeneration
with cartilage injury, to some extent, which might because
of the damage in surgery procedure or instability after
reconstruction of ACL. The gross findings revealed that
reconstructed ligament was wrapped by synovial membrane,
but two bundles of tendon were still distinguishable (Figures
3(g)–3(i)).
3.4. Bone Tunnel Measurement. The cross-sectional images
perpendicular to the longitudinal axis of bone tunnel were
reconstructed in high-resolution CT.The newly formedmin-
eralized tissue could be examined by screening all slices of
Table 1: Bone tunnel measured by CT and failure load of grafts.
Group Bone tunnel (mm) Failure load (N)
1M 3M 3M
REC 7.50 ± 1.80 10.16 ± 2.62∗ 34.58 ± 4.08
PLLA 5.96 ± 0.90 6.72 ± 1.66 82.59 ± 3.33∗
BIO 5.32 ± 2.45 4.20 ± 1.87 141.50 ± 3.90∗
REC: reconstruction group, PLLA: reconstruction with PLLA scaffold, and
BIO: reconstruction with E7 peptide conjugated PLLA scaffold.
Student’s test was used and significance of ∗𝑃 < 0.05.
each sample and the minimal diameter of bone tunnel could
be calculated. In both control group andPLLA reconstruction
group, the bone tunnel was larger at 3 months after surgery
than 1 month, which was known as the “enlargement of bone
tunnel.” Though in BIO reconstruction group there was no
obvious enlargement at 3 months, bone tunnel was smaller
than the other two groups both at 1 and 3 months, which
was 5.32 ± 2.45 and 4.20 ± 1.87mm, respectively (Table 1).
The consecutive CT images showed that there was no obvious
mineralized tissue formed in tibial and femoral bone tunnels
after 4 and 12 weeks in all groups (Figures 4(b) and 4(d)).
After CT scan, the biomechanical test or histological staining
was performed to further examine the changes of ligament-
bone insertion.
3.5. Biomechanical Analysis. Four specimens in each group
at 3 months after surgery were tested to evaluate tensional
properties of the reconstructed ACL. Results showed that
all substitution complex in BIO reconstruction group were
broken in the midpart of regenerated ligaments during
mechanical test. Two of four specimens in PLLA group
were pulled out of ligament insertion sites, while in control
group there was one. The load-deformation curves changed
smoothly from a flat slope to a steep one with extension of
implants and suddenly fell at failure load. The control group
recorded a maximum tensile load of 34.58 ± 4.08N, while
the PLLA reconstruction group had a failure load of 82.59
± 3.33N. The failure load in BIO reconstruction group was
141.50 ± 3.90N at 12 weeks postoperatively, which was also
significantly higher than that of control (𝑃 < 0.05) (Table 1).
3.6. Histological Assessment of Ligament-Bone Insertion. His-
tological observation demonstrated that the fibrovascular
connective tissue, fibrocartilage, and the Sharpey’s fibers were
gradually developed between the implants and bone tunnel in
BIO reconstruction group. At 4 weeks postoperatively, only
a thin layer of fibrovascular connective tissue was observed
on the interface of regenerated ligament in control and PLLA
reconstruction groups (Figures 5(a) and 5(b)). But in BIO
reconstruction group the implant-bone interface was filled
with loose fibrocartilage tissue with a few chondrocytes scat-
tered between bone and regenerated ligament (Figure 5(c)).
After 12 weeks, the thin layer of connective tissue became
much denser in PLLA reconstruction group (Figure 5(e))
while in control group, the more organized perpendicular
collagen fibers resembling the Sharpey’s fibers were observed
to form the indirect junction between ligament and bone
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Figure 1: Schematic illustration of electrospinning devices and scanning electron microscope observation of nanofibers characteristics in
lattice-like electrospun scaffolds. (a) Schematic diagram of electrospun scaffold device showed lattice-like fibers collecting by copper wire
grid. (b) Picture of scaffold showed general view of lattice-like PLLA meshes. ((c), (e), and (f)) Micrographs showed nanofibers distribution
in different regions of lattice-like PLLA meshes. Detailed view showed local enlarged fibers on ridge (e) and nonwoven region (f) of each
lattice. (d) Histogram showed distribution of nanofibers’ diameter in scaffolds.
at 12 weeks (Figure 5(d)). At the same time, fibrocartilage
appeared with tide line mark between ligament and bone in
BIO reconstruction group. A gradual transition from bone,
mineralized fibrocartilage and fibrocartilage, into the tendon
substance was successfully reconstructed (Figure 5(f)).
At 3 months after surgery, collagen type II, I, and III
distribution of insertion site was detected by immuno-
histochemical and Sirius red staining, respectively. Results
indicated that a large amount of collagen fibers making up
of type III and I grow from ligament to bone in control
group (Figure 6(a)), while little mature cartilage tissue was
found at insertion site in this group by collagen II staining
(Figure 6(d)). In PLLA and BIO reconstruction groups,
collagen III amount decreased at insertion site while collagen
I increased (Figures 6(b) and 6(c)). Meanwhile fibrocarti-
lage with aligned chondrocytes was found in BIO group
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Figure 2: Laser scanning confocal microscopy image showed attachment of MSCs on different scaffolds. Morphology ofMSCs was displayed
by F-actin (red) and nuclei (blue). Cell attachment and spreading on E7 conjugated PLLA meshes were shown in both nonwoven and near
ridge regions of lattice ((a), (c)). MSCs that grew on PLLA meshes were shown as control ((b), (d)).
by immunohistochemical staining (Figure 6(f)). In PLLA
group, few collagen II fibers and chondrocytes indicated an
immature insertion site (Figure 6(e)).
4. Discussion
The ligament-bone insertion is important for the effective
transmission of mechanical force and the reduction in stress
gradient between the soft ligament and hard bone tissue.
The healing of ligament-bone insertion afterACL reconstruc-
tion is of vital importance for the stability of implantation
especially at early stage. Many kinds of approaches like
cytokines, biomaterials, biological and chemistry reagents,
stem cells, and genes were added to strengthen the healing
of ligament-bone insertion [19–23]. Their objectives were
the same, which is to promote local bone formation. While
drilling bone tunnel,many bonemarrowMSCs and cytokines
were released and leaked out into the articular cavity. Using
these mixture would be more convenient and effective than
using extrinsic MSCs supplement. In our study, nanofibrous
meshes which wrapped two ends of tendon graft can fill the
interspace between tendon and bone tunnel and increase
the contact area to absorb the leaking MSCs from bone
marrow. Meanwhile our results indicated higher adhesion
level of MSCs on nanofibrous meshes conjugated with E7
peptide which was proved to have specific affinity to MSCs.
The specific affinity peptide togetherwith physical absorption
ability of nanofibrous scaffold promoted the utilization of
endogenous bone marrow MSCs.
The ultimate goal in the design of biomimetic materials
for use in tissue engineering is to generate biocompatible scaf-
folds with appropriate mechanical and chemical properties.
Recent efforts have therefore been focused on the construc-
tion and modification of surfaces targeted to support tissue-
specific cell functions including adhesion, growth, differen-
tiation, motility, and the expression of tissue-specific genes
[24]. There are three types of modification of biomimetic
surfaces tomimic natural ECM: physical properties, chemical
signals, and the nanoscale topography of microenviron-
mental adhesive sites. Recently, the development of new
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Figure 3: Pictures showing rabbit ACL reconstruction surgery procedure and gross morphology of reconstructed ACL at 3 months after
surgery. Hamstring tendon grafts were harvested from both two knees of each rabbit (a). PLLA scaffold or PLLA scaffold with E7 peptide
conjugation was wrapped at two ends of tendons in PLLA reconstruction group and BIO reconstruction group (b) and braided with nylon
thread (c). The right knee joint of each rabbit was exposed and original ACL was removed. Bone tunnels were made from the ACL femur
attachment sites to the lateral femoral condyles (d), as well as from the ACL tibial attachment sites to the medial tibia (e). After placing the
transplants into two bone tunnels, both two ends were fixed by bone bridge (f). At 90 degree flexion of knee joint, both reconstructed ACL
and cartilage of femoral condyle could be exposed in control group (g), PLLA reconstruction group (h), and BIO reconstruction group (i).
nanotechnologies allowing the construction of a geometri-
cally defined microenvironment for cells at the nanoscale
could induce specifically differentiation of MSCs. In others’
researches, aligned nanofibrous scaffolds can induce MSCs
to differentiate into ligament, tendon fibroblasts, or fibro-
chondrocytes [25–27]. In our and others’ research, lattice-like
nanofibrous meshes can induce osteogenic differentiation of
MSCs, which is more important in ligament-bone healing,
through integrin signaling in vitro [28]. So we testified it
by these in vivo experiments. Histological staining indicated
a fibrous tissue connection of ligament to bone in control
group with tendon grafts only, while in PLLA scaffold groups
with or without peptide there was fibrocartilage formation
at different levels. This was confirmed by specific stain of
collagen type I, II, and III. It has been known that normal
ligament and bone were mainly composed of type I collagen
while repaired scar tissue was mainly made up of type III
collagen. In control group, the insertion site was filled with
disorderly arranged collagen III and I which formed an
indirect junction. That coincided with early stage healing of
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Figure 4: Femoral and tibial tunnels measured by CT scanning. Scanning plane confirmed in femora (a) and tibia (c). Minimum diameter
of bone tunnel was measured in cross-section of femoral (b) or tibial (d) tunnel. Spacing between cross-sections was 0.5mm.
ligament to bone in clinic [29], while at insertion sites of BIO
reconstruction groups, chondrocytes and collagen type II
were found indicating a process of endochondral ossification.
Mechanical property is another key point in early healing
of ACL reconstruction. After surgery the ligament bone
healing process needs more than a year in clinic. During
this time, patients are not allowed to participate in strenuous
exercise. And the mechanical properties during this time are
important for prospective knee joint stability. In our study, at
3 months after surgery, mechanical properties of substitution
complex were significantly different among 3 groups. Failure
load of complexes in both PLLA group and BIO group was
significantly higher than that in control group. But only in
BIO group, all implantations were broken from the middle
of tendons, while in other two groups there were specimens
pulling out of bone tunnel. These results showed stronger
early stage healing of ligament to bone using autologous
tendon and PLLA scaffold with E7 peptide conjugation
transplantation. In rabbit, the reported maximum ACL force
is about 138.6% of body weight [30]. According to this data,
the maximum native ACL force in this study is about 40N
(rabbit weight: 2.5–3.0 kg).The average failure load of control
group was under 40N. And the PLLA and BIO scaffold
groups were higher than it, 82.59 ± 3.33 and 141.50 ± 3.90N,
respectively.
Results of bone tunnel measurement showed no signifi-
cant statistical differences in PLLA group and BIO group at
1 and 3 months. Only in control group there was significant
enlargement of bone tunnel. But the diameter was smaller in
BIO scaffolds implantation groups than that in control group.
Both results indicated that composite scaffold of lattice-
like nanofibrous meshes can promote early stage healing
of ligament-bone insertion site after ACL reconstruction of
rabbit by narrowing bone tunnel and accelerating collagen
structure remodeling to form direct junction.
5. Conclusions
In the present study, a substitution complex was designed
by incorporating electrospinning nanofibrous meshes into
autologous tendon. By modification of nanotopographical
properties to lattice-like, the scaffold was suitable for MSCs
proliferation, osteogenic differentiation, and active function.
To absorb native MSCs from bone marrow, MSCs specific
affinity peptide E7 was conjugated to nanofibrous meshes.
After implantation of grafts for 3 months, the regenerated
ligament-bone insertion exhibited abundant ECM (collagen
I, II, and III) and fibrocartilage growth. The tensile strength
of substitution complex was shown to be better than control.
The findings of this study imply that nanofibrous scaffold
with specific MSCs affinity peptide has great potentials
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Figure 5: Histological assessment of ligament-bone insertion at 1 and 3 months after reconstruction surgery. H-E staining indicated
connective tissues growing in ligament-bone insertion of control group, PLLA reconstruction group, and BIO reconstruction group at 1
month ((a)–(c)) and 3 months ((d)–(f)). Magnification: 200x. T: tendon; B: bone; FS: fibrous synovium; FC: fibrocartilage; S: Sharpey’s fiber;
UFC: uncalcified fibrocartilage; CFC: calcified fibrocartilage; TM: tide line mark.
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Figure 6: Sirius red and immunohistochemical staining of ligament-bone insertion at 3 months after ACL reconstruction surgery. Sirius
red staining observed by polarized light microscope indicated distribution of collagen type I (red) and III (green) of control group, PLLA
reconstruction group, and BIO reconstruction group ((a)–(c)). Specific immunohistochemical staining showing distribution of collagen type
II at ligament-bone insertion in 3 groups ((d)–(f)). Magnification: 100x. T: tendon; B: bone.
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in accelerating ligament-bone healing process after ACL
reconstruction.
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Nanostructured substrates have been recognized to initiate transcriptional programs promoting cell proliferation. Specifically 𝛽-
catenin has been identified as transcriptional regulator, activated by adhesion to nanostructures. We set out to identify processes
responsible for nanostructure-induced endothelial𝛽-catenin signaling. Transmission electronmicroscopy (TEM) of cell contacts to
differently sized polyethylene terephthalate (PET) surface structures (ripples with 250 to 300 nm and walls with 1.5𝜇mperiodicity)
revealed different patterns of cell-substrate interactions. Cell adhesion to ripples occurred exclusively on ripple peaks, while cells
were attached to walls continuously.The Src kinase inhibitor PP2 was active only in cells grown on ripples, while the Abl inhibitors
dasatinib and imatinib suppressed 𝛽-catenin translocation on both structures. Moreover, Gd3+ sensitive Ca2+ entry was observed
in response to mechanical stimulation or Ca2+ store depletion exclusively in cells grown on ripples. Both PP2 and Gd3+ suppressed
𝛽-catenin nuclear translocation along with proliferation in cells grown on ripples but not onwalls. Our results suggest that adhesion
of endothelial cells to ripple structured PET induces highly specific, interface topology-dependent changes in cellular signalling,
characterized by promotion ofGd3+-sensitiveCa2+ entry and Src/Abl activation.Wepropose that these signaling events are crucially
involved in nanostructure-induced promotion of cell proliferation.
1. Introduction
Understanding the basic mechanisms by which cells recog-
nize and respond to specific surface topologies is of outstand-
ing importance for the development of novel biomaterials to
advance tissue engineering applications. We and others have
demonstrated that growth of vascular endothelial cells is
governed not only by the type of culture substrate and its
surface chemistry but also by surface topography [1–3]. Many
studies have focused on optimisation of the biocompatibility
of polymer substrates to improve cell adhesion and promote
proliferation [4], whilemechanisms underlying the control of
cell functions by nanoarchitectured substrates remain elusive.
Micro- and nanostructures on polyethylene terephthalate
(PET) substrates produced by laser irradiation were recently
discovered to activate endothelial 𝛽-catenin signaling which
leads to nuclear translocation of the transcriptionally active
protein and enhanced proliferation of human microvascular
endothelial cells (HMEC). The extent of these effects was
dependent on size and periodicity of surface structure topog-
raphy. In particular, transcription levels of the 𝛽-catenin
target gene cyclin D1 were significantly different on ripples
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and walls. This observation led to the hypothesis that cell
growth on various surface structures on PET substrates
differentially activates specific pools of 𝛽-catenin [5].
𝛽-catenin is an important signaling molecule in endothe-
lial cells and part of adherens junctions. When released from
contact sites or as newly synthesized protein, cytosolic 𝛽-
catenin is phosphorylated by a destruction complex that
includes glycogen synthase kinase 3𝛽 (GSK3𝛽) which marks
the protein for degradation by the proteasome [6]. Upon inhi-
bition of this destruction, complex 𝛽-catenin accumulates
and translocates to the nucleus where it binds to transcription
factors and induces target gene transcription [7–10]. 𝛽-
catenin possesses a multitude of regulatory phosphorylation
sites, which are substrates of serine/threonine and tyrosine
kinases [11]. Cell attachment to the extracellular matrix
(ECM) can initiate clustering of integrins and activation of
downstream targets such as integrin-linked kinase (ILK) [12],
focal adhesion kinase (FAK) [13], or Src kinases [14, 15].
Src and FAK are able to phosphorylate 𝛽-catenin directly
[16–18] or block its proteasomal degradation by inhibiting
its phosphorylation by GSK3𝛽 via the phosphatidylinositol
3-kinase (PI3K)/Akt pathway [19]. Phosphorylation of FAK
and 𝛽-catenin may also be controlled by stimulation of
mechanosensitive ion channels [20] as well as by mechanical
stress, which leads to enhanced calcium influx downstream
of Src [21].
In this study, we set out to identify cellular mechanisms
that trigger 𝛽-catenin translocation and consequently pro-
liferation in endothelial cells growing on nanopatterned
substrates. We demonstrate that adhesion of endothelial
cells to nanostructured PET substrates activates 𝛽-catenin
by enhanced tyrosine phosphorylation and calcium signaling
through mechanosensitive ion channels.
2. Material and Methods
Laser generation and characterization of structured PET sub-
strates, cell culture of HMEC, immunocytochemistry, and
confocal microscopy were performed as described recently
[5].
In short: for immunostainings, HMEC-1 cells [22, 23]
were seeded on the different substrates and fixed and
immunostained with the anti-𝛽-catenin antibody (1 : 150,
BD Biosciences), anti-Ki67 antibody (1 : 300, Abcam), anti-
P397-FAK antibody (1 : 250, Abcam), or anti-VE-cadherin
(1 : 150, BDBiosciences) after 48 h of culture. For the inhibitor
experiments, inhibitors were added to the culture medium
6 h prior to fixation.
Nuclear to cytosolic ratios of 𝛽-catenin were determined
by marking ROIs (regions of interest) in the phase contrast
image for the nuclei and cytosols. The ROIs were then
transferred to the corresponding fluorescence image and the
mean fluorescence intensity for every ROI was determined,
using Image J software. Finally, the ratio of nuclear to
cytosolic intensity was calculated.
2.1. Reagents and Antibodies. All chemicals were purchased
from Sigma Aldrich (Steinheim, Germany) unless otherwise
stated: anti-Ki67 (1 : 300, Abcam, Cambridge, MA), anti-
Tyr397-FAK (1 : 250, Abcam), PP2 (4-amino-5-(4-chloro-
phenyl)-7-(dimethylethyl) pyrazolo[3,4-d]pyrimidine; Cal-
biochem/Merck, Darmstadt, Germany), imatinib (Cayman
Chemical, Tallinn, Estonia), FuraRed AM (Molecular
Probes, Life Technologies Corporation, UK), and BHQ (2,5-
di-t-butyl-1,4-benzohydrochinone).
2.2. Transmission Electron Microscopy (TEM). Cells culti-
vated on the different substrates were embedded with a small
piece of their substrate. For this, they were fixed in a mixture
of 2% formaldehyde, 2.5% glutardialdehyde in 0.1M sodium
cacodylate buffer, pH 7.4 for 1 h at room temperature. They
were then rinsed in the same buffer, treated with 2% osmium
tetraoxide (in the same buffer) for 1 h, rinsed, and dehydrated
in a series of graded alcohols. They were then embedded
in TAAB epoxy resin (TAAB laboratories Equipment Ltd,
Aldermaston, UK) with propylene oxide as an intermedium.
Sections of 70 nm thickness were counterstained with uranyl
acetate and lead citrate and visualised using an FEI Tec-
nai 20 (FEI, Hillsboro, OR, USA) transmission electron
microscope operated at 120 kV acceleration voltage. Electron
micrographs were made with a Gatan Ultrascan 1000 CCD
camera (Gatan, Inc, Pleasanton, CA, USA).
2.3. Measurement of Intracellular Calcium Levels Using
FuraRed AM. Cells cultivated on the different substrates
were loaded for 40min at 37∘Cwith FuraRed AM. Base levels
of calcium content were recorded for 1min before perfusion
was started. Cells were continuously perfused with buffer
containing 140mM NaCl, 15mM HEPES, 10mM glucose,
2mM MgCl
2
, and 2mM CaCl
2
and treated with 15 𝜇M
2,5-di-t-butyl-1,4-benzohydrochinone (BHQ) for 5min as
indicated. For preincubation, cells were treated with 10𝜇M
gadoliniumchloride (Gd3+) for 6 h before the experimentwas
started, and Gd3+ was present throughout the experiment.
Measurements were carried out on a Till iMIC microscope
(Till Photonics, Gra¨fling, Germany).
3. Results
3.1. Ripples and Wall Structures Generate a Divergent Pattern
of Physical Contact with the Basal Membrane of Endothelial
Cells. Experiments were performed with HMEC cultured on
two different types of structured PET surfaces representing
distinct range of pattern size. Ripples characterized by a
periodicity of 250 to 300 nm were compared to walls with
a periodicity of 1.5 𝜇m [5]. Electron micrographs of these
structures are shown in Figure 1. Flat, pristine PET was used
as a control to evaluate potential effects induced by the
polymer itself. Lower panel of Figure 1 shows TEM images of
HMEC grown on the different nanoarchitectures with focus
on the contact area between cell membranes and the surface
of the substrate.
Contact between the basal membrane of the endothelial
cells and flat, pristine PET surfaces is continuous and straight,
whereas punctual contact sites are exclusively observed
between the basal endothelial membrane and the peaks on
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Figure 1: Electron microscopy of laser-irradiated PET substrates. Upper panel: SEM images of resulting structures after excimer laser
irradiation of PET substrates. Left: ripples, 6000 pulses of linear polarized KrF laser radiation (𝜆 = 248 nm) at a fluence of 9mJ cm−2. Right:
walls, 30 pulses of ArF laser radiation (𝜆 = 193 nm) at fluences of 30mJ cm−2. Lower panel: TEM images of HMEC grown on pristine PET
(flat, left) or laser irradiated with surface topography (ripples, middle; walls, right); PM and arrow indicate basal plasma membrane; PET and
arrow indicate border of PET substrate.
the ripple surface, and cells do not adhere to ripple valleys.
In contrast, on wall structures, the basal plasma membrane
was found continuously attached to the surface, thereby
forming contact on peaks and in valleys of the structure.This
observation suggests that divergent attachment architectures
of endothelial membranes are generated by contact to these
substrates, resulting in the initiation of divergent signaling
pathways.
3.2. Promotion of𝛽-Catenin Translocation by Ripple Structures
Involves Tyrosine Phosphorylation. Divergent mechanisms of
𝛽-catenin activation by differently sized nanostructures were
already suggested by the previously reported observation
that both ripples and wall structures are capable of initiating
nuclear translocation of 𝛽-catenin, albeit with divergent con-
sequences for𝛽-catenin target gene expression [5]. To analyse
the role of tyrosine kinase activation in detail, we charac-
terized transcriptional activation of cells grown on different
surface structures in response to kinase inhibitors. Figures
2(a)–2(d) show inhibition of 𝛽-catenin nuclear translocation
in HMEC cultured on the different substrates in the presence
of the tyrosine kinase inhibitors PP2 (50 nM), an inhibitor
of the Src family of kinases [24], dasatinib (3𝜇M), which
inhibits Src, ILK, and Abl kinases [25–27], and imatinib
(2 𝜇M), which inhibits Abl kinases only [28].
To quantify translocation levels, the nuclear to cytoso-
lic ratios of 𝛽-catenin immunofluorescence were calcu-
lated (Figure 2(e)). Translocation on ripples was significantly
reduced by all three inhibitors, indicating that both Src as well
as Abl kinases are essential for that process.The translocation
on wall structures, by contrast, was sensitive to Abl kinase
inhibition by dasatinib and imatinib, while PP2 was barely
effective. These findings further strengthen our hypothesis
that differently sized structures activate 𝛽-catenin signal-
ing by divergent mechanisms involving alternative tyrosine
kinases.
To test for involvement of focal adhesion kinase (FAK)
which is phosphorylated on Tyr397 in response to integrin
signaling as a potential initial step of enhanced tyrosine phos-
phorylation, we immunostained the cells with an antibody
against the active form of FAK (Figure 3). Interestingly, we
observed high immunoreactivity on flat, pristine PET and on
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Figure 2: Nanostructure-induced 𝛽-catenin translocation involves tyrosine phosphorylations. Confocal microscopy images of 𝛽-catenin
distribution (red) in HMEC grown on the indicated substrate. Lower panels: representative profile plots along the indicated cell section
(yellow line) show intensity distribution of 𝛽-catenin as relative immunofluorescence intensity (𝑦-axis) along the distance in pixel (𝑥-axis).
Scale bars represent 10𝜇m. CTRL (a); for inhibitor experiments, cells were incubated for 6 h at 37∘C with 50 nM PP2 (b), 3 𝜇M dasatinib
(DB, (c)), 2 𝜇M imatinib (IB, (d)). Bar graphs representing the nuclear to cytosolic ratio of 𝛽-catenin immunofluorescence (e); values ± SEM;
𝑛 ≥ 60 cells from 3 independent experiments, calculated from 3 different images of each experiment; ∗𝑃 < 0.05; ∗∗𝑃 < 0.001 compared to
CTRL.
ripples, but none on walls. This result further supports the
concept that different molecular mechanisms of transcrip-
tional control are initiated by ripples and walls structures.
Nonetheless, activation of FAK alone is not sufficient to
explain the observed enhancement of𝛽-catenin translocation
and proliferation by cell adhesion to ripples.
3.3. Divergent Impact of Ripples and Wall Structures on
Endothelial Ca2+ Signaling—Evidence for Promotion of
Mechanosensitive Ca2+ Entry by Ripples. Another potential
mechanism associated with enhanced tyrosine phosphor-
ylation is Ca2+ signaling. Ca2+ entry was reported to control
Src activity and Src phosphorylation, which appears as
a hallmark of endothelial cells grown on ripples. In turn,
Src was found essential for certain mechanisms of Ca2+
entry [19, 21, 29]. This evidence and the observed differences
in cell substrate adhesion architecture (Figure 1(b)) led us
to hypothesize that mechanosensitive Ca2+ entry may be
affected in a specific manner by structured PET substrates.
To test our hypothesis, we stimulated cells grown on the
different substrates by perfusion-induced shear stress and
by depletion of intracellular stores with BHQ as a selective
inhibitor of sarcoplasmic/endoplasmic reticulum calcium
ATPase (SERCA), [30]. Involvement of mechanosensitive
and/or store-operated Ca2+ entry (SOCE) was tested with
Gd3+, a common blocker of these cation channels [31, 32].
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Figure 3: Activation of focal adhesion kinase (FAK) is observed on flat and ripples but not on wall structures. Confocal microscopy images
showHMEC grown on the indicated substrate, fixed and immunostained with an antibody against the active form of FAK phosphorylated on
Tyr397 (red). White square indicates the magnified part (lower panel, microscopic zoom in). Scale bars represent 10 𝜇m. In Supplementary
Figure 2 available online at http://dx.doi.org/10.1155/2013/251063, the images of Figure 3 are shown at enhanced brightness to visualize cell
borders and the cell number.
We observed enhanced content of Ca2+ stores by FuraRed
AM measurements in cells cultured on ripples as com-
pared to wall structures or flat substrate. Our experiments
revealed significant differences inmechanosensitive Ca2+ sig-
naling. Figure 4(a) illustrates basal levels of cytosolic calcium
recorded before and after activation of flow-induced shear by
perfusion (2min). Flow-induced mechanical stress initiated
a significant elevation of cytosolic Ca2+ in cells on all three
substrates. When cells were preincubated with Gd3+ (10 𝜇M),
flow-induced Ca2+ elevation on ripples and on flat substrates
was abolished, while Ca2+ signals on cells attached to walls
remained elevated. Another difference in endothelial Ca2+
signaling was observed when Ca2+ entry was promoted by
BHQ-induced store depletion. BHQelicited a profound cellu-
lar Ca2+ response in cells grown on ripples (Figures 4(b) and
4(c)), while cells grown on walls displayed a modest response
to BHQ. Gd3+ sensitivity of Ca2+ entry into cells grown
on ripples was also clearly evident during stimulation with
BHQ. Collectively, these results suggest that mechanosensi-
tive channels, which may be linked to Src kinase activation,
govern Ca2+ homeostasis in cells grown on ripples.
3.4. Gd3+ Inhibits 𝛽-Catenin Translocation and Proliferation
Induced by Ripples but Not by Wall Structures. The observa-
tion of Gd3+ sensitive calcium signaling on ripples prompted
us to test whether Gd3+ also had an impact on nuclear
translocation of 𝛽-catenin. In fact, preincubation with Gd3+
(10 𝜇M) for 6 h significantly reduced nuclear translocation of
cells grown on ripples, while there was no effect observed in
cells grown on wall structures (Figure 5).
As reported recently [5], culture of HMEC on ripples
as well as on wall structures results in enhanced prolif-
eration levels. To investigate the correlation of nuclear 𝛽-
catenin translocation and enhanced proliferation, we tested
the effects of Gd3+ and tyrosine kinase inhibition by PP2,
dasatinib, and imatinib on the expression levels of the
proliferation marker Ki67.
By preventing the translocation of 𝛽-catenin, either by
inhibiting tyrosine phosphorylation or blocking the mechan-
osensitive ion channels, proliferation in cells grownon ripples
was significantly reduced down to levels in cells grown
on flat substrates. Src kinase inhibition again showed no
effect on cells grown on wall structures, whereas Abl kinase
inhibition led to reduced cell proliferation. Consistent with
the observed differences in Ca2+ signaling, Gd3+ failed to
inhibit proliferation in cells adherent to walls (Figure 6).
4. Discussion
4.1. Periodicity of Substrate Topography Determines Basal
Membrane Architecture. Increasing evidence suggests that
cell proliferation is strongly affected by specific interactions
with the culture substrate. Topographical characteristics
appear as important determinants of this interaction and
govern cell growth through multiple signaling pathways.
Our results from Figure 1(b) are in line with findings of
Teixeira et al. [33], who reported that lamellipodia of cells
were able to adhere to valleys of grooves with a width of
2.1 𝜇m but not with narrower valleys only 330 nm wide. They
further observed that cells could be elongated and aligned
along the structures without focal adhesions and suggested
6 Journal of Nanomaterials
Ripples Walls
Perfusion 2 mM Ca Perfusion 2 mM Ca
BHQ BHQ
Ra
tio
 F
45
0/
48
0
1.6
1.2 Ra
tio
 F
45
0/
48
0
1.6
1.2
CTRL
Gd
CTRL
Gd
Time (min)
0 3
Time (min)
0 3
(a)
Gd
Ra
tio
 F
45
0/
F4
80
1.2
1.0
∗ ∗∗ n.s.
No perfusion
2 min perfusion
− − −+ + +
Flat Ripples Walls
(b)
Ra
tio
 F
45
0/
F4
80 1.5
1.2
∗∗
No perfusion
2 min perfusion
Gd − − −+ + +
Flat Ripples Walls
Pe
ak
 o
f B
H
Q
 re
sp
on
se
(c)
Figure 4: Ripples structures promote a Gd3+-sensitive Ca2+ entry pathway in endothelial cells. Substrates were fixed in a perfusion chamber
and after recording the base line for 1min perfusion with 2mM calcium buffer was started. All experiments were carried out with or without
Gd3+ preincubation for 6 h. Then, 15 𝜇M BHQ was applied. Time course of FuraRed AM measurement of cells grown on the indicated
substrate is shown in (a). Data are calculated in 10 sec intervals and averaged. Bar graphs show calcium levels at 30 sec (no perfusion) and
after 2min perfusion (b).Themaximum peak after 15𝜇MBHQ stimulation in CTRL and preincubated cells is shown in (c). 𝑛 ≥ 40 cells from
3 independent experiments; values for FuraRed AM ratios ± SEM; ∗𝑃 < 0.05; ∗∗𝑃 < 0.001; n.s. = not significant.
that the assembly of these structures was not necessary for
contact guidance of epithelial cells. Consistent with these
morphological observations, we failed to detect formation
of focal adhesions in terms of phosphorylated FAK (Tyr397)
when cells were grown on wall structures (Figure 3), which
substantially promote alignment of HMEC [5]. Ohara and
Buck [34] proposed that focal adhesion contacts are con-
strained to the peaks of closely spaced nanostructures since
limited flexibility of the cell membrane leads to bridging the
valleys. Thus focal adhesions were located almost exclusively
on top of ridges. This is consistent with our observations that
cells growing on ripples had contact to the structure on peaks
only (Figure 1(b)).
We conclude that spacing of parallel surface structures
is an essential determinant of cell-substrate contact and of
formation of focal adhesions. Our results clearly demonstrate
size-dependent differences in endothelial cell-substrate inter-
actions and formation of adhesion contacts on nanostruc-
tured PET.
4.2. Role of Tyrosine Kinase Phosphorylations in 𝛽-Catenin
Nuclear Translocation. Recently, 𝛽-catenin was identified
as a key player in nanostructure-induced control of cell
proliferation [5]. The functions of 𝛽-catenin correspond
to certain subcellular localizations of the protein and are
governed by a multitude of regulatory phosphorylations [11].
ILK, FAK as well as Src kinases are able to phosphorylate 𝛽-
catenin directly and/or influence the cytoplasmic availability
of 𝛽-catenin by phosphorylation of GSK3𝛽 or, even more
indirectly, via impact on the PI3K/Akt pathway [16–18, 35].
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Figure 5: Nuclear translocation of 𝛽-catenin on ripples is sensitive to Gd3+. Confocal microscopy images of 𝛽-catenin distribution (red)
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Figure 6: Sensitivity of endothelial proliferation on ripples and
wall structures to kinase inhibitors, and Gd3+ Bar graphs represent
the nuclear immunofluorescence intensity levels of the proliferation
marker Ki67. Cells were grown on the indicated substrate and
incubated for 6 h at 37∘C with 50 nM PP2, 3 𝜇M dasatinib (DB),
2 𝜇M imatinib (IB), 10 𝜇M Gd3+ (Gd), or without inhibitor for
control (Values ± SEM; 𝑛 ≥ 120 from 3 independent experiments,
calculated from 3 different images of each experiment; ∗𝑃 < 0.05;
∗∗𝑃 < 0.001 compared to CTRL) (representative confocal images of
HMEC immunolabeled with an antibody against Ki67 are shown in
Supplementary Figure 3).
Our results provide compelling evidence for the induc-
tion of divergent 𝛽-catenin phosphorylation states by differ-
ently sized micro/nanostructures. We cannot exclude that 𝛽-
catenin distribution is in part disturbed via a reduction of
junctional stability. Nonetheless, HMEC cells are able to form
mature cell-cell adhesions when grown on nanostructured
surfaces (Supplementary Figure 1). Based on our pharma-
cological analysis, it is suggested that the mechanism which
initiates 𝛽-catenin nuclear translocation on ripples involves
both Src and Abl kinases, while Src kinases are not involved
on wall structures. An interference of these mechanisms with
the Wnt/𝛽-catenin pathway is likely and requires further
investigation.
4.3. Periodicity of Substrate Topography Determines Calcium
Signaling. Numerous studies reported the involvement of Src
kinase signaling in cyclinD1 regulation, cell cycle progression
and proliferation [36–38]. Src activity and phosphorylation
are strongly dependent on Ca2+ [19, 21, 29]. Moreover,
it has been reported that the activity of Src, in turn, is
able to promote SOCE fluxes [39–41], which represent an
important Ca2+ entrymechanism in endothelial cells relevant
for proliferation [42]. Mechanical stress is another factor
reported to induce Ca2+ influx downstream of Src [21].
Interestingly, we observed a similar level of shear-induced
Ca2+ elevation on all three substrates. Nonetheless, on flat
substrates and on ripples, this Ca2+ influx was abolished
by Gd3+, a common blocker of mechanosensitive cation
channels, while Gd3+ failed to suppress flow-induced Ca2+
rises in cells grown on wall structures. This observation
further substantiates the divergent signaling characteristics
of cells grown on the different surface topologies. Our
results indicate the expression of a particular Gd3+ insensitive
subset of mechanosensitive channels in cells grown on wall
structures. It is tempting to speculate that such a Gd3+-
insensitive subset is formed by K+ channels [32], which
may confer hyperpolarisation of the plasma membrane and
thereby promote Ca2+ influx into endothelial cells [43].
Endothelial cells grown on ripples display a substantially
enhanced SOCE. This phenomenon may well be related to
the enhanced Src activity [39–41, 44]. It is important to note
that Src and Ca2+ entry are mutually amplifying signaling
processes, with Src activity being Ca2+ dependent and SOCE
being promoted by Src tyrosine phosphorylation [19, 21, 39–
41]. At present, we cannot tell which of these processes is
initially triggered by the substrate topology. Nonetheless, it
appears conceivable to conclude a feed-forward interaction
between tyrosine phosphorylation and SOCE being involved
in the effects of ripple structures on endothelial gene tran-
scription. Concomitantly enhanced SOCE and Src activity
are likely to generate a positive feedback mechanism that
promotes 𝛽-catenin tyrosine phosphorylation (Figure 7).
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4.4. Tyrosine Phosphorylation and Calcium Signaling Are
Essential for Nanostructure-Induced Cell Proliferation. Our
experiments identified Src and SOCE activation as key
upstream signals involved in𝛽-catenin activation in endothe-
lial cells grown on ripples, while these processes appear irrele-
vant for the effects of wall structures. Consistently, inhibition
of Src kinases by PP2 or inhibition of Ca2+ entry by Gd3+ had
no effect on expression of the proliferation marker Ki67 in
cells adherent to wall structures but significantly suppressed
Ki67 expression in cells grown on ripples. Inhibition of Abl
kinases by dasatinib and imatinib on the other hand elicited
profound effects on proliferation in cells grown on both types
of structures.
In aggregate, our results suggest that enhanced endothe-
lial proliferation initiated by ripples is mediated by joint
promotion of tyrosine kinase activity with a leading role of
Src and calcium signaling.
5. Conclusion
We report significant differences in signalling events initi-
ated by 250 to 300 nm ripples and 1.5 𝜇m wall structures
and demonstrate that activation of 𝛽-catenin signaling is
strongly dependent on periodicity of PET surface struc-
tures. Both micro-(walls-) and nano-(ripple-) structures
induce endothelial 𝛽-catenin signaling and proliferation by
enhanced tyrosine phosphorylation. Nanostructured ripples
control 𝛽-catenin via activation of multiple tyrosine kinases,
including Src and promotion of SOCE calcium signaling.
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This paper deals with the development of novel nanocarriers using layer by layer carbohydrate coating of caffeic acid loaded solid
lipid nanoparticles (SLNs) to improve stability and colon delivery of the poorly water-soluble caffeic acid. Three biopolymers
(chitosan, alginate, and pectin) in different concentrations (0.1, 0.25, and 0.5%) were electrostatically coated over the SLN surface.
The size and zeta potential of produced nanocarriers were measured using photon correlation spectroscopy. Mathematical models
(i.e., zero-order, first-order, Higuchi, Ritger-Peppas, reciprocal powered time,Weibull, and quadratic models) were used to describe
the release and kinetic modeling in gastrointestinal solution (GIS). Also, antioxidant activity of caffeic acid during the release in
GIS was investigated using DPPH and reducing activity methods. The prepared treatments coated by alginate-chitosan as well as
pectin-chitosan coated SLN at the concentration of 0.1% showed nanosized bead; the latter efficiently retarded the release of caffeic
acid in gastric media up to 2.5 times higher than that of SLN. Zeta potential values of coated samples were found to significantly
increase in comparison to SLN indicating the higher stability of produced nanocarriers. Antioxidant activity of caffeic acid after
gastric release did not result in the same trend as observed for caffeic acid release from different treatments; however, in line with
less caffeic acid release in the intestine solution by the effect of coating, lower antioxidant activity was determined at the end stage
of the experiment.
1. Introduction
Caffeic acid (3,4-dihydroxycinnamic acid) is a natural antiox-
idant found in various agricultural products such as fruits,
vegetables, tea, olive oil, and coffee bean [1]. It acts as an anti-
oxidant by scavenging oxygen-free radicals and chelating
prooxidant metal ions [2]. Caffeic acid has also shown anti-
microbial properties against Escherichia coli, Bacillus cereus,
Staphylococcus aureus, Listeria monocytogenes, and some
yeast [3]. However, it suffers from low stability in UV irra-
diation and oxygen presence [2, 3]. On the other hand, low
aqueous solubility and bitter taste limit its application for
food fortification.
Nanoencapsulation of food bioactives possesses different
advantages including masking unpleasant taste, possibility
of application of low soluble compounds, and protection
against unfavorable environmental and processing condi-
tions [4]. It is also supposed that colon delivery of food
bioactives, particularly in nanocarriers is favorable due to
higher bioavailability and positive effect on natural intestine
flora. Solid lipid nanoparticles (SLNs) are new generation of
nanocarriers which attract increasing attention due to their
advantages such as high encapsulation efficiency, slow degra-
dation rate, and possibility of large scale production [5].They
have been produced and characterized for encapsulating of
hesperetin for food fortification. In spite of the different
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benefits, there are some limitations possess to SLN including
their initial rapid release (burst release) and their low stability
[6]. Therefore, modification of nanocarriers is necessary to
overcome these limitations.
Chitosan (poly[𝛽-(1–4)-2-amino-2-deoxy-d-glucopyra-
nose]; CH) is the second most abundant polysaccharides in
nature after cellulose.There are some valuable characteristics
possess to chitosan (e.g., biocompatibility, biodegradability,
bioadhesiveness, and antimicrobial properties) which lead to
its application for encapsulation of food bioactives [5, 7, 8].
However as a weak base with a pK
𝑎
value of the d-glu-
cosamine residue of about 6.2–7.0, it is soluble in acidic
media [9]. Hence, chitosan cannot be considered as
a protective biopolymer for encapsulating of bioactives
against the gastric media and therefore might not be alone
applied for colon delivery.
Alginate (AL) is a water soluble linear anionic polysac-
charide formed from alternating blocks of 1–4 linked 𝛼-L-
guluronic and 𝛽-Dmannuronic acid residues. It has been
reported to be mucoadhesive, biodegradable, and biocom-
patible [10, 11]. Gel formation of AL is induced using cross-
linking with divalent cations such as Ca+2. The gelation and
cross-linking of the AL are mainly achieved by exchanging
of sodium ions from the guluronic acids with the Ca+2 ions,
and zipping of guluronic groups to form the egg-box-like
conformation [12]. Alginate also shows pH sensitivity, while
in contrast to chitosan, the release of encapsulated bioactive
could be postponed in low pH, which is advantageous
for colon delivery of acidic sensible bioactive ingredients
[8, 13, 14].
Pectin (PEC) is a linear anionic polysaccharide, mainly
consisting of linearly connected 𝛼-(1→ 4)-d-galacturonic
acid residues and is considered as a biocompatible, biode-
gradable, nontoxic, and mechanically resistant against phys-
ical shear. Pectin is classified as low methoxyl (LM, with a
25–50% degree of methoxylation) and high methoxyl (HM,
with a 50–80% degree of methoxylation). LM pectin can also
form an egg-box-like conformation gel by ionotropic gelation
in presence of divalent Ca2+ ions [15]. Similar to alginate, LM
pectin is pH sensitive and is favorable for food bioactive oral
delivery.
Caffeic acid is a sensitive compound against oxidative
degradation and also shows poor aqueous solubility and bitter
taste. Therefore, its protection is necessary before its appli-
cation for food fortification. To our knowledge, there is not
any effort to enhance stability of caffeic acid. Therefore, the
aims of this work were to produce and characterize novel
nanocarriers for entrapment of caffeic acid and investigate the
effect of encapsulation on caffeic acid antioxidant properties
after release in gastrointestinal condition.
2. Materials and Methods
2.1. Materials. Caffeic acid was purchased from Sigma-
Aldrich (USA). Chitosan (low molecular weight, MW
150000), sodium alginate, and LM pectin were supplied by
Sigma-Aldrich Company (Canada). Glycerol monostearate
(GMS; Condea, Germany), glycerol behenate (Compritol 888;
Gattefosse´, France), and Tween 80 (Merck, Germany) were
applied at analytical grade. All other chemicals and reagents
were at least of analytical grade.
2.2. Methods
2.2.1. SLN Production. The SLN production method was
adjusted based on the procedure mentioned in a previous
study [6]. Briefly, the aqueous phase was added to caffeic
acid containing melted lipid phase at 80∘C and stirred in
2000 rpm for 1min. To form coarse and nanoemulsions the
preemulsion was subjected to bath (10min; Powersonic 505;
Hwashin Technology, Gyeonggi-do, Republic of Korea) and
probe (1min, in amplitude 50% and power of 100W-TT13
probe; Bandelin, Germany, Berlin) sonication, respectively.
In order to prevent temperature increase, the probe sonicator
was inactive in 2 second intervals.The attained emulsion was
cooled down in an ice bath for 30minutes to recrystallize lipid
forming SLN. The encapsulation load and efficiency were
determined using centrifugation method [6].
2.2.2. SLN Layer by Layer Coating. Chitosan solution was
prepared by dissolving into acetic acid (0.1%) and stirring
overnight. Alginate and pectin were dissolved in distilled
water. SLNs were coated layer by layer coating of alginate or
pectin with chitosan. A solution of 7.5mL chitosan (0.1%)
was added dropwise into a beaker containing 15mL SLN
solution under 1000 rpm stirring. Then, 15mL of alginate
or pectin solution (0.1, 0.25, and 0.5%) was dropped into
the SLN-chitosan solution. Finally, appropriate amount of
18mM calcium chloride solution was dropped into resulted
solution, the pH was set on 5.2, and prepared nanoparticles
were held with an additional stirring for 30min to form uni-
form particle size. Subsequently, for future characterization,
nanoparticles were freeze-dried at −80∘C in 0.001mbar for
48 h using a freeze-dryer (Christ Alpha LD, Germany).
2.2.3. Particle Size and Zeta Potential. The average particle
size and zeta potential were determined by photon elec-
tron spectroscopy (PCS) using Zetasizer (NanoSizer 3000,
Malvern Instruments, Malvern, UK).The size measurements
were performed at a fixed angle of 90 degrees using the
volume distribution. The polydispersity index (PDI) mea-
sures the size distribution of the nanocarriers. The lower
the PDI, the narrower the size distribution. Zeta poten-
tial which is an indicator of surface charge was measured
based on mean electrostatic mobility applying Helmholtz-
Smoluchowski equation [16].
2.2.4. Morphology Characterization. Morphological study of
the SLN and coated nanoparticles was performed using trans-
mission electronmicroscopy (TEM). Sampleswere negatively
stained with uranyl acetate (2%) and dried on carbon coated
grids at room temperature.
2.2.5. Caffeic Acid Release and Kinetic Modeling. Caffeic acid
releasewas studied in gastric and intestinal solutions applying
dialysis bag method at 37∘C and 100 rpm. Two milliliters
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caffeic acid loaded SLN or solution of freeze-dried coated
samples (with equal amount of caffeic acid) were sealed into
dialysis bag (Sigma, Canada) with a 12 kDa cut-off. The bag
was then placed into a 40mL gastric buffer for 2 h. It was
subsequently subjected to the intestinal buffer (50mL) for 6 h.
At appropriate time intervals, the amount of released caffeic
acid was determined spectrophotometrically at wavelength
of 295 nm. The release data were kinetically evaluated by
zero-order, first-order, Higuchi, Rigter-Peppas, reciprocal
powered time, Weibull, and quadratic models (see (1)–(7))
[6, 17, 18]:
𝐶 = 𝐾𝑡, (1)
𝐶 = [1 − exp (−𝐾𝑡)] × 100, (2)
𝐶 = 𝐾𝑡0.5, (3)
𝐶 = 𝐾𝑡𝑛, (4)
(
1
𝐶
− 1) =
𝐾
𝑡𝑎
, (5)
ln [− ln (1 − 𝐶)] = 𝑎
𝑤
ln 𝑡 − ln 𝑏
𝑤
, (6)
𝐶 = 100 (𝐾
1
𝑡2 + 𝐾
2
𝑡) , (7)
where C is caffeic acid concentration (%) at time t, K is
kinetic constant, and n is release exponent. The latest is used
to characterize different release mechanisms. Encapsulant
release from spherical carriers with 0.43 ≤ 𝑛 is controlled by
Fickian diffusionmechanism, and 𝑛 ≥ 0.85 is commanded for
dissolution phenomenon, and 0.43 < 𝑛 < 0.85 is governed by
combination of two mechanisms [19].
The shape parameter, a
𝑤
, in Weibull model characterizes
thecurve as either exponential (a
𝑤
= 1) (Case 1), sigmoid, S-
shaped, with upward curvature followed by a turning point
(a
𝑤
> 1) (Case 2), or parabolic, with a higher initial slope and
after that consistent with the exponential (a
𝑤
< 1) (Case 3)
[18].
2.2.6. Reducing Activity Measurement. Either the gastric or
intestinal buffers were subjected to reducing activity test
as an indicator for antioxidative capability of the released
caffeic acid. The method was adopted from Rekha [20].
A test sample or distilled water (control) (0.5mL) was
added to 0.5mL potassium ferricyanide solution 1% (Merck,
Germany) and 0.5mL sodium phosphate buffer (0.02M, pH
7). The mixture was incubated at 50∘C for 20min and then
0.5mL trichloroacetic acid (0.5mL, Merck, Germany) was
added. The mixture was centrifuged at 780 g for 5min. The
upper layer (1.5mL) was mixed with 0.1% ferri chloride
(0.2mL,Merck, Germany) and the absorbance wasmeasured
at 700 nm.The higher absorbance of the givenmixture would
present the higher reducing activity. The following equations
were used to indicate the concentrations of caffeic acid
balanced with the reducing activity of the released caffeic
acid.
Reducing activity standard curve in gastric buffer:
𝑥 = 32.3𝑦 − 1.25.
Reducing activity standard curve in intestinal buffer:
𝑥 = 55𝑦 − 7.5.
(8)
2.2.7. DPPH Radical Scavenging Activity. Free radical scav-
enging activity of the gastric and intestinal solution contain-
ing caffeic acid wasmeasured by DPPHmethod, as described
by Shinde et al. with minor modifications [21]. Briefly, 0.2mL
of each sample was added to 3.8mL DPPH ethanol solution
(final concentration was adjusted at 0.1mM) in a test tube.
Themixture was mixed vigorously for 1min by vortexing and
was left to stand at room temperature in the dark for 30min.
Thereafter, the absorbance of the sample was measured using
the UV-visible spectrophotometer at 517 nm against ethanol
blank. A negative control (control) was taken after adding
DPPH solution to 0.2mL of the respective gastric of intestinal
buffer. The percent of DPPH discoloration of the sample was
calculated according to the following equation:
Percentage of discoloration = [1 − (
𝐴 sample
𝐴control
)] × 100.
(9)
The scatter plots of absorbance against different concen-
tration of caffeic acid in gastric and intestinal condition were
provided individually, and the following equations were used
for each of the media.
DPPH discoloration standard curve in gastric buffer:
𝑥 = 126 − 53.9𝑦.
DPPH discoloration standard curve in intestinal buffer:
𝑥 = 182 − 355𝑦.
(10)
2.2.8. Statistical Analysis. All experiments were performed at
least with 3 replications, and the average valueswere reported.
Statistical analyses were carried out using MSTAT software
(version C). Data were subjected to analysis of variance
(ANOVA), and means were compared using “Duncan” test
at 5% significant level.
3. Results and Discussion
SLN, AL-CH, and PEC-CH coated SLNs were produced to
enhance stability and functionality of caffeic acid. Encap-
sulation efficiency and load of produced SLN were 71.21 ±
1.2% and 4.73 ± 0.35%, respectively. It is noteworthy that in
a previous paper, it has been indicated that chemical com-
positions of the materials did not change during layer by
layer coating [8]. In the following subsections, some fea-
tures of developed nanocarriers such as size, zeta potential,
4 Journal of Nanomaterials
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Figure 1: TEMmorphology of caffeic acid loaded SLN (b) and PEC-CH coated SLN (a).
morphology, and release behavior are studied; the effect of
different treatments on antioxidant activity of caffeic acid is
discussed afterwards.
3.1. Size, Zeta Potential, and Morphological Characterization.
Size, PDI, and zeta potential values of produced nanocarriers
were tabulated in Table 1.
As expected, the SLN showed the smallest size
(49.65±1.12 nm).The developed SLNs are significantly small
in comparison to some produced SLN [6, 22] and NLC
[23, 24]. The smaller size of the particles leads to their faster
movement due to Brownian motion and therefore higher
dispersion stability against the gravity. On the other hand,
zeta potential value of produced SLN was found to be near
zero (−2.57±1.03mV).This low zeta potential in comparison
to the literature data [25, 26] is due to the fact that there
is almost the same positive and negative electron charge
over the nano carriers’ surface. Zeta potential is a crucial
factor in nanoparticle stability. The particles with higher
zeta potential show bigger repulsion force which leads to
higher dispersion stability against aggregation. The low zeta
potential of caffeic acid loaded SLN could be attributed to
the neutral nature of applied lipid. Therefore, surface coating
of nanoparticle using charged biopolymer could enhance
their zeta potential. The results indicated that coating lead
to increase of size and zeta potential. With the increasing
coating concentration, the sizes of nanocarriers significantly
(𝑃 < 0.05) increased in consequence. The negatively charged
calcium alginate complex in pregel state can interact with
positively charged chitosan [27]. The negative zeta potential
of AL-CH coated SLN shows that Ca-AL properly covered
the chitosan surface and therefore could be well protected
against acidic condition in the gastric medium. Similar
results were obtained by Mladenovska research team [28, 29]
who showed AL-CH biopolymer had negative zeta potential.
The absolute values of zeta potential of AL-CH coated
nanoparticles increased by alginate concentration.
PEC-CH coated SLN in 0.1% pectin concentration
showed size of 52.60 ± 0.31 nm (Table 1). However, in higher
concentrations of pectin, the micron size beads were con-
structed; therefore, their size and zeta potential were not
reported due to the unreliability of the applied instrument.
Similar results were obtained in our previous study for
hesperetin loaded nanoparticles [8]. The micron size PEC-
CHbeadswere also reported in the literature [30, 31].The sur-
face charge of pectin was found to be negative [32]. The pos-
itive zeta potential of 0.1% pectin-chitosan coated nanopar-
ticles might be attributed to low pectin concentration and
presence of chitosan on the surface of nanoparticles. Luo et al.
produced chitosan coated NLC and observed that the zeta
potential of NLC (−0.45mV) increased by chitosan coating
(+20.70mV) [33].
The PDI values of all produced nanocarriers were found
to be lower than 0.5 indicating their narrow size distribution.
The morphological images of SLN and PEC-CH coated
nanoparticles obtained from transmission electron micros-
copy were depicted in Figure 1.
The obtained sized from TEM was in accordance with
PCS analysis. Both SLN and coated nanoparticles showed
spherical shape.The double shell layer in coated carrier could
be obviously observed in TEM image.
3.2. Caffeic Acid Release. Two drawbacks of SLN, namely, low
zeta potential and rapid release in gastric media motivated
us to produce coated SLN. The release profiles of developed
nanocarriers were shown in Figure 2.
Release and absorption of encapsulated food bioactives
are supposed to be in intestine for higher bioavailability.
More than 55% of caffeic acid released from SLN during
the first two hours in gastric media (Figure 2(a)), and
therefore, it was necessary to modify SLN for bioactive
protection against gastric condition. AL-CH and PEC-
CH coated nanoparticles could both retard caffeic acid
release in gastric condition. Caffeic acid releases from AL-
CH coated nanoparticles in the first 2 hours were found
to be 30.32 ± 0.08, 24.66 ± 1.00, and 29.05 ± 0.99 for
alginate concentrations of 0.1, 0.25, and 0.5%, respectively
(Figure 2(b)). No significant difference was observed among
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Table 1: Size, PDI, and zeta potential of developed caffeic acid loaded nanocarriers.
Nanocarrier Size (nm) Polydispersity index (PDI) Zeta potential (mV)
SLN 49.65 ± 1.12 0.47 + 0.02 −2.57 ± 1.03
AL-CH coated SLN-0.1% 74.26 ± 8.26 0.45 ± 0.07 −21.87 ± 3.04
AL-CH coated SLN-0.25% 109 ± 7.22 0.49 ± 0.05 −31.60 ± 2.32
AL-CH coated SLN-0.5% 235.93 ± 24.1 0.33 ± 0.03 −35.20 ± 3.41
PEC-CH coated SLN-0.1% 52.60 ± 0.31 0.42 ± 0.01 14.75 ± 0.35
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Figure 2: Caffeic acid release profile of SLN (a), coated AL-CH (b), and PEC-CH (c) SLN in gastrointestinal conditions.
caffeic acid release for the three applied concentrations. The
release in gastric solution from AL-CH was found to be
delayed due to cross-linking of guluronic acids with the
Ca+2 ions and the amino groups of chitosan. On the other
hand, in the intestinal condition, the slower release could
be attributed to the insoluble chitosan blended in the gel
structure. PEC-CH coated carriers in pectin concentration of
0.1% were found to be the most efficient against caffeic acid
release in gastric media (19.43± 0.59% of caffeic acid release)
(Figure 2(c)). At higher concentrations, it seems that pectin
could not properly cover the particle surface and therefore
was not capable of decelerating caffeic acid release in gastric
media.Themicron size of pectin coated carriers in concentra-
tions of 0.25 and 0.50% shows that additional pectin tends
to be aggregated and failed to completely cover the par-
ticle surface. Pectin can form a rigid gels by the action
of calcium ions cross-linking the galacturonic acid chains
[34].
It is also said to resist the proteases and amylase which are
active in the upper gastrointestinal tract.
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Table 3: Antioxidant activity changesa of released caffeic acid from nanocarriers in gastric and intestinal simulated condition.
Treatment DPPH assay (%) Reducing activity (𝜇g/mL of caffeic acid)
Gastric media Intestine media Gastric media Intestine media
T1 5.85 ± 1.34 8.39 ± 2.56 12.44 ± 0.61 4.7 ± 0.34
T2 0.00 0.19 ± 0.09 5.3 ± 0.19 1.23 ± 0.10
T3 9.16 ± 1.04 3.7 ± 0.61 9.36 ± 1.07 0.96 ± 0.05
T4 0.00 2.15 ± 0.88 21.48 ± 0.11 0.38 ± 0.33
T5 11.24 ± 0.21 7.8 ± 1.86 5.6 ± 0.93 2.3 ± 1.28
T6 15.6 ± 3.37 0.00 0.27 ± 0.1 0.83 ± 0.23
T7 3.07 ± 0.23 3.2 ± 0.73 4.78 ± 1.16 3.84 ± 0.68
T1: caffeic acid released from solid lipid nanoparticles.
T2: caffeic acid released from solid lipid nanoparticles coated with 0.1% PEC-CH.
T3: caffeic acid released from solid lipid nanoparticles coated with 0.25% PEC-CH.
T4: caffeic acid released from solid lipid nanoparticles coated with 0.5% PEC-CH.
T5: caffeic acid released from solid lipid nanoparticles coated with 0.1% AL-CH.
T6: caffeic acid released from solid lipid nanoparticles coated with 0.25% AL-CH.
T7: caffeic acid released from solid lipid nanoparticles coated with 0.5% AL-CH.
aResults are expressed as the means of three replications ± standard error of mean.
Themodeling results for four different kinetic models are
tabulated in Table 2.
Rigter-Peppas and reciprocal powered time models pro-
vided better capability to describe release behavior of caffeic
acid.The poor ability of zero-order model demonstrated that
the release mechanism was concentration dependent. Low
correlation coefficients of Higuchi model for pectin coated
SLN in concentrations of 0.25% and 0.5% could be attributed
to the swelling nature of these nanocarriers and weakness
of this model for swellable polymers. Rigter-Peppas was
found to be the most appropriate model describing release
of hesperetin from coated nanostructure lipid carriers and
Higuchi the least appropriate model due to swellability of
biopolymers [8]. The n values of the Rigter-Peppas model
were found to be lower than 0.43 indicating that the release
mechanism is governed by the Fickian mechanism. Kinetic
study ofWeibullmodel demonstrated that a
𝑤
values are lower
than 1 which indicated a parabolic release curve with a higher
initial slope and then a consistent exponential release. These
results showed that although burst release was decreased by
carbohydrate coating, however, initial release is still exist.
3.3. Antioxidant Activity. The results of antioxidant prop-
erties of released caffeic acid in the gastric and intestine
solutions for different treatments measured by a couple of
distinct experimental methods are presented in Table 3.
Among different treatments, the highest antioxidant
activity of the released caffeic acid in the intestine solution
obtained for the trial contained noncoated particles (T1)
was in line with the highest concentration of caffeic acid
excreted in intestine simulated buffer in the given treatment.
Instead, in the former phase, in the gastric solution, the
measured antioxidant activity in each trial did not represent
the trend observed in the caffeic acid release. It seems that
the determined antioxidant activity was influenced by the
nature of the coated material used in this study. Based on
a previous study, pure caffeic acid is an effective DPPH-
free radical scavenger and showed appropriate total reducing
power [35]. In accordance with the results of PEC-CH (0.1%)
coated treatment in retarding caffeic acid diffusion in gastric
solution, antioxidant activity was shown to be lower in this
treatment than in noncoated nanocarriers (control).Though,
the given treatment did not give rise to the enhancement
of this property in the latter step as well. It is noteworthy
that the results obtained from reducing activity method were
concentration dependent, and therefore, their comparison for
different release values might be imprecise.
The results was also shown to be highly influenced by
the pH of the media; thus, in the present study, two indi-
vidual conditions were considered for assessing the DPPH-
free radicals scavenging capability of caffeic acid in differ-
ent gastrointestinal conditions that unlikely contributes the
test’s precision. In vitro liberation of encapsulated phenolic
component bioactive has been shown to be pH dependent
and acidic environment accelerate the diffusion of protected
bioactive [36].
Antioxidant property is defined as the ability of com-
pounds to inhibit or suppress the oxidation process by
scavenging the free radicals and/or reactive oxygen species.
Methods to determine overall antioxidant activities are
divided into two major categories; (i) methods in which
the measurement is carried out based on transition of
one electron from an antioxidant molecule to an oxidizing
agent and (ii) methods in which the hydrogen releasing
power of antioxidant molecule is regarded as the antioxidant
capability [37]. In the present study, both methods were
applied; however, the negative charge on the surface of coated
nanoparticles (pectin and alginate) may interfere with the
hydrogen donation properties of caffeic acid, leading to
sophisticated results.
Based on previous studies, examining a distinct food
sample by different antioxidative evaluation methods does
not necessarily end up to similar results, and different
experiments may result in different responses in quantity
and even quality of antioxidant characteristic of a tested
sample [38]. Here, in this study, such difference was seen
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betweenDPPH assay and reducing activity test for both kinds
of media, particularly in the gastric buffer, convening that
the methodology for evaluating antioxidative characteristics
of these structures need to be optimized in future studies.
The necessity of application of modified DPPH assay for the
determination of antioxidant properties of nanoparticles was
also stated by others [39]. Using polymeric nanoparticles of
L, D lactid-co-glycolid, Pool et al. [36] showed that encap-
sulation of antioxidant biochemical like quercetin and cate-
chin resulted in the higher antioxidant capability than their
free forms. Inhibition of superoxide production and chelating
the prooxidant ions were used in their study as the antiox-
idative indexes; however, the corresponded protocols were
adjusted upon the tests condition.
4. Conclusions
In this study, development and release kinetic modeling of
novel nanocarriers encasing caffeic acid were pursued. Solid
lipid nanoparticles were first used for encapsulation of caffeic
acid, while its burst release and low zeta potential made them
inappropriate carriers for colon delivery. Layer by layer coat-
ing of SLN was therefore performed using alginate-chitosan
and pectin-chitosan in different concentrations. Micron size
carriers were constructed in higher concentrations (0.25 and
0.5%) of pectin-chitosan treatments, and nanosize parti-
cles with capability of control release were achieved using
alginate-chitosan and 0.1% pectin-chitosan samples. How-
ever, the antioxidant properties of the produced nanocarriers
in the intestine simulated buffer were not improved by any
of the employed treatments which may root by the nature
of the coating material. Since bioavailability of nutraceuticals
is improved by their colon delivery, developed nanocarriers
could be applied for the production of functional fortified
food.
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Nano-𝛽-tricalcium phosphate/collagen (n-𝛽-TCP/Col) is considered with good osteoconductivity. However, the therapeutic
effectiveness of n-𝛽-TCP/Col scaffolds in combination with autologous bone marrow stromal cells (BMSCs) remains to be
elucidated for the repair of critical-sized bone defects. In this study, we found that n-𝛽-TCP/Col scaffolds exhibited high
biocompatibility in vitro. The introduction of BMSCs expanded in vitro to the scaffolds dramatically enhanced their efficiency
to restore critical-sized bone defects, especially during the initial stage after implantation. Collectively, these results suggest that
autologous BMSCs in n-𝛽-TCP/Col scaffolds have the potential to be applied in bone tissue engineering.
1. Introduction
In recent years, a critical-sized bone defect has been defined
as an intraosseous wound that will not spontaneously heal
completely without surgical intervention [1, 2]. Bone auto-
grafting is currently considered to be the “gold standard”
for clinical treatment. However, it is always associated with
irregular rates of resorption, pain, and morbidity of the
donor site, and it requires additional surgical procedures [3].
Therefore, alternatives to autologous bone grafting are the
subject of intensive research.
Recently, tissue engineering approaches have proven to
be very effective in bone regeneration. Successful repair of
bone defects has been investigated in many animal species
including mice [4], rats [5, 6], rabbits [7], canines [8], and
goats [9]. Selection of the most appropriate scaffold for
application in bone tissue engineering is a critically important
step towards tissue-engineered product [10, 11]. 𝛽-Tricalcium
phosphate (𝛽-TCP) is a bioactive and biodegradable ceramic
that has been widely used as a scaffold for bone repair
because of its excellent biocompatibility, reabsorbability, and
osteoconductive properties [12, 13]. However, the use of 𝛽-
TCP is limited because of its brittleness and low plasticity
[14]. Biocompatible polymers, such as collagen (Col), are also
regarded as applicable candidates for use in bone regener-
ation scaffolds. However, there are a number of practical
problems for their use alone, including an uncontrollable
degradation rate in vivo and poor mechanical properties
compared with those of natural hard tissues [15, 16].
To overcome the limitations of bioceramics and biopoly-
mers, ceramic/polymer composite materials have been ex-
plored for preparation of bone tissue engineering scaffolds
[17, 18]. Using a biomimetic strategy, composites based on 𝛽-
TCP and Col have been developed with a three- dimensional
structure to fill bone defects, which show promise because of
compositional and structural analogies to natural bone [19–
21]. In our previous study [22], we designed and fabricated a
novel three-dimensional porous tissue engineering scaffolds
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using nanosized 𝛽-TCP (n-𝛽-TCP)/Col composite materials.
The n-𝛽-TCP particles (about 300 nm) can be distributed
homogenously in the skeleton of a collagen fibril network
in which n-𝛽-TCP particles bind tightly to collagen fibrils.
These composite scaffolds have been found to repair small
bone defects. However, the therapeutic effectiveness of n-𝛽-
TCP/Col scaffolds in combination with seed cells remains to
be elucidated for the repair of critical-sized bone defects.
Bone marrow stromal cells (BMSCs) are multipotent and
have the ability to differentiate into osteoblastic, chondro-
cytic, and adipocytic lineage cells. BMSCs exhibit advantages
over other cell types and have been wildly used in bone
tissue engineering [23]. However, isolation of bone marrow
has some disadvantages in clinical practice, especially to
obtain sufficient cell numbers for transplantation into large
bone defects. To obtain enough cell numbers, much bone
marrow aspiration is needed which would lead to an invasive
and painful procedure and increase the risk of morbidity
and infection. Expansion of BMSCs in vitro is an alternative
strategy to gain enough cells for implantation.
The goal of this study was to explore the therapeutic effec-
tiveness of in vitro expanded autologous BMSC-loaded n-
𝛽-TCP/Col scaffolds for repairing critical-sized bone defects
of the rabbit mandible. At 4 and 8 weeks after implanta-
tion, gross examination, cone beam computed tomography
(CBCT) scanning, and histological analysis were used to
assess new bone formation and scaffolds degradation.
2. Materials and Methods
2.1. Fabrication and Characterization of n-𝛽-TCP/Col Scaf-
folds. 𝛽-TCP (∼300 nm particle size) was synthesized by
calcining an amorphous calcium phosphate precursor [24].
n-𝛽-TCP/Col scaffolds were prepared as reported in our
previous study [25]. Briefly, type I collagen (Sigma-Aldrich
Co., USA) was dispersed in a diluted hydrochloric acid
solution (pH 2) at room temperature.𝛽-TCPwas added to the
collagen suspension with stirring at a 3 : 1 (w/w) ratio. After
formation of a uniform suspension, the crossing-linking
reagent glutaraldehyde (Shanghai Pharm Co., China) was
added to the mixture. After freezing in liquid nitrogen, the
mixture was lyophilized to obtain the porous n-𝛽-TCP/Col
composite. After soaking in deionized water for 4 days
with daily changes to remove unreacted glutaraldehyde, the
porous composite was lyophilized again to form the n-𝛽-
TCP/Col composite scaffolds.
The surface morphology and structure of the nanofibers
were observed by scanning electron microscopy (SEM,
S-4700; Hitachi, Japan). Fourier-transform infrared spec-
troscopy (FT-IR, 8700; Nicolet, USA) was used to evaluate
the chemical structure of the composite scaffolds.
2.2. Isolation, Characterization, andOsteogenicDifferentiation
of Rabbit BMSCs. All animal experiments were performed
in accordance with a protocol approved by the Laboratory
Animal Care and Use Committee of Peking University. All
reagents were purchased from Sigma-Aldrich Co. (St. Louis,
MO)unless otherwise stated. BMSCswere isolated frombone
marrow aspirates of New Zealand white rabbits (12 weeks old,
2.5–3 kg, 𝑛 = 12). Briefly, the bone marrow aspirate was
washed three times withHanks’ balanced salt solution, plated
onto 100mm dishes, and cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, USA) supplemented with
10% fetal bovine serum (FBS) (HyClone, USA), 100U/mL
penicillin, and 100mg/mL streptomycin at 37∘Cwith 5%CO
2
.
After 72 hours, nonadherent cells were removed by changing
themedium. To characterize the surfacemarker expression of
BMSCs, passage 3 cells were stainedwith an anti-rabbit CD34
antibody (1 : 200; Abcam, Cambridge, MA) for immuno-
histological analysis (Figure 1(b)). At 80–90% confluence,
adherent passage 3 cells were trypsinized, harvested, and
subcultured in osteogenic medium. The osteogenic medium
consisted of DMEM supplemented with 10% FBS, 50mg/mL
ascorbic acid-2-phosphate, 100 nM dexamethasone, 10mM
𝛽-glycerophosphate, 100U/mL penicillin, and 100mg/mL
streptomycin. After 1 week of culture, the osteogenic differ-
entiation of BMSCs was confirmed by alkaline phosphatase
(ALP) staining.
2.3. Growth and Bioactivity of Rabbit BMSCs in n-𝛽-TCP/Col
Scaffolds. The fabricated n-𝛽-TCP/Col scaffolds (10 × 8 ×
3mm3) were sterilized with ethylene oxide and prewetted
in osteogenic medium for 24 h. BMSCs that had been cul-
tured in osteogenic medium for 1 week were seeded in the
prewetted n-𝛽-TCP/Col scaffolds (2 × 107 cells/scaffold), and
then the cell/scaffold constructs were placed in 24-well plates.
The cell/scaffold constructs were incubated for 3 hours to
allow cell attachment, and then an additional 1mL of culture
medium was added to each well. After 3 days of culture,
the constructs were fixed in 2.5% glutaraldehyde and serially
dehydrated in an increasing ethanol gradient, air-dried, and
sputter coated with gold prior to imaging by SEM at 20 kV.
At 1, 3, and 7 days of culture, cell proliferation was
assayed using a CCK-8 kit (Dojindo, Japan) and enzyme-
linked immunosorbent assay reader (Bio-Rad, Hercules, CA,
USA) at an absorbance wavelength of 450 nm. The ALP
activity of the adherent cells was also assessed using an
Alkaline Phosphatase Assay Kit (Abcam, Cambridge, MA,
USA) according to the manufacturer’s instructions.
2.4. Experimental Animal Model. Twelve healthy New Zea-
land white rabbits were divided into two groups, one group
for implantation of n-𝛽-TCP/Col scaffolds alone and the
other for n-𝛽-TCP/Col scaffolds combined with autologous
BMSCs expanded in vitro.The rabbits were anesthetized with
pentobarbital sodium and a 3 cm parallel incision was made
along the inferior border of the mandible on both sides. The
periosteum was then retracted to expose the submaxilla. A
critical-sized defect, 10 × 8 × 3mm3, was made in the Buccal-
lingual direction on one side of the mandible of each rabbit.
The scaffolds alone or MSC/scaffold constructs were inserted
into the defected. The mucoperiosteal flaps were carefully
sutured over the defect area using 3-0 absorbable sutures.The
rabbits were sacrificed at 4 and 8 weeks after implantation for
tissue processing.
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Figure 1: Characteristics of the n-𝛽-TCP/Col scaffolds. (a) Macroscopic image, (b) SEM image, and (c) FT-IR spectra of the n-𝛽-TCP/Col
scaffolds.
2.5. Gross Observation and CBCT Examination. At 4 and 8
weeks after implantation, the scaffolds and surrounding tis-
sues were excised and fixed in 10% neutral buffered formalin.
Each mandible defect site was assessed by gross observation,
and the morphology of the reconstructed mandibles at 8
weeks after-implantation was assessed by CBCT scanning (J.
Morita Mfg. Corp., Kyoto, Japan) at 60KV and 2.0mA.
2.6. Histological Evaluation and Histomorphometry. At 4 and
8 weeks after implantation, rabbit mandibles were subjected
to tissue processing and sectioning as reported previously
[26]. Briefly, the tissue samples were fixed in 10% neutral
buffered formalin for 7 days, followed by decalcification and
dehydration, and finally embedded in paraffin and sectioned
at 5mm thicknesses. Hematoxylin and eosin (H&E) staining
was performed on serial tissue sections, and images were cap-
tured under amicroscope (CX21; Olympus, Japan). For semi-
quantitative evaluation, histomorphometric analyses were
performed according to a previously reported method [27]
with slight modifications. The bone tissue area and residual
scaffold materials area were measured using ImageJ software
(National Institutes of Health, Bethesda, MD, USA) in three
randomly selected areas (1 × 1mm2) per histological section.
The bone area and residual scaffold materials area were
expressed as the percentages of the total tissue area measured
in each group.
2.7. Statistical Analysis. Quantitative data are presented as the
mean ± standard deviation. Statistical differences between
groups were evaluated by the Student’s 𝑡-test using SPSS 13.0
(SPSS Science).The critical level of statistical significance was
set at 𝑃 < 0.05.
3. Results and Discussion
3.1. Physicochemical Properties of n-𝛽-TCP/Col Scaffolds.
Figure 1 shows the morphology and structure of n-𝛽-
TCP/Col scaffolds. The composite scaffolds were white and
opaque with spongy appearance (Figure 1(a)) and intercon-
nected porous structure. 𝛽-TCP particles were distributed
well and homogeneously in the skeleton network of collagen
fibrils (Figure 1(b)). The network structure of collagen fibrils
was caused by the acidic environment during fabrication.
Collagen fibrils are composed of numerous polypeptide
chains with carboxyl groups that interconnect via covalent
and hydrogen bonds [28]. In dilute acid solutions, H+
ions tend to react with these polypeptide chains, leading
to the disassembly of the collagen fibrils and subsequent
formation of a network structure. The porosity of the com-
posite scaffolds was around 95%. The interconnected porous
structure may have beneficial effects on cell proliferation
and nutritive transportation for applications in bone tissue
engineering [29]. In FT-IR spectra (Figure 1(c)), adsorption
bands were clearly detected, which corresponded to 𝛽-TCP
(PO
4
3−: 1627 and 1572 cm−1) and collagen (COO−: ∼1541,
1448, and 1399 cm−1). These results further confirmed that
n-𝛽-TCP/Col scaffolds with an integrated structure can
be formed by acid-treated collagen and nanosized 𝛽-TCP
particles through chemical bonds.
3.2. Bioactivity of BMSCs in n-𝛽-TCP/Col Scaffolds In Vitro.
In the present study, we isolated and purified rabbit BMSCs
based on their ability to form adherent clonogenic cell clus-
ters. The isolated BMSCs formed adherent colonies in which
the majority of the cells exhibited fibroblastic spindle shapes
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Figure 2: Characterization of rabbit BMSCs and in vitro bioactivity of BMSCs in n-𝛽-TCP/Col scaffolds. (a) Micrograph of BMSCs cultured
in regular medium for 3 days. (b) CD34 immunohistological staining of BMSCs cultured in regular medium. (c) ALP staining of passage
3 BMSCs cultured in osteogenic medium for 7 days. (d) SEM micrographs of induced BMSCs in the n-𝛽-TCP/Col scaffolds after 3 days of
culture. (e) CCK-8 assay results of the proliferation of BMSCs in n-𝛽-TCP/Col scaffolds at various time points. (f) Change of ALP activity in
BMSCs in direct contact with the n-𝛽-TCP/Col scaffolds after 10 days of incubation in osteogenic medium (BMSCs cultured on tissue culture
plates were used as the control).
(Figure 2(a)). Positive staining for CD34 confirmed that the
cells displayed a characteristic of BMSCs (Figure 2(b)). To
investigate their osteogenic differentiation potential, the cells
were cultured in osteogenic medium. After 7 days of induc-
tion, the cells showed extensive positive staining for ALP,
thereby exhibiting an osteogenic phenotype (Figure 2(c)).
Figure 2(d) shows representative phase-contrastmicrographs
of BMSCs attached to the scaffolds after 3 days of culture.
BMSCs mostly showed a fusiform shape, and they were
adhered well to the scaffold surfaces and bridged the micro-
pores with their pseudopodia. These features indicated that
the scaffold appeared to have no negative effects on cell mor-
phology and viability. The results of cell proliferation assays
are shown in Figure 2(e). At day 3, there was no significant
difference in the cell number between BMSCs seeded in n-𝛽-
TCP/Col scaffolds and cells cultured on tissue culture plates
(TCPS). At day 7, there were more cells in the n-𝛽-TCP/Col
scaffolds compared with those in TCPS. This higher level of
cell proliferation may be attributed to the porous structure
of the n-𝛽-TCP/Col scaffolds, which provides a large surface
area for cell spreading [30]. Collectively, these results indicate
that the n-𝛽-TCP/Col scaffolds promote the attachment and
proliferation of BMSCs.
Differentiation of BMSCs is a key process for bone regen-
eration. In our in vitro experiments, differentiation of the
BMSCs into osteoblastic cells in n-𝛽-TCP/Col scaffolds was
quantitatively measured by ALP activity (Figure 2(f)). ALP
activity is an early marker that identifies osteoblastic cells
and is considered as an important factor in bone differenti-
ation and mineralization [31, 32]. After 1 day of osteogenic
stimulation, low ALP activity was detected, indicating few
BMSCs had differentiated into osteoblastic cells. However,
after further stimulation, the level of ALP activity increased
substantially (𝑃 < 0.05).These results indicate that n-𝛽-TCP/
Col scaffolds improve the osteogenic differentiation ability of
BMSCs.
3.3. Osteogenesis of BMSCs Hybridized with n-𝛽-TCP/Col
Scaffolds In Vivo. To evaluate the osteogenic potential and
effects of autologous BMSCs in n-𝛽-TCP/Col scaffolds in
vivo, a rabbit mandible defect was selected to assess the
performance of the biomaterial [23]. A critical-sized defect
model is imperative for the evaluation of biomaterials in
bone defect repair [33, 34].Therefore, we established a critical
defect (10× 8× 3mm3) in themandible of each rabbit. During
the experiment, all rabbits remained in good health and did
not show any wound complications.
Figure 3 shows macroscopic images of the implantation.
At 4 weeks after implantation, the surface of defects in
the only scaffolds group was partially filled with callus
bone, while a large proportion of the residual scaffold was
observed in the defect site (Figure 3(a1)). In contrast, a
larger area was filled with callus bone in defects implanted
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Figure 3: Macroscopic images of the implantation sites at 4 weeks (a) and 8 weeks (b). (a1 and b1) n-𝛽-TCP/Col scaffolds and (a2 and b2)
BMSC/scaffold constructs.
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Figure 4: CBCT images of rabbit mandible defects with n-𝛽-TCP/Col scaffolds (a–c) or BMSC/scaffold constructs (d–f) at 8 weeks after
implantation. (a, d) Coronal section, (b, e) sagittal section, (c, f) and horizontal section. Red arrows denote the surgical site.
with BMSC/scaffold constructs, and the boundary between
scaffolds and host bone was unclear because of active
osteogenesis in the implantation area (Figure 3(a2)). At 8
weeks after implantation, the wounds were well healed and
there were few differences in the hardness and appear-
ance of newly formed bone and normal osseous tissues in
the BMSC/scaffold construct group (Figure 3(b2)). In con-
trast, in the only scaffolds group, there was still a proportion
of the scaffolds retained in the defects (Figure 3(b1)), which
was confirmed by CBCT scanning (Figure 4). These results
indicate that BMSC/scaffold constructs provide a better
osteogenic outcome than that of pure scaffolds.
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Figure 6: Newly formed bone area (a) and residual scaffolds area (b) in rabbit mandible defects at 4 and 8 weeks after implantation.
Figure 5 shows the histological results of mandible defect
repair, indicating different trends of bone regeneration and
scaffolds degradation from the two groups. In the scaf-
folds only group, the defect was mainly occupied by an
abundance of residual scaffolds with a dense structure at 4
weeks after implantation (Figure 5(a)). In addition, residual
scaffolds were present in the defect despite the obvious
appearance of newly formed bone at 8 weeks after implan-
tation (Figure 5(c)). In contrast, BMSC/scaffold constructs
exhibited not only high biocompatibility but also faster and
more efficient osteogenesis in the defect area. At 4 weeks
after implantation, a small amount of residual scaffolds with
a loose structure was observed in the center of defects that
were mostly dominated by newly formed bone (Figure 5(b)).
Moreover, osteoblasts (an indication of bone formation) were
observed at the interface between the scaffolds and bone.
From these results, seeded BMSCs might differentiate into
osteoblast in vivo and probably account for the improved
bone formation,which is consistentwith previous report [23].
At 8 weeks after implantation, there was almost complete
restoration of the bone defects with little residual materials
(Figure 5(d)). The histological observations were confirmed
by quantitative analyses of the percentages of newly formed
bone and residual scaffolds (Figure 6).
These results indicate that incorporation of in vitro
expanded autologous BMSCs into the porous n-𝛽-TCP/Col
scaffolds enhances the efficiency of bone regeneration, espe-
cially during the initial period after implantation. Our
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findings can be explained by the fact that the interconnected
macropores of the n-𝛽-TCP/Col scaffolds facilitate cell infil-
tration into the interior of the scaffolds [35]. When culture-
expanded autologous BMSCs at a relatively high cell density
are preseeded into scaffolds, BMSCs differentiate towards
osteoblasts during the early period after implantation, which
increases the rate of bone regeneration. In summary, the
n-𝛽-TCP/Col scaffolds hybridized with culture-expanded
autologous BMSCs presented not only high biocompatibility
but also faster and more effective bone defect restoration.
4. Conclusions
In the present study, we have successfully prepared porous
n-𝛽-TCP/Col composite scaffolds with an interconnected
porous structure and 𝛽-TCP particles that are homoge-
neously distributed in the skeleton network of the collagen
fibrils. Our results show that n-𝛽-TCP/Col scaffolds exhibit
high biocompatibility in vitro. Introduction of autologous
BMSCs into the scaffolds dramatically enhances the efficiency
of critical-sized bone defects restoration, especially during
the initial stage after implantation. Collectively, these results
suggest that culture-expanded autologous BMSCs in n-𝛽-
TCP/Col scaffolds have the potential to be applied in bone
tissue engineering.
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The aim of the present research is to formulate and evaluate polymeric nanosuspensions containing three model water
insoluble drugs, nifedipine (NIF), carbamazepine (CBZ), and ibuprofen (IBU) with various physicochemical properties. The
nanosuspensions were prepared from hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP) by a cosolvent
technique with polyethylene glycol (PEG-300) and water as the cosolvents. Physicochemical and morphological characteristics of
the nanosuspensions (particle size, polydispersity index, and crystallinity) have been correlated with the drug release behaviour.
The effects of polymer, drug ratio on the physical, morphological, and dissolution characteristics of the drugs are reported. Drug
release is significantly enhanced from the nanosuspensions; for example, the maximum NIF, IBU, and CBZ concentrations after 8-
hour dissolution are increased approximately 37, 2, and 1.2 times, respectively, in comparison with the pure powdered drugs. Based
on this solubilization enhancement performance, the nanosuspensions have potential for increasing the orally dosed bioavailability
of NIF, IBU, and CBZ.
1. Introduction
More than 40% of new chemical entities (NCE) are water
insoluble compounds which currently make up 1/3 of the
United States Pharmacopeia recognised drugs [1, 2]. Water
insoluble compounds (BCS Class II) have poor aqueous
solubility and imperfect dissolution, which causes their
low bioavailability [3]. Generation of drug nanosuspensions
presents one solution to delivery of water insoluble drugs.
Nanosuspensions have been defined as drug carriers with
particle size range within 10–1000 nm [4]. Therefore, for-
mulating new dosage forms to achieve adequate bioavail-
ability has become a serious and challenging scientific,
industrial, and medical issue. Water insoluble drugs are
typically formulatedwith the help of various excipients whose
aim is to improve drug dissolution rate and storage stabil-
ity. Interaction of reactive functional groups of excipients
with the drug molecules increases active surface area and
consequently dissolution rate [5]. The use of excipients in
formulations of insoluble drugs has proven ability to increase
drug dissolution rate, but limitations such as toxicity of some
surfactant compounds and limited drug loading have been
identified [6]. According to the Noyes-Whitney equation,
smaller particle size with higher surface area in contact with
biological media leads to an enhanced drug dissolution rate
[7, 8]. Hence, scaling down convention drug powders to
nanoparticles enhances drug solubility and bioavailability.
Nanosuspensions can be prepared by different methods such
as high pressure homogenization and media milling. How-
ever these techniques have drawbacks such as contamination
of final products, broad particle size distributions, and the
need for high energy input [9, 10]. The co-solvent technique
has been extensively used to prepare in situ nanosuspensions
[11–17] and has numerous advantages over evaporation or
heating-cooling techniques, such as being fast and easy to
perform and suitable for thermolabile compounds.
The aim of this work is to explore solid-state and dissolu-
tion characteristics of polymeric nanosuspensions prepared
by a co-solvent technique. Water insoluble drugs nifedipine
(NIF), carbamazepine (CBZ), and ibuprofen (IBU) with
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different physiochemical properties (Table 1) were selected
and used in realistic extended release doses. Commonly
used pharmaceutical polymers hydroxypropyl methylcellu-
lose (HPMC) and polyvinylpyrrolidone (PVP) were used as
stabilisers/crystal growth inhibitors [18–21]. In addition to
crystal inhibition, the HPMC polymer acts as a hydrophilic
matrix agent which forms a strong viscous gel in contact
with aqueous media, facilitating extended drug release [22].
The influence of polymer : drug ratio on nanoparticle for-
mation, drug stabilization, and dissolution characteristics
were explored. Drug crystallinity and polymorphic forms
in nanosuspension polymeric matrices consisting of dif-
ferent polymers ratio were investigated using differential
scanning calorimetry (DSC). The molecular structure and
specifications of model drugs (nifedipine, carbamazepine,
and ibuprofen) and excipients (mannitol, PEG-300, HPMC,
and PVP) which were used in this study are presented in
Table 1.
2. Materials and Method
2.1. Materials. High-purity (Milli-Q) water was used
throughout the study (ph = 6.5 ± 0.5). PEG-300
(Sigma Aldrich, Australia) was used as the co-solvent.
Hydroxypropyl methylcellulose (HPMC) containing
28–30% methoxyl and 7–12% hydroxypropyl content,
polyvinylpyrrolidone (PVP), and mannitol: ≥98% (Sigma-
Aldrich) were used as received. Model drugs (NIF: ≥98%
TLC, CBZ: ≥98% TLC, IBU: ≥98%GC) and phosphate buffer
(pH = 7.4) were also purchased from Sigma-Aldrich.
2.2. Preparation of Nanosuspensions. Nanosuspensions of
model drugs were prepared by the co-solvent technique [30].
This technique includes mixing of two different phases. The
first phase (organic phase) is PEG-300 with dissolved model
drugs (NIF: 30mg, CBZ: 400mg, IBU: 400mg dissolved in
5 gr of PEG-300). The second phase (aqueous phase) where
the model drugs are almost insoluble contains dissolved
polymers (HPMC & PVP) (Table 2). The two phases were
sonicated for 2 hours. Upon subsequent addition of mannitol
(10%w/v), the system was additionally sonicated for 2 hours.
2.3. Freeze Drying/Lyophilization and Redispersibility of
Nanosuspensions. Nanosuspension formulations were
lyophilized using mannitol as cryoprotectant. The freeze
drying (Alpha 1-2 LDplus) was performed at a temperature
of −70∘C and vacuum 0.09mbar for 72 hours. The
redispersibility of lyophilized samples was investigated
by manual shaking of 5mg in glass vial with 20mL PBS
(pH = 7.4). Formation of aggregates or precipitates was
monitored visually.
2.4. Particle Size Analysis. Size and polydispersity index (the
width of particle size distribution) of nanosuspensions were
measured with dynamic light scattering (Zetasizer Nano ZS,
Malvern Instruments, Ltd.). Refractive index values of PBS:
pH = 7.4 (1.33) as the continuous phase and HPMC/PVP
polymers with refractive index value of 1.45 were used in the
size measurements. Nanosuspensions were diluted 1 : 100 in
PBS (pH = 7.4) and measured in the specified cuvettes at
23 ± 0.5∘C in triplicate.
2.5. Differential Scanning Calorimetry (DSC). Differential
scanning calorimetric (DSC) analysis was carried out using
TA Instruments model 2920. Samples (5–10mg) were heated
under nitrogen atmosphere on an aluminium pan at a rate
of 10∘C/min over the temperature range of 25 and 300∘C. An
empty pan of the same type was utilized as the reference. DSC
thermograms were obtained by using TA universal analysis
software. Calibrations of temperature and heat flow were
performed with indium.
2.6. In Vitro Release Study. In vitro release of model drugs
from nanosuspensions was studied for 8 hours using Vankel
USP apparatus type 2 (paddle method) at the rotation speed
of 50 rpm and 900mL of phosphate buffer (pH = 7.4) as
a dissolution medium. The dissolution test was thermo-
regulated at 37 ± 0.5∘C. Sample aliquots of 4mL were
withdrawn from the receptor chamber at determined time
intervals (0.5, 1, 2, 3, 4, 5, 6, 7, and 8 hours) and replaced with
fresh buffer medium.The aliquots were then filtered through
a Millipore membrane filter (0.45 𝜇m). The concentrations
of NIF, IBU, and CBZ in the samples were analysed spec-
trophotometrically at a wavelength of 234, 263, and 283 nm,
respectively.
2.7. Kinetics of Drug Release. In order to investigate the drug
release mechanism, in vitro release data were fitted by the
following equations [31].
(a) Consider zero-order release:
𝑄 = 𝑄
0
+ 𝐾
0
𝑡, (1)
where𝑄 is the amount of drug dissolved at particular
time, 𝑡, 𝑄
0
is the initial amount of drug in solution at
𝑡 = 0, and𝐾
0
is the zero-order release constant.
(b) Consider first-Order release:
ln𝑄 = ln𝑄
0
+ 𝐾
1
𝑡, (2)
where𝐾
1
is the first order release constant.
(c) Consider Hixson-Crowell cube root release:
𝑄1/3 = 𝑄1/3
0
− 𝐾
𝑐
𝑡, (3)
where𝐾
𝑐
is the cube root law release constant.
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Table 1: Characteristics of model water insoluble drugs (NIF, CBZ, and IBU) and excipients (HPMC, PVP, PEG-300, and mannitol) used in
this study.
Name and characteristics Structure
Nifedipine
Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate
Appearance: a yellow crystalline powder
Molecular weight: 346.3
Solubility: practically insoluble in water, sparingly in
dehydrated alcohol, freely in acetone
Indication: calcium channel blocker [23]
Log P: 2.2 [24]
Solubility in PBS (pH 7): 0.0056 g/L [25]
H3C
H3C
O
O O
O
H
N CH3
CH3
NO2
Carbamazepine
5H-dibenzo[b,f]azepine-5-carboxamide
Appearance: a white crystalline powder
Molecular weight: 236.3
Solubility: practically insoluble in water, soluble in
alcohol and acetone
Indication: anticonvulsant and mood-stabilizing [23]
Log P: 2.67 [26] O
N
NH2
PVP
Molecular weight: 29000
Specifications: improving the wettability, dissolution
rate, and crystal inhibitor [20, 21, 27]
ON
H
H
n
Ibuprofen
(RS)-2-(4-(2-methylpropyl)phenyl)propanoic acid
Appearance: a white to off-white crystalline powder
Molecular weight: 206.3
Solubility: practically insoluble in water, very soluble in
alcohol and acetone, Chloroform, methyl alcohol,
slightly soluble in ethyl acetate.
Indication: anti-inflammatory [23]
Log P: 3.6 [28]
Solubility in PBS (pH 7.4): 25.16mcg/mL [29]
H3C
O
CH3
CH3
OH
PEG-300
Monomer: ethylene oxide
Molecular weight: 285–315
Application: cosolvent
OH
O
H n
Mannitol
(2R,3R,4R,5R)-hexan-1,2,3,4,5,6-hexol
Application: converting the drug nanosuspensions to a
stable solid form and easy redispersibility
OH OH
OH
HO
HO HO
HPMC
Molecular weight: 86000
Specifications: improving the wettability, dissolution
rate, and crystal inhibitor [18, 19, 27]
RO
RO
RO
O
OOO OR
OR
R = H or CH3 or
OR
OR
OR
CH3
H
∗
n
x
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Table 2: Amount of polymers used in nanosuspension formula-
tions.
Drug Sample label
Organic phase
PEG-300
(wt%)
Aqueous phase
HPMC/PVP
(ratio 1 : 1) (wt%)
NIF
A
1 43.36 4.32
A2 31.16 31.2
A3 23.77 47.54
A4 16.11 64.44
CBZ
A1 42.01 4.2
A2 30.48 30.5
A3 23.36 46.72
A4 15.92 63.68
IBP
A1 42.01 4.2
A
2 30.48 30.5
A3 23.36 46.72
A
4 15.92 63.68
3. Results and Discussion
3.1. Lyophilization and Redispersibility of Nanoparticles. To
remove water from the nanoparticle system, freeze drying,
also known as lyophilization, was employed. The basic
principle of freeze drying is to remove water from a frozen
sample by sublimation and desorption under vacuum [32,
33]. However, the process generates various stresses which
destabilise nanoparticles. In order to protect the particles
from freezing and desiccation stresses, cryoprotectants or
lyoprotectants are incorporated into the formulation before
freeze drying. Freeze drying is generally carried out below the
𝑇
𝑐
temperature. 𝑇
𝑐
can be defined as collapse temperature in
which the particles cannot maintain their microscopic struc-
ture. Hence, nanoparticles have the chance to immobilize
within the glassy matrix of the cryoprotectants [34].
Lyophilization helps in converting a nanosuspension
formulation, that is, liquid dispersion into a solid formwhich
can be reconstituted prior to use. Nanosuspension formula-
tions were lyophilized using mannitol as cryoprotectant at
a constant concentration level (10%w/v). Mannitol acts as a
carrier which prevents nanoparticle aggregation during the
freeze drying process. Figure 1 shows the nanosuspension
samples with and without mannitol. Freeze dried nanosus-
pensions without mannitol appeared as off-white fluffy and
sheet-like materials and large aggregates were also observed.
Nanosuspensions with mannitol formed a powder easily
redispersible in PBS after manual shaking.
3.2. Particle Size and Size Distribution. The effect of the poly-
mer : drug ratio on the size of the nanoparticles was studied
using four different batches A
1
, A
2
, A
3
, and A
4
. The mean
particle size for all different drug formulations (NIF, CBZ,
and IBU) varied in the range from 426.4 nm to 995.4 nm.The
mean PDI values for all formulations varied in the range of
0.4 to 0.687. It is inferred from the results that the polymer
and drug type have significant effect on the particle size. This
could be explained by the interaction of PVP with HPMC
in aqueous media. The interaction between the methoxy and
hydroxypropoxy groups of HPMC with carbonyl group of
PVP creates a hydrogen bonding layer which covers the drug
particles [35]. Hence hydrogen bonding prevents or retards
crystal growth which results in smaller particle size. The
other possible reason could be due to a specific drug-polymer
interaction which forms compacted structure at higher
polymer concentrations. Figure 2(a) shows that the particle
size decreases with increasing the amount of polymers. The
particle size of CBZ and IBU in nanosuspension formulations
did not show any significant indication regarding the polymer
ratio (Figures 2(b) and 2(c)) due to no significant drug-
polymer interaction to form a compacted structure.
3.3. In Vitro Drug Dissolution Studies. Several formulations
(as shown in Table 2) were prepared to evaluate the effect
of the polymer : drug ratio on the drug dissolution profiles.
The percentage release of pure drugs and drugs in polymer
matrix as a function of time is presented in Figure 3 for the
NIF (a), IBU (b), and CBZ (c). It can be seen that solubility
of model drugs from the polymer matrix in PBS (PH = 7.4)
at 37∘C ± 0.5∘C is higher than that of pure drugs. The data
shows that the dissolution of NIF and IBU in the highest
concentration of polymer matrix increased approximately 37
and 2 times, respectively, in comparison with the pure drug.
Figure 3(c) shows that in the case of CBZ there was only a
moderate increase in dissolution (1.2 times) at the highest
concentration of polymers used. The general trend is that
the extent of dissolution increases with increasing polymers
content (Figure 3). Figure 4 illustrates that incorporation of
polymers in the formulations has direct influence on the drug
release profile compared to pure drug. Possible reasons for
increased dissolution of drug nanosuspensions are (a) smaller
drug particles in nanosuspension formulation compared to
pure drugs, (b) interaction of HPMC and PVP as crystal
growth inhibitor of drugs particles, (c) adsorption of drugs
on the carriers which leads to increased surface area [36]
and (d) methoxy and hydroxypropoxy groups of HPMCwith
carbonyl group of PVP form a hydrogen bonding with the
molecules of drugs, that is, molecular complex formation,
which results in improvement of dissolution of model drugs.
In addition, the other advantage of using HPMC in the
formulation is formation a gel around the particles which
forms a barrier against diffusion of the dissolved drugs into
dissolution medium and hence controls the release [22].
3.4. Kinetics of Drug Release. The in vitro dissolution data
were fitted by various kinetic models; the release constants
and regression coefficients (R2) are shown in Table 3. Among
the models tested, for the first 2 hours, the drug release
profiles for NIF batch A
4
were best fitted by zero-order
kinetics based on the regression coefficient (R2) of 0.9858.
Release of the constant amount of drug in specific time points
characterises zero order kinetics. The zero-order process
indicates that the drug release mechanism is not dependent
on the drug concentration [37, 38]. The Hixson-Crowell
model which plots the cube root of cumulative percentage of
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Figure 1: Physical state of drugs nanosuspensions without mannitol (a) and with mannitol (b).
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Figure 2: Comparison between size and polymer ratio: NIF (a), CBZ (b), and IBU (C) (𝑛 = 3).
drug release versus the time showed an excellent fit for the
batch A
4
of IBU (R2: 0.9984). The Hixson-Crowell kinetics
describes drug release from systems where there is a change
in surface area and diameter of particles [39, 40]. For different
CBZ nanosuspensions, no strong indication of fitting was
observed. R2 value for batches A
2
, A
3
, and A
4
of CBZ was
between 0.6836 and 0.8082.
3.5. Differential Scanning Calorimetry (DSC) Studies.
Figure 5 shows the DSC curves for pure drugs (NIF, CBZ,
and IBU) and drug nanosuspensions with different polymer
content. Pure nifedipine, carbamazepine, and ibuprofen
exhibit a sharp melting endotherm peaks at 174.76∘C,
192.65∘C, and 74.77∘C, respectively, and corresponding to
their melting points and crystalline nature [23]. Figure 5
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Figure 3: In vitro release of NIF (a), IBU (b), and CBZ (c) nanosuspensions in phosphate buffer PH = 7.4 at 37∘C ± 0.5∘C (𝑛 = 3).
shows that formulations with higher concentration of
polymers display lower enthalpy and melting temperature.
The reason for such behaviour is polymers-drug interaction
which prevents drug particles from rearranging within the
polymer network. Figure 5 shows that the drug-free sample
(carrier) prepared by the same method (co-solvent method)
exhibited two broad melting endotherm peaks at 87.74∘C
and 159.74∘C. The endotherm peaks indicate the partial
crystallinity of the carrier. The endotherms peaks of NIF,
CBZ, and IBU nanosuspension formulations are presented
in the Table 4. No endotherm peaks corresponding to the
melting points of pure crystalline nifedipine, carbamazepine,
or ibuprofen were observed. Similar behaviour has been
reported for the triamterene in Gelucire 44/14 and PEG
[41], cinnarizine in Gelucire 53/10 [42], and paracetamol
in PEG 4000 [43]. Hence, the DSC results suggest that
drugs progressively dissolved in the polymer matrix upon
heating during the DSC measurements. Craig [44] has
Journal of Nanomaterials 7
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
Batch
Pure NIF
D
iss
ol
ut
io
n 
(%
)
A1 A2 A3 A4
(a)
70
60
50
40
30
20
10
0
Pure IBU
Batch
D
iss
ol
ut
io
n 
(%
)
A1 A2 A3 A4
(b)
6
5
4
3
2
1
0
D
iss
ol
ut
io
n 
(%
)
Batch
Pure CBZ A1 A2 A3 A4
(c)
Figure 4: Comparison of the dissolution for NIF (a), IBU (b), and CBZ (c) in form of pure drug and nanosuspensions (𝑛 = 3).
Table 3: Kinetic release rate constants and correlation coefficients of various kinetic models (first 2 hours).
Drug Sample label Zero order First order Hixson-Crowell
𝐾
0
𝑅2 𝐾
1
𝑅2 𝐾
2
𝑅2
NIF
A
1
0.0038 0.9500 0.0471 0.9453 0.0068 0.9469
A
2
0.0235 0.9260 0.2001 0.9015 0.0325 0.9099
A
3
0.0195 0.7963 0.0881 0.7847 0.0177 0.7885
A
4
0.0392 0.9858 0.1754 0.9751 0.0353 0.9790
CBZ
A1 0.0045 0.0262 0.0010 0.0263 0.0005 0.0262
A2 0.0214 0.8082 0.0045 0.8076 0.0025 0.8078
A3 0.0064 0.7631 0.0014 0.7630 0.0008 0.7630
A4 0.0171 0.6843 0.0038 0.6836 0.0020 0.6838
IBU
A1 0.5817 0.9195 0.0230 0.9167 0.0220 0.9176
A2 3.7847 0.9115 0.0230 0.9167 0.1531 0.8975
A3 5.9004 0.9240 0.1435 0.9065 0.1614 0.9125
A4 2.0760 0.9978 0.0387 0.9982 0.0475 0.9984
previously suggested that the drug may be dissolved in
the molten polymer, such as PEG, over a wide range of
temperatures. The characteristic DSC peak of the carrier
matrix without endothermic peaks due to drug melting
indicates that the drugs were dissolved in the molten carrier
during the measurements. The DSC and dissolution data
indicate that in the presence of polymers, the drugs were
subsequently transformed into their amorphous ormolecular
forms.
4. Conclusion
The potential of NIF, CBZ, and IBU nanosuspensions for
increasing the dissolution rate and extent was demonstrated.
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Figure 5: DSC thermoghrams of NIF, CBZ, and IBU: pure drug (F), nanosuspension formulations: batch A
1
(E), batch A
2
(D), batch A
3
(C),
batch A
4
(B), and carrier (A) (the spectra are offset in vertical direction for clarification).
Table 4: Heat flow and endothermic peaks of drug formulations
obtained from DSC measurements.
Drug Sample label Heat flow (W/g) Endotherm peaks (∘C)
NIF
A
1
−2.435 155.69
A2 −1.049 and −1.216 88.93 and 160.46
A3 −0.8706 and −1.053 83.45 and 152.11
A4 −0.804 and −0.7874 82.97 and 142.82
CBZ
A
1
−2.473 155.69
A2 −0.867 and −1.765 89.41 and 156.17
A3 −1.298 and −1.125 93.70 and 150.68
A4 −1.152 and −0.8744 97.56 and 143.05
IBP
A
1
−1.69 157.60
A2 −1.082 and −1.404 96.80 and 157.36
A3 −1.318 and −1.024 93.22 and 152.35
A4 −1.115 and −0.8825 98.47 and 145.20
Nanosuspensions were prepared by the cosolvent technique
which is a simple method without the need for any com-
plicated instruments. Due to formation of nanosuspensions,
the dissolution rates of drugs were increased in comparison
with the pure drugs. The results also showed that extent of
dissolution of the drugs from polymer matrix was affected by
changing the drug: polymer (HPMC & PVP) ratio and the
highest dissolution of NIF (0.26%), CBZ (4.56%), and IBU
(55.24%)were observed at the highest concentrations of poly-
mers (batch A
4
). The results of DSC studies demonstrated
that amorphous fractions of model drugs NIF, CBZ, and IBU
increase upon increasing polymer level in the nanosuspen-
sion formulations. The results confirmed that the co-solvent
technique can be used to prepare drug nanosuspensions
using HPMC and PVP as carriers as a means of increasing
the dissolution rates.
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Electrospinning is employed to prepare conductive polypyrrole nanofibers with uniform morphology and good mechanical
strength. Soluble PPy was synthesized with NaDEHS as dopant and then applied to electrospinning with or without PEO as
carrier. The PEO contents had great influence on the morphology and conductivity of the electrospun material. The results of
these experiments will allow us to have a better understanding of PPy electrospun nanofibers and will permit the design of effective
electrodes in the BMIs fields.
1. Introduction
Electrospinning is a broadly applied technology used to
fabricate nanofibers from a wide range of materials including
both natural and synthetic polymers [1]. A high voltage
electrostatic field is used to induce the ejection of a liquid jet
which stretches into continuous fibers in the submicron range
[2].The electrospunmaterial exhibits unique features such as
uniform ultrafine fibers, high surface-to-volume ratio, tun-
able porous structures, and controllable composition,making
it capable to achieve the desired result from its prosperities
and functionality. These qualities allow the materials to be
successfully applied in various fields such as biosensor [3],
tissue engineering scaffold [4], drug delivery [5], wound
dressing [6], and protective clothing [7].
Polypyrrole (PPy) is one of the most widely investigated
conductive polymers due to its easy synthesis, high con-
ductivity, good environmental stability, and biocompatibility
[2]. In the past decades, it has been applied in biosensors
[8], electrodes [9], and especially nerve tissue engineering
scaffolds [10]. For instance, George et al. [11] found that the
PPy film could support the growth of nerve system. Either of
these applications would prefer to have a high surface area
for a given mass or volume, which would provide a large
interface in sensing, to enhance the ions transportation for
electrode or to promote cell growth as the scaffold.This could
be realized using electrospinning to generate PPy nanofibers
with porous structure. It is possible to coat the electrospun
PPy nanofibers on materials like electrodes prior to inserting
them in the brain which can help relieve some damage done
to the tissues as well as provide better results due to the
more positive interaction between the coated electrodes and
the cells. This will be helpful to the development of brain-
machine interfaces (BMIs) biomedical devices.
In the present work, we have developed a way to electro-
spinning PPy solution with carrier into ultrafine fibers. Using
scanning electron microscopy (SEM), Fourier transform-
infrared spectroscopy (FTIR), XPS, and four-probe method,
the morphology, chemical composition, and conductivity of
the nanofibers were examined. The results of these experi-
ments will allow us to have a better understanding of PPy
electrospun nanofibers and will permit the design of effective
electrodes in the BMIs fields.
2. Experimental
2.1. Synthesis of Soluble PPy [12]. Soluble PPywas synthesized
at 0∘C by 0.06mol NaDEHS (Sigma-Aldrich) dissolved in
180mL distilled water as the dopant and 0.12mol Pyrrole
(Sinopharm) added. 0.018mol APS (Xilong Chemical) dis-
solved in 20mL distilled water solely as the oxidant was
slowly added into the NaDEHS solution with vigorous string.
The polymerization was carried out for 24 h at 0∘C and
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Figure 1: FT-IR Spectrum of NaDEHS doped PPy.
terminated by pouring the solution into methanol. The PPy
powder was collected by filtering and was dried at 60∘C for
24 h.
FT-IR (Magna-IR 750, Nicole) and XPS (Axis Ultra,
Kratos) were employed to demonstrate the PPy powder.
2.2. Electrospinning of PPy Fibers. PPy and PEO were dis-
solved in CHCl
3
with the concentration 8wt% and 4wt%,
respectively. PEO and PPy solutions were then mixed with
the ratios of 1 : 10, 1 : 8, 1 : 6, 1 : 4, and 1 : 2. The 8wt% PPy and
PEO/PPy blends were prepared for electrospinning.
Electrospinning was carried out with a 10 kV voltage and
0.8mL/h flow rate. A ground screen covered by aluminum
sheet was placed 10 cm from the tip of the syringe. The
nonwoven fibers were collected and characterized by SEM
(Quanta 200F, FEI).
2.3. Conductivity Characterization. The conductivity of each
sample is measured using the four-probe method. After-
wards, the 1 : 10 ratio PEO/PPy nanofibers was kept in the
30∘C, 40∘C, 50∘C, 60∘C, and 70∘C atmosphere orderly, and
the conductivity at each temperature was recorded.
3. Results
3.1. Synthesis of Soluble PPy. The formation of PPy and the
doping of NaDEHS are confirmed with FT-IR spectroscopy
in the range of 4000–650 cm−1 as shown in Figure 1.The peak
at 905.0 is associated to the out-of-plane vibration of =C–
H; the wide peak at 1166.9 cm−1 is associated with the N–C
stretching; and the peaks at 1373.55 cm−1 and 1026.94 cm−1
are corresponding to the =C–H plan vibration, while the
peak at 1726.67 cm−1 corresponds to the C=O vibration in
NaDEHS.
The XPS analysis is shown in Figure 2 while the quanti-
tative element analysis is in Table 1. The N element is from
PPy, while the presence of S and Na confirmed the doping of
NaDEHS.
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Figure 2: XPS analysis of NaDEHS doped PPy.
Table 1: Quantitative element analysis of NaDEHS doped PPy.
Name Position Area % Conc.
Na 1s 1071.65 2592.8 0.28
S 2p 168.00 6989.5 1.89
N 1s 399.95 16082.2 6.10
O 1s 531.80 67833.9 15.73
C 1s 284.80 116790.6 76.00
3.2. Morphology of PPy Nanofibers. Figure 3 presents the
SEM images of electrospun PEO/PPy nanofibers with dif-
ferent ratios. PPy nanofibers are nonuniform with droplets,
and the material is fragile. When PEO is added, cylindrical
fibers are formed. As the ratio of PEO increases, there are
less droplets and broken ends.The diameter statistics of fibers
of PEO/PPy nanofibers are shown in Figure 4. The fibers
are thinner, and the diameters are more uniform with more
PEO component due to the change of solution viscosity and
surface tension.
3.3. Conductivity. There is a linear relationship between the
conductivity of these nanofibers and the content of PEO as
shown in Figure 5 (𝑅2 = 0.9571). As the content of PEO
varies, the conductivity increased by one-order of magnitude
ranged from 1.44 × 10−3 S⋅cm−1 to 2.45 × 10−4 S⋅cm−1.
By increasing the temperature, we found that the conduc-
tivity of the 1 : 10 ratio PEO/PPy nanofibers rises following the
power function 𝜎 = 𝐴 exp(B/T) (𝑅2 = 0.9939), which is a
typical property of semiconductor.
4. Discussion
These significant characteristic peaks of PPy in the FT-IR
spectrum demonstrate the formation of PPy, while the C=O
liberation peak at 1726.67 cm−1 in FT-IR spectrum and the
S and Na elements in XPS characterization illustrate that
the NaDEHS has been successfully doped into PPy. In the
quantitative element analysis, the ratio of N and S is about
3.2 : 1, suggesting that in the polymer chain the mole ratio
of Py unit and NaDEHS is around 3. As the pure PPy
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powder is insoluble in most solvent due to the strong internal
interactions within and between the chains; the doping of
NaDEHS result in the solubility in CHCl
3
.
The doped PPy solution cannot be preceded into smooth
fibers, and the electrospun web is fragile. To enhance the
electrospinning process, PEO is added as carrier, and the
resulted fibers are much more smooth and ultrafine.
The droplets and broken ends in the fibers are because
of inadequate viscosity, which could be increased by adding
PEO into PPy solution. So the fibers become longer andmore
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Figure 5: Electrical conductivity of PEO/PPy nanofibers as a function of PEO content and 1 : 10 PEO/PPy nanofibers as function of
temperature. (a) Electrical conductivity of PEO/PPy nanofibers as a function of PEO content; (b) electrical conductivity of 1 : 10 PEO/PPy
nanofibers as function of temperature.
uniform as the ratio of PEO and PPy rise. As in the 1 : 2
PEO/PPy electrospun materials, the long nanofibers exhibit
a cylindrical morphology and are randomly distributed in a
uniform and dense way. Since PEO is a flexible material, the
mechanical strength of PEO/PPy nanofibers is improved.
The size of the fibers could also be affected by the ratio of
PEO and PPy. As the viscosity increases, the surface tension,
which the dividing of the jets has to overcome, also increases.
So the splitting ability of the jets declines and results in
thicker fibers. Without the splitting, the diameters of the
fibers exhibit narrower distribution.
Although the electrospinning process is promoted, the
conductivity of the material will reduce and exhibit a liner
relation with the contents of PEO. Pure PPy is semiconductor
because of the delocalized 𝜋 bond, while the presence of PEO
molecular leads to the fold and twist of the conjugated chain,
which would limit the delocalization of electrons. Also, the
conductive PPy content will become discontinuous because
of PEO, which finally reduce the conductivity.
For semiconductor, as the temperature rises, more elec-
trons are activated and transit into conduction band. Mean-
while, the migration rate will also grow with the temperature,
resulting in the better conductivity of the material. In the
study of the 1 : 10 PEO/PPy electrospunmaterial, the conduc-
tivity grows with temperature following the power function,
demonstrating that after adding PEO, the PPy remains to be
semiconductor.
5. Conclusion
In summary, the soluble PPy is synthesized by doping
NaDEHS. The conductive nanofibers web could be fabri-
cated by electrospun PEO/PPy composite. Increase in the
content of PEO will enhance the electrospinning process
and the mechanical strength of the fiber web but meanwhile
reduce the conductivity. Also, the conductivity will increase
as temperature rises following a power function like most
semiconductors. This work shows the potential of applying
electrospun PPy nanofibers to the BMIs fields.
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We report a robust magnetic-membrane-based microfluidic platform for controllable chemical release. The magnetic membrane
was prepared by mixing polydimethylsiloxane (PDMS) and carbonyl-iron nanoparticles together to obtain a flexible thin film.
With combined, simultaneous regulation of magnetic stimulus and mechanical pumping, the desired chemical release rate can
easily be realized. For example, the dose release experimental data was well fitted by a mathematical sigmoidal model, exhibiting
a typical dose-response relationship, which shows promise in providing significant guidance for on-demand drug delivery. To
test the platform’s feasibility, our microfluidic device was employed in an experiment involving Escherichia coli culture under
controlled antibiotic ciprofloxacin exposure, and the expected outcomes were successfully obtained. Our experimental results
indicate that such a microfluidic device, with high accuracy and easy manipulation properties, can legitimately be characterized as
active chemical release system.
1. Introduction
Controllable release describes materials or devices that can
control the release time or the release rate of chemicals or
both.This technique has provided broad usefulness in differ-
ent fields such as foods, cosmetics, pesticides, and agricultural
industries [1, 2], while the most important application is
active drug release [3]. It is well known that how and when
a drug is delivered can have a significant effect on its potency.
Traditional drug-release systems are characterized by imme-
diate and uncontrolled drug-delivery kinetics, such system
is usually referred to as passive drug release. Under such
circumstance, it is possible that a given drug concentration
dangerously approaches its toxic threshold to subsequently
fall below the level with effective potency. From the viewpoint
of the pharmacotherapy optimization, drug release should
be controlled in accordance with the potent purpose and
the pharmacological properties of active substances. This
purpose has given great impetus to the concept known as
active drug release, which first arose in the 1960s. Typically,
controlled or active release is used to achieve sustained or
pulsatile drug release. The rationale is to maintain drug
concentration in the target receptors at a desired value as
long as necessary [4]. What is actively controlled, in other
words, is the drug-release rate and duration [5]. Compared
with conventional dosage protocols, controlled drug release
systems offer numerous advantages such as enhanced efficacy
and reduced toxicity [6].
In recent years, many of the thrusts into the field have
spurred the rapid development of advanced drug-release
systems and made numerous new discoveries. One popular
approach involves incorporation of drug molecules into
the matrix of microscopic polymer spheres or capsules [7,
8]. Most are fabricated with polymers having particular
physical or chemical characteristics, such as good biodegrad-
ability, biocompatibility or sensitive responses to PH value
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[9–11], temperature [12], light intensity [13, 14], external
electric [15] or magnetic field [16], glucose [17], and others.
Additionally, recent achievements in microtechnologies have
been applied in designing drug-release microdevices, for
example, microneedles and implantable microchips [18–
20], which possess inherent advantages such as hand-held
portability, sample saving, and implantable properties. The
aforementioned controlled drug-release systems, moreover,
can circumvent problems that are commonly encountered
in traditional drug-release methods. However, some of these
systems fail to achieve any desired complex release profile
or involve complicated design and fabrication. To address
these problems, we here introduce a novel prototypical
microfluidic controlled-chemical-release platform based on a
magnetic-field-actuated composite membrane which incor-
porates carbonyl-iron nanoparticles for actuation by mag-
netic field. Compared with existing release systems, our
platform possesses such remarkable advantages as simple
fabrication, easy manipulation, and high accuracy. And we
demonstrate the microfluidic chip’s feasibility for the real-
ization of customizable release profiles as well as its general
applicability in the drug release for biological system.
2. Experiments, Results, and Analyses
2.1. Materials. Polydimethylsiloxane (PDMS) was used in
the fabrication of both the microfluidic chip and magnetic
composite membrane due to its good flexibility, biocompati-
bility, and transparency, among other merits. The magnetic
membrane used as the drug-delivery component, consists
of carbonyl-iron (CI) nanoparticles mixed with PDMS, so-
called CI-PDMS [21]. Due to its high magnetization and
good mechanical elasticity, the CI-PDMS magnetic mem-
brane shows good vibration characteristics under an external
alternativemagnetic field [21]. Ciprofloxacin andGFP recom-
binant E. coli bacteria in L-Broth standard growth medium,
one liter of which contains 10 g tryptone, 5 g yeast extract, 10 g
sodium chloride, and 2mL ampicillin solution (100mg/mL),
were employed in the biological experimentation.
2.2. Microfluidic Chip Fabrication. Figure 1(a) schematizes
the three-dimensional microfluidic chip fabrication proce-
dure. It can be seen in the upper-left area of the figure,
premixed PDMS gel (Sylgard 184 Silicone Elastomer, Dow
Corning Corporation; weight ratio of prepolymer : cross-
linker = 10 : 1) wasmixed with CI nanoparticles and degassed,
after which it was spun-coated on a Teflon-treated glass wafer
so as to form thin layers of CI-PDMS. After solidification
in an oven (65∘C, 2 hours), a CI-PDMS membrane of about
100 𝜇m in thickness was fabricated to the desired size using
the laser-cutting technique. The CI-PDMS composite prop-
erties can be found in our previous report [21]. The chamber
layers were patterned directly onto a cured PDMS sheet by
laser cutting, as shown in the upper-right area of Figure 1(a).
The aforementioned layers were bounded together by means
of oxygen plasma bonding. The same steps were repeated for
the fabrication of the diffusion PDMS membrane and the
lower chamber layers. The microfluidic chip shown in the
lower inset of the figure consists of two individual chambers
separated by a diffusionmembrane, while at the bottomof the
chip, a CI-PDMS magnetic membrane is located. It should
be pointed out that other hydrophilic polymer films (e.g.,
MEMBRA-CELMC18 X 100 CLR, Viskase Companies, USA)
also can be used as the diffusion membrane and that the
bonding methodology is similar to that for PDMS thin film.
Figures 1(b)-1(c) show the top and bottom views, respectively,
of a well-made microfluidic chip including five reservoirs,
each one with diameter of 1000 𝜇m and depth of 0.1 cm.
2.3. Working Mechanism of Microfluidic Chip. The experi-
mental setup shown in Figure 2 was used to test the release
characteristics of themicrofluidic chip. In the upper chamber,
water was injected to the full; sodium chloride (NaCl)
solution of 0.5mol/L was pumped to the bottom chamber
with flow rate 0.04mL/h. Two platinum electrodes, mounted
in the upper chamber and connected to a digital multimeter
(Agilent 34411A), were used to determine the solution’s
conductance variationwhen theNaCl diffused from the lower
chamber to the upper one through the diffusion membrane.
An electromagnet positioned directly beneath the CI-PDMS
membrane of the microchip served to actuate membrane
vibration via push-pull movement when acted on by an
alternative current within the 60–110Hz frequency range,
while two syringe pumps controlled the flow status of two
fluids to the two chambers. LabVIEW software was utilized
for device control and data collection.
2.4. Determination of Chemical-Release Profiles. Figure 3(a)
presents the NaCl ion concentration’s variation profiles
resulting from the changes of electrical conductance in the
upper chamber when the solution diffused from the lower
chamber through the membrane. Based on the proportional
relationship between conductance and ion concentration, the
vertical axis is normalized to the original conductance and
represents ion concentration. These profiles can be realized
under different working conditions of the electromagnet and
syringe pump 2 (in the current experiment, syringe pump 1
was used only forwater filling and usuallywas kept in theOFF
state). The ON/OFF signals for both the electromagnet and
syringe pump 2 are illustrated in Figure 3(b). For example,
when syringe pump 2 was ON and the electromagnet was
OFF over the entire working duration, the solution diffused
naturally through the membrane without any actuated func-
tion, the corresponding variation of the NaCl ion concentra-
tion delivery route in the upper chamber is drawn as curve 2.
It can be seen that the magnetic field applied to the magnetic
membrane obviously strengthens the diffusion effect caused
by membrane vibration. NaCl diffused very rapidly initially
and then slowly approached the saturation value. Other
routes could also be obtained by varying theON/OFF states of
electromagnet and syringe pump 2.The demonstrated curves
are plotted in Figure 3(a) and the corresponding actuated
signals are shown in Figure 3(b).
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Figure 1: The preparation of drug delivery microfluidic chip and real pictures: (a) schematical fabrication process; (b) top view of this chip;
(c) bottom view of this chip.
Sigmoidal fitting to the experimental data was carried
out with the following Boltzmann equation of software
OriginPro-8:
𝑦 =
𝐴
1
− 𝐴
2
1 + 𝑒(𝑥−𝑥0)/𝑑𝑥
+ 𝐴
2
, (1)
where 𝑦 represents the ion concentration measured in the
upper chamber, 𝐴
1
and 𝐴
2
are the initial and final values of
the ion concentration, respectively, 𝑥
0
is the inflection point
at which 𝑦 shows the most significant change, and 𝑑𝑥 relates
to the slope of the tangent line at 𝑥
0
. These parameters are
clearly illustrated in the upper-right inset of Figure 3(a).
Since the ion concentration was normalized to 1 as the
maximum, 𝐴
1
and 𝐴
2
in (1) can be fixed to 0 and 1,
respectively. Thus, (1) can be rewritten as
𝑦 =
1
1 + 𝑒−(𝑥−𝑥0)/𝑑𝑥
. (2)
From (2), we can simply obtain 𝑦󸀠(𝑥
0
) = 1/4𝑑𝑥 and
𝑦󸀠󸀠(𝑥
0
) = 0.
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Figure 2: Cross-section view of the microfluidic device.
The first-order derivative of (2) at 𝑥
0
is inversely pro-
portional to the parameter 𝑑𝑥, the smaller value of which
signifies the larger ion concentration changes per unit time.
The inflection point 𝑥
0
marks the time at which the growth
rate of the solution’s diffusion effect of solution shifts from
acceleration to deceleration. Therefore, the second-order
derivative at 𝑥
0
equals zero.
Interpreting the parameters in their biological mean-
ings is helpful in understanding the corresponding drug-
release characteristics. From a pharmacological standpoint,
the 𝑥
0
value can be used to differentiate drug administration
rates, acceleration or deceleration, the steepness factor 𝑑𝑥
representing a most significant response per unit change
in administered dose. Accordingly, these parameters can be
utilized as indicators in evaluating the potency and efficacy
of administrated drugs. If assigning any arbitrary values
to 𝑥
0
and 𝑑𝑥, we can, based on the solution diffusion
results, purposely construct a new delivery route by proper,
simultaneous manipulation of the respective magnetic field
and pumping signals. In this way, active drug release can be
achieved.
Figure 3(a) clearly shows good agreement between the
fitting results from above mathematical model and the
experimental data. Table 1 indicates that the values for 𝑥
0
and 𝑑𝑥 differ from each other for different curves, which
result from the combined regulation of themagnetic field and
mechanical pumping. From the fitted value, we note that 𝑑𝑥
and 𝑥
0
for curve 1 are much smaller than those for curve 2.
Biological Experimentation for Dose-Response Assessment.
The sigmoid-shaped curve in Figure 3(a) represents a typical
dose-response relationship, which is the most fundamental
and pervasive concept in toxicology [22]. Studying dose-
response model is crucial to determine the “safe” and “haz-
ardous” levels and dosages of drugs to which organisms are
exposed. It is known that dose- responses can be elucidated
in cell culture preparations wherein there is a discrete
and controlled pharmacologic environment. Additionally,
Table 1: Fitting parameters for curves 1–5 in Figure 3(a).
Parameter Curve
1 2 3 4 5
𝑥
0
28.85 67.84 140.55 194.07 246.1
𝑑𝑥 16.45 43.42 54.7 27.24 16.98
a comparison of dose-response curves among drugs can
identify both the therapeutic and the toxic effects of the
potential drugs. Thus, given the above experimental results,
we deduced that if we substituted, in a biological experi-
ment, ciprofloxacin solution and growth medium (L-Broth)
for sodium chloride and water, respectively, similar dose-
response consequences could be observed. Ciprofloxacin is a
synthetic chemotherapeutic antibiotic of the fluoroquinolone
drug class [23, 24], while E. coli is a gram-negative rod-
shaped bacterium commonly found in the lower intestine of
warm-blooded organisms (endotherms). Pharmacologically,
ciprofloxacin can inhibit the reproduction and genetic mate-
rial repairment of GFP recombinant E. coli bacteria.
In order to verify our hypothesis and characterize the
established drug-delivery platform for realistic application,
ciprofloxacin was pumped into the lower chamber and GFP
recombinant E. coli bacteria with L-Broth standard growth
medium in the upper compartment. One liter of this medium
contains 10 g tryptone, 5 g yeast extract, 10 g sodium chloride,
and 2mL ampicillin solution (100mg/mL). Similar to the
microfluidic chip shown in Figure 2, the chip used in the
present experiment consisted of five pairs of reservoirs
labeled C1, C2, C3, C4, and C5, respectively. The drug-
delivery routes of ciprofloxacin for C1–C5 were consistent
with curves 1–5 described in Figure 3(a), but the experiment
was carried out for 120min. During the experiment, fluores-
cent images of E. coli in the chip reservoirs were taken by
a Canon camera (EOS 5D, Mark II) equipped with a macro
lens.
We extracted the average light intensity from each optical
image using Adobe Photoshop software, and the results are
illustrated in Figure 4, where it is evident that in chamber C5,
the E. coli grew andmultiplied very well.The intensity of fluo-
rescence doubled every 20min during the first one and a half
hours, since initially less drug amount was diffused to the cell
chamber. Thereafter, the growth rate decreased somewhat.
The reason lies in the limitation of L-Broth growth medium;
that is, it becomes deficient after one-hour cell culture;
consequently, the drug effect increased more rapidly. With
regard to chamber C1, at first the ciprofloxacin concentration
reached a high level, prevented cells from reproduction, and
in that way maintained the cell concentration at a relatively
low level during the 2-hour experiment. As for chamber C4,
at the very outset the ciprofloxacin concentration was low
enough not to cause much effect, and so the cells grew very
well. However, after one hour, more and more drug diffused
from the lower chamber through the diffusion membrane
to the upper one. This highly concentrated ciprofloxacin
successfully inhibited cell reproduction and genetic material
repairmen. As a result, the cells in chamber C4 multiplied
little during the last 20min of the experiment. From this
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Figure 4: Antibacterial property of loaded fluoroquinolone
ciprofloxacin in E. coli. The drug delivery routes of ciprofloxacin
to E. coli chambers C1–C5 correspond to curves 1–5 shown in
Figure 3(a), respectively. The column bars indicate the fluorescent
intensity in each chamber which reflects the rough number of
bacterial inside.
experiment on the antimicrobial effect, we can conclude
that E. coli is capable of enhancing its drug resistance when
ciprofloxacin increases slowly at the initial stage, even though
the final dose is the same. These results agree very well with
the normalized diffusion profiles in Figure 3(a).That is to say,
the drug-delivery profiles indicate that treatment doses and
duration times can be modulated for the desired task.
3. Conclusions
By utilizing magnetic nanoparticles, we successfully demon-
strated amicrodevice for chemical release.This kind of device
has numerous potential advantages, such as being simple to
fabricate and operate, high precision in chemical release, and
low cost. The present research explicated the formulaic dose-
response drug-release property based on the magnetically
actuatedmembrane.The active functionality of amicrofluidic
device, all of its processing digitized via actuated signals, was
demonstrated in an investigation of the antibacterial property
of loaded fluoroquinoloneCiprofloxacin in E. coli.The results
clearly indicated the device’s potential to control dosage at
a satisfactory level, thereby illustrating the promise of such
a controlled drug-release method. Specifically, by changing
the size of the drug reservoir, the amount of medication can
be accurately controlled; hence, a variety of drugs, especially
sensitive or highly potent drugs, potentially can be delivered
in a safe manner using the microdevice.
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Silica nanoparticles are being developed and tested vigorously in drug delivery systems to treat various diseases. There are many
advantages of using silica nanoparticles as a nanodelivery system because they are relatively inexpensive to produce, chemically
inert, thermally stable and can be tailored to contain porous structures for drug encapsulation and to be hydrophilic for higher
solubility in the human body. Despite these tremendous benefits, one of the pivotal requirements of these drug delivery systems is
to be biocompatible with the human body. In this study, the cytotoxicity of colloidal amorphous silica nanoparticles synthesized
using the micelle formation method has been tested against normal human foreskin fibroblast cell line (Hs27) as well as selected
human bone carcinoma (U-2 OS), human breast cancer (MCF-7), and human cervical carcinoma (HeLa) and (Ca Ski) cell lines to
determine the IC50 values. Two different sizes of silica nanoparticles, 20 nm and 40 nm, were used to study the relationship between
their size and the level of toxicity exerted on the different cells being tested.The cytotoxicity results indicated that 20 nm and 40 nm
silica nanoparticles significantly reduce cell viability in a dose- and cell-type-dependent manner in the normal and cancerous cells
tested.
1. Introduction
Nanomedicine is the application of nanotechnology or nano-
materials in the healthcare field. Nanomedicine as an evo-
lution of the modern medicine has provided a different
paradigm in the way the modern medical practitioners can
approach or treat various illness or disorders. Nanomedicine
has offered various tools to lift the limitations that have
existed in the conventional medicine, hence ensuring higher
success in the treatment and diagnosis of disease. One of the
tools of nanomedicine being widely applied is nanodelivery
systems to carry drugs into the human body [1, 2]. There
are various benefits of employing nanodelivery systems for
drug delivery purposes. For instance, by reducing the size of
the drugs into nanosized formulations, the drug dissolution
rate can be increased, thereby improving the drug absorption
and bioavailability in the body. Apart from that, drugs can
be delivered at the desired site of action in the human
body, thereby improving the therapeutic index of the drugs
by increasing their efficiency and reducing their toxicity.
For example, chemotherapeutic drugs administered at high
dosages in the human body to destroy tumor cells can
inadvertently destroy the surrounding healthy tissues or cells
as well, thereby eliciting unwanted ill effects. Another major
advantage of employing nanoparticle to deliver drugs is to
provide protection for easily degraded or short half-life drugs,
such as small peptides and nucleic acids to prolong the
pharmacological effects.
Nanomaterials, engineered or synthesized for the pur-
pose of delivering the drugs, are the major component of the
drug delivery system which may ensure its success or failure.
Nanomaterials used in nanodelivery systems can exist in
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various forms and types. Nanoparticles are a subset of nano-
materials which can be tailored for specific usage depending
on the material and method of synthesis. Silica nanoparticle
is a type of nanoparticle that is being developed and tested
vigorously in drug delivery systems to treat various diseases
[3–6].There aremany advantages of using silica nanoparticles
as a nanodelivery system because they are relatively inex-
pensive to produce, chemically inert, and thermally stable.
Apart from that, depending on the methods used to produce
the silica nanoparticles, it can be tailored to contain porous
structures for drug encapsulation and to be hydrophilic for
higher solubility and stability in the human body.
Despite these tremendous benefits, one of the pivotal
requirements of these drug delivery systems is to be biocom-
patible with the human body. Hence the nanoparticles used
as a drug delivery system must be preferably nontoxic and
must not elicit the body’s natural immune responses at the
doses administered. In other words, the nanoparticles should
be considerably inert and any form of toxicity elicited at the
intended target site, tissues, or cells should be solely due to
the action of the drug molecules alone. This is important
because if the nanoparticles exhibit high levels of toxicity, it
will damage or kill healthy cells along with the diseased cells,
and, by eliciting the body’s natural immune responses, the
nanoparticles will be effectively cleared by the macrophages
in the circulation system before reaching the intended target.
Therefore, preliminary studies must be conducted on the
biocompatibility or cytotoxic potential of the nanoparticles
on human tissues or cells as a basic prerequisite before it can
be deemed to be utilized as a drug delivery system.
The cytotoxic potential of the nanoparticles can bemainly
attributed to its physicochemical properties such as its size,
shape, chemical purity, surface chemistry, and colloidal
stability [7]. Much research has been done to relate the
physicochemical properties of nanoparticles to their cytotox-
icity. Because each type of nanoparticles has its own distinct
physicochemical features, the toxic effects exerted on the cells
may also vary. Some of the toxic effects are irreversible and
permanent, leading to cell deaths and some are reversible;
after the exposures to nanoparticles are removed, the cells
may begin to proliferate normally. The mechanism of action
that leads to the cells deaths may also be different. The toxic
effect of the nanoparticles can bemeasured using in vitro cell-
based assays [8].
In this study, the cytotoxicity of colloidal amorphous
silica nanoparticles synthesized using the micelle formation
method has been tested against normal human foreskin
fibroblast cell line (Hs27) as well as selected human bone
carcinoma (U-2 OS), human breast cancer (MCF-7), and
human cervical carcinoma (HeLa) and (Ca Ski) cell lines to
determine the IC50 values. Different sizes of silica nanopar-
ticles were used to study the relationship between its size and
the level of toxicity exerted on the different cells being tested.
2. Materials and Methods
2.1. Materials for Colloidal Silica Nanoparticles Synthesis.
Vinyltrimethoxysilane (98%) and Tween 80 were purchased
from Sigma Aldrich. 2-Butanol, ammonia 35%, and dialysis
tubing (12–14KDa) were obtained from Fisher Scientific.
2.2. Synthesis and Characterization of Colloidal Silica Nano-
particles. Silica nanocolloids spheres were prepared by
micelle formation approach, where Tween 80 anionic surfac-
tant was introduced in the presence of water (solvent) and
butanol (cosolvent), and ammonium was added to adjust the
pH. Typical preparation involved rapid mixing of reagents
under vigorous stirring at room temperature of 24∘C. The
mixture was then transferred into a preheated reactor. After
an hour, vinyltrimethoxysilane (Si precursor) was added.The
effect of Si precursor amount, butanol amount, and reaction
temperature on the formation and size distribution of silica
was studied. The mixture usually began to turn to a turbid
white in about 5–15min, as silica nanoparticles were formed.
The mixture was left overnight with a continuous stirring
rate of 320 rpm. The silica nanocolloids produced were then
subjected to dialysis process for 4-5 days using dialysis tubing
12–14KDa to remove the surfactant.
To investigate the relationship between the physicochem-
ical properties and toxicities, characterization of the silica
nanoparticles was performed using transmission electron
microscopy (TEM), X-ray diffractometer (XRD), dynamic
light-scattering (DLS) methods, and NIR-UV-Vis spec-
trophotometer, which provided information on the nanopar-
ticles morphology, crystallinity, size distribution, and con-
centrations, respectively.
To investigate themorphology and size distribution of the
silica nanoparticles, a drop of the particle suspension in the
test medium was dried on a carbon-coated 200 mesh copper
grid and imaged with a transmission electron microscope
(Model FEI CM12 version 3.2 image analysis systems 120 kV).
The images from TEM were analyzed using ImageJ software
whereby 100 particles were measured. For X-ray diffraction
(XRD) analysis, the samples were dried in an oven at
120∘C overnight. XRD analysis was performed using CuK𝛼
radiation from 5–90∘ (Bruker AXS D8) to determine the
crystallinity of silica nanoparticles.The images were analyzed
with EVA software. Particles size distribution was evaluated
using Zetasizer (Model ZEN 3600, Nanoseries, Malvern
Instruments). The concentration of silica nanoparticles was
measured by using UV-Visible near infrared spectropho-
tometer (UV-Vis 3600, Shimadzu), with absorbance value
taken at peak of 233 nm.
2.3. Human Normal and Cancer Cell Lines and Reagents.
U-2 OS (HTB-96) human osteosarcoma, MCF-7 (HTB-22)
human breast adenocarcinoma, HeLa (CCL-2) human cer-
vical cancer, Ca Ski (CRL-1550) human cervical cancer, and
Hs27 (CRL 1634) human foreskin fibroblast cell lines were
all obtained from the American Type Culture Collection
(ATCC), USA. The growth media: McCoy’s 5a medium,
Dulbecco’s Modified Eagle Medium (DMEM), DMEM/F12
medium, RPMI 1640 medium, fetal bovine Serum (FBS),
penicillin-streptomycin, and trypsin were obtained from
Invitrogen, USA.The phosphate buffer solution (PBS) tablets
were obtained from AMRESCO, USA. The cell proliferation
reagent (WST-1) was obtained from Roche, USA.
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2.3.1. Cell Culture. MCF-7, HeLa, and Hs27 cells were main-
tained in DMEM. U-2 OS cells were maintained in McCoy’s
5a medium. Ca Ski cells were maintained in RPMI 1640
medium.The cells were cultured in the appropriate medium,
supplemented with 5–10% fetal bovine serum and 1%
penicillin-streptomycin, using 25 cm2 flasks in a 37∘C incu-
bator with 5% CO
2
in humidified incubator.
2.3.2. Cell Subculture. To subculture the cells, the cells were
divided and the culture medium was replaced with fresh
medium as follows. First, the old medium was removed, and
then the cells were rinsed briefly with PBS to wash the cells.
One to twomL of trypsin was then added, and the flask
was incubated at 37∘C and 5% CO
2
for 5 minutes. After the
cells had detached from the lower part of the flask, 20mL of
medium was added to the flask and the culture was divided
in to two parts. One part was then transferred to a new flask.
2.4. Cell Proliferation Assay. The cells were grown until they
were confluent. Then, the cells were trypsinised and the
number of viable cells was counted with a hemocytometer to
prepare a cell suspension. Two hundred microlitres of sus-
pension containing 1 × 104 cells was seeded in each well of a
96-well microtiter plate (BD, USA) and incubated overnight
at 37∘C with 5% CO
2.
In the following day, the medium was
replaced and the cells were treated with silica nanoparticles
with varying concentrations and maintained at 37∘C with
5% CO
2
for 24–72 hours. After the incubation period, the
old medium was discarded from the wells and rinsed with
PBS before adding fresh culture medium with a final volume
of 100𝜇L per well. Then, 10 𝜇L of WST-1, cell proliferation
reagent, was added to each well.Themicrotiter plate was then
incubated again for 2 hours at 37∘C with 5% CO
2
. After the
incubation period, the cell viability was measured using an
ELISA reader (Multiskan Spectrum) at 450 nm.
2.5. Statistical Analysis. The experiment was carried out in
three replicates. Microsoft Excel templates were used for the
collection of raw data and transformation of the data to the
proper format for GraphPad Prism 5.0 software. Prism was
used to calculate the concentrations associated with 50%
viability (IC50 values) with 95% confidence limits using aHill
function nonlinear regression analysis.
3. Results and Discussion
3.1. Synthesis and Characterization of Silica Nanoparticles. In
this study, we synthesized colloidal amorphous silica nano-
particles of two different sizes for drug delivery purposes
using the micelle formation method. Primarily, silica can be
present in two forms, crystalline and amorphous.We selected
amorphous form of silica because it has higher solubility
in water as opposed to crystalline form of silica which has
very low water solubility [9]. The solubility of amorphous
silica in water at body pH is normally around 130–150 ppm
(𝜇g/mL) [10]. Apart from that, amorphous silica can dissolve
into body fluid as silicic acid and is then removed through
urine [11, 12]. The micelle formation method was used to
synthesize the silica nanoparticles because it produces more
homogenous particle size distribution and can directly entrap
drugmolecules insidemicelles structure before forming silica
nanoparticles. Schematic diagram in Figure 1 illustrates the
formations of silica nanoparticles using micelle formation
approach. Silica nanoparticles formdue to hydrolysis, alcohol
condensation, and water condensation. Hydrolysis occurs
when Si precursor, organosilanes reacts with water and 2-
butanol in the aqueous solvent and forms siloxane bridge
(1). Hydrolysis process is enhanced with the addition of
ammonia by producing more hydroxyl ions (OH−) to react
with organosilanes. For alcohol and water condensations,
silanols react with each other to form crosslinking between
Si–O–Si chains until all Si precursors reacted (equations (2)
and, see (3) [13, 14]):
hydrolysis:
Si(OR)
4
+ 𝑛H
2
O 󳨀→ Si(OR)
4
− 𝑛(OH)
𝑛
+ 𝑛ROH (1)
alcohol condensation:
Si–OR +HO–Si 󳨀→ Si–O–Si + ROH (2)
water condensation:
Si–OH +HO − Si 󳨀→ Si–O–Si +H
2
O (3)
Both kinds of silica nanoparticles were observed to be
spherical in shape under TEM as shown in Figure 2, with
average size of 20 nm ± 3.5 nm and 40 nm ± 4.6 nm, analyzed
using Image J software whereby 100 particles were measured.
The X-ray diffraction patterns of the silica nanoparticles are
shown in Figure 3. XRD diffractogram shows that a broad
peak is present at 2 theta = 10–30∘ for both the silica nanopar-
ticles, verifying it to be of amorphous structure. Particle size
distributions for the 20 nm and 40 nm silica nanoparticles
are shown in Figures 4(a) and 4(b), respectively. The Z-
average hydrodynamic diameter and polydispersity index of
the silica nanoparticles were measured by dynamic light-
scattering techniques to determine the particle size distri-
butions. The Z-average value and polydispersity index (PdI)
value for 20 nm silica nanoparticles are 47.80 nm and 0.099,
respectively. The Z-average value and polydispersity index
(PdI) value for 40 nm silica nanoparticles are 64.45 nm and
0.097, respectively. The Z-average value for both the silica
nanoparticles is larger compared to the primary diameter
as determined by TEM. This is because the Z-average is a
hydrodynamic parameter and is usually affected by surface
charge of the particles as the samples were measured in its
colloidal form whereas TEM measurements of the samples
were taken in dry conditions. The graphs in Figures 4(a)
and 4(b) which exhibit narrow particle size distributions
about an average value and a polydispersity index value of
<0.100 for both the silica nanoparticles indicate that the
particles are monodispersed. Monodisperse suspensions of
nanoparticles contain particles of nearly the same size and
are better suited for studying size-dependent toxic effects as
opposed to using polydispersed suspensions of nanoparticles
which may mask size effects. The concentration of silica
nanoparticles was measured in absorbance (OD) taken at
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Figure 1: Formation of silica nanoparticles using micelle formation method.
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Figure 2: TEM images and histograms of particle size distribution from TEM analysis.
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Figure 3: XRD patterns of colloidal amorphous silica nanoparticles.
a peak value of 233 nm by using UV-Visible near infrared
spectrophotometer. The optical properties of silica nanopar-
ticles are caused by surface defects related to large surface
to volume ratio [15]. These structural defects are classified
into paramagnetic and nonparamagnetic defects, which can
be characterized by optical absorption in a broad range of
wavelengths: near-infrared, visible, and ultraviolet (UV) [16].
A single absorption band was observed at 233 nm (∼5 eV)
during photometric scanning of both the silica nanoparticles
in the UV range as shown in Figure 5.This optical absorption
band at 5 eV is one of the oldest known nonparamagnetic
defects in amorphous silica and also known as the “𝐵
2
band.” This band is attributed to occur due to some form of
oxygen deficiency in the silica network [17, 18].Therefore, we
were able to validate that the optical absorption exhibited at
233 nm was due to silica nanoparticles, hence rationalizing
our method of measuring the concentration of colloidal
silica nanoparticles in this manner. The absorbance values
at peak 233 nm for 20 nm and 40 nm silica nanoparticles
are tabulated in Table 2. From Figure 6, it can be seen that
the intensity of the peak for 40 nm silica nanoparticles is
slightly higher than 20 nm silica nanoparticles suggesting that
bigger particles have higher UV absorption. Similar findings
were reported by Rahman and coworkers who carried out
experiments on size-dependent physicochemical and optical
properties of silica nanoparticles. They have observed that
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Figure 4: Particle size distribution of (a) 20 nm silica nanoparticles and (b) 40 nm silica nanoparticles.
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Figure 5: Optical absorption of 20 nm and 40 nm silica nanoparti-
cles in UV range.
the intensity of the peak slightly decreases as the sizes of silica
particles decrease and attributed their findings to the intense
interparticle interactions at smaller particle size, that is,
aggregation phenomena which could decrease the exposure
of the E centers present at the silica surface to the UV light
source [19].
3.2. Acute Cytotoxicity. To study the cytotoxic effect of the
20 nm and 40 nm colloidal amorphous silica nanoparticles
against the selected normal and cancerous human cell lines,
WST-1 assay was used to measure the amount of cell viability.
The cell lines used for this study are Hs27, U-2 OS, MCF-
7, HeLa, and Ca Ski. All the cell lines were exposed to the
silica nanoparticles for a period of 24 h to measure the acute
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Figure 6: Cell viability assay for silica nanoparticles on U-2 OS cell
line. The cell line was treated with 20 nm and 40 nm silica nanopar-
ticles for 24 h with IC
50
of 0.011 OD and 0.015 OD, respectively.
cytotoxicity. Since the particles were produced in colloidal
form, the concentration of the silica nanoparticles were mea-
sured in absorbance (OD) taken at a peak value of 233 nm.
Subsequently we have used the absorbance (OD) as a unit
of particle mass concentration to perform the cytotoxicity
testing with concentrations ranging from 1 to 0.002 OD. The
results for the IC50 are also presented in absorbance (OD).
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Table 1: List of IC50 based on the size of nanoparticles and the cells
tested.
Cell lines Size of nanoparticles (nm) IC50 (absorbance OD)
U-2 OS 20 0.01118
40 0.01555
MCF-7 20 0.05408
40 0.07288
Hs27 20 0.01967
40 0.01438
HeLa 20 0.09516
40 0.08063
Ca Ski 20 0.03821
40 0.02447
Table 2: Absorbance values (OD) of 20 nm and 40 nm silica nano-
particles.
Blank silica NPs
colloids (nm)
Absorbance value
at peak 233 nm
(OD)
Absorbance value at peak
233 × dilution factor 100
(OD)
20 2.028 202.8
40 2.713 271.3
In our effort to correlate the effect of size of the silica
nanoparticles to its cytotoxic potential, we have tried to stan-
dardize and control all the other physicochemical parameters
that may exist between the different-sized nanoparticles used
in this experiment as discussed in the characterization of
nanoparticles section. To minimize variability in production
process the same batch of synthesized silica nanoparticles
was used to perform the cytotoxicity assays. Preliminary
steps were taken to evaluate the suitability of using WST-
1-based assay in this study by measuring the interference
of silica nanoparticles on WST-1 reagents and its reaction
products for all the cell lines at the similar concentrations
of silica nanoparticles used for the cytotoxicity assay before
proceeding with the experiment. Also, appropriate blanks
and controls were included when performing cytotoxicity
assays. Hence, any interference that may exist during cyto-
toxicity testing attributable to factors other than size of the
nanoparticles can be safely ruled out.
The acute cytotoxicity of the silica nanoparticles is pre-
sented as a percentage of the cell viability versus concen-
tration in Figures 6 to 10. The IC50 values were calculated
from the graphs to determine the concentration of the
silica nanoparticles needed to inhibit 50% of the cells from
proliferating. Table 1 presents the IC50 values of the silica
nanoparticles. In this study, the silica nanoparticles have been
proven to inhibit the proliferation of both the normal and
cancer cell lines that were tested in a dose-dependentmanner.
This is evident: as the concentration of silica nanoparticles
increases, the percentage viability of the cells decreases for
all the cell lines tested as shown in Figures 6 to 10. Thus,
our results are in general agreement with previously reported
studies on the dose-dependent cytotoxicity of amorphous
silica nanoparticles [20, 21].The results also reveal differences
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Figure 7: Cell viability assay for silica nanoparticles on MCF-7 cell
line. The cell line was treated with 20 nm and 40 nm silica nanopar-
ticles for 24 h with IC
50
of 0.054 OD and 0.072 OD, respectively.
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Figure 8: Cell viability assay for silica nanoparticles on Ca Ski cell
line. The cell line was treated with 20 nm and 40 nm silica nanopar-
ticles for 24 h with IC
50
of 0.038 OD and 0.024 OD, respectively.
in the responses among the five cell lines tested. Based on the
results obtained, 20 nm nanoparticles were shown to bemore
toxic compared to 40 nm sized nanoparticles in U-2 OS and
MCF-7 cell lines as shown in Figures 6 and 7, respectively.
However, in both the human cervical cancer cell lines tested,
Ca Ski andHeLa, as well as on Hs27 cell line, 40 nm nanopar-
ticles were shown to be more toxic compared to 20 nm sized
nanoparticles as shown in Figures 8, 9 and 10, respectively.
Thus, our data indicate that the size of silica nanoparticles
does not relate to its cytotoxicity in a straightforwardmanner.
In fact studies based on the size-dependent cytotoxicity of
amorphous silica nanoparticles have produced contradictory
Journal of Nanomaterials 7
40nm
20nm
0
50
100
150
Absorbance (OD)
C
el
l v
ia
bi
lit
y 
(%
)
−50
10−2 10−1 100 101
Figure 9: Cell viability assay for silica nanoparticles on HeLa cell
line. The cell line was treated with 20 nm and 40 nm silica nanopar-
ticles for 24 h with IC
50
of 0.095 OD and 0.081 OD, respectively.
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Figure 10: Cell viability assay for silica nanoparticles on Hs27 cell
line. The cell line was treated with 20 nm and 40 nm silica nanopar-
ticles for 24 h with IC
50
of 0.019 OD and 0.014 OD, respectively.
results. For example, several independent researchers have
found that smaller-sized silica nanoparticles induced severe
cellular damage in lung cancer cells, myocardial cells, and
human endothelial cells [20–22]. This was attributed to the
fact that smaller nanoparticles have larger ratio of surface area
to weight, leading to more contact with the cells to induce
damage [23–25]. This may explain our current findings of
higher toxicity induced by 20 nm particles on MCF-7 and
U-2 OS cell lines. On the other hand, some researchers
have found that bigger-sized silica nanoparticles may exert
higher toxicity against the cells tested. For instance, Lu and
coworkers have reported that 20 nm silica nanoparticles are
more cytotoxic than 7 nm particles on human hepatoma cells
[26]. One possible explanation could be the protein corona
formation on the surface of silica nanoparticles that may
alter the cytotoxic potential of the nanoparticles. It has
been established by numerous in vitro studies that vari-
ous nanoparticles are able to adsorb serum proteins from
tissue culture media, which affected the toxicity of the
nanoparticles [27, 28]. Tenzer and coworkers have reported
particle-size-dependent binding of several proteins involved
in blood coagulation [29]. They studied the long-lived blood
plasma-derived corona on monodispersed amorphous silica
nanoparticles differing in size and observed that the type of
nanoparticle corona formation is significant even if the size
of the particles only differs in 10 nm. Therefore it is possible
that the type of protein corona formed on the 40 nm silica
nanoparticles is significantly different from the one formed
on 20 nm silica nanoparticles, thus rendering it to be more
cytotoxic to Ca Ski, HeLa, and Hs27 cell lines. Since our
results do not support size-dependent toxicity on the cell
lines tested, the only other probable reason we could infer
is that toxicity of silica nanoparticles is cell type dependent.
Plausible explanation for this can bemade on the basis that as
different cell types have different physiological function, their
interaction with nanoparticles can also differ considerably.
These results are in line with those of Yu and coworkers, who
demonstrated that the ability of silica nanoparticles to inhibit
cell proliferation of macrophages and lung carcinoma cells
was cell type dependent [30]. Similar findings were reported
by kroll and coworkers who performed cytotoxicity screening
of 23 engineered nanomaterials using a test matrix of ten
cell lines and three different assays [31]. Their findings have
suggested that even when assessing nanomaterials toxicity to
cells originating from the same organ, the outcome highly
depends on the cell type used and attributed the occurrence
to sensitivity of cell lines.
4. Conclusion
The aim of this study was to assess the cytotoxic responses
of five different human cell lines exposed to two different-
sized monodispersed amorphous silica nanoparticles. In
conclusion, we have demonstrated that 20 nm and 40 nm
silica nanoparticles significantly reduce cell viability in a
dose- and cell type-dependent manner in the normal and
cancerous cells tested. Therefore, more research is necessary
to investigate the underlying mechanisms of the cytotoxic
effects of silica nanoparticles before they can be used in drug
delivery and controlled release applications.
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Some polymeric additives were studied to understand their effects on the amorphous phase of ibuprofen (IBU), used as a poorly
water soluble pharmaceutical model compound.The amorphous IBU in bulk, as well as in nanopores (diameter ∼24 nm) of anodic
aluminum oxide, was examined with the addition of poly(acrylic acid), poly(N-vinyl pyrrolidone), or poly(4-vinylphenol). Results
of bulk crystallization showed that they were effective in limiting the crystal growth, while the nucleation of the crystalline phase
in contact with water was nearly instantaneous in all cases. Poly(N-vinyl pyrrolidone), the most effective additive, was in specific
interaction with IBU, as revealed by IR spectroscopy.The addition of the polymers was combined with the nanoscopic confinement
to further stabilize the amorphous phase. Still, the IBU with addition of polymeric additives showed sustained release behavior.
The current study suggested that the inhibition of the crystal nucleation was probably the most important factor to stabilize the
amorphous phase and fully harness its high solubility.
1. Introduction
Enhancing the bioavailability of active pharmaceutical ingre-
dients (APIs) is becoming increasingly important because of
themounting problem of their sparing solubility.The solubil-
ity problem has escalated in the recently developed APIs, as it
occurs in about 60% of them [1]. To overcome this problem,
the enhancement of bioavailability is realized by the increase
of the dissolution rate. In the dissolution rate, the importance
of the surface area (𝐴) and solubility (𝐶
𝑠
) is well recognized,
for example, from the Noyes-Whitney equation: (dissolution
rate) = 𝑘
𝑑
𝐴(𝐶
𝑠
−𝐶
𝑏
), where 𝑘
𝑑
is the rate constant and𝐶
𝑏
is the
bulk concentration [2–4].
The increase of the surface area has been investigated
through nanoformulation. Nanocrystals of the poorly soluble
APIs as well as polymeric nanoparticles containing the APIs
have been extensively studied in the recent years [5, 6]. Also,
the increase of the solubility has been explored by changing
the intermolecular interactions of the APIs. Amorphous
phases, cocrystals, and polymorphs are some of the represen-
tative examples [7–9].
We have previously reported the formation of an amor-
phous API through the confinement within nanoporous
anodic aluminum oxide (AAO) using ibuprofen (IBU) as a
model API [10]. In the case of IBU, the kinetically stabilized
amorphous phase rapidly changed into a crystalline form
during the release experiment, as was similarly observed
in the amorphous IBU stabilized within polymer matrices
(IBU/polymer = ca. 20 : 80) [11, 12]. These results suggested
that the stability of the amorphous phase in contact with
water would be the key component to successfully utilize the
high solubility of the amorphous phase [13]. In addition, the
crystallization of IBU is implicated in the possibly damaging
effects on the stomach membrane [12]. In the present study,
some polymeric additives (IBU/polymer = 90 : 10) were tested
in their ability to stabilize the amorphous phase in bulk, as
well as in nanopores (diameter ∼24 nm) of anodic aluminum
oxide.
2. Materials and Methods
2.1. Fabrication of AAOwith Nanopores. AAOs with nanopo-
res were prepared from the Al foil (99.999%, Goodfellow;
thickness 0.5mm) through the two-step anodization tech-
nique [10, 14, 15]. Before anodization, Al was electropolished
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Figure 1: Chemical structures of (a) ibuprofen (IBU), (b) poly(acrylic acid) (PAA), (c) poly(N-vinyl pyrrolidone) (PVP), and (d) poly(4-vinyl
phenol) (PVPh).
in a perchloric acid/ethanol (1 : 4 by volume) solution for
10min (4∘C, 20V) to reduce surface roughness. Perchloric
acid (60%) was purchased from Sigma-Aldrich (ACS grade),
and ethanol was from Daejung Chemicals and Metals (extra
pure grade; Siheung, Korea).
First anodization was performed in 0.3M sulfuric acid
(aq) for 12 h (4∘C, 25V).Then, the anodized alumina layers on
both sides of Alwere removed in chromic acid (aq) (18 gCrO
3
and 40.4mL phosphoric acid in 1 L water) for 3 h (65∘C),
after which well-ordered dimples were made on Al surfaces.
Second anodization on the dimpled Al was conducted in
0.3M sulfuric acid (aq) for 24 h (4∘C, 25V) to obtain AAO
with nanopores. The one side of the AAO substrate was
masked with a teflon tape, and the alumina on the other side
was removed in 5wt% NaOH (aq). This was followed by the
removal of the remaining Al in cupric acid (aq) (17 g CuCl
2
in 500mLHCl (aq) and 500mL water) to finally obtain AAO
substrates with nanopores.The average diameter of the nano-
poreswas calculated bymeasuring about 240 pores fromSEM
micrographs (JSM-6701F, JEOL). Sulfuric acid (95–98%) and
phosphoric acid (>85%) were purchased from Sigma-Aldrich
(ACS grade). Sodium hydroxide, hydrochloric acid (35–
37%), and copper(II) chloride were obtained from Daejung
Chemicals and Metals (extra pure grade; Siheung, Korea).
Chromium trioxide (99.5%) was from Acros.
2.2. Solidification of IBU/Polymers in AAO and Their Release
Behavior. Ibuprofen (IBU, purity > 98%) was purchased
from Sigma. Poly(acrylic acid) (PAA, 𝑀
𝑤
1,800 g/mol) and
poly(N-vinyl pyrrolidone) (PVP, 𝑀
𝑤
10,000 g/mol) were
from Sigma-Aldrich. Poly(4-vinyl phenol) (PVPh, 𝑀
𝑤
10,000 g/mol)was obtained fromPolysciences, Inc. (Warring-
ton, PA). Structures of the polymers are shown in Figure 1.
IBU and each polymer (9 : 1 by weight) were well mixed
for 30min using a ball mill (MM200, Retsch; frequency 5Hz,
two stainless steel balls of diameter 9mm).Themixed powder
(ca. 1mg) was then placed on the AAO substrate, and it
was melted at 130–165∘C using a temperature controlled hot
plate (HS180, Misung Scientific Co., Seoul, Korea). The melt
filled the nanopores by the capillary force assisted by a slight
mechanical force (pushed through a polyimide (DuPont)
film). The external surfaces of AAO substrates were carefully
cleaned using cotton swabs for any residual material; the
absence of which was microscopically confirmed afterwards.
The amount of material filled in the AAO was measured
by weight (CP225D, Sartorius). Then, the infused AAO sub-
strates were placed in the cells of differential scanning calo-
rimeter (DSC: 821e, Mettler-Toledo) and precalibrated using
indium for enthalpy and temperature. Thermal treatment in
DSC was performed by cyclic heating and cooling (2 times)
from 25∘C to 130–150∘C (heating and cooling rates at 10 and
20∘C/min, resp.). Also, the same experiment was performed
on neat IBU.
After the thermal treatment in DSC, the AAO samples
were immediately used for the release test at room temper-
ature (20–24∘C). Each sample was immersed in deionized
water (2mL in a quartz UV cell, pH∼6), and the IBU release
was monitored by measuring the UV absorbance at 214 nm
using a UV/Vis spectrophotometer (Agilent 8453, Agilent).
The wavelength was selected for the maximum UV absorb-
ance for IBU, and the IBU concentration was calculated from
the absorbance using a preconstructed calibration curve.The
UV cell was covered with a paraffin film to prevent any water
evaporation during the measurements. Deionized water
(resistivity > 18.2MΩ-cm) was obtained from a Direct-Q
(Millipore). The release experiments were independently
repeated three times.
2.3. Optical Microscopy and Fourier Transform Infrared Spec-
troscopy. The effect of polymers on the crystallization of IBU
was studied using optical microscopy (OM: BX51, Olympus).
Ball-milled samples of IBU and IBU/polymers (3–5mg) were
placed on glass slides and shielded with cover glass. They
were melted at 140–165∘C for 10min using a hot stage (FP90,
Mettler-Toledo).The melt was withdrawn from the hot stage,
and its glass cover was removed. It was naturally cooled
to form amorphous solid during this process. Then, a drop
(30 𝜇L) of deionized water was placed at the center, and the
cover glass was restored. OM images were taken after 1, 2, and
3min of water contact in the transmissionmode under cross-
polarization and with a 530-nm retardation plate (U-TP530,
Olympus).
Fourier transform infrared spectroscopy (FTIR: Cary
660, Agilent Technologies) was also used in the transmission
mode (400–4000 cm−1) to analyze any structural changewith
addition of polymers. Ball-milled andmelt/cooled samples of
IBU and IBU/polymerswere groundwithKBr (>99%, Sigma-
Aldrich) to prepare the IR specimen.
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Figure 2: OM micrographs showing crystal growth from the amorphous IBU (a)–(c), IBU/PAA (d)–(f), IBU/PVP (g)–(i), and IBU/PVPh
(j)–(l).
3. Results and Discussion
3.1. Effects of Polymeric Additives on IBU Crystallization.
When IBU or IBU/polymer (9 : 1) mixtures were melted and
solidified on glass slides, clear solid films were obtained.
These did not show birefringence under cross-polarization,
which indicated the formation of amorphous phases. When
the amorphous phases were exposed to water, regions of
birefringence showed up nearly instantaneously. Figure 2
shows the temporal evolution of the amorphous-to-crys-
talline transformation for IBU ((a)–(c)), IBU/PAA ((d)–(f)),
IBU/PVP ((g)–(i)), and IBU/PVPh ((j)–(l)). The initial form
of the crystalline phase was oval shaped, as indicated by
white arrowheads at the various places of Figure 2. Then, the
crystalline phase became disk shaped probably through the
assembled formation of the ovals sharing the center of the
disk as their common corner. Also, the peripheries of the
disk-shaped crystalline phase grew outward with time.
The nucleation of the crystalline phase seemed not very
much suppressed by the addition of polymers in this bulk
experiments. In all cases, the crystalline phase could be
found within 1min of water contact (Figure 2). By contrast,
the growth of the crystals was significantly affected by the
presence of polymers. The growth rate was in the follow-
ing order: IBU (73.9 ± 4.2 𝜇m/min) > IBU/PVPh (59.4 ±
5.4 𝜇m/min) ≈ IBU/PAA (57.2 ± 7.5 𝜇m/min) > IBU/PVP
(41.7 ± 7.6𝜇m/min). The crystal growth was measured from
the increased distance of the crystal edge from the center of
the disks or assemblies, and the directions were chosen to
avoid possible external hindrance such as void and adjacent
crystalline phases. PVP was most effective in reducing the
growth speed of the crystalline phase. Also, its effect was
unique in that the crystalline formation of the spherulitic
shape was least complete.
IR spectra were examined to probe possibly strong inter-
molecular interactions between IBU and polymers. Spectra
of IBU with and without polymeric additives were shown
in Figure 3(a), and those of neat polymers were displayed in
Figure 3(b).Overall, there are only subtle changes fromwhich
the intermolecular interactions could be inferred. The peaks
related to IBU, the main component (90wt%), remained
the same. The interpretation on the intermolecular inter-
action was from the peaks related to polymers, the minor
component (10 wt%). First, the C=O stretching peak of
PAA (1710 cm−1) overlapped too much with that of IBU
(1721 cm−1). However, the lack of significant shoulder forma-
tion, which could occur from the downshift of the PAA peak
[16], suggested insignificant intermolecular interactions
between IBU and PAA. Second, the C=O stretching peak
(marked with asterisks) of PVP (1664 cm−1) showed signif-
icant red shift (1640 cm−1), which suggested strong interac-
tion, probably hydrogen bonding with the OH group of IBU.
Similar shifts were previously observed for PVP, when inti-
mate interactions were established [17–19]. Finally, the broad
OH stretching peaks of PVPh were at about 3380 (peak) and
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Figure 3: IR spectra of (a) IBU with and without polymeric additives and (b) neat polymers.
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Figure 4: SEM micrographs of nanoporous AAO: (a) before IBU filling, (b) after IBU filling and surface cleaning, and (c) after thermal
treatment in DSC.
3522 (shoulder) cm−1: the former for the hydrogen-bonded
groups and the latter for the free groups [20, 21]. The overlap
with peaks of IBU made it difficult to accurately assess the
possible changes of the PVPh peaks, but the general shapes
and positions of the PVPh peaks appeared not significantly
altered. Overall, the IR experiments showed that PVP inter-
acted more strongly with IBU than PAA and PVPh did at
this level of concentration. (Further increase of the polymer
concentrationwas not pursued because of the practicalities of
drug formulation.) Note that the strong interaction of PVP is
in good agreement with the OM observation of bulk crystal-
lization, where the crystalline phase with PVP seemed less
mature than with other polymers, and its growth rate was
most significantly reduced (Figures 2(g)–2(i)).
3.2. IBU in the Nanoporous AAO Substrates. The pore diam-
eter of the AAO substrates utilized in the present study
was 24 ± 2 nm, of which representative image was shown
in Figure 4(a). The two-step anodization technique, as
described in the experimental section, successfully formed
the nanopores.The conditions to generate this particular pore
diameter were chosen based on the results of the previous
study, where pore diameter less than or equal to 55 nm was
necessary to form and stabilize amorphous IBUduring solidi-
fication [10].
Amount of IBU (and polymer when present) infused in
the AAO pores was 0.62–1.34mg, which corresponded to the
51–88% filling. The percentage was calculated as previously
reported [10]: (Filled%) = {(Measured mass of infused mate-
rials)/(Maximum possible mass of infused materials)} × 100,
where (Maximum possible mass of infused materials) =
{(Measuredmass of AAO)/(Density of AAO)}× {porosity/(1
− porosity)} × (Density of infused materials). Densities of
IBU and AAO were taken as 1.06 and 3.1 g/cm3, respectively
[22, 23].WhenPVP, PVPh, or PAAwas present as an additive,
their density of 1.25, 1.16, or 1.22 g/cm3 was considered for the
calculations [24–26]. Representative image of AAO filled
with IBU was shown in Figure 4(b).
After IBU/polymer infusion in AAO, the thermal behav-
ior of the infused material was observed during resolidifica-
tion using DSC. No melting was observed, which indicated
successful formation of amorphous phase (Figure 5). This
result was as expected because our previous study showed the
kinetic stabilization of the amorphous phase when the spatial
confinement was less than or equal to 55 nm [10]. Note that
the IBU not in subject of such confinement showed melting
behavior at ca. 74–76∘C [10]. Representative image of AAO
filled with IBU, after the thermal treatment, was shown in
Figure 4(c).
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Figure 6: Release behavior of IBU from AAO substrates. (a) Cumulative release percentage and (b) flux were shown along with the release
time.
Release behavior of IBU from AAO was summarized in
Figure 6. In all cases, the cumulative release (Figure 6(a))
increased slowly with time, probably due to the low solubility
of IBU (e.g., 1.54 × 10−3mol/L at 25∘C and pH 6.1 for
crystalline IBU) [10, 27].The IBU concentration after 180min
was less than 10−4mol/L in all cases; it wasmuch smaller than
the equilibrium concentration indicating that the current
results were from the early stage of the IBU dissolution. The
addition of polymeric additives decreased the cumulative
release. Also, it generally increased the variation among the
repeated release experiments, suggesting that the variation
increasewas probably due to the inhomogeneous distribution
of polymer molecules. In spite of the variation, all repeats
showed the same release trends. The IBU flux (Figure 6(b))
also showed the similar trends. The flux decreased dramati-
cally as a function of time in all cases, and it was diminished
with addition of polymers. Note that the UV absorption of
the polymers at the wavelength used to monitor IBU release
(214 nm) was determined negligible as follows. First, the
aqueous solutions of PVP, PAA, and PVPh had maximum
absorbance at 195, 195, and 190 nm, respectively. Second,
assuming that the release of IBU and polymer was propor-
tional to the composition, the corresponding polymer solu-
tions were prepared, and their UV absorbance was measured
at 214 nm.TheUVabsorption of the polymers was at themost
two hundredth of the total absorbance observed for the IBU
release.
The reason of the decreased flux with time was already
reported in our previous study [10]. The initially high flux (0
to 5min) was because of the large solubility of amorphous
IBU, and the decrease with time was due to the crystallization
of IBU in contact with water [10]. The water contact was
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known to start the crystallization of the amorphous IBU
almost instantaneously [11, 28], and thiswas also confirmed in
our bulk crystallization (Figure 2), where the initiation of the
crystallization was found in less than 1min.
The basis of the decreased flux with polymer addition
could be found from two different sources. First, the polymer
molecules associated with IBU appeared to act as diffusion
barriers, as previously observed with other APIs [29]. In
particular, PVPh with the most hydrophobic characteristics
showed the most pronouncedly diminished release behavior.
Second, the addition of polymer did not stabilize the amor-
phous IBU enough to increase its release rate. In the bulk
crystallization study (Figure 2), the polymers decreased the
growth rate of the crystals.However, they did not significantly
hinder the nucleation of the crystalline phase. Since IBU was
confined in the pores of 24 nm diameter, nucleation followed
by growth in nanoscalemight be enough to form a crystalline
“cap” that essentially stopped the unobstructed release from
any remaining amorphous phase [11].
4. Conclusions
In summary, the AAO substrates were employed to generate
amorphous IBU with polymeric additives by confining them
within the nanopores (diameter, 24 nm).The amorphous IBU
had tendency to rapidly crystallize uponwater contact, which
was the origin of the temporal decrease of the IBU release
flux [10, 11, 28]. The polymeric additives, which retarded the
crystal growth, were less effective in inhibiting the nucleation
of the crystalline phase. In addition, the IBU with polymeric
additives showed the sustained release behavior, probably
because of the polymer molecules acting as the diffusion
barriers. Since the temporal decrease of the flux was insignif-
icantly affected by the polymers, the present study suggests
that the inhibition of the crystal nucleation is the key aspect of
stabilizing the amorphous IBU in the nanoscopic confine-
ment, which is essential to make full use of its high solubility
(ca. 6 times higher than that of the bulk crystalline phase)
[10].
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